TABLE OF CONTENTS:

- About ISHLT .......................................................... 2
- Board of Directors .................................................. 4
- Scientific Program Committee .................................. 6
- Abstract Reviewers .................................................. 7
- Committees ............................................................ 15
- Scientific Councils .................................................. 19
- Past Presidents ....................................................... 22
- Award Recipients ................................................... 24
- Daily Schedule Foldouts ........................................... 24-37
- Corporate Partners .................................................. 30
- Continuing Medical Education ................................... 32
- Scientific Session Highlights ..................................... 36
- Meeting Rooms Floor Plan ......................................... 50
- ISHLT Academy Program .......................................... 53
- Program At a Glance .................................................. 64
- Scientific Program .................................................... 80
- List of Exhibiting Companies ...................................... 228
- Exhibit Hall and Poster Floor Plan .............................. 230
- Exhibitors ............................................................... 232
The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy.

ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 2700 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, transplant coordinators and infectious disease specialists. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.

ABOUT ISHLT

THE PURPOSES OF THE SOCIETY ARE:

1. To associate persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease, and related sciences.
2. To encourage and stimulate basic and clinical research in these disciplines and to promote new therapeutic strategies.
3. To hold scientific meetings featuring presentations and discussions relevant to these disciplines.
4. To sponsor a scientific journal for the publication of manuscripts related to these disciplines.
5. To establish and maintain an international registry for heart and lung transplantation.
6. To award research grants and establish endowments for the study of these disciplines.
OFFICERS

Lori J. West, MD, DPhil, President
University of Alberta, Edmonton, Alberta, Canada

David O. Taylor, MD, President-Elect
Cleveland Clinic, Cleveland, OH, USA

John Dark, MB, FRCS, Past President
Freeman Hospital, Newcastle upon Tyne, United Kingdom

Duane Davis, MD, Secretary-Treasurer
Duke University Medical Center, Durham, NC, USA

DIRECTORS

Raymond L. Benza, MD
Allegheny General Hospital, Pittsburgh, PA, USA

Susan M. Chernenko, RN, MN, NP
Toronto General Hospital, Toronto, Ontario, Canada

Maria G. Crespo-Leiro, MD
Hospital Universitario A Caruna, La Coruna, Spain

James F. George, PhD
University of Alabama at Birmingham, Birmingham, AL, USA

Allan R. Glanville, MBBS, MD, FRACP
St. Vincent’s Hospital, Sydney, Australia

Richard Kirk, MA FRACP, FRCPC
Freeman Hospital, Newcastle upon Tyne, United Kingdom

Patricia A. Uber, PharmD
University of Maryland, Baltimore, MD, USA

J. David Vega, MD
Emory Clinic, Atlanta, GA, USA

Geert M. Verleden, MD, PhD
University Hospital Gasthuisberg, Germany

Florian M. Wagner, MD
University Heart Center Hamburg, Hamburg, Germany

George M. Wieseltaler, MD
University of California San Francisco, CA, USA

EX OFFICIO BOARD MEMBERS

Mandeep R. Mehra, MD, Editor-in-Chief,
Journal of Heart and Lung Transplantation
Brigham & Women’s Hospital, Boston, MA, USA

Marshall I. Hertz, MD,
Thoracic Transplant Registry Medical Director
University of Minnesota, Minneapolis, MN, USA

Stuart C. Sweet, MD, PhD,
2012 Scientific Program Chair
St. Louis Children’s Hospital, St. Louis, MO, USA

Heather J. Ross, MD, MHSc, FRCP(c),
Development Committee Chair
Toronto General Hospital, Toronto, CANADA,
Amanda W. Rowe, ISHLT Executive Director

STAFF

Amanda W. Rowe
Executive Director

Phyllis Glenn
Director of Membership Services

Lisa A. Edwards
Director of Meetings

Lee Ann Mills
Director of Operations

Susie Newton
Communications Manager
Webmaster
ANNUAL MEETING SCIENTIFIC PROGRAM COMMITTEE

PROGRAM CHAIR:
Stuart C. Sweet, MD, PhD, St. Louis, MO, USA

PRESIDENT:
Lori J. West, MD, DPhil, Edmonton, Alberta, Canada

Allan R. Glanville, MD, FRACP, Sydney, Australia
Carla C. Baan, MD, Rotterdam, The Netherlands
Mark L. Barr, MD, Los Angeles, CA, USA
Gerald J. Berry, MD, Stanford, CA, USA
Stephen C. Clark, MD, Newcastle Upon Tyne, United Kingdom
Lara Danziger-Isakov, MD, MPH, Cleveland, OH, USA
Marc De Perrot, MD, Toronto, ON, Canada
Marion Delcroix, MD, Leuven, Belgium
Annette J. DeVito Dabbs, RN, PhD, Pittsburgh, PA, USA
Stephan M. Ensminger, MD, PhD, Erlangen, Germany
Melanie D. Everitt, MD, Salt Lake City, UT, USA
Reda Girgis, MB, BCh, Baltimore, MD, USA
Daniel R. Goldstein, MD, New Haven, CT, USA
Cynthia J. Gries, MD, MSc, Pittsburgh, PA, USA
Richard Kirk, MA FRCP FRCPC, Newcastle Upon Tyne, United Kingdom
Lorriana E. Leard, MD, San Francisco, CA, USA
Deborah J. Levine, MD, San Antonio, TX, USA
Bronwyn J. Levvey, RN, Grad Dip, Melbourne, Australia
Joren C. Madsen, MD, DPhil, Boston, MA, USA
Kenneth R. McCurry, MD, Cleveland, OH, USA
Mandeep R. Mehra, MD, MBBS, FACC, FACP, Baltimore, MD, USA
Soon J. Park, MD, Rochester, MN, USA
Richard N. Pierson, III, MD, Baltimore, MD, USA
Evgenij V. Potapov, MD, PhD, Berlin, Germany
Luciano Potena, MD, PhD, Bologna, Italy
Eulalia Roig, MD, Barcelona, Spain
Heather J. Ross, MD, MHSc, FRCP(c), Toronto, ON, Canada
Josef Stehlik, MD, PhD, Salt Lake City, UT, USA
Lynne W. Stevenson, MD, Boston, MA, USA
David O. Taylor, MD, Cleveland, OH, USA
Dirk Van Raemdonck, MD, PhD, Leuven, Belgium
Erik A. M. Verschuuren, MD, PhD, Groningen, The Netherlands
Glen P. Westall, FRACP, PhD, Melbourne, Australia

ABSTRACT REVIEWERS

Clemens Aigner, MD, Medical University of Vienna, Vienna, Austria
Arezu Z. Aliabadi, MD, Medical University of Vienna, Vienna, Austria
Claus B. Andersen, MD, D.M.Sci, Rigshospitalet, Copenhagen, Denmark
Annalisa Angelini, MD, University of Padua, Padova, Italy
Samantha J. Anthony, PhD, MSW, Hospital for Sick Children/McMaster University, Toronto, ON, Canada
Christopher J. Arendt, PharmD, RPh, Mayo Clinic, Rochester, MN, USA
Agnes M. Azimzadeh, PhD, University of Maryland, Baltimore, MD, USA
Aditya Bansal, MD, Ochsner Clinic Foundation, New Orleans, LA, USA
David A. Baran, MD, FACC, Newark Beth Israel Medical Center, Newark, NJ, USA
Christian Benden, MD, St. Vincent’s Hospital, Sydney, Australia
Elizabeth Clark Benedetti, PharmD, Baptist Memorial Hospital, Memphis, TN, USA
Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA
Sangeeta Bhorade, MD, University of Chicago Medical Center, Chicago, IL, USA
Eliane Billaud, PhD, APHP, Universite Paris Descartes-Hopital European Georges Pompidou, Paris, France
Filio Billia, MD, PhD, FRCPC, University Health Network, Toronto, ON, Canada
Emma Birks, MD, PhD, FRCPC, University of Louisville/Jewish Hospital, Louisville, KY, USA
Arie Blitz, MD, University Hospitals Case Medical Center, Cleveland, OH, USA
Annette Boehler, MD, University Hospital Zurich, Zurich, Switzerland
Michael Bowdish, MD, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
Patrick Bruneval, MD, Universite Paris Descartes-Hopital European Georges Pompidou, Paris, France
Marie M. Budev, DO, MPH, The Cleveland Clinic, Cleveland, OH, USA
Clare L. Burdett, MBBS, MRCS, Freeman Hospital, Newcastle upon Tyne, United Kingdom
Margaret M. Burke, FRCPATH, Royal Brompton and Harefield NHS Foundation Trust, Middlesex, United Kingdom
Charles E. Canter, MD, St. Louis Children’s Hospital, St. Louis, MO, USA
Javier Carbone, MD, PhD, Gregorio Maranon Hospital, Madrid, Spain
Michael P. Carboni, MD, Duke University Medical Center/Duke Children’s Hospital, Durham, NC, USA
Joern Carlsen, MD, PhD, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Marilia Cascalho, MD, PhD, University of Michigan, Ann Arbor, MI, USA
Murali Chakinala, MD, Washington University School of Medicine, St. Louis, MO, USA
Daniel C. Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, Queensland, Australia
Susan Chambers, MSN, CRNP, University of Pennsylvania, USA
Kevin M. Chan, MD, University of Michigan, Ann Arbor, MI, USA
Cecilia Chaparro, MD, Toronto General Hospital, Toronto, ON, Canada
Susan M. Chernenko, RN, MN, NP, Toronto General Hospital, UHN, Toronto, ON, Canada
Anson W. Cheung, MD, St. Paul’s Hospital, Vancouver, BC, Canada
Jason D. Christie, MD, University of Pennsylvania, Philadelphia, PA, USA
Tamara Claridge, PharmD, BCPS, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Adam B. Cochrane, PharmD, BCPS, Inova Fairfax Hospital, Arlington, VA, USA
Bernice Coleman, PhD, ACNP-BC, Cedars Sinai Med Center, Los Angeles, CA, USA
Jennifer Conway, MD, FRCPC, The Hospital for Sick Children, Toronto, ON, Canada
Hannah Copeland, MD, University of California San Diego School of Medicine, San Diego, CA, USA
Jennifer Cowger, MD, MS, University of Michigan Medical Center, Ann Arbor, MI, USA
Barbara Czerska, MD, Florida Hospital Transplant Center, Orlando, FL, USA
Hiroshi Date, MD, Kyoto University, Kyoto, Japan
Kyle L. Dawson, PharmD, BCPS, The Methodist Hospital, Houston, TX, USA
Teresa De Marco, MD, FACC, University of California, San Francisco, San Francisco, CA, USA
Roel A. de Weger, PhD, University Medical Center, Utrecht, The Netherlands
Juan F. Delgado Jimenez, MD, 12 de Octubre Universitare Hospital, Madrid, Spain
Smita A. Desai, DO, Southern California Permanente Group (Kaiser Permanente), San Diego, CA, USA
Tobias Deuse, MD, PhD, University Heart Center Hamburg, Hamburg, Germany
Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Francesco Di Chiara, MD, University of Padua, Padova, Italy
Esme Dijke, PhD, University of Alberta, Edmonton, AB, Canada
Daniel Dilling, MD, FACP, FCCP, Loyola University, Chicago, IL, USA
Anne I. Dipchand, MD, FRCPCC, Hospital for Sick Children, Toronto, ON, Canada
Fabienne Dobbels, PhD, Katholieke Universiteit Leuven, Leuven, Belgium
Robert D. Dowling, MD, University of Louisville, Louisville, KY, USA
Stavros G. Drakos, MD, Utah Cardiac Transplant Program, Salt Lake City, UT, USA
Lieven J. Dupont, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium
Peter M. Eckman, MD, University of Minnesota, Minneapolis, MN, USA
Jeffrey D. Edelman, MD, University of Washington, Seattle, WA, USA
Thomas M. Egan, MD, University of North Carolina, Durham, NC, USA
Howard J. Eisen, MD, Drexel University College of Medicine and Hahnemann University Hospital, Philadelphia, PA, USA
Christopher R. Ensor, PharmD, BCPS-CV, The Johns Hopkins Hospital, Baltimore, MD, USA
Eric Epailly, MD, Les Hôpitaux Universitaires de Strasbourg, France
Michel E. Erasmus, MD, PhD, University Medical Center Groningen, Groningen, The Netherlands
Michele Estabrook, Washington University School of Medicine, St Louis, MO, USA
Patrick Evrard, MD, PhD, CHU Mont-Godinne, Universite Catholique de Louvain, Belgium
Gregory A. Ewald, MD, Washington University School of Medicine, St Louis, MO, USA
Albert Faro, MD, Washington University, St. Louis, MO, USA
Marny Fedrigo, MD, PhD, University of Padua, Padua, Italy
Brian Feingold, MD, MS, Children’s Hospital of Pittsburgh of UPMS, Pittsburgh, PA, USA
David S. Feldman, MD, PhD, Minneapolis Heart Institute, Minneapolis, MN, USA
Erika D. Feller, MD, University of Maryland, Baltimore, MD, USA
Arnt E. Fiane, MD, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Ashi Firouzi, Royal Brompton & Harefield Hospital, Middlesex, United Kingdom
Michael C. Fishbein, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Andrew J. Fisher, PhD, FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Katrina Ford, BSc BPharm MSc MRPS, Great Ormond Street Hospital NHS Trust, London, United Kingdom
Veronica Franco, MD, MSPH, Ohio State University, Columbus, OH, USA
Robert P. Frantz, MD, Mayo Clinic, Rochester, MN, USA
Darren H. Freed, MD, PhD, FRCSC, University of Manitoba, Winnipeg, MB, Canada
Robert J. Gajarski, MD, University of Michigan, C.S. Mott children’s Hospital, Ann Arbor, MI, USA
Kimberly L. Gandy, MD, PhD, Children’s Mercy Hospitals and Clinics, Kansas City, MO, USA
Lois J. Geist, University of Iowa, Iowa City, IA, USA
Andrew E. Gelman, PhD, Washington University School of Medicine, St. Louis, MO, USA
James F. George, PhD, University of Alabama at Birmingham, Birmingham, AL, USA
Michael M. Givertz, MD, Brigham and Women’s Hospital, Boston, MA, USA
Martin J. Goddard, BA, BM, ChB, FRCS, FRCPath, Papworth Hospital NHS Trust, Cambridge, United Kingdom
Northwestern Hospital, Minneapolis, MN USA

Susan D. Moffatt-Bruce, MD, PhD, The Ohio State University, Columbus, OH, USA

Paul J. Mohacsi, MD, eMBA, University Hospital Bern, Bern, Switzerland

Martha L. Mooney, MD, Sentara Norfolk Transplant Center/EVMS, Virginia Beach, VA, USA

Matthew R. Morrell, MD, University of Pittsburgh, Pittsburgh, PA, USA

Michiel Morshuis, MD, Heart and Diabetic Center North-Rhine Westphalia, Bad Oeynhausen, Germany

Roland G. Nador, MD, University of Alberta, Edmonton, AB, Canada

Nandini Nair, MD, PhD, FSVM, FACC, FACP, Scott and White Hospital, Temple, TX, USA

Takeshi Nakatani, MD, PhD, National Cerebral and Cardiovascular Center, Osaka, Japan

Desley Neil, MBBS, PhD, BMedSC, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom

Ivan, Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Arne Neyrinck, MD, University Hospitals Leuven, Kessello, Belgium

Fabrizio Oliva, MD, Ospedale Niguarda, Milan, Italy

Takahiro Oto, MD, Okayama University, Okayama, Japan

Robert F. Padera, MD, PhD, Brigham & Women’s Hospital, Boston, MA, USA

Francis D. Pagani, MD, PhD, University of Michigan, Ann Arbor, MI, USA

Robert L. Page, II, PharmD, MSPH, FCCP, FAHA, BCPS, University of Colorado School of Medicine and Pharmacy, Denver, CO, USA

Elfriede Pahl, MD, Heart Transplantation Institution: Children’s Memorial Hospital, Northwestern Feinberg School of Medicine, Wilmette, IL, USA

Scott M. Palmer, MD, MHS, Duke University Medical Center, Durham, NC, USA

Salpy V. Pamboukian, MD, MSPH, University of Alabama at Birmingham, Birmingham, AL, USA

Jignesh Patel, MD, PhD, Cedars-Sinai Heart Institute, Beverly Hills, CA, USA

Daniel F. Pauly, MD, PhD, University of Florida, Gainesville, FL, USA

Felix Perez-Villa, MD, PhD, Hospital Clinic Barcelona, Spain

Michael G. Petty, PhD, RN, CCNS, ACNS-BC, University of Minnesota Medical Center, Fairview, Minneapolis, MN, USA

Si M. Pham, MD, University of Miami/Jackson Memorial Hospital, Miami, FL, USA

Jan Pirk, MD, IKEM Praha Czech Rep., Prague, Czech Republic

Guatam V. Ramani, MD, University of Maryland, Baltimore, MD, USA

J. Eduardo Rame, MD, DPhil, University of Pennsylvania, Philadelphia, PA, USA

Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

Hermann Reichenspurner, MD, PhD, University Heart Centre Hamburg Eppendorf, Hamburg, Germany

Monica P. Revelo, MD, PhD, University of Utah, Murray, UT, USA

Alexandra Rice, FRCPath, Harefield Hospital, London, United Kingdom

Jonathan D. Rich, MD, University of Chicago Medical Center, Chicago, IL, USA

E. Rene Rodriguez, MD, Cleveland Clinic Foundation, Cleveland, OH, USA

Stuart Russell, MD, Johns Hopkins Hospital, Baltimore, MD, USA

Zeena Safdar, MD, FCCP, FACP, Baylor College of Medicine, Houston, TX, USA

Marc G. Schecter, MD, Baylor College of Medicine, Houston, TX, USA

Robert J. Schilz, DO, PhD, University Hospitals, Case Medical Center, Cleveland, OH, USA

Christof Schmid, MD, University Medical Center Regensburg, Regensburg, Germany

Sonja Schrepfer, MD, PhD, University Heart Center Hamburg, Stanford, CA, USA

Stephan Schueler, MD, PhD, FRCS, Newcastle upon Tyne Hospitals Foundation Trust/Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Martin Schweiger, MD, Medical University, Graz, Austria

Javier Segovia, MD, PhD, Hospital Universitario Puerta De Hierro, Madrid, Spain

Keyur B. Shah, MD, Virginia Commonwealth University, Richmond, VA, USA

Monica R. Shah, MD, MHS, MSJ, National Heart Lung and Blood Institute, McLean, VA, USA

Pali D. Shah, MD, Johns Hopkins, Baltimore, MD, USA

Michael Shullo, PharmD, University of Pittsburgh, Pittsburgh, PA, USA

Sara J. Shumway, MD, University of Minnesota, Minneapolis, MN, USA

Fernanda P. Silveira, MD, MS, Univ of Pittsburgh, Pittsburgh, PA, USA

Marc A. Simon, MD, MS, University of Pittsburgh, Pittsburgh, PA, USA

Jonathan P. Singer, MD, MS, University of California San Francisco, San Francisco, CA, USA

Tajinder P. Singh, MD, MSc, Children’s Hospital of Boston, Boston, MA, USA

Cumara C. Sivathasan, MBBS, FRCS, FAMS, National Heart Centre, Singapore, Singapore

Nikolaos Skartsis, MD, Brigham and Women’s Hospital, Boston, MA, USA

Jackeline M. Smits, MD, PhD, Eurotransplant, Leiden, The Netherlands

Gregory I. Snell, MBBS, FRACP, MD, Alfred Hospital, Melbourne, Australia

Amparo Sole, MD, PhD, Hospital Universitario y Politecnico la Fe, Valencia, Spain

Alexander Stepanenko, MD, German Heart Institute, Berlin, Germany

Susan Stewart, FRCPath, Papworth Hospital, Cambridge, United Kingdom

Valentina Stosor, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Sean M. Studer, MD, MSc, Newark Beth Israel Medical Center, Newark, NJ, USA
Benjamin Sun, MD, Minneapolis Heart Institute, Minneapolis, MN, USA
W. H. Wilson Tang, MD, Cleveland Clinic, Gates Mills, OH, USA
Josef Thul, MD, Kinderherzzentrum Universitat, Giessen, Germany
Yoshiya Toyoda, MD, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Patricia A. Uber, PharmD, University of Maryland, School of Medicine, Baltimore, MD, USA
Walter Uber, PharmD, Medical University of South Carolina, Charleston, SC, USA
Simon Urschel, MD, University of Alberta, Edmonton, AB, Canada
Caroline Van De Wauwer, MD, University Medical Center, Groningen, The Netherlands
Wim van der Bij, MD, PhD, University Hospital Groningen, Groningen, The Netherlands
Josef Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium
Wickii T. Vigneswaran, MD, FACS, University of Chicago, Chicago, IL, USA
Florian M. Wagner, MD, University Heart Center Hamburg Eppendorf, Hamburg, Germany
Rajat Walia, MD, FCCP, St. Joseph’s Hospital & Medical Center, Phoenix, AZ, USA
Gregor Warnecke, MD, Hannover Medical School, Hannover, Germany
David Weill, MD, Stanford University Medical Center, Stanford, CA, USA
Robert G. Weintraub, MB BS FRACP FACC, Royal Children’s Hospital, Parkville, Australia
Michel White, MD, FRCPc, FACC, FESC, Montreal Heart Institute, Montreal, QC, Canada
Connie White-Williams, PhD, RN, FAAN, University of Alabama at Birmingham, Birmingham, AL, USA
Christopher H. Wigfield, MD, FRCS, Loyola University Medical Center, Maywood, IL, USA
Markus J. Wilhelm, MD, University Hospital Zurich, Zurich, Switzerland
Keith M. Wille, MD, University of Alabama at Birmingham, Birmingham, AL, USA
Gayle L. Winters, MD, Brigham and Women’s Hospital, Boston, MA, USA
Stephanie T. Yerkovich, PhD, The Prince Charles Hospital, Brisbane, Australia
Nizar Yonan, MB ChB, MD, FRCS(CTh), University Hospital of South Manchester, S. Manchester, United Kingdom
Roger D. Yusen, MD, MPH, Washington University School of Medicine, St. Louis, MO, USA
Phillip C. Zakowski, MD, Cedars Sinai Medical Center, Los Angeles, CA, USA
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

EDUCATION COMMITTEE

Allen S. Anderson, MD, FACC, Chair and Heart Failure Workforce Leader
Stuart C. Sweet, MD, PhD, 2012 Scientific Program Chair
Heather J. Ross, MD, MHSc, FRCP(c), Basic Science & Translational Research-to be determined
David Baran, MD, Heart Failure & Transplant Medicine, Council Workforce Leader
Fernanda Silveira, MD, Infectious Diseases, Council Workforce Leader
Matthew Morrell, MD, Junior Faculty and Trainees, Council Workforce Leader
Roberta C. Bogaev, MD, FACC, FACP, Mechanical Circulatory Support Council Workforce Leader
Michael Petty, PhD, RN, CCNS, CNS, Nursing Health Sciences & Allied Health Council Workforce Leader
E. Rene Rodriguez, MD, Pathology Council Workforce Leader
Daphne Hsu, MD, Pediatric Transplantation, Council Workforce Leader
Dana McGlothlin, MD, Pulmonary Hypertension Council Workforce Leader
Christopher H. Wigfield, MD, FRCS, Pulmonary Transplantation Council Workforce Leader
Beatriz Diaz Molina, MD, At Large Member
Keith McNeil, FRACP, At Large Member
Andreas O. Zuckermann, MD, At Large Member

GRANTS AND AWARDS COMMITTEE

Duane Davis, MD, Chair
Mark L. Barr, MD, Past Chair
Lori J. West, MD, DPhil, Reviewers
Carla C. Baan, PhD, Reviewers
Marshall I. Hertz, MD, Reviewers
Judy A. Currey, PhD, Reviewers
JHLT EDITORIAL BOARD

MandDeep R. Mehra, MBBS, FACC, FACP, Editor-in-Chief
Patricia A. Uber, PharmD, Executive Editor
Michelle Kraft, Journal Office Manager
Mar!a Rosa Costanzo, MD (Editor Emeritus, 1995-1999)
Consulting Editor
James K. Kirklin, MD (Editor Emeritus 2000-2009)
Consulting Editor
James F. George, PhD, Editorial Office Consultants
Jonathan B. Oren5, MD (USA), Editorial Office Consultants
Jayan Parameshwar, FRCP (UK), Editorial Office Consultants
Richard N. Pierson, III, MD (USA), Editorial Office Consultants
Hector O. Ventura, MD (USA), Editorial Office Consultants
Claus B. Andersen, MD, D.M.Sc (Denmark), Editorial Board Consultants
AnHanna Angelini, MD (Italy), Editorial Board Consultants
Marcelo CantaroVich, MD (Canada), Editorial Board Consultants
Charles E. Canter, MD (USA), Editorial Board Consultants
Pablo E. Castro, MD (Chile), Editorial Board Consultants
John V. Conte, MD (USA), Editorial Board Consultants
Paul A. Corris, MB FRCP (UK), Editorial Board Consultants
Duane Davis, MD (USA), Editorial Board Consultants
John Dark, MB, FRCS (UK) Editorial Board Consultants
Mary Amanda Dew, PhD (USA) Editorial Board Consultants
Fabienne Dobbels, MSc, PhD (Belgium), Editorial Board Consultants
Howard J. Eisen, MD (USA), Editorial Board Consultants
Roger W. Evans, PhD (USA), Editorial Board Consultants
Michael C. Fishbein, MD (USA), Editorial Board Consultants
Edward R. Garrity, Jr., MD (USA), Editorial Board Consultants
Alan R. Glanville, MD, FRACP (Australia), Editorial Board Consultants
Kate Gould, FRCPa+h (UK), Editorial Board Consultants
Shahid Husain, MD, MS (Canada), Editorial Board Consultants
Valluvan Jeevanandam, MD (USA), Editorial Board Consultants
Maryl R. Johnson, MD (USA), Editorial Board Consultants
Shaf Keshavjee, MD, FRCSC (Canada), Editorial Board Consultants
Jon Kobashigawa, MD (USA), Editorial Board Consultants
JoAnn Lindenfeld, MD (USA), Editorial Board Consultants
Bruce McManus, MD, PhD (Canada), Editorial Board Consultants
Bruno M. Meiser, MD (Germany), Editorial Board Consultants
Martha L. Mooney, MD (USA), Editorial Board Consultants
Jonah Odim, MD, (USA) Editorial Board Consultants
Francesco Parisi, MD (Italy), Editorial Board Consultants
Myung H. Park, MD (USA), Editorial Board Consultants
Evgenij V. Potapov, MD, PhD (Germany), Editorial Board Consultants
Luciano Potena, MD, PhD (Italy), Editorial Board Consultants
Joseph G. Rogers, MD (USA), Editorial Board Consultants
Heather J. Ross, MD, MHSc, FRCP(c)(Canada), Editorial Board Consultants
Lewis J. Rubin, MD (USA), Editorial Board Consultants
Stephan Schueler, MD, PhD, FRCS (UK), Editorial Board Consultants
Keyur B. Shah, MD (USA), Editorial Board Consultants
Mark S. Slaughter, MD (USA), Editorial Board Consultants
Randall C. Starling, MD, MPH (USA), Editorial Board Consultants
Stuart C. Sweet, MD, PhD (USA), Editorial Board Consultants
Geert Verleden, MD, PhD, (Belgium) Editorial Board Consultants
Aaron B. Waxman, MD, PhD (USA), Editorial Board Consultants
Steve A. Webber, MB ChB, MRCP (USA), Editorial Board Consultants
Lori J. West, MD, D.Phil (Canada), Editorial Board Consultants
Michael Zaklinczynski, MD, (Poland), Editorial Board Consultants

PROFESSIONAL STANDARDS AND GUIDELINES COMMITTEE

James K. Kirklin, MD, Chair
Maria Rosa Costanzo, MD, Past Chair
Naveen Periera, MDm, Heart Failure Workforce Leader
Amparo Sole, MD, PhD, Infectious Diseases Workforce Leader
Susan D. Moffatt-Bruce, MD, PhD, Junior Faculty & Trainee Workforce Leader
David S. Feldman, MD, PhD, FACC, FAHA, Mechanical Circulatory Support Workforce Leader
Connie White-Williams, PhD, RN, FAAN, Nursing, Health Sciences & Allied Health Workforce Leader
Carmela D. Tan, MD, Pathology Workforce Leader
Robert J. Boucek, Jr. MD, Pediatric Transplantation Workforce Leader
Evelyn Horn, MD, Pulmonary Hypertension Workforce Leader
David Weill, MD, Pulmonary Transplantation Workforce Leader
Diego H. Delgado, MD, At Large Member
Maria G. Crespo-Leiro, MD, At Large Member
Daniela Pini, MD, At Large Member

REGISTRIES AND DATABASES COMMITTEE

Marshall I. Hertz, MD, Chair
Josef Stehlik, MD, Heart Failure
Paolo A. Grossi, MD, PhD, Infectious Diseases Workforce Leader
Shahid Husain, MD, MS, Infectious Diseases Workforce Leader
Jennifer A. Cowger, MD, MS, Pediatric Infectious Diseases Workforce Leader
Jaap Lahpor, MD, PhD, Pulmonary Hypertension Workforce Leader
Robert F. Padera, MD, PhD, Pulmonary Hypertension Workforce Leader
Richard E. Chinnock, MD, Pediatric Transplantation Workforce Leader
Mardi Gomberg-Maitland, MD, MSc, Pulmonary Hypertension Workforce Leader
Fernando Torres, MD, PA, Pulmonary Hypertension Workforce Leader
Shaf Keshavjee, MD, Pulmonary Transplantation Workforce Leader

16

17
THORACIC TRANSPLANT REGISTRY STEERING COMMITTEE

Marshall I. Hertz, MD, Medical Director
Josef Stehlik, MD, MPH, Associate Medical Director, Heart
Jason D. Christie, MD, Associate Medical Director, Lung/Heart-Lung
Richard Kirk, MA, FRCP, FRCPC, Senior Associate Medical Director, Pediatric Heart
Anne I. Dipchand, MD, Associate Medical Director, Pediatric Lung/Heart-Lung
Christian Benden, MD, Associate Medical Director, Pediatric Lung
Fabienne Dobbels, PhD, Associate Medical Director, Outcomes
Axel Rahmel, MD, Associate Medical Director, OEO Relations
Leah Edwards, PhD, Associate Medical Director, Biostatistics
Jaime Williamson, SAS Analyst
Kathryn A. Philibin, RN, TII Liaison
Anna Kucheryavaya, Assistant Biostatistician

LINKS NEWSLETTER EDITORIAL STAFF

Vincent G. Valentine, MD, Editor-in-Chief
Susie Newton, Managing Editor
Roger W. Evans, PhD, Senior Associate Editor
Allan R. Glenville, MBBS, MD, FRACP, Senior Associate Editor
Maryl R. Johnson, MD, Senior Associate Editor
Lori J. West, MD, DPhil, Senior Associate Editor
Emma Birks, FRCP, PhD, Associate Editor-Cardiology
Stavros G. Drakos, MD, Associate Editor-Cardiology
Lee R. Goldberg, MD, MPH, Associate Editor-Cardiology
Nancy P. Blumenthal, CRNP, Associate Editor-Nursing
Daniel Dilling, MD, Associate Editor-Junior Faculty & Trainees
Stanley I. Martin, MD, Associate Editor-Infectious Diseases
Tereza Martinu, MD, Associate Editor-Pulmonary
Javier Carbone, MD, PhD, International Correspondents Board, Spain
Bronwyn J. Levey, RN, Grad Dip Clin Ep, International Correspondents Board, Australia
Takeshi Nakatani, MD, PhD, International Correspondents Board, Japan
Luciano Potena, MD, PhD, International Correspondents Board, Italy
Stephan Schubert, MD, International Correspondents Board, Germany
Andreas Zuckermann, MD, International Correspondents Board, Austria

BASIC SCIENCE AND TRANSLATIONAL RESEARCH

Kimberly L. Gandy, MD, Chair
Sonja Schrepfer, MD, PhD, Vice Chair
Lori J. West, MD, DPhil, Board Liaison
James F. George, PhD, Board Liaison

MECHANICAL CIRCULATORY SUPPORT

Francis D. Pagani, MD, PhD, Chair
Jeffrey J. Teuteberg, MD, Vice Chair
Emma J. Birks, MRCGP, PhD, Past Chair
J. David Vega, MD, Board Liaison
George M. Wieselthaler, MD, Board Liaison
Soon J. Park, MD, Annual Program Committee Representative
Evgenij V. Potapov, MD, PhD, Annual Program Committee Representative
Josef Stehlik, MD, MPH, Annual Program Committee Representative
David S. Feldman, MD, PhD, FACC, FAHA, Standards & Guidelines Workforce Leaders
Roberta C. Bogaev, MD, FACC, Education Workforce Leaders
Jaap Lahpor, MD, PhD, Registries & Databases Workforce Leaders
Evgenij V. Potapov, MD, Communications Workforce Leaders
Mario C. Deng, MD, Development Liaison

HEART FAILURE AND TRANSPLANT MEDICINE

Lee R. Goldberg, MD, MPH, Chair
David Brad Dyke, MD, Vice Chair
David A. Baran, MD, Past Chair
David O. Taylor, MD, Board Liaison
Maria G. Crespo-Leiro, MD, Board Liaison
Lynne W. Stevenson, MD, Annual Program Committee Representative
Luciano Potena, MD, PhD, Annual Program Committee Representative
Eulalia Roig, MD, Annual Program Committee Representative
Joren C. Madsen, MD, DPhil, Annual Program Committee Representative
Naveen Pereira, MD, Standards & Guidelines Workforce Leader
David A. Baran, MD, Education Workforce Leader
Jof Re Stehlík, MD, Registries & Databases Workforce Leader
David P. Nelson, MD, Communications Workforce Leader
Robert C. Bourge, MD, Development Liaison

INFECTIONOUS DISEASES
Lara Danziger-Isakov, MD, MPH, Chair
Martha L. Mooney, MD, Past Chair
Patricia A. Uber, PharmD, Board Liaison
Erik A.M. Verschuuren, MD, PhD, Annual Program Committee Representative
Lara Danziger-Isakov, MD, MPH, Annual Program Committee Representative
Amparo Sole, MD, PhD, Standards & Guidelines Workforce Leader
Fernanda Silveira, MD, Education Workforce Leader
Paolo A. Grossi, MD, PhD, Registries & Databases Workforce Leader
Shahid Husain, MS, MBBS, MD, Registries & Databases Workforce Co-Leader
Stanley I. Martin, MD, Communications Workforce Leader

NURSING, HEALTH SCIENCES AND ALLIED HEALTH
Nancy P. Blumenthal, CRNP, Chair
Annemarie Kaan, MCN, RN, Vice Chair
Bernice L. Coleman, RN, PhD, Past Chair
Susan M. Chernenko, RN, MN, NP, Board Liaison
Annette J. Devito-Dabbs, RN, PhD, FAAN, Annual Program Committee Representative
Bronwyn J. Levey, RN, Grad Dip Clin Ep, Annual Program Committee Representative
Connie White-Williams, MSN, Standards & Guidelines Workforce Leader
Michael G. Petty, PhD(c), RN, CCNS, CNS, Education Workforce Leader
Fabienne Dobbelts, PhD, Registries & Databases Workforce Leader
Judy A. Currey, PhD, Grants and Awards Workforce Leader
Bronwyn J. Levey, RN, Grad Dip Clin Ep, Communications Workforce Leader
Arzella K. Walters, RN, MA, Clinical Coordinator

PATHOLOGY
Gerald J. Berry, MD, Chair
Patrick Bruneval, Vice Chair
Annalisa Angelini, MD, Past Chair
James F. George, PhD, Board Liaison
Gerald J. Berry, MD, Chair, Annual Program Committee Representative

Carmela D. Tan, MD, Standards & Guidelines Workforce Leader
E. Rene Rodriguez, MD, Education Workforce Leader
Robert F. Padera, MD, PhD, Registries & Databases Workforce Leader
James B. Atkinson, MD, PhD, Communications Workforce Leader

PEDIATRIC TRANSPLANTATION
Beth Kaufman, MD, Chair
Melanie Everitt, MD, Vice Chair
Elfriede Pahl Schuette, MD, Past Chair
Richard Kirk, MA, FRCP, FRCPCH, Board Liaison
Melanie Everitt, MD, Annual Program Committee Representative
Richard Kirk, MA, FRCP, FRCPCH, Annual Program Committee Representative
Robert J. Boucek, Jr., MD, Standards & Guidelines Workforce Leader
Daphne Hsu, MD, Education Workforce Leader
Richard E. Chinnock, MD, Registries and Databases Workforce Leader
Kimberly L. Gandy, MD, Communications Workforce Leader

PULMONARY HYPERTENSION
Myung Park, MD, Chair
Robert P. Frantz, MD, Vice Chair
Raymond L. Benza, MD, Past Chair
Raymond L. Benza, MD, Board Liaison
Marc De Perrot, MD, Annual Program Committee Representative
Marion Delcroix, MD, Annual Program Committee Representative
Reda Girgis, MB, BCh, Annual Program Committee Representative
Evelyn Horn, MD, Standards & Guidelines Workforce Leader
Dana P. McGlothlin, MD, Education Workforce Leader
Mardi Gomberg-Maitland, MD, MSc, Registries & Databases Workforce Leader
Fernando Torres, MD, PA, Registries & Databases Workforce Leader
Deborah J. Levine, MD, Communications Workforce Leader
Srinivas Murali, MD, Development Workforce Leader

PULMONARY TRANSPLANTATION
Lianne G. Singer, MD, FRCPC, Chair
David Weill, MD, Vice Chair
Michael Mulligan, MD, Vice Chair-Elect/Secretary
Geert M. Verleden, MD, PhD, Past Chair
Duane Davis, MD, Board Liaison
Deborah J. Levine, MD, Annual Program Committee Liaison
Mark L. Barr, MD, Annual Program Committee Liaison
Glen P. Westall, FRACP, PhD, Annual Program Committee Liaison
Stephen C. Clark, MD, Annual Program Committee Liaison
Lorriana Leard, MD, Annual Program Committee Liaison
David Weill, MD, Standards & Guidelines Workforce Leader
Christopher H. Wigfield, MD, FRCS, Education Workforce Leader
Shaf Keshavjee, MD, Registries & Databases Workforce Leader
Roger D. Yusen, MD, MPH, Quality of Life Workforce Leader
Patrick Evrard, MD, Development Liaison Workforce Leader
PAST SCIENTIFIC PROGRAM CHAIRS

<table>
<thead>
<tr>
<th>Year</th>
<th>Location</th>
<th>Chair 1</th>
<th>Chair 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>1981</td>
<td>San Francisco, CA</td>
<td>Edward B. Stinson, MD and Michael L. Hess, MD</td>
<td></td>
</tr>
<tr>
<td>1982</td>
<td>Phoenix, AZ</td>
<td>Michael Kaye and Bernard Gersh</td>
<td></td>
</tr>
<tr>
<td>1983</td>
<td>New Orleans, LA</td>
<td>Stuart W. Jamieson, MD and Mark E. Thompson, MD</td>
<td></td>
</tr>
<tr>
<td>1984</td>
<td>New York, NY</td>
<td>Randall B. Griep, MD</td>
<td></td>
</tr>
<tr>
<td>1985</td>
<td>Anaheim, CA</td>
<td>Terence A. H. English and Hillel Laks</td>
<td></td>
</tr>
<tr>
<td>1986</td>
<td>New York, NY</td>
<td>John C. Baldwin, MD</td>
<td></td>
</tr>
<tr>
<td>1987</td>
<td>New Orleans, LA</td>
<td>James B. Young, MD</td>
<td></td>
</tr>
<tr>
<td>1988</td>
<td>Los Angeles, CA</td>
<td>Jon K. Kobashigawa, MD</td>
<td></td>
</tr>
<tr>
<td>1989</td>
<td>Munich, Germany</td>
<td>Bruno Reichart, MD</td>
<td></td>
</tr>
<tr>
<td>1990</td>
<td>San Diego, CA</td>
<td>D. Glenn Pennington, MD</td>
<td></td>
</tr>
<tr>
<td>1991</td>
<td>Paris, France</td>
<td>John B. O’Connell, MD</td>
<td></td>
</tr>
<tr>
<td>1992</td>
<td>San Diego, CA</td>
<td>Eric A. Rose, MD</td>
<td></td>
</tr>
<tr>
<td>1993</td>
<td>Boca Raton, FL</td>
<td>Maria Rosa Costanzo, MD</td>
<td></td>
</tr>
<tr>
<td>1994</td>
<td>Venice, Italy</td>
<td>John Wallwork, MBChB, FRCS</td>
<td></td>
</tr>
<tr>
<td>1995</td>
<td>San Francisco, CA</td>
<td>Leslie W. Miller, MD</td>
<td></td>
</tr>
<tr>
<td>1996</td>
<td>New York, NY</td>
<td>William A. Baumgartner, MD</td>
<td></td>
</tr>
<tr>
<td>1997</td>
<td>London, England</td>
<td>Stephan Schueler, MD</td>
<td></td>
</tr>
<tr>
<td>1998</td>
<td>Chicago, IL</td>
<td>James B. Young, MD</td>
<td></td>
</tr>
<tr>
<td>1999</td>
<td>San Francisco, CA</td>
<td>Mark L. Barr, MD</td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td>Osaka, Japan</td>
<td>Jon Kobashigawa, MD</td>
<td></td>
</tr>
<tr>
<td>2001</td>
<td>Vancouver, Canada</td>
<td>David O. Taylor, MD</td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td>Washington, DC</td>
<td>Robert C. Robbins, MD</td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td>Vienna, Austria</td>
<td>Bruce R. Rosengard, MD</td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>San Francisco, CA</td>
<td>Mandeep R. Mehra, MD</td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td>Philadelphia, PA</td>
<td>Shaf Keshavjee, MD</td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>Madrid, Spain</td>
<td>John Dark, MB, FRCS</td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>San Francisco, CA</td>
<td>Duane Davis, MD</td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td>Boston, MA</td>
<td>Lori J. West, MD, DPhil</td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>Paris, France</td>
<td>Randall C. Starling, MD, MPH</td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>Chicago, IL</td>
<td>Hermann Rechenspurner, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>San Diego, CA</td>
<td>Richard N. Pierson, III, MD</td>
<td></td>
</tr>
</tbody>
</table>

PAST EDITORS, JOURNAL OF HEART AND LUNG TRANSPLANTATION

<table>
<thead>
<tr>
<th>Year</th>
<th>Editor</th>
</tr>
</thead>
<tbody>
<tr>
<td>1981-1985</td>
<td>Jacques G. Losman, MD</td>
</tr>
<tr>
<td>1986-1994</td>
<td>Michael P. Kaye, MD</td>
</tr>
<tr>
<td>1995-1999</td>
<td>Maria Rosa Costanzo, MD</td>
</tr>
<tr>
<td>2000-2009</td>
<td>James K. Kirklin, MD</td>
</tr>
<tr>
<td>2010-PRESENT</td>
<td>Mandeep R. Mehra, MD</td>
</tr>
</tbody>
</table>

MEDICAL DIRECTORS, THORACIC ORGAN TRANSPLANT REGISTRY

<table>
<thead>
<tr>
<th>Year</th>
<th>Director</th>
</tr>
</thead>
<tbody>
<tr>
<td>1987-1993</td>
<td>Michael P. Kaye, MD</td>
</tr>
<tr>
<td>1993-2001</td>
<td>Jeffrey D. Hosenpud, MD</td>
</tr>
<tr>
<td>2001-PRESENT</td>
<td>Marshall I. Hertz, MD</td>
</tr>
</tbody>
</table>
## Wednesday

<table>
<thead>
<tr>
<th>Time</th>
<th>Congress Hall</th>
<th>Forum Hall</th>
<th>Meeting Hall 1</th>
<th>Panorama Hall</th>
<th>Meeting Hall 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>PRE-MEETING SYMPOSIUM 1 Mechanical Circulatory Support Outcomes</td>
<td>PRE-MEETING SYMPOSIUM 2 Rejection Surveillance</td>
<td>PRE-MEETING SYMPOSIUM 3 Lung Tx Dysfunction</td>
<td>PRE-MEETING SYMPOSIUM 4 Cardiogenic Shock Before &amp; After Heart Tx</td>
<td>PRE-MEETING SYMPOSIUM 5 Neurocognitive, Psychosocial Issues in Children</td>
</tr>
<tr>
<td>9:30 AM</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>9:45 AM</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>11:15 AM</td>
<td>PRE-MEETING SYMPOSIUM 7 New Devices New Approaches</td>
<td>PRE-MEETING SYMPOSIUM 8 ABCs of AMR</td>
<td>PRE-MEETING SYMPOSIUM 9 Ex-Vivo Lung Perfusion</td>
<td>PRE-MEETING SYMPOSIUM 10 Right Ventricular and Pulmonary Vascular Load</td>
<td>PRE-MEETING SYMPOSIUM 11 MCS in Congenital Heart Disease &amp; Pediatrics</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>LUNCH BREAK</td>
<td>LUNCH BREAK</td>
<td>LUNCH BREAK</td>
<td>LUNCH BREAK</td>
<td>LUNCH BREAK</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>CONCURRENT SESSION 1 VADs and Community</td>
<td>CONCURRENT SESSION 2 Advanced Heart Failure Decision Making</td>
<td>CONCURRENT SESSION 3 BOS Animal Models</td>
<td>CONCURRENT SESSION 4 Juggling Donor Risk</td>
<td>CONCURRENT SESSION 5 LVAD Optimization</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>4:15 PM</td>
<td>OPENING PLENARY SESSION Overcoming Political Barriers</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:45 PM</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>6:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year</td>
<td>Name and Degree</td>
<td>Affiliation and Sponsor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>----------------</td>
<td>------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1995</td>
<td>Frances L. Johnson, MD</td>
<td>(supported by Ortho-Biotech)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1996</td>
<td>Tuija S. Ikonen, MD</td>
<td>(supported by Roche)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1997</td>
<td>Jonathan Chen, MD</td>
<td>(supported by Roche)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1998</td>
<td>George Juang, MD</td>
<td>(supported by Ortho-Biotech)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1999</td>
<td>Kelly S.A. Blair, MD</td>
<td>(supported by Roche)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td>Christian A. Gleissner, MD</td>
<td>(supported by Novartis)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2001</td>
<td>Ruediger Hoebelt, MD</td>
<td>(supported by Novartis)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td>Ethan A. Kay, MD</td>
<td>(supported by Ortho-Biotech)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td>Frances L. Johnson, MD</td>
<td>(supported by Ortho-Biotech)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>Jonathan Chen, MD</td>
<td>(supported by Roche)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td>Christian A. Gleissner, MD</td>
<td>(supported by Ortho-Biotech)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ISHLT TRANSPLANT RESEARCH FELLOWSHIP GRANTS Continued**

<table>
<thead>
<tr>
<th>Year</th>
<th>Name and Degree</th>
<th>Affiliation and Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>Rachel L. Anderson, MBBS</td>
<td>(supported by Roche)</td>
</tr>
<tr>
<td>2007</td>
<td>J. Raymond Fitzpatrick, MD</td>
<td>(supported by Ortho-Biotech)</td>
</tr>
<tr>
<td>2007</td>
<td>Howard I. Huang, MD</td>
<td>(supported by Novartis)</td>
</tr>
<tr>
<td>2008</td>
<td>Jonathan Choy, PhD</td>
<td>(supported by Ortho-Biotech)</td>
</tr>
<tr>
<td>2009</td>
<td>Hua Shen, MD, PhD</td>
<td>(supported by Ortho-Biotech)</td>
</tr>
<tr>
<td>2010</td>
<td>Mi-Kyung Song, PhD</td>
<td>(supported by Ortho-Biotech)</td>
</tr>
<tr>
<td>2011</td>
<td>Jose Nativi, MD</td>
<td>(supported by Ortho-Biotech)</td>
</tr>
</tbody>
</table>

**ISHLT TRANSPLANT REGISTRY EARLY CAREER AWARD**

<table>
<thead>
<tr>
<th>Year</th>
<th>Name and Degree</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>Beth D. Kaufman, MD</td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td>Cynthia Gries, MD, MSc</td>
<td>(supported by Astellas)</td>
</tr>
<tr>
<td>2010</td>
<td>Jennifer Comway, MD, FRCP</td>
<td>(supported by Novartis)</td>
</tr>
</tbody>
</table>

**ISHLT NURSING AND SOCIAL SCIENCES RESEARCH GRANT**

<table>
<thead>
<tr>
<th>Year</th>
<th>Name and Degree</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1997</td>
<td>Eileen Collins, RN, PhD</td>
<td></td>
</tr>
<tr>
<td>1999</td>
<td>Jeannie Salyer, PhD</td>
<td>(supported by Novartis)</td>
</tr>
<tr>
<td>2000</td>
<td>Nancy M. Albert, MSN, RN</td>
<td>(supported by Ortho-Biotech)</td>
</tr>
<tr>
<td>2003</td>
<td>Diane H. Lavalid, RN, MN, PhD</td>
<td>(supported by Ortho-Biotech)</td>
</tr>
<tr>
<td>2005</td>
<td>Janet E. Madill, PhD</td>
<td>(supported by Ortho-Biotech)</td>
</tr>
<tr>
<td>2007</td>
<td>Deidre L. Logan, PhD</td>
<td>(supported by Ortho-Biotech)</td>
</tr>
<tr>
<td>2008</td>
<td>Annemarie F. Kaan, MCN</td>
<td>(supported by Ortho-Biotech)</td>
</tr>
<tr>
<td>2010</td>
<td>Thierry Troosters, PhD</td>
<td>(supported by Ortho-Biotech)</td>
</tr>
<tr>
<td>2011</td>
<td>Jose Nativi, MD</td>
<td>(supported by Ortho-Biotech)</td>
</tr>
<tr>
<td>TIME</td>
<td>CONGRESS HALL</td>
<td>FORUM HALL</td>
</tr>
<tr>
<td>--------</td>
<td>---------------</td>
<td>------------</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>CONCURRENT SESSION 7</td>
<td>VAD Dark Side</td>
</tr>
<tr>
<td>8:15 AM</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>CONCURRENT SESSION 13</td>
<td>VADs Razer Edge</td>
</tr>
<tr>
<td>9:15 AM</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>10:15 AM</td>
<td>LUNCH BREAK</td>
<td>LUNCH BREAK</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>MINI ORAL SESSION 1</td>
<td>MCS</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>CONCURRENT SYMPOSIUM 2</td>
<td>Caregivers</td>
</tr>
<tr>
<td>12:15 PM</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>1:15 PM</td>
<td>LUNCH BREAK</td>
<td>LUNCH BREAK</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>MINI ORAL SESSION 1</td>
<td>MCS</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>CONCURRENT SESSION 11</td>
<td>Tolerance</td>
</tr>
<tr>
<td>3:15 PM</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>4:15 PM</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>CONCURRENT SYMPOSIUM 3</td>
<td>MCS Timing</td>
</tr>
<tr>
<td>5:15 PM</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>6:15 PM</td>
<td>CONCURRENT SESSION 24</td>
<td>AHF Tx Contraindications</td>
</tr>
<tr>
<td>6:30 PM</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>7:00 PM</td>
<td>EXHIBIT HALL RECEPTION</td>
<td>6:15 pm – 7:00 pm</td>
</tr>
</tbody>
</table>
NURSING AND SOCIAL SCIENCES EXCELLENCE IN RESEARCH AWARD

2005  Mary Amanda Dew, PhD
2006  Kathleen L. Grady, PhD, RN
2007  Christianne Kugler, PhD
2008  Annette DeVito Dabbis, RN, PhD
2009  Connie White-Williams, MSN
2010  Bronwyn Lewey, RN
2011  Samantha J. Anthony, PhD, MSW

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL BEST MCS PAPER AWARD

2009  Nishant Shah, MD (supported by Thoratec)
2010  Jose N. Nativi, MD (supported by Thoratec)

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL FELLOWSHIP GRANT

2009  Sasa D. Borovic, MD (supported by Thoratec)
2010  Iki Adachi, MD (supported by Thoratec)
2011  Dan Spiegelstein, MD (supported by Thoratec)

The International Society for Heart and Lung Transplantation is Most Grateful for the Educational Grants and Support of:

Gold Level Partner
UNITED THERAPEUTICS EUROPE

Silver Level Partner
ACTELION
ASTELLAS PHARMA
GILEAD SCIENCES
THORATEC

Bronze Level Partner
ONE LAMBDA
NOVARTIS PHARMA

Corporate Level Partner
BAYER
(in support of the Pulmonary Hypertension Sessions)
HEARTWARE

Toward this 32nd Annual Meeting and Scientific Sessions

CONTINUING MEDICAL EDUCATION INFORMATION

ACCREDITATION STATEMENT

The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

ISHLT designates this live activity for a maximum of 28 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.
<table>
<thead>
<tr>
<th>TIME</th>
<th>CONCURRENT HALL</th>
<th>CONCURRENT SESSION 25</th>
<th>CONCURRENT SESSION 26</th>
<th>CONCURRENT SESSION 27</th>
<th>CONCURRENT SESSION 28</th>
<th>CONCURRENT SESSION 29</th>
<th>CONCURRENT SESSION 30</th>
<th>CONCURRENT SESSION 31</th>
<th>CONCURRENT SESSION 32</th>
<th>CONCURRENT SESSION 33</th>
<th>CONCURRENT SESSION 34</th>
<th>CONCURRENT SESSION 35</th>
<th>POSTER VIEWING</th>
<th>EXHIBIT HALL OPEN</th>
<th>CLUB B</th>
<th>CLUB C</th>
<th>CLUB D</th>
<th>MEETING HALL 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td></td>
<td>CONCURRENT SESSION 25</td>
<td>VAD Future</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
EDUCATIONAL OBJECTIVES

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their needs.

EDUCATIONAL GOALS

The educational goals of this activity are: to enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies and medical advances.

TARGET AUDIENCE

The audience for this program includes physicians, surgeons, scientists, nurses and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end stage heart or lung disease.

LEARNING OBJECTIVES

At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of:

1. Understanding organ donor selection and management, organ allocation, procurement, preservation and ex-vivo treatment, and their implications for organ viability and recipient outcomes.
2. Understanding the state-of-the-art treatment approaches to clinical left heart failure, right heart failure and lung failure, including criteria for and outcome implications of transplant versus non-transplant therapies as well as management of psychosocial problems and end of life situations.
3. Comparing and evaluating the advantages and disadvantages of various mechanical circulatory and respiratory support systems and their associated patient selection criteria.
4. Understanding the underlying pathophysiology of and state-of-the-art treatment for pulmonary hypertension.
5. Evaluating and treating infectious and treatment-related complications of VAD therapy and heart and lung transplantation.
6. Comparing and evaluating the advantages and disadvantages of various pharmacologic, non-pharmacologic and biologic immunosuppression techniques.
7. Evaluating and developing patient specific strategies for post-heart and lung transplant treatment that maximize patient outcomes and minimize immunosuppression-related side-effects.
8. Understanding methods to maximize patient outcomes by diagnosing, monitoring and treating immunologic complications of heart and lung transplantation, including antibody mediated rejection and chronic forms of allograft dysfunction.
9. Evaluating issues of controversy in the selection of candidates for heart and lung transplantation, such as age, prior transplantation and co-morbidities.
10. Describing and assessing the impact of psychosocial and behavioral issues on clinical post-transplant outcomes and quality of life for patients.
11. Identifying current animal and other laboratory models relevant to the basic science of transplant immunobiology and understanding their application to the transplant setting.
12. Understanding the importance and utilization of techniques to detect and quantify HLA and non HLA antibodies in the immunobiology of donor and recipient matching and subsequent post-transplant management.
13. Evaluating pediatric specific aspects of heart and lung failure and thoracic transplantation, including pharmacotherapy, developmental issues and unique psychosocial situations.
<table>
<thead>
<tr>
<th>TIME</th>
<th>FORUM HALL</th>
<th>MEETING HALL 1</th>
<th>PANORAMA HALL</th>
<th>MEETING HALL 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>CONCURRENT SESSION 36</td>
<td>CONCURRENT SESSION 37</td>
<td>CONCURRENT SESSION 38</td>
<td>CONCURRENT SESSION 39</td>
</tr>
<tr>
<td>8:15 AM</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>8:30 AM</td>
<td>PLENARY SESSION Information Technology Pre &amp; Post Tx Care</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15 AM</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>CONCURRENT SESSION 42 Featured Abstracts</td>
<td>CONCURRENT SESSION 43 BAD VADS</td>
<td>CONCURRENT SESSION 44 HTx Registry</td>
<td>CONCURRENT SESSION 45 Growing Up with a HTx</td>
</tr>
<tr>
<td>12:45 PM</td>
<td>COUNCIL REPORTS 12:45 pm – 2:15 pm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:15 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:30 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MEETING HALL 5</th>
<th>NORTH HALL</th>
<th>MEETING HALL 2</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>CONCURRENT SESSION 40</td>
<td>CONCURRENT SESSION 41</td>
<td></td>
<td>8:00 AM</td>
</tr>
<tr>
<td>Non-PAH PH</td>
<td>Back to Basics</td>
<td></td>
<td>8:15 AM</td>
</tr>
<tr>
<td></td>
<td>BREAK</td>
<td></td>
<td>8:30 AM</td>
</tr>
<tr>
<td></td>
<td>BREAK</td>
<td></td>
<td>9:00 AM</td>
</tr>
<tr>
<td></td>
<td>BREAK</td>
<td></td>
<td>11:15 AM</td>
</tr>
<tr>
<td></td>
<td>BREAK</td>
<td></td>
<td>11:30 AM</td>
</tr>
<tr>
<td>12:45 PM</td>
<td>ISHLT BOARD OF DIRECTORS MEETING 2:30 pm – 7:00 pm</td>
<td></td>
<td>12:45 PM</td>
</tr>
<tr>
<td>2:15 PM</td>
<td></td>
<td></td>
<td>2:15 PM</td>
</tr>
<tr>
<td>2:30 PM</td>
<td></td>
<td></td>
<td>2:30 PM</td>
</tr>
<tr>
<td>7:00 PM</td>
<td></td>
<td></td>
<td>7:00 PM</td>
</tr>
</tbody>
</table>
Thursday  ISHLT TRADITIONS:
Following tradition, Thursday’s plenary will include the annual Thoracic Organ Transplant and Mechanical Circulatory Support Registry Reports. Then we will be challenged as transplant professionals to aid in the efforts led by the World Health Organization to raise awareness of access, safety and ethical issues in cell, tissue and organ transplantation by Luc Noel MD of the World Health Organization. The plenary session will close with presentation of the Lifetime Achievement award to Sharon Hunt for her many roles in Heart Transplantation Medicine beginning with its birth at Stanford and continuing today as well as her ongoing contributions to the ISHLT.

Friday Morning  THE AGING IMPERATIVE: ETHICS, ECONOMICS AND RESOURCE ALLOCATION
The aging of our population impacts health care in multiple domains and is increasingly affecting delivery of care to patients with heart and lung failure. Mi-Kyung Song PhD, RN, University of North Carolina, will teach us about how to help aging patients make health care decisions and Axel Rahmel, Medical Director of Eurotransplant will provide a systems perspective. The session will also include presentations on aging and immunobiology, assessment of “frailty” in elderly patients and the ethics of allocation of scarce resources.

Friday Afternoon  NEW HORIZONS:
Prepare for a glimpse of future research in key areas of our society. Harald Ott, MD, Massachusetts General Hospital, will tantalize us with descriptions and images of bio-artificial organs. The session will continue with talks on the use of functional imaging to assess graft function, the future of stem cell research and the pursuit of tolerance and will close with a discussion of the importance of pulsatile flow in mechanical circulatory support by Mandeep Mehra, MD.

Saturday  INCORPORATING INFORMATION TECHNOLOGY INTO PRE AND POST-TRANSPLANT CARE:
Information technology in health care is expanding in multiple dimensions, including personal and system-based electronic health records, the use of social networking to improve patient communication and the use of information technology to provide more efficient and effective care. Cleveland Clinic Chief Information Officer C. Martin Harris MD will provide a broad overview of the impact IT is having on health care, followed by presentations on the use of technology in the care of heart failure patients, those receiving mechanical circulatory support and transplant recipients.

JOINTLY SPONSORED SESSIONS
Beginning with the pre-meeting symposia, joint symposia that bring together speakers and members from various disciplines will be spread throughout the program – a highlight will be two consecutive symposia: AMR Part 1: The ABCs of AMR: Antibodies, B Cells, and Complement and AMR Part 2: The DEFs of AMR: Detecting the Antibodies, Evaluating the Biopsy and Finally, the Patient. These two sessions will bring together pathologists, immunologists and experts in clinical heart and lung transplantation. Other symposia will feature experts in pulmonary hypertension, heart failure and mechanical circulatory support to shed light on the right ventricle.
Pediatricians will share the podium with their adult colleagues in several sessions, including Management of the Failing Fontan Patient Across the Age Spectrum, Congenital Heart Disease: Pulmonary Hypertension Dilemmas in Pediatric and Adult Patients and MCS in Congenital Heart Disease & Pediatrics.

DONOR MANAGEMENT, ORGAN PRESERVATION AND ALLOCATION

Highlights of sessions related to donor and organ management include an update on the use of ex-vivo techniques in Ex-Vivo Perfusion of Heart and Lungs – Why, With What and How?, a cutting edge session entitled: Thoracic Organ Donors: Optimal Management and New Avenues and finally a timely session co-sponsored by the infectious disease council – Risky Business: Infectious Risk in Donors and Recipients, featuring Camille Kotton, MD, FIDSA, Massachusetts General Hospital/Harvard Medical School, presenting on The ‘Well-Travelled’ Donor: What are the Risks? These sessions will provide attendees with important new information about managing donors and donor organs.

HEART FAILURE AND TRANSPLANTATION

As one of the core disciplines of ISHLT, Heart Failure and Transplant Medicine will be among the most prominent topics discussed in Prague. Clinical handling of advanced heart failure and heart transplant patients will remain the nucleus of the six dedicated concurrent symposia, two of which have been designed to foster interactivity between panel discussants and the audience. However, the invited speakers will additionally provide a broad perspective towards the basic mechanisms of the pathological processes to understand practical applicability of molecular biology techniques, clinical relevance of the novel immuno-biology processes involved in graft rejection and a multidisciplinary outlook of patient’s care, involving LVAD and pharmacological management of PH. The cutting edge of cellular and antibody-mediated acute rejection will be covered in three consecutive Satellite Symposia. The first, Past, Present and Future of Cardiac Allograft Surveillance will deal with the changing patterns and clinical manifestations of acute rejection, the role of endomyocardial biopsy monitoring in the modern era and the clinical reliability of novel non-invasive tools based on molecular biology techniques. The second and third symposia, focusing on AMR, will discuss novel targets for treatment and updates of the pathological classification. Thursday’s Satellite Symposium session, Tough Situations in Cardiac Transplantation, will offer the audience the possibility to interact with an expert panel chaired by Mandeep Mehra on two controversial clinical scenarios in the management of long-term heart transplant recipients. A novel perspective on CAV, moving beyond the mere concept of coronary intimal thickening, will be provided in the Satellite session, Large and Small Vessels Disease in Cardiac Transplantation, covering the concept of vascular remodeling, morphology and function of coronary microvasculature and therapeutic targets and tools. On Friday, the Satellite session The Leading Edge of Immunosuppression In Heart Transplantation: Evidence, Perspectives and Clinical Practice, will grant insights from clinical trials and clinical practice of modern immunosuppression. This rich international menu of concurrent symposia, seasoned by oral abstract sessions, is expected to fully feed transplant cardiologists hunger for cutting-edge education, within the heart of old Europe.

RESPIRATORY FAILURE AND LUNG TRANSPLANTATION

Another of the core disciplines at the foundation of our society, management of respiratory failure and pulmonary replacement therapy, will be prominent topics throughout the meeting. In addition to the pulmonary aspects of antibody mediated rejection to be included in the pre-meeting AMR sessions, the first pre-meeting symposium devoted to lung transplantation, Evolving Concepts Of Chronic Lung Allograft Dysfunction, will review new concepts of chronic lung allograft dysfunction and will reflect some of the conclusions and recommendations reached by the joint ISHLT/ATS/ERS task force on care of the lung transplant recipient. Advances In Pulmonary Transplant Surgery, another pre-meeting symposium, will include presentations on airway complications, mechanical bridging and ex-vivo lung perfusion.

Concurrent symposia on Thursday and Friday include the session, Special Considerations: Cystic Fibrosis and Lung Trans-
SESSION HIGHLIGHTS

plantation, which will review the complicated microbiology, surgical considerations and psychosocial issues associated with transplant of the CF patient. An international review of Lung Transplantation for Pulmonary Arterial Hypertension will focus on the impact that regional variability in listing status, organ allocation and the type of organ transplantation have on outcomes, and finally a session on Challenges in Pediatric Lung Transplant that will close with a presentation on transition of the pediatric lung transplant recipient to adult care.

INFECTIOUS DISEASES

Infectious Diseases will be significantly highlighted during a variety of symposia during the meeting. In CMV & Beyond we will highlight emerging viruses in thoracic transplantation as well as discuss developing issues with cytomegalovirus. Bad Bugs – What Can We Do? includes discussions of the impact of multi-drug resistant gram negative organisms, VRE and MRSA and Clostridium difficile, with a focus on prevention. Infectious diseases will also be woven into sessions sponsored by other councils, including talks on infections in Mechanical Circulatory Support and in transplant candidates with Cystic Fibrosis. Finally, we will have the opportunity to evaluate the Risky Business of Transplantation, focusing on candidates and donors with chronic hepatitis and history of international travel.

NURSING, HEALTH SCIENCE AND ALLIED HEALTH

The 2012 NHSAH program highlights include a presentation for the Incorporating Information Technology into Pre- and Post-Transplant Care plenary session titled, Using Technology to Promote Self-Monitoring and Health Outcomes after Transplantation. The NHSAH council also played a major role in developing the plenary Aging Demographic Imperative: Ethics, Economics & Resource Allocation and three key symposia.

Children and adolescents frequently face significant developmental challenges from the time of transplant through the time they transition to adult programs. Neurocognitive, Psychosocial and Behavioral Issues in Children and Adolescents is a pre-meeting symposium jointly facilitated by pediatric and nursing councils to address non-clinical issues (psychosocial, behavioral and neurocognitive) in children after thoracic transplantation.

Caregivers are a crucial component to successful outcomes for our patients, thus in the Focus on Caregivers – Investing in our Patients’ Future symposium, a panel of experts will outline unique approaches to address needs of caregivers so they can continue to provide optimal care to transplant recipients and MCS patients.

In recognizing that transplantation is a chronic condition, development of self-management strategies is a key component to improving long-term outcomes post thoracic transplantation. Presenters in the symposium Self Management in End-Stage Heart Lung Disease and Transplantation will describe important principles of ‘self-management,’ including management of the medical and pharmaceutical regimens, emotions and new life roles for both adult and pediatric patients.

MECHANICAL CIRCULATORY SUPPORT

The mechanical circulatory support field continues to grow, and so will its representation at the 32nd Annual Meeting and Scientific Sessions. A comprehensive MCS program will start on Tuesday with the ISHLT Academy dedicated to mechanical support.
SESSION HIGHLIGHTS

During pre-meeting symposia, didactic sessions will include Optimizing Outcomes in Patients with Right Heart Failure in Need of Mechanical Circulatory Support, providing an overview of different RV risk assessment approaches before LVAD implant. Cardiogenic Shock Before and After Heart Transplantation will review options, from ECMO to total artificial heart, that are available for patients in severe cardiogenic shock before and after heart transplantation. New Devices, New Approaches will explore new developments in LVADs and their clinical applications. Current approaches to MCS in children will be highlighted in MCS in Congenital Heart Disease & Pediatrics. The final pre-meeting symposium will be The Longer The Better – Chronic Medical Management of MCS focusing on how to optimize long-term MCS.

During the main meeting, the MCS Concurrent symposia on Thursday and Friday will include MCS: When Is It Too Soon or Too Late? providing the latest information on patient selection for device therapy at both ends of the heart failure spectrum – specifically when is a patient too sick to receive a VAD and how early in the HF disease trajectory can we consider VAD implant, and on Friday, MCS Recovery – How Do We Get There, intended to showcase our understanding of this process and possible approaches that could make myocordial recovery a treatment goal.

A number of abstract sessions, mini-orals and poster sessions with focus on MCS will provide ample opportunity for discussing new research as well as pondering old problems. Finally, topics with direct relevance to the MCS field will be addressed at a closing plenary session titled Incorporating Information Technology into Pre- and Post-Transplant Care.

PEDIATRICS

Forget the sight-seeing! Every day of the 2012 scientific meeting in Prague is packed with sessions of interest to the pediatric transplant specialist. This year’s symposia promote crosstalk between specialists of shared interests through collaborative sessions related to pulmonary hypertension in the session, Congenital Heart Disease: PH Dilemmas in Pediatric and Adult Patients, lung transplant challenges specific to the child and young adult in the session, Challenges in Pediatric Lung Transplant, pediatric mechanical circulatory support in everyday practice in the session, MCS in Congenital Heart Disease & Pediatrics as well as not-so-basic information needed for a basic understanding of transplant immunology in infants. You may discover some gems about managing the adolescent transplant patient’s cognitive, psychosocial and behavioral dilemmas in the Czech Republic that can be more broadly applied to other adolescents in your life – Neurocognitive, Psychosocial and Behavioral Issues in Children and Adolescents. And just when you need respite from the castle-
Hypertension Dilemmas in Pediatric and Adult Patients providing useful information on the management of patients with pulmonary hypertension associated with congenital systemic to pulmonary shunts, particularly those with unrepaired shunts.

Concurrent symposia on Thursday and Friday will open with a worldwide tour of Lung Transplantation for Pulmonary Arterial Hypertension – A Review and Panel Discussion, focusing on the impact that regional variability in listing status, organ allocation and the type of organ transplantation (lung versus heart-lung) have on outcomes. On Friday, Following the RV Through Thick and Thin will provide a thorough overview of the problem of RV dysfunction in patients with CHF due to LV diseases, with a pathophysiological overview of PH secondary to LV dysfunction and finally Pulmonary Hypertension in Chronic Parenchymal Lung Diseases: Does it Matter? will highlight increasing recognition of pulmonary hypertension as a serious complication of chronic obstructive and interstitial lung diseases.

PATHOLOGY

Again this year, pathologists will be front and center with two pre-meeting symposia focused on all aspects for antibody mediated rejection in clinical heart and lung transplantation – AMR Part 1: The ABCs of AMR: Antibodies, B Cells and Complement and AMR Part 2: The DEFs of AMR: Detecting the Antibodies, Evaluating the Biopsy and Finally, the Patient.

The pre-meeting symposia will open with Past, Present and Future of Cardiac Allograft Surveillance a session intended to review the usefulness and pitfalls of endomyocardial biopsy monitoring in current clinical practice, including practical information regarding the use of genomics and proteomics-based methodologies.

Concurrent symposia on Thursday and Friday will include Large and Small Vessels Disease in Heart Transplantation reviewing the importance of pathological features involving large epicardial and small intramyocardial vessels in cardiac allograft vasculopathy and a case-based discussion Solving the Enigmatic: Cases in Heart and Lung Transplantation.
BASIC SCIENCE
This year the Program Committee made an effort to complement important clinical symposia with presentations from members of the newly formed Basic Science and Translational Research council. This is particularly evident in the Past, Present and Future of Cardiac Allograft Surveillance and AMR Part 1: The ABCs of AMR: Antibodies, B Cells and Complement sessions.

Another pre-meeting symposium, Innate Immunity in Cardiothoracic Transplantation will provide information on emerging innovative modalities for studying innate immunity and the concurrent symposium Coagulation and Transplantation – The Clot Thickens will review the role platelets and complement may play in immune stimulation following thoracic transplantation.

Basic science and translational research will also be highlighted in plenary sessions on stem cells (Sonja Schrepfer) and tolerance (Sophie Brouard) as well as the joint ISHLT/ESOT symposium including presentations on T-regs (Carla Baan), clinical experience with belatacept and the relationship between ABO incompatibility and HLA antibodies.

Finally, the Caves Award competition session will continue to highlight original research by our young academic scientists, who present their most compelling experimental and clinical research to a jury of senior scientists and interested members.

PHARMACY AND PHARMACOLOGY
Members of the new Pharmacy and Pharmacology Council will be featured Thursday morning in the inaugural symposium in a series entitled A Lifecycle Journey in… sponsored by the ISHLT Pharmacy and Pharmacology Council. This series, focusing on therapeutic aspects that uniquely involve emerging or established knowledge in the pharmacology and pharmacy, envisions using an enduring case to create a panel facilitated and audience supported best practice based discussion at predefined key “journey intervals.”

In this session the focus will be on the lifecycle of Advanced Heart Failure and Cardiac Transplantation with special emphasis on the “journey points” of Mechanical Circulatory Support and anticoagulation, post-transplant development of Antibody Mediated Rejection and late complications that demand innovative immunosuppressive strategies.

JUNIOR FACULTY AND TRAINEES
Again this year, Junior Faculty and Trainees are encouraged to submit cases for the popular Clinical Case Dilemmas in Thoracic Transplantation session where tough cases are presented by junior faculty to expert discussants (these cases must be submitted via the standard abstract submission process, the deadline is November 18).

We are also planning to reprise the “Mentor Lunch,” on Thursday. In this setting, junior faculty and trainees can learn about Getting Your Next Job, Balancing Work and Family and other topics of special interest (pre-registration is required and limited).
Created in response to goals developed at the ISHLT 2006-2007 Strategic Planning Meeting, the **ishlt academy** draws on the wealth of experience and expertise within the society to deliver high quality educational experiences with the goal of enabling our members to improve and maintain the highest possible standards in the care of patients with advanced heart and lung disease and those undergoing heart or lung transplantation.

The **ishlt academy** represents the ‘brand name’ that will be associated with the educational opportunities offered by the ISHLT to its members and interested non-members.

The purpose of the **ishlt academy** is to develop an enduring resource of education in core competencies in the field of cardiopulmonary transplantation, mechanical and biological support of the failing heart, advanced lung disease (including pulmonary vascular disease) and cell replacement therapy. These educational endeavors will complement the ISHLT’s existing activities in the promulgation of new science, registry analyses, guideline statements and monograph series as a consolidated activity designed to train and educate young clinicians, trainees and those looking for a refresher course in clinical practice mandates in the field.
The opportunities provided by the ishlt academy will be multi-modality and multi-disciplinary and will be guided by the identified educational needs or ‘practice gaps’ of ISHLT members. When available, core curriculum and competency documents for different disciplines within the society will guide content of ishlt academy activities. The activities of the academy will run throughout the societies interface with its members with material provided in written format via articles in the Journal of Heart and Lung Transplantation, via the ISHLT Monograph series, and via educational meetings.

On Tuesday, April 17, 2012, a day prior to the 2012 Annual Meeting, we are conducting the third ishlt academy: Core Competencies in Mechanical Circulatory Support.

The ishlt academy: Core Competencies in Mechanical Circulatory Support will provide a concise review of clinical knowledge and essential professional skills to facilitate the surgical and medical management of patients with advanced heart failure who are being assessed for and who have received durable mechanical circulatory support. The course consists of focused presentations covering a broad array of topics for both inpatient and outpatient management with an emphasis on a practical approach to patient care, implementing best practices and clinical problem solving. All lectures will be delivered by internationally recognized experts in the field and include cardiologists, cardiac surgeons, critical care physicians and VAD coordinators.

Audience participation and interaction with the faculty will be actively encouraged throughout the Academy with Question and Answer sessions following each major topic and by limiting the enrollment to 200 participants.

The educational workforce of the Mechanical Circulatory Support Counsel of the ISHLT is confident this will be the most comprehensive and valuable summary for practitioners in the field of mechanical circulatory support.

Accreditation Statement
The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
ISHLT designates this live activity for a maximum of 9.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.
Learning Objective
At the conclusion of this meeting, participants will have improved competence and professional performance in their ability to:

1. Recognize the various types of mechanical circulatory support, their outcomes, and rates of adverse events.

2. Identify the clinical signs and risk factors of advanced heart failure in order to optimally time implantation.

3. Recognize the medical and social factors which impact patient outcomes on MCS.

4. Optimize implantation techniques and pump selection.

5. Manage patients after MCS in the intensive care unit, as an inpatient and as an outpatient.

6. Diagnose and manage common clinical dilemmas and adverse events in patients after MCS.

Educational Goals
The educational goals of this activity are to provide a concise review of clinical knowledge and essential professional skills to facilitate best practice of surgical and medical aspects involved in the care of patients during assessment as candidates and as recipients of mechanical circulatory support.

Target Audience
While all members are invited to enroll, this course is primarily designed to be of benefit for clinicians and allied professionals who are in the early stages of their careers or who are in training, are part of a new program or desire an update on the current state of the field.
9:00 AM – 9:15 AM
Risk Prediction Models – Review of Risk Prediction, What They Can and Can't Tell Us: MV02, SHRM, etc., Keith D. Aaronson, MD, University of Michigan, Ann Arbor, MI, USA

9:15 AM – 9:30 AM
Timing of Implantation – When is the Patient “Sick Enough” to Implant MCS; Andrew J. Boyle, MD, Aurora St. Luke’s Medical Center of Aurora Health Care Metro, Inc, Milwaukee, WI, USA

9:30 AM – 9:45 AM
Q & A

9:45 AM – 10:00 AM
BREAK

SECTION 3: Medical Considerations

10:00 AM – 10:15 AM
RV Assessment and Prediction – Brief Overview of Impact of RV Failure, Pre-Operative Assessment and Management of the RV, Risk Prediction; Case Examples, David S. Feldman, MD, PhD, FAHA, FACC, Minneapolis Heart Institute, Minneapolis, MN, USA

10:15 AM – 10:30 AM

10:30 AM – 10:45 AM
Infection: ISHLT Consensus – Overview of the ISHLT Consensus Guideline Definition of Infections, Margaret Hannan, MD, Mater Hospital, Dublin, Ireland

10:45 AM – 11:00 AM
Q & A

SECTION 4: Surgical Considerations

11:00 AM – 11:15 AM
Implantation 101 – Overview of the Most Crucial Surgical Considerations: Inflow Cannula/Pump Placement, Driveline, etc., Nader Moazami, MD, Minneapolis Heart Institute, Minneapolis, USA

11:15 AM – 11:30 AM
How Much Else is Too Much? – Concomitant Operative Procedures: TV, Aortic Valve, Prior Dor, Congenitals, Roland Hetzer, MD, PhD, Berlin Heart Institute, Germany

11:30 AM – 11:45 AM
Matching Pumps to Patients – Considerations for Device Type, Type of Flow Based Upon Patient Factors, Mark S. Slaughter, MD, University of Louisville, Louisville, KY, USA

11:45 AM – NOON
Q & A

NOON – 1:15 PM
LUNCH This time is meant to provide an opportunity for participants and speakers to interact.

SECTION 5: Pediatric Considerations

1:15 PM – 1:30 PM
Pediatric Perspective – On Current State of Technology, Patient/Device Selection, Medicals/Surgical Considerations, David L.S. Morales, MD, Texas Children’s Hospital, Houston, TX, USA

1:30 PM – 1:45 PM
Post-Op Pearls in the ICU – Managing the Patient in the Immediate Post-Operative Period, Angela Rajek, MD, University of Vienna, Austria

1:45 PM – 2:00 PM
Managing the RV – Post-Operative Approach to the RV: Surgical Considerations, Pump Speed, INO, Inotropes, etc., Martin Strueber, MD, Hannover Medical School, Hannover, Germany

2:00 PM – 2:15 PM
Anticoagulation – Overview of the Timing and Type of Anticoagulation, Means to Monitor State of Anticoagulation, Anticoagulation Management for Elective Procedures, Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, Canada

2:15 PM – 2:30 PM
Q & A
SECTION 7: Transition of Home

2:30 PM – 2:45 PM
Teaching/Patient Assessment – Outline of Approach to Teaching Patient and Their Family Community, Michael G. Petty, PhD, RN, CCNS, CNS, University of Minnesota Medical Center-Fairview, Minneapolis, MN, USA

2:45 PM – 3:00 PM
Keeping Patients at Home – Community Support, Restrictions, Role of Local Providers, Karl E. Nelson, RN, MBA, Integris Baptist Medical Center, Oklahoma City, OK, USA

3:00 PM – 3:15 PM
Quality of Life and Functionality Capacity – The Need For, Timing Of and Measures To Assess, Kathleen L. Grady, PhD, APN, Northwestern University, Chicago, IL

3:15 PM – 3:30 PM
Q & A

SECTION 8: Long-Term Management

3:45 PM – 4:00 PM
GI Bleeding – Review of Pathophysiology, Incidence and Diagnostic/Therapeutic Approach, Daniel J. Goldstein, MD, Montefiore-Einstein Medical Center, Bronx, NY

4:00 PM – 4:15 PM
Driveline Infections – Definition (ISHLT Consensus Statement), Prevention, Treatment, Evgenij Potapov, MD, PhD, Berlin Heart Institute, Berlin, Germany

4:15 PM – 4:30 PM
Outpatient Management – Clinic Structure, Typical Items Addressed, Focused Medical Management (BP, Rhythms, Etc), Rehab, Joseph G. Rogers, MD, Duke University Medical Center, Durham, NC, USA

4:30 PM – 4:45 PM
Role of Imaging – Echo: Basic Views, How to Assess Functionality, Set Speed, How Often, Case Presentation; CT: When it is Useful, What can Really be Assessed, Case Presentations, Shashank S. Desai, Inova Fairfax Hospital, Falls Church, VA, USA

SECTION 9: Trouble Shooting – Case Presentations

5:15 PM – 5:25 PM
RV Function, Michele Pilato, MD, ISMETT, Palermo, Italy

5:25 PM – 5:35 PM
Driveline, Chris Salerno, MD, St. Vincent Medical Center, Indianapolis, IN

5:35 PM – 5:45 PM
Hemolysis/Bleeding, Sean P. Pinney, MD, Mount Sinai Medical Center, New York, NY, USA

5:45 PM – 5:55 PM
Thrombus, George M. Wieselthaler, MD, University of California San Francisco, CA, USA

SECTION 10: Review

6:00 PM – 6:15 PM
ISHLT MCS Guidelines, Jeffrey J. Teuteberg, MD, University of Pittsburgh, Pittsburgh, PA, USA, Andreas Zuckermann, MD, University of Vienna, Austria, and David S. Feldman, MD, PhD, FAHA, FACC, Minneapolis Heart Institute, Minneapolis, MN, USA

6:15 PM – 6:45 PM
RECEPTION
The President’s Cocktail Reception will be held Friday evening at the Prague Municipal House, which is often referred to as “the Art-Nouveau Jewel of Prague.” One ticket to this event is included with all scientific session registration fees. Additional tickets may be purchased. As always, you can expect plenty of food, drink, music and friends.
TUESDAY, APRIL 17, 2012

7:30 AM – 6:45 PM
ISHLT ACADEMY: CORE COMPETENCIES IN MECHANICAL CIRCULATORY SUPPORT
(MEETING HALL 1)

8:00 AM – 2:00 PM
ISHLT BOARD OF DIRECTORS MEETING
(MEETING HALL 2)

9:00 AM – NOON
CARDIAC AMR WORKSHOP
(CLUB B)

1:00 PM – 5:00 PM
PULMONARY AMR WORKSHOP
(CLUB B)

2:00 PM – 4:00 PM
ISHLT COMMITTEE ON INTERNATIONAL and INTER-SOCIETY POLICY MEETING
(MEETING HALL 2)

IMACS STEERING COMMITTEE MEETING
(CLUB C)

THORACIC TRANSPLANT REGISTRY STEERING COMMITTEE MEETING
(CLUB D)

3:00 PM – 6:00 PM
REGISTRATION DESK OPEN
(CONGRESS HALL FOYER)

4:00 PM – 6:00 PM
EDUCATION COMMITTEE MEETING
(CLUB C)

REGISTRIES & DATABASES COMMITTEE MEETING
(CLUB D)

STANDARDS AND GUIDELINES COMMITTEE MEETING
(MEETING HALL 2)

6:00 PM – 7:00 PM
DCD REGISTRY STEERING COMMITTEE MEETING
(CLUB D)

6:30 AM – 6:30 PM
SPEAKER READY ROOM OPEN
(CLUB H)
WEDNESDAY, APRIL 18, 2012

7:00 AM – 6:00 PM
SPEAKER READY ROOM OPEN
(CLUB H)

7:00 AM – 7:00 PM
REGISTRATION DESK OPEN
(CONGRESS HALL FOYER)

8:00 AM – 4:30 PM
EXHIBIT BOOTH SET-UP
(CONGRESS HALL FOYER)

8:00 AM – 1:00 PM
POSTER HALL SET-UP
(CONGRESS HALL FOYER)

8:00 AM – 9:30 AM
PRE-MEETING SYMPOSIUM 1:
Optimizing Outcomes in Patients with Right Heart Failure in Need of Mechanical Circulatory Support
(FORUM HALL)

PRE-MEETING SYMPOSIUM 2:
Past, Present and Future of Cardiac Allograft Surveillance
(MEETING HALL 1)

PRE-MEETING SYMPOSIUM 3:
Evolving Concepts of Chronic Lung Allograft Dysfunction
(PANORAMA HALL)

PRE-MEETING SYMPOSIUM 4:
Cardiogenic Shock Before and After Heart Transplantation
(MEETING HALL 4)

PRE-MEETING SYMPOSIUM 5:
Neurocognitive, Psychosocial and Behavioral Issues in Children
(MEETING HALL 5)

PRE-MEETING SYMPOSIUM 6:
Potpourri of Special Topics in Pulmonary Hypertension
(This session is supported by an educational grant from Gilead.)
(NORTH HALL)

9:00 AM – 7:00 PM
PRESS OFFICE OPEN
(MEETING ROOM 2.4)

9:30 AM – 9:45 AM
COFFEE BREAK
(CONGRESS HALL FOYER)

9:45 AM – 11:15 AM
PRE-MEETING SYMPOSIUM 7:
New Devices, New Approaches
(FORUM HALL)

PRE-MEETING SYMPOSIUM 8:
The ABCs of AMR: Antibodies, B Cells and Complement/Coagulation
(MEETING HALL 1)

PRE-MEETING SYMPOSIUM 9:
Ex Vivo Perfusion of Heart and Lungs – Why, with What and How?
(PANORAMA HALL)

PRE-MEETING SYMPOSIUM 10:
The Right Ventricle and Pulmonary Vascular Load in Health and Disease
(MEETING HALL 4)

PRE-MEETING SYMPOSIUM 11:
MCS in Congenital Heart Disease & Pediatrics
(MEETING HALL 5)

PRE-MEETING SYMPOSIUM 12:
CMV and Beyond: Important Viruses in Thoracic Transplantation
(NORTH HALL)

11:15 AM – 11:30 AM
COFFEE BREAK
(CONGRESS HALL FOYER)

11:30 AM – 1:00 PM
PRE-MEETING SYMPOSIUM 13:
The Longer the Better – Chronic Medical Management of MCS
(FORUM HALL)

PRE-MEETING SYMPOSIUM 14:
The DEFs of AMR: Detecting the Antibodies, Evaluating the Biopsy, and Finally, the Patient
(MEETING HALL 1)
PRE-MEETING SYMPOSIUM 15:  
Advances in Pulmonary Transplant Surgery  
(PANORAMA HALL)

PRE-MEETING SYMPOSIUM 16:  
Thoracic Organ Donors: Optimal Management and New Avenues  
(MEETING HALL 4)

PRE-MEETING SYMPOSIUM 17:  
Innate Immunity in Cardiothoracic Transplantation  
(MEETING HALL 5)

PRE-MEETING SYMPOSIUM 18:  
Congenital Heart Disease: Pulmonary Hypertension Dilemmas in Pediatric and Adult Patients  
(NORTH HALL)

1:00 PM - 1:30 PM  
BOX LUNCH PICK-UP  
(BUFFET, 1ST FLOOR)

1:00 PM - 3:00 PM  
LUNCH BREAK

1:00 PM - 3:00 PM  
MECHANICAL CIRCULATORY SUPPORT COUNCIL MEETING  
(PANORAMA HALL)

NURSING, HEALTH SCIENCES and ALLIED HEALTH COUNCIL MEETING  
(MEETING HALL 5)

PULMONARY HYPERTENSION COUNCIL MEETING  
(CLUB B)

PEDIATRIC TRANSPLANT COUNCIL MEETING  
(CLUB C)

PATHOLOGY COUNCIL MEETING  
(CLUB D)

1:00 PM - 4:45 PM  
POSTER MOUNTING  
(CONGRESS HALL FOYER)

3:00 PM - 4:15 PM  
CONCURRENT SESSION 1:  
How VADs Impact Our Community  
(FORUM HALL)

CONCURRENT SESSION 2:  
Decision Making in Advanced Heart Failure: Bridge, Recover, Transplant  
(MEETING HALL 1)

CONCURRENT SESSION 3:  
What Do Animal Models Teach Us About BOS?  
(PANORAMA HALL)

CONCURRENT SESSION 4:  
The Right Donor at the Right Time: Juggling the Risk  
(MEETING HALL 4)

CONCURRENT SESSION 5:  
Optimizing the LVAD Experience  
(MEETING HALL 5)

CONCURRENT SESSION 6:  
An Ounce of Prevention and Managing Infection  
(NORTH HALL)

4:15 PM - 4:45 PM  
COFFEE BREAK/VISIT EXHIBITS/VIEW POSTERS  
(CONGRESS HALL FOYER)

4:45 PM - 7:00 PM  
EXHIBIT HALL OPEN and POSTER VIEWING  
(CONGRESS HALL FOYER)

4:45 PM - 6:00 PM  
OPENING PLENARY SESSION:  
Overcoming Political Barriers  
(CONGRESS HALL)

6:00 PM - 7:00 PM  
PULMONARY TRANSPLANT COUNCIL QOL WORKFORCE MEETING  
(CLUB D)

6:00 PM - 7:00 PM  
EXHIBIT HALL OPEN and POSTER VIEWING OPENING RECEPTION  
(CONGRESS HALL FOYER)
THURSDAY, APRIL 19, 2012

7:00 AM – 7:00 PM
SPEAKER READY ROOM OPEN
(CLUB H)

7:00 AM – 7:00 PM
REGISTRATION DESK OPEN
(CONGRESS HALL FOYER)

8:00 AM – 7:00 PM
PRESS OFFICE OPEN
(MEETING ROOM 2.4)

8:00 AM – 7:00 PM
POSTER VIEWING
(CONGRESS HALL FOYER)

8:00 AM – 9:15 AM
CONCURRENT SYMPOSIUM 1:
A Lifecycle Journey in Advanced Heart Failure
and Transplantation
(MEETING HALL 4)

CONCURRENT SESSION 7:
The Dark Side of VADs
(CONGRESS HALL)

CONCURRENT SESSION 8:
Heart Transplantation: Trends in Complications
and Risk Factors
(FOREUM HALL)

CONCURRENT SESSION 9:
Lessons from Lung Transplant Database Analysis
(MEETING HALL 1)

CONCURRENT SESSION 10:
Pulmonary Hypertension: Advances in Diagnosis
and Therapy
(FOREUM HALL)

CONCURRENT SESSION 11:
Tolerance: To the Bench and Back
(MEETING HALL 5)

CONCURRENT SESSION 12:
Bad Bugs: Donors, Recipients and the Consequences
(NORTH HALL)

9:00 AM – 7:00 PM
EXHIBIT HALL OPEN
(CONGRESS HALL FOYER)

9:15 AM – 9:45 AM
COFFEE BREAK/VISIT EXHIBITS/VIEW POSTERS
(CONGRESS HALL FOYER)

9:45 AM – 11:30 AM
PLENARY SESSION:
ISHHLT Traditions
(CONGRESS HALL)

11:30 AM – NOON
COFFEE BREAK/VISIT EXHIBITS/VIEW POSTERS
(CONGRESS HALL FOYER)

NOON – 1:15 PM
CONCURRENT SYMPOSIUM 2:
Focus on Caregivers: Investing in Our
Patients’ Future
(MEETING HALL 5)

CONCURRENT SESSION 13:
MCS: Balancing on the Razor’s Edge
(CONGRESS HALL)

CONCURRENT SESSION 14:
What’s New in Immune Surveillance in Heart
Transplantation
(FOREUM HALL)

CONCURRENT SESSION 15:
Clinical Aspects of Lung Transplantation
(MEETING HALL 1)

CONCURRENT SESSION 16:
Bringing Hearts Alive and Kicking
(FOREUM HALL)

CONCURRENT SESSION 17:
B-Cells, Antibodies and Graft Injury
(MEETING HALL 4)

CONCURRENT SESSION 18:
AMR in Thoracic Transplantation:
Are We Making Progress?
(NORTH HALL)

1:15 PM – 1:45 PM
BOX LUNCH PICK-UP
(BUFFET, 1ST FLOOR)

1:15 PM – 3:15 PM
LUNCH BREAK
1:15 PM – 3:15 PM
JUNIOR FACULTY MENTOR LUNCH
(CLUB A)

PULMONARY TRANSPLANTATION COUNCIL MEETING
(NORTH HALL)

HEART FAILURE AND TRANSPLANT MEDICINE COUNCIL MEETING
(CLUB B)

PHARMACY AND PHARMACOLOGY COUNCIL MEETING
(CLUB C)

INFECTIOUS DISEASES COUNCIL MEETING
(CLUB D)

1:30 PM – 3:00 PM
MINI ORAL SESSION 1:
Mechanical Circulatory Support
(MEETING HALL 1)

MINI ORAL SESSION 2:
Heart and Pediatric Transplantation
(MEETING HALL 4)

MINI ORAL SESSION 3:
Pulmonary Hypertension and Lung Transplantation
(MEETING HALL 5)

3:15 PM – 4:30 PM
CONCURRENT SYMPOSIUM 3:
Mechanical Circulatory Support: When is it Too Soon or Too Late?
(FORUM HALL)

CONCURRENT SYMPOSIUM 4:
Large and Small Vessels Disease in Heart Transplantation
( FORUM HALL)

CONCURRENT SYMPOSIUM 5:
Tough Situations in Cardiac Transplantation: Bring in the Experts
(MEETING HALL 1)

CONCURRENT SYMPOSIUM 6:
Lung Transplantation for Pulmonary Arterial Hypertension – A Review and Panel Discussion
(PANORAMA HALL)

CONCURRENT SYMPOSIUM 7:
Special Considerations: Cystic Fibrosis and Lung Transplantation
(MEETING HALL 4)

CONCURRENT SYMPOSIUM 8:
Risky Business: Infectious Risk in Donors and Recipients
(MEETING HALL 5)

CONCURRENT SYMPOSIUM 9:
Coagulation and Transplantation – The Clot Thickens
(NORTH HALL)

4:30 PM – 5:00 PM
COFFEE BREAK/VISIT EXHIBITS/POSTER VIEWING
(CONGRESS HALL FOYER)

5:00 PM – 6:15 PM
CONCURRENT SYMPOSIUM 10:
Joint ISHLT/IPTA Symposium
(NORTH HALL)

CONCURRENT SESSION 19:
MCS: Desired Outcomes – Can We Get There
(CONGRESS HALL)

CONCURRENT SESSION 20:
Advanced Heart Failure: When is a Contraindication Not a Contraindication to Transplant
(FORUM HALL)

CONCURRENT SESSION 21:
Therapeutics of Lung Transplantation
(MEETING HALL 1)

CONCURRENT SESSION 22:
Pulmonary Hypertension: Assessment and Prognosis
(PANORAMA HALL)

CONCURRENT SESSION 23:
Clinical Case Dilemmas in Thoracic Transplantation
(MEETING HALL 4)

CONCURRENT SESSION 24:
Heart Failure: Back to Basics
(MEETING HALL 5)

6:15 PM – 7:00 PM
PAST PRESIDENT’S COUNCIL MEETING and RECEPTION
(CLUB B)

6:15 PM – 7:00 PM
EXHIBIT HALL RECEPTION AND POSTER VIEWING
(CONGRESS HALL FOYER)
FRIDAY, APRIL 20, 2012

7:00 AM – 6:00 PM
REGISTRATION DESK OPEN
(CONGRESS HALL FOYER)

7:00 AM – 6:30 PM
SPEAKER READY ROOM OPEN
(CLUB H)

8:00 AM – 5:00 PM
POSTER VIEWING
(CONGRESS HALL FOYER)

8:00 AM – 7:00 PM
PRESS OFFICE OPEN
(MEETING ROOM 2.4)

8:00 AM – 9:15 AM
CONCURRENT SYMPOSIUM 11:
Management of the Failing Fontan Patient
 Across the Age Spectrum?
(MEETING HALL 4)

CONCURRENT SESSION 25:
VAD Future: Recovery and New Devices?
(CONGRESS HALL)

CONCURRENT SESSION 26:
Heart Transplant Immunosuppression:
What Can We Learn from Clinical Trials
(FORUM HALL)

CONCURRENT SESSION 27:
Basic Science of Lung Transplantation
(MEETING HALL 1)

CONCURRENT SESSION 28:
Right Ventricle Function
(PANORAMA HALL)

CONCURRENT SESSION 29:
Role of Physical Activity in the Pre and
Post-Transplant Setting
(MEETING HALL 5)

CONCURRENT SESSION 30:
Innate Immunity and Ischemia Reperfusion Injury
(NORTH HALL)

9:00 AM – 5:00 PM
EXHIBIT HALL OPEN
(CONGRESS HALL FOYER)

9:15 AM – 9:45 AM
ANNUAL BUSINESS MEETING
(CONGRESS HALL)

9:15 AM – 9:45 AM
COFFEE BREAK/ VISIT EXHIBITS/ POSTER VIEWING
(CONGRESS HALL FOYER)

9:45 AM – 11:15 AM
PLENARY SESSION:
The Aging Imperative: Ethics, Economics
 and Resource Allocation
(CONGRESS HALL)

11:15 AM – 11:45 AM
COFFEE BREAK/ VISIT EXHIBITS/ VIEW POSTERS
(CONGRESS HALL FOYER)

11:45 AM – 1:00 PM
CONCURRENT SYMPOSIUM 12:
MCS Recovery – How Do We Get There
(CONGRESS HALL)

CONCURRENT SYMPOSIUM 13:
The Leading Edge of Immunosuppression in
Heart Transplantation: Evidence, Perspectives
 and Clinical Practice
(FORUM HALL)

CONCURRENT SYMPOSIUM 14:
Following the RV Through Thick and Thin
(MEETING HALL 1)

CONCURRENT SYMPOSIUM 15:
Solving the Enigmatic: Cases in Heart and
Lung Transplantation
(PANORAMA HALL)

CONCURRENT SYMPOSIUM 16:
Bad Bugs – What Can We Do?
(MEETING HALL 4)

CONCURRENT SYMPOSIUM 17:
Pulmonary Hypertension in Chronic Parenchymal
Lung Diseases: Does it Matter?
(MEETING HALL 5)

CONCURRENT SYMPOSIUM 18:
Challenges in Pediatric Lung Transplant
(NORTH HALL)
1:00 PM – 1:30 PM
BOX LUNCH PICK-UP
(BUFFET, 1ST FLOOR)

1:00 PM – 3:00 PM
LUNCH BREAK

1:00 PM – 3:00 PM
JHLT EDITORIAL BOARD MEETING
AND LUNCH
(CLUB B)

BASIC SCIENCE AND TRANSLATIONAL
RESEARCH COUNCIL MEETING
(CLUB C)

JUNIOR FACULTY AND TRAINEE
COUNCIL MEETING
(CLUB D)

COUNCIL CHAIRS LUNCH MEETING
(MEETING HALL 2)

1:15 PM – 2:15 PM
CONCURRENT SYMPOSIUM 19:
Joint ISHLT/ESOT Symposium
(MEETING HALL 1)

1:15 PM – 2:45 PM
MINI ORAL SESSION 4:
Mechanical Circulatory Support II
(PANORAMA HALL)

MINI ORAL SESSION 5:
Heart Transplantation
(MEETING HALL 4)

MINI ORAL SESSION 6:
Lung Transplantation, Infectious Diseases
and Donor Management
(MEETING HALL 5)

MINI ORAL SESSION 7:
Basic Science and Immunobiology, Heart
Transplantation and Infectious Diseases
(NORTH HALL)

3:00 PM – 4:30 PM
PLENARY SESSION:
New Horizons
(FORUM HALL)

4:30 PM – 5:00 PM
COFFEE BREAK/VISIT EXHIBITS/VIEW POSTERS
(CONGRESS HALL FOYER)

4:30 PM – 5:00 PM
2013 SCIENTIFIC PROGRAM COMMITTEE MEETING
(CLUB B)

5:00 PM – 11:59 PM
EXHIBIT HALL TEAR DOWN
(CONGRESS HALL FOYER)

5:00 PM – 11:59 PM
POSTER HALL TEAR DOWN
(CONGRESS HALL FOYER)

5:00 PM – 6:15 PM
CONCURRENT SYMPOSIUM 20:
Self Management in End Stage Heart and Lung
Disease and Transplantation
(MEETING HALL 5)

CONCURRENT SESSION 31:
Right Ventricle – Staying Alive
(FORUM HALL)

CONCURRENT SESSION 32:
End Stage Congenital Heart Disease:
Opportunities and Challenges
(MEETING HALL 1)

CONCURRENT SESSION 33:
Stealing Beauty after Lung Transplantation
(PANORAMA HALL)

CONCURRENT SESSION 34:
Fishing Lungs from the Donor Pool
(MEETING HALL 4)

CONCURRENT SESSION 35:
Philip K. Caves Award Candidate Presentations
(NORTH HALL)

7:30 PM – 8:30 PM
PRESIDENT’S COCKTAIL RECEPTION
PRAGUE MUNICIPAL HOUSE
SATURDAY, APRIL 21, 2012

7:00 AM – 11:30 AM
REGISTRATION DESK OPEN
(Congress Hall Foyer)

7:00 AM – 1:00 PM
Speaker Ready Room Open
(Club H)

8:00 AM – 9:15 AM
CONCURRENT SESSION 36:
Pediatric Mechanical Circulatory Support
(Forum Hall)

CONCURRENT SESSION 37:
Heart Transplantation: Outcomes with Patients with CAV and/or Alloantibody
(Meeting Hall 1)

CONCURRENT SESSION 38:
‘Hitting the Right Spot’ – New Targets in Immunosuppression
(Meeting Hall 4)

CONCURRENT SESSION 39:
Secondary (Non-PAH) Pulmonary Hypertension
(Meeting Hall 5)

CONCURRENT SESSION 40:
Getting Back To Basics
(North Hall)

9:15 AM – 9:30 AM
Coffee Break
(Congress Hall Foyer)

9:30 AM – 11:15 AM
Plenary Session:
Incorporating Information Technology into Pre and Post-Transplant Care
(Forum Hall)

11:15 AM – 11:30 AM
Coffee Break
(Congress Hall Foyer)

11:30 AM – 12:45 PM
CONCURRENT SESSION 42:
Featured Abstracts
(Forum Hall)

CONCURRENT SESSION 43:
Bad VADs
(Meeting Hall 1)

CONCURRENT SESSION 44:
Heart Transplantation: What Can We Learn from Registry Data
(Panorama Hall)

CONCURRENT SESSION 45:
Growing Up with a Heart Transplant: Adolescence, Antibodies and Pharmacogenetics
(Meeting Hall 4)

CONCURRENT SESSION 46:
Mechanisms of Acute Injury and Organ Preservation
(Meeting Hall 5)

CONCURRENT SESSION 47:
Evolving Infections in a New Era
(North Hall)

12:45 PM – 1:15 PM
Box Lunch Pick-Up
(Buffet – 1st Floor)

12:45 PM – 2:15 PM
Council and Committee Reports to the Board and Membership
(Meeting Hall 4)

2:30 PM – 7:00 PM
ISHLT Board of Directors Meeting
(Meeting Hall 2)
# Scientific Program

32nd Annual Meeting & Scientific Sessions
April 18-21, 2012

All meetings and activities will take place at the Prague Congress Centre unless otherwise specified. All papers will be presented in English.

### Tuesday, April 17, 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 AM</td>
<td>ISHLT Academy: Core Competencies in Mechanical Circulatory Support</td>
<td>Meeting Hall 1</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>ISHLT Board of Directors Meeting</td>
<td>Meeting Hall 2</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>Cardiac AMR Workshop</td>
<td>Club B</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Pulmonary AMR Workshop</td>
<td>Club B</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>ISHLT Committee on International and Inter-Society Policy Meeting</td>
<td>Meeting Hall 2</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>IMACS Steering Committee Meeting</td>
<td>Club C</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Thoracic Transplant Registry Steering Committee Meeting</td>
<td>Club D</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Registration Desk Open</td>
<td>Congress Hall Foyer</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Education Committee Meeting</td>
<td>Club C</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>Registries &amp; Databases Committee Meeting</td>
<td>Club D</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>Standards and Guidelines Committee Meeting</td>
<td>Meeting Hall 2</td>
</tr>
<tr>
<td>6:30 PM</td>
<td>DCD Registry Steering Committee Meeting</td>
<td>Club D</td>
</tr>
<tr>
<td>6:30 AM</td>
<td>Speaker Ready Room Open</td>
<td>Club H</td>
</tr>
</tbody>
</table>

All meetings and activities will take place at the Prague Congress Centre unless otherwise specified. All papers will be presented in English.
WEDNESDAY, APRIL 18, 2012

7:00 AM – 6:00 PM
SPEAKER READY ROOM OPEN
(CLUB H)

7:00 AM – 7:00 PM
REGISTRATION DESK OPEN
(CONGRESS HALL FOYER)

8:00 AM – 4:30 PM
EXHIBIT BOOTH SET-UP
(CONGRESS HALL FOYER)

8:00 AM – 1:00 PM
POSTER HALL SET-UP
(CONGRESS HALL FOYER)

8:00 AM – 9:30 AM

PRE-MEETING SYMPOSIUM 1  (FORUM HALL)
Optimizing Outcomes in Patients with Right Heart Failure in Need of Mechanical Circulatory Support

CHAIRS: David S. Feldman, MD, PhD, FAHA, FACC and Ugolino Livi, MD, FECTS

8:00 AM Predicting Right Heart Failure after LVAD Implant, Stephan Schueler, MD, PhD, FRCS, Newcastle Upon Tyne Hospitals Trust, United Kingdom

8:15 AM RV Dysfunction in MCS: What is the Transcript Signature of RV/LV in Mechanically Assisted Patients, J. Eduardo Rame, MD, MPhil, University of Pennsylvania, Philadelphia, PA

8:30 AM Three Perspectives: Patient with a Failing RV

8:30 AM Triage with Medicines, Michael M. Givertz, MD, Brigham & Women's Hospital, Boston, MA

8:40 AM Triage with BiVADs, Thomas Krabatsch, MD, PhD, Deutsches Herzzentrum Berlin, Germany

8:50 AM TAH Is It, Vigneshwar Kasirajan, MD, Virginia Commonwealth University Medical Center, Richmond, VA

9:00 AM Right Heart Failure Late after LVAD Implant, Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, Ontario, Canada

9:15 AM Panel Discussion

8:00 AM – 9:30 AM

PRE-MEETING SYMPOSIUM 2  (MEETING HALL 1)
Past, Present and Future of Cardiac Allograft Surveillance

CHAIRS: Maria Frigerio, MD and Keyur B. Shah, MD

8:00 AM The Changing Epidemiology of Acute Rejection, David O. Taylor, MD, Cleveland Clinic Foundation, Cleveland, OH

8:20 AM The Genomics of Rejection, Randall C. Starling, MD, MPH, Cleveland Clinic Foundation, Cleveland, OH

8:40 AM The Proteomics of Rejection, Bruce McManus, MD, PhD, RCS, FCAHS, James Hogg Research Centre, Vancouver, Canada

9:00 AM Integrating Invasive and Non-Invasive Tools: A Clinician’s Perspective, Sharon A. Hunt, MD, Stanford University Medical Center, Palo Alto, CA

9:20 AM Questions and Answers

8:00 AM – 9:30 AM

PRE-MEETING SYMPOSIUM 3  (PANORAMA HALL)
Evolving Concepts of Chronic Lung Allograft Dysfunction

CHAIRS: Keith C. Meyer, MD, MS and Paul A. Corris, MB, FRCP

8:00 AM BOS: Definitions and Emerging Phenotypes, Geert Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

8:25 AM Emerging Pathways in BOS: Autoimmunity, David S. Wilkes, MD, Indiana University School of Medicine, Indianapolis, IN

8:45 AM Emerging Pathways in BOS: Epithelial – Mesenchymal Transition, Daniel C. Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, Australia

9:05 AM Future Therapies for BOS, Andrew J. Fisher, PhD, FRCP, Institute of Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

8:00 AM – 9:30 AM

PRE-MEETING SYMPOSIUM 4  (MEETING HALL 4)
Cardiogenic Shock Before and After Heart Transplantation

CHAIRS: Nader Moazami, MD and Nicholas G. Smedira, MD

8:00 AM Cardiogenic Shock – How Long Should Be the ECMO Bridge?, Aly El Banayosy, MD, Penn State Hershey Medical Center, Hershey, PA

8:12 AM What is the Direction of the Bridge in Cardiogenic Shock?, Pascal Leprince, MD, PhD, Hospital Pitie-Salpetriere, Paris, France
### PRE-MEETING SYMPOSIUM 5: Neurocognitive, Psychosocial and Behavioral Issues in Children

**CHAIRS:** Kathleen L. Grady, PhD, APN and Susan M. Chernenko, RN, MN, NP

**8:00 AM** Neurocognition: What happens after Thoracic Transplantation in Children and Adolescents? Richard E. Chinneck, MD, Loma Linda University Children’s Hospital, Loma Linda, CA

**8:12 AM** Helping Children Make Psychosocial and Educational Adjustments after Transplantation, Connie Williams-Williams, RN, PhD, FAAN, University of Alabama at Birmingham, AL

**8:24 AM** Adolescence and Adherence: “The Perfect Storm,” Sabina De Geest, RN, PhD, University of Basel, Switzerland

**8:36 AM** Parenting Children with Thoracic Transplantation: Stress, Coping and Letting Go, Diana A. Sheller, PhD, Children’s Hospital of Pittsburgh of UPMC and University of Pittsburgh, PA

**8:48 AM** No Longer a Child – Not Quite an Adult: How to Help the Adolescent Recipient Transition to Adulthood, Efriehed Pahl, MD, Children’s Memorial Hospital, Chicago, IL

**9:00 AM** Quality Of Life In Pediatric Thoracic Transplantation: Trading One Illness For Another, Jo Wray, PhD, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom

**9:12 AM** Panel Discussion

### PRE-MEETING SYMPOSIUM 6: Potpourri of Special Topics in Pulmonary Hypertension

*(This session is supported by an educational grant from Gilead.)*

**CHAIRS:** Raymond L. Benza, MD and Fernando Torres, MD

**8:00 AM** Extracorporeal Mechanical Support and the Community Hospitals: How to Make it Work, Christoph Schmid, MD, University Medical Center Regensburg, Germany

**8:36 AM** What is the Best Surgical Option in the Setting of Primary Graft Failure?, Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

**8:48 AM** Surgical Technique of ECMO Placement – Balance between Invasiveness and Effectiveness, Amt E. Fiane, MD, Rikshospitalet, Oslo, Norway

**9:00 AM** TAH – Standard Solution in Shock?, Michiel Morshuis, MD, Heart Center NRW, Bad Oeynhausen, Germany

**9:12 AM** Panel Discussion

### PRE-MEETING SYMPOSIUM 7: New Devices, New Approaches

**CHAIRS:** Matthias Loebe, PhD and Martin Strueber, MD

**9:45 AM** Axial vs. Centrifugal Pumps, Francis D. Pagani, MD, PhD, University of Michigan, Ann Arbor, MI

**9:57 AM** LVAD: Partial vs. Full Flow Support?, Bartley P. Griffith, MD, University of Maryland School of Medicine, Baltimore, MD

**10:09 AM** VAD Therapy in Heart Failure with Preserved Systolic Function, Soon J. Park, MD, Mayo Clinic, Rochester, MN

**10:21 AM** Machine or Biology? The Future for a Patient with a Failing Heart is with Machines, James K. Kirklin, MD, University of Alabama at Birmingham, AL

**10:33 AM** Machine or Biology? The Future for a Patient with a Failing Heart is with Stem Cells, Andor Terzic, MD, PhD, Mayo Clinic, Rochester, MN

**10:45 AM** Machine or Biology? The Future for a Patient with a Failing Heart is with Xenotransplantation, Christopher G. A. McGregor, MB, FRCS, MD(Hons), Mayo Clinic and University College London, Rochester, MN, USA and London, United Kingdom

**10:57 AM** Panel Discussion
**PRE-MEETING SYMPOSIUM 8**  (MEETING HALL 1)
The ABCs of AMR: Antibodies, B Cells and Complement/Coagulation

**CHAIRS:** Gerald J. Berry, MD and Thalachallour Mohanakumar, PhD

9:45 AM *Clinical Context Case Presentations*
9:45 AM Luciano Potena, MD, PhD, University of Bologna, Italy
9:50 AM Todd L. Astor, MD, Massachusetts General Hospital, Boston, MA
9:55 AM B Cells / Plasma Cells, Esme Dijke, PhD, University of Alberta, Edmonton, Canada
10:15 AM Complement and Coagulation, Steven Sacks, MD, PhD, MRC Centre for Transplantation, King’s College London, United Kingdom
10:35 AM A Rational Approach To Treatment Strategies, Richard Kirk, MA FRCP FRCPCH, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
11:05 AM Discussion

**PRE-MEETING SYMPOSIUM 9**  (PANORAMA HALL)
Ex Vivo Perfusion of Heart and Lungs – Why, with What and How?

**CHAIRS:** Dirk Van Raemdonck, MD, PhD and Steven S.L. Tsui, MD, FRCS

9:45 AM *Part I: Kidney – Ex Vivo Machine Perfusion of Kidneys*, Rutger J. Ploeg, MD, PhD, FRCS, University of Oxford, United Kingdom
10:00 AM *Part II: Heart – Ex Vivo Perfusion of Hearts with the Transmedics Device – European Experience*, Christoph Knosalla, MD, PhD, MHBA, German Heart Institute, Berlin, Germany
10:15 AM *Ex Vivo Perfusion of Hearts with the Transmedics Device – U.S. Experience*, Abbas Ardehali, MD, David Geffen School of Medicine, University of California Los Angeles School of Medicine, Los Angeles, CA
10:30 AM *Part III: Lung – Clinical Experience with Warm Asanguinous Ex-Vivo Lung Perfusion in Toronto*, Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, Canada
10:45 AM *Clinical Experience with Asanguinous Ex-Vivo Lung Perfusion Utilizing the Vivoline System*, Stephen C. Clark, BMedSci(Hons), BM, BS, DM, FRCSC(Th), Freeman Hospital, Newcastle Upon Tyne, United Kingdom
10:57 AM *Clinical Experience with Warm Blood Lung Perfusion – Transmedics*, Gregor Warnecke, MD, Hannover Medical School, Hannover, Germany
11:09 AM Discussion

**PRE-MEETING SYMPOSIUM 10**  (MEETING HALL 4)
The Right Ventricle and Pulmonary Vascular Load in Health and Disease

**CHAIRS:** Marc Humbert, MD, PhD and John T. Granton, MD

9:45 AM *The Pulmonary Vasculature and Right Ventricular Afterload*, Ryan J. Tedford, MD, Johns Hopkins Medical Institutions, Baltimore, MD
10:05 AM *The Right Ventricle in Exercise*, Rajeev Saggar, MD, Heart-Lung Institute, St. Joseph Hospital & Medical Center, Phoenix, AZ
10:20 AM *Pathophysiology of RV Failure*, Stephen C. Mathai, MD, MHS, Johns Hopkins University, Baltimore, MD
10:35 AM *Assessment and Management of RV Failure*, Anton Vonk-Noordegraaf, MD, PhD, VU Medisch Centrum, Amsterdam, The Netherlands
11:00 AM Panel Discussion

**PRE-MEETING SYMPOSIUM 11**  (MEETING HALL 5)
MCS in Congenital Heart Disease & Pediatrics

**CHAIRS:** Ivan M. Rebeyka, MD and Christopher S. Almond, MD, MPH

9:45 AM *Implantable VADs in Children and Adults with Congenital Heart Disease*, David L. S. Morales, MD, Texas Children’s Hospital and Baylor College of Medicine, Houston, TX
9:57 AM *Is Two Better than One? Indications for Bi iVAD vs. LVAD Placement in Children*, Holger W. Buchholz, MD, University of Alberta, Stollery Children’s Hospital and Mazankowski Alberta Heart Institute, Edmonton, Canada
10:09 AM *Beyond the Surgery – Preventing Thromboembolic Complications During Long-term VAD Support*, M. Patricia Massicotte, MSc, MD, MHSc, University of Alberta, Stollery Children’s Hospital, Edmonton, Canada
10:21 AM *VAD Options for the Single Ventricle Patient*, Olaf Reinhardt, MD, Stanford University, Stanford, CA
10:33 AM *Heart Transplant or VAD in Children and Adults with Congenital Heart Disease – Strategies for Improving Transplant Outcome*, Robert Jaquiss, MD, Duke University School of Medicine, Durham, NC
10:45 AM *Going Home: Hospital Discharge on VAD Support in Children*, William Neil Wrightson, RN, Newcastle Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
10:57 AM Panel Discussion
9:45 AM – 11:15 AM

PRE-MEETING SYMPOSIUM 12 (NORTH HALL)
CMV and Beyond: Important Viruses in Thoracic Transplantation

CHAIRS: Martha L. Mooney, MD and Martin R. Zamora, MD

9:45 AM EBV Infection and PTLD: Beyond the Viral Load, Steven A. Webber, MBChB, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA

10:00 AM Respiratory Viruses: Beyond RSV, Peter M. Hopkins, MBBS FRACP HONOURS, The Prince Charles Hospital, Brisbane, Australia

10:15 AM Beyond Abdominal Organs: HIV+ Thoracic Transplant Candidates, Paolo Antonio Grossi, MD, PhD, University of Insubria, Varese, Italy

10:30 AM Beyond HSV: Human Herpes Viruses in Transplantation, Lara Danziger-Isakov, MD, MPH, Cleveland Clinic Foundation, Cleveland, OH

10:45 AM Beyond Prophylaxis: CMV Immune Monitoring, Martina Sester, PhD, Saarland University, Homburg, Germany

11:00 AM Panel Discussion: CMV & Beyond: Clinical Dilemmas in Thoracic Transplant Recipients

MODERATORS: Martin R. Zamora, MD and Camille N. Kotton, MD, FIDSA

11:15 AM – 11:30 AM
COFFEE BREAK (CONGRESS HALL FOYER)

11:30 AM – 1:00 PM

PRE-MEETING SYMPOSIUM 13 (FORUM HALL)
The Longer the Better – Chronic Medical Management of MCS

CHAIRS: Evgenij V. Potapov, MD, PhD and Sudhir S. Kushwaha, MD

11:30 AM Fine Tuning Pump Performance, Mark S. Slaughter, MD, University of Louisville, Louisville, KY

11:42 AM Arrhythmia Management: Beyond Amiodarone, Salpy V. Pamboukian, MD, MSPH, University of Alabama at Birmingham, AL

11:54 AM Aortic Insufficiency: An Achilles Heel for Long-Term Support?, Roland Hetzer, MD, PhD, German Heart Institute, Berlin, Germany

12:06 PM Long-Term Infection Prevention, Margaret M. Hannan, MD, Mater Hospital, Dublin, Ireland

12:18 PM G.I. Bleeding: What is the Optimal Strategy for Diagnosis and Management?, Jeffrey J. Teuteberg, MD, University of Pittsburgh, Pittsburgh, PA

12:30 PM Getting Back to Life: Sex, Driving and Rock-n-Roll – What, if any, Restrictions are Reasonable?, Karl E. Nelson, RN, MBA, Integris Baptist Medical Center, Oklahoma City, OK

12:42 PM Panel Discussion

11:30 AM – 1:00 PM

PRE-MEETING SYMPOSIUM 14 (MEETING HALL 1)
The DEFs of AMR: Detecting the Antibodies, Evaluating the Biopsy, and Finally, the Patient

CHAIRS: Allan R. Glanville, MBBS, MD, FRACP and Jon Kobashigawa, MD

11:30 AM Antibody Detection, Dolly B. Tyan, PhD, D(ABHI) Stanford University, Palo Alto, CA

12:00 PM Pathology: New Nomenclature / Classification, Charles C. Marboe, MD, Columbia University Medical Center and the New York Presbyterian Hospital, New York, NY

12:30 PM Clinical Correlate: What Does It All Mean? What are the Big Unanswered Questions?

12:30 PM Lung: Martin P. Iversen, MD, PhD, Rigshospitalet, Copenhagen, Denmark

12:40 PM Heart: A. G. Kfoury, MD, FACC, Intermountain Medical Center, UTAH Cardiac Transplant Program, Murray, UT

11:30 AM – 1:00 PM

PRE-MEETING SYMPOSIUM 15 (PANORAMA HALL)
Advances in Pulmonary Transplant Surgery

CHAIRS: Stephen C. Clark, BMedSci(Hons), BM, BS, DM, FRCS(C-Th) and Christopher H. Wigfield, MD, FRCS

11:30 AM Airway Complications, Michael S. Mulligan, MD, University of Washington School of Medicine, Seattle, WA

12:00 PM Mechanical Bridging to Lung Transplantation, Martin Strueber, MD, Hannover Medical School, Hannover, Germany

12:30 PM Practical Issues with EVLP, Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, Canada

11:30 AM – 1:00 PM

PRE-MEETING SYMPOSIUM 16 (MEETING HALL 4)
Thoracic Organ Donors: Optimal Management and New Avenues

CHAIRS: Kenneth R. McCurry, MD and Gregory I. Snell, MD

11:30 AM The Impact of Brain Death in Thoracic Organ Donor, Arne P. Neyrinck, MD, University Hospitals Leuven, Belgium

11:40 AM Hormonal Therapy in Thoracic Organ Donor: Does It Work?, Robert S. Bonser, MD, FRCS, FRCP, Queen Elizabeth Hospital Birmingham, United Kingdom

12:00 PM Ventilatory Strategies and Inhaled Therapies to Increase Donor Lung Yield, Lorraine B. Ware, MD, Vanderbilt University, Nashville, TN
12:00 PM  The Agonal Phase in Controlled Donation after Cardiac Death: Does it Matter? Bronwyn Lewey, RN, BEd, Stu Grad Dip Clin Epi, The Alfred Hospital, Melbourne, Australia

12:40 PM  Potential for Heart Transplantation from Donors after Cardiac Death? Ayyaz Ali, MD, PhD, Papworth Hospital, Cambridge, United Kingdom

11:30 AM – 1:00 PM

PRE-MEETING SYMPOSIUM 17  (MEETING HALL 5)

Innate Immunity in Cardiothoracic Transplantation

CHAIRS: Andrew Gelman, PhD and Daniel R. Goldstein, MD

11:30 AM  Acute Lung Injury after Lung Transplantation, Andrew E. Gelman, PhD, Washington University School of Medicine, St. Louis, MO

11:50 AM  Imaging the Innate Immune System after Lung Transplantation, Daniel Kreisel, MD, PhD, Washington University School of Medicine, St. Louis, MO

12:10 AM  Clinical Markers of Innate Immunity after Lung Transplantation, Jason D. Christie, MD, MS, University of Pennsylvania School of Medicine, PA

12:30 AM  Role of NK Cells and Neutrophils in Cardiac Allograft Dysfunction, Joren C. Madsen, MD, DPhil, Massachusetts General Hospital, Boston, MA

12:50 AM  Panel Discussion

11:30 AM – 1:00 PM

PRE-MEETING SYMPOSIUM 18  (NORTH HALL)

Congenital Heart Disease: Pulmonary Hypertension Dilemmas in Pediatric and Adult Patients

CHAIRS: Christian Benden, MD and Mardi Gomberg-Maitland, MD, MSC

11:30 AM  Congenital Heart Disease and Pulmonary Hypertension: Classification and Understanding Why All Defects are Not the Same, Ian Adatia, MBChB, MRCP, FRCP(C), University of Alberta, Edmonton, Canada

11:45 AM  Unrepaired Systemic to Pulmonary Shunts and PAH: To Close Or Not to Close? That is the Question, Daphne T. Hsu, MD, Children’s Hospital at Montefiore/Albert Einstein College of Medicine, Bronx, NY

12:00 PM  Medical Management of CHD Associated PAH: Do’s and Don’ts for this Challenging Population, Richard Krasuski, MD, The Cleveland Clinic Foundation, Cleveland, OH

12:15 PM  Use of PAH Directed Therapies in Patients with Single Ventricles, Brian D. Hanna, MD, PhD, Children’s Hospital of Pennsylvania, Philadelphia, PA

12:30 PM  Balancing the Risks of Transplantation for CHD Today: Should we be Reserving this Therapy as a Last Resort or Consider Earlier Referral over Multiple Palliative Procedures? Jonathan M. Chen, MD, New York Presbyterian, New York, NY

12:45 PM  Panel Discussion
**3:00 PM – 4:15 PM**

### CONCURRENT SESSION 1

**How VADs Impact Our Community**

**CHAIRS:** Leslie W. Miller, MD and Heather J. Ross, MD, MHSc, FRCP(c)

#### 3:00 PM

1. **Initial Results of the Destination Therapy Post-FDA Approval Study with a Continuous Flow Left Ventricular Assist Device: A Prospective Study Using the INTERMACS Registry**; U.P. Jorde, S.S. Kushwaha, A.J. Tatooles, Y. Naka, G. Bhat, J.W. Long, D.A. Horstromshof, R.L. Kormos, J.J. Teuteberg, M.S. Slaughter, E.J. Birks, D.J. Farrar, S.J. Park, Columbia University Medical Center, New York, NY; Mayo Clinic, Rochester, MN; Advocate Christ Medical Center, Oak Lawn, IL; Integris Baptist, Oklahoma City, OK; University of Pittsburgh, PA; University of Louisville, KY; Thoratec Corporation, Pleasanton, CA.

#### 3:12 PM

2. **Improved Survival of Patients on UNOS Waiting List Activities in Patients with Left Ventricular Assist Device**; J.J. Teuteberg, G. Stewart, M. Jessup, R.L. Kormos, B. Sun, O.H. Frazier, D. Naftel, L. Stevenson, Heart and Vascular Institute, University of Pittsburgh, PA; Cardiology, Brigham and Women's Hospital, Boston, MA; Cardiology, University of Pennsylvania, Philadelphia, PA; Cardiology, Texas Heart Institute, Dallas, TX; Cardiology, University of Alabama, Birmingham, AL.

#### 3:24 PM

3. **Implant Strategies for Continuous Flow LVAD Therapy in INTERMACS – Impact on Outcomes and Variability over Time**; J.J. Teuteberg, G. Stewart, M. Jessup, R.L. Kormos, B. Sun, O.H. Frazier, D. Naftel, L. Stevenson, Heart and Vascular Institute, University of Pittsburgh, PA; Cardiology, Brigham and Women's Hospital, Boston, MA; Cardiology, University of Pennsylvania, Philadelphia, PA; Cardiology, Texas Heart Institute, Dallas, TX; Cardiology, University of Alabama, Birmingham, AL.

#### 3:36 PM

4. **Outcomes of Patients Implanted with a Left Ventricular Assist Device at Non-Transplant Open Heart Surgery Centers**; M.R. Katz, E.M. Horn, M.G. Dickinson, G.R. Zeeki, A. Salemi, J.P. Slater, Cardiac Surgery/Advanced Heart Failure Center, Bon Secours Heart & Vascular Institute, Richmond, VA; Division of Cardiology/Dept Cardiothoracic Surgery, Weill Cornell Medical College, New York, NY; Richard DeVos Heart and Lung Transplant Program, Frederik Meijer Heart & Vascular Institute Spectrum Health, Grand Rapids, MI; Department of Cardiovascular Medicine, Morristown Memorial Hospital, Morristown, NJ.

#### 3:48 PM

5. **High Event Rates in Medically Managed Advanced Heart Failure Patients Followed at VAD Centers**; G.C. Stewart, M.M. Kittleson, J. Cowger, C. Patel, F. Johnson, M. Mounts, P. Patel, E. Rame, J. Testani, M. Guglin, J. Teuteberg, L.W. Stevenson, Brigham and Women's Hospital, Boston, MA; Cedars Sinai Heart Institute, Los Angeles, CA; University of Michigan, Ann Arbor, MI; Duke University, Durham, NC; University of Iowa, Iowa City, IA; Cleveland Clinic, Cleveland, OH; University of Texas Southwestern, Dallas, TX; University of Pennsylvania, Philadelphia, PA; University of South Florida, Tampa, FL.

### CONCURRENT SESSION 2

**Decision Making in Advanced Heart Failure: Bridge, Recover, Transplant**

**CHAIRS:** Fabrizio Oliva, MD and Peter Eckman, MD

#### 3:00 PM

1. **Outcomes after Heart Transplantation in Adult Recipients Based on Medical Urgency Status/Criteria: Implications for Heart Allocation in the USA**; D. Vega, L.B. Edwards, Surgery, Emory University School of Medicine, Atlanta, GA; Research, UNOS, Richmond, VA.

#### 3:12 PM

2. **Can the Seattle Heart Failure Model Help in Predicting Death in a Cohort of High Urgent and Urgent Heart Transplant Candidates**; J.M. Smits, E. de Vries, A. Rahmel, B. Meiser, H. Reichenspurmer, M. Strueben, Euromitransplant, Leiden, Netherlands; University Hospital Munich, Munich, Germany; University Hospital Effendorf, Hamburg, Germany; Hannover Medical School, Hannover, Germany.

#### 3:24 PM


#### 3:36 PM

4. **Successful Use of Percutaneously Placed Axillary-Subclavian Intra-Aortic Balloon Pumps That Permit Ambulation as a Bridge to Heart and Multi-Organ Transplantation**; J.D. Estep, A.M. Cordero-Reyes, A. Bihmaraj, M. Loebe, B. Bruckner, S. Scheinin, B. Ramlawi, G. Torre-Amione, The Methodist DeBakey Heart & Vascular Center, The Methodist Hospital, Houston, TX; Cardiology, Hospital San Jose Tec de Monterrey, Monterrey, NL, Mexico.

#### 3:48 PM

5. **Advanced Heart Failure Requiring Emergency Surgical Therapy: Emergency Heart Transplantation with Marginal Donors vs. LVAD Implant**; A. Forni, B. Chiomiento, A. Mazzucco, G. Faggian, Cardiac Surgery, University Hospital of Verona, Verona, Italy.

#### 4:00 PM

6. **Outcomes with Use of Continuous Outpatient Milrinone Infusions in Patients with Advanced Heart Failure (AHF)**; P. Muthusamy, S. Madan, K. Mowers, D.E. Langholz, J.D. Call, M.B. Hanrahan, A.T. Davis, H. Pehwa, M.G. Dickinson, Cardiology, Fredrik Meijer Heart & Vascular Institute/Spectrum Health, Grand Rapids, MI; Grand Rapids Medical Education Partners, Grand Rapids, MI; Michigan State University/College of Human Medicine, Grand Rapids, MI; Coram Home Infusion Group, Grand Rapids, MI.
**CONCURRENT SESSION 3**

**What Do Animal Models Teach Us About BOS?**

**CHAIRS:** Marshall I. Hertz, MD and Annette Boehler, MD

---

**3:00 PM** (294) Alpha 1-Antitrypsin Improves Lung Function in a Rat Lung Transplantation Model; W. Gao,1,3 M. Chen,3 M. Jhajj,2 M. Cypel,2,3 S. Keshavjee,2,3 M. Liu,1,2,3 1Physiology, University of Toronto, Toronto, ON, Canada; 2Surgery, University of Toronto, Toronto, ON, Canada; 3Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada.

---

**3:12 PM** (14) Administration of Antibodies to Self Antigens (K - 1 Tubulin and Collagen V) Results in Obliterative Bronchitis after Syngeneic Mouse Lung Transplantation; V. Subramanian,1 M. Takenaka,1 V. Tirveedhi,1 N. Beneshoff,1 S. Yamamoto,1 A.E. Gelman,1 A. Patterson,1 T. Mohanakumar,1,2 1Surgery, Washington University, St. Louis, MO; 2Pathology and Immunology, Washington University, St. Louis, MO.

---

**3:24 PM** (15) The Pro-Inflammatory Cytokine IL-17 Acts Directly on Bronchiolar Epithelium – Implications for Chronic Lung Allograft Dysfunction Pathogenesis; S.T. Yerkovich,1,2 M. E. Tan,1 K.A. Sinclair,1 A. Fiene,1 P.M. Hopkins,1,2 D.C. Chambers,1,2 1Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia; 2School of Medicine, The University of Queensland, Brisbane, Australia.

---

**3:36 PM** (16) Release of ATP by Injured Pulmonary Cells Triggers Th17 Dependent Lung Allograft Rejection; S. Sugimoto,1 D. Kreisel,1 A.S. Krupnick,1 A.E. Gelman,1 Surgery, Washington University in Saint Louis, Saint Louis, MO.

---

**3:48 PM** (17) Zinc Suppresses Pathogenesis of Bronchiolitis Obliterans Via Inhibition of IL-6 Receptor; T. Nakagiri,1,2 M. Inoue,1,2 M. Minami,1,2 N. Sawabata,1,2 M. Okumura.1 Departments of General Thoracic Surgery, Osaka University Graduate School of Medicine, Suita-City, Osaka, Japan.

---

**4:00 PM** (18) Prolonged Ischemic Time Exacerbates the Development of Chronic Gastric Fluid Aspiration-Associated Bronchiolitis Obliterans in Rat Pulmonary Allografts; J.-C. Chang,1,2,3 T. Tang,1,4 J. Leung,1 M.G. Hartwig,1 W. Parker,1 R.D. Davis,1 S.S. Lin,1,2,5 1Department of Surgery, Duke University Medical Center, Durham, NC; 2Department of Pathology, Duke University Medical Center, Durham, NC; 3Division of Thoracic and Cardiovascular Surgery, Buddhist Tzu Chi General Hospital, Hualien, Taiwan; 4The Thoracic and Cardiovascular Surgery, The Second Xiangya Hospital, Changsha, Hunan, China; 5Department of Immunology, Duke University Medical Center, Durham, NC.

---

**WITHDRAWN**

---

**3:00 PM** (20) The Effect of Oversizing Donor Cardiac Allografts on In-Hospital Outcomes in Pediatric Heart Transplant Recipients; E.D. McFeely,1 R.K. Singh,2 M.E. Richmond,2 W.A. Zuckereman,2 T.M. Lee,2 L. Gilmore,2 R. Rodriguez,2 J.M. Chen,2 L.J. Addonizio,2 1Columbia University College of Physicians and Surgeons, New York, NY; 2Pediatric Cardiology, Columbia University Medical Center, New York, NY; 3Pediatric Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

---

**3:00 PM** (21) Risk Factors for and Risk of Graft Loss after Pediatric Heart Retransplantation: Analysis of the ISHLT Registry; J. Conway,1 L.B. Edwards,2 R. Kirk,3 B. McCrindle,1 C. Manlihot,1 A.I. Dipchand,1 1Labatt Family Heart Center, The Hospital for Sick Children, Toronto, ON, Canada; 2International Society of Heart and Lung Transplant Registry, Addison, TX; 3Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

---

**3:00 PM** (22) Is Lung Transplantation Survival Better in Infants? Analysis of over 80 Infants; M.S. Khan,1 J.S. Heinle,1 I. Adachi,1 B. Shirkey,2 M.G. Schecter,4 G.B. Mallory,3 D.L.S. Morales,1 1Congenital Heart Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX; 2Congenital Heart Surgery, Texas Children's Hospital, Houston, TX; 3Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX.

---

**3:00 PM** (23) Risk-Stratification and Transplant Benefit in Children Listed for Heart Transplant; T.P. Singh,2 C.S. Almond, G. Piercey, K. Gauvreau. Cardiology, Children's Hospital Boston, Boston, MA.

---

**3:00 PM** (24) Predicting 1-Year Survival in Pediatric Heart Transplant Candidates with Cardiomyopathy: An Analysis of the PHTS Database; K.R. Schumacher,1 D. Nafte1,2,5 M. Tresler,2 R. Kirk,2 C. Almond,1 T.P. Singh,2 R. Spicer,2 T.M. Hoffman,2 D. Hsu,2 C. Canter,2 M. Zamberlan,1 R.J. Gajarski,1 1Congenital Heart Center, University of Michigan, Ann Arbor, MI; 2University of Alabama, Birmingham, AL; 3Freeman Hospital, Newcastle upon Tyne, United Kingdom; 4Boston Children's Hospital, Boston, MA; 5Children's Hospital Medical Center, Cincinnati, OH; 6Nationwide Children's Hospital, Columbus, OH; 7The Children's Hospital at Montefiore, New York, NY; 8St. Louis Children's Hospital, St. Louis, MO.
CONCURRENT SESSION 5  
(MEETING HALL 5)  
Optimizing the LVAD Experience

**CHAIRS:** Bernice Coleman, PhD, ACNP-BC and Michelle Harkess, RN, MCN

**3:00 PM** (25) **LVAD Family Caregivers: Impact of Social Support (SS) on Perceived Burden and Quality of Life (QOL);** M. Petty, K. Savik, K. Nursing, University of Minnesota Medical Center, Fairview, Minneapolis, MN; School of Nursing, University of Minnesota, Minneapolis, MN.

**3:12 PM** (26) **Predictors of Health-Related Quality of Life at 6 Months after Left Ventricular Assist Device Implantation: Findings from INTERMACS;** S. Wissman, D.C. Naftel, S.L. Myers, J.K. Kirklin, A. Moskowitz, A. Gelins, F.D. Pagani, J.B. Young, K.L. Grady, Surgery, Ohio State University, Columbus, OH; Surgery, University of Alabama, Birmingham, AL; Health Evidence and Policy, Mount Sinai School of Medicine, New York, NY; Surgery, University of Michigan, Ann Arbor, MI; Medicine, Cleveland Clinic, Cleveland, OH; Surgery/Cardiac Surgery, Northwestern University, Chicago, IL.

**3:24 PM** (27) **Improving Patient Satisfaction in Wound Care of Left Ventricular Assist Device Exit Sites;** N. Robinson Smith, N. Wrightson, G. MacGowan, T. Butt, F. Oezalp, K. Gould, S. Schueler. Mechanical Circulatory Support for Advanced Heart Failure Team, The Newcastle upon Tyne NHS Foundation Trust Freeman Hospital, Newcastle upon Tyne, United Kingdom.

**3:36 PM** (28) **Improvement in Quality of Life after Left Ventricular Assist Device Implant Is Similar, Regardless of Baseline Severity of Heart Failure;** K.L. Grady, D.C. Naftel, L. Stevenson, M.A. Dew, G. Weidner, F.D. Pagani, J.K. Kirklin, S. Myers, J.T. Baldwin, M.R. Shah, J.B. Young, Surgery/Cardiac Surgery, Northwestern University, Chicago, IL; Surgery, University of Alabama, Birmingham, AL; Medicine, Brigham and Women’s Hospital, Boston, MA; Psychiatry, University of Pittsburgh, PA; Biology, San Francisco State University, Tiburon, CA; Surgery, University of Michigan, Ann Arbor, MI; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Medicine, Cleveland Clinic, Cleveland, OH.

**3:48 PM** (29) **Quality of Life Is Higher in Destination Therapy Compared with Bridge to Transplantation Patients Following Ventricular Assist Device Implantation;** F.M. McNeil, C.S. Lee, H.K. Song, A.Y. Kim, A. Rosenfeld, School of Nursing, Oregon Health & Science University, Portland, OR; School of Medicine, Oregon Health & Science University, Portland, OR.

**4:00 PM** (30) **After Hour VAD Coverage: VAD Training Is Not Required;** M.K. Saraswat, S.L. Ullrich, R.L. Fioretti, T.J. George, C.A. Beatty, J.V. Conte, G.J. Whitman. The Division of Cardiac Surgery, Johns Hopkins Medical Institutions, Baltimore, MD.

---

CONCURRENT SESSION 6  
(NORTH HALL)  
An Ounce of Prevention and Managing Infection

**CHAIRS:** Shahid Husain, MD, MS and Alexander Stepanenko, MD

**3:00 PM** (31) **Pump-Related Infections (PRI) after Implantation of Continuous-Flow Left Ventricular Devices (CF LVADs): Analysis of 2900 Patients from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS);** F. Kamdar, P. Eckman, D. Goldstein, C. Sai-Sudhaker, S. Aggarwal, F. Pagani, R. John, University of Minnesota, Minneapolis, MN; Montefiore Medical Center, Bronx, NY; Ohio State University Medical Center, Columbus, OH; Mid America Heart and Vascular Institute, Kansas City, MO; University of Michigan, Ann Arbor, MI.

**3:12 PM** (32) **Modified HeartMate II Driveline Externalization Technique Significantly Decreases Incidence of Infection and Improves Long-Term Survival;** S.A. Akhter, M.J. Russo, A. Singh, T.B. Valeroso, E.M. Johnson, A.S. Anderson, S.E. Fedson, G. Kim, J. Rich, V. Jeevanandam, Surgery, University of Chicago Medical Center, Chicago, IL; Medicine, University of Chicago Medical Center, Chicago, IL.

**3:24 PM** (33) **Prevention of Driveline Infection after Left Ventricular Assist Device Implantation: Are Prophylactic Antibiotics Necessary?;** J.M. Russo, S. Maltais, J. Cowger, L.D. Joyce, R.C. Daly, S.J. Park, K. Aaronson, F.D. Pagani, Cardiovascular Surgery, Mayo Clinic College of Medicine, Rochester, MN; Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN; Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI.


**3:48 PM** (35) **Classification of Ventricular Assist Device Infections According to ISHLT Formulation and Device Generation;** C. Guerrero-Miranda, D.A. Baran, O. Emmanuel, J. Pieretti, N. Hochbaum, M.E. Goldschmidt, M.J. Zucker, S. Pardi, E. Bishburg. Transplant Center, Newark Beth Israel Medical Center, Newark, NJ.

**4:00 PM** (36) **Right-to-Left Hemispheric Predominance of Cerebrovascular Lesions and Its Association with Systemic Infection in Patients Undergoing Left Ventricular Assist Device Implantation;** T.S. Kato, T. Ota, P.C. Schulze, M. Farr, N. Uriel, U. Jorde, H. Akashi, H. Takayama, Y. Naka, T. Yamashita, N. Robinson, N. Wrightson, G. MacGowan, T. Butt, F. Oezalp, K. Aaronson, F.D. Pagani, S. Aggarwal, J.K. Kirklin, A. Gelins, F.D. Pagani, R. John, University of Minnesota, Minneapolis, MN; Montefiore Medical Center, Bronx, NY; Ohio State University Medical Center, Columbus, OH; Mid America Heart and Vascular Institute, Kansas City, MO; University of Michigan, Ann Arbor, MI.
THURSDAY, APRIL 19, 2012

7:00 AM – 7:00 PM
SPEAKER READY ROOM OPEN
(CLUB H)

7:00 AM – 7:00 PM
REGISTRATION DESK OPEN
(CONGRESS HALL FOYER)

8:00 AM – 7:00 PM
PRESS OFFICE OPEN
(MEETING ROOM 2.4)

8:00 AM – 7:00 PM
POSTER VIEWING
(CONGRESS HALL FOYER)

8:00 AM – 9:15 AM

CONCURRENT SYMPOSIUM 1  (MEETING HALL 4)
A Lifecycle Journey in Advanced Heart Failure and Transplantation

CHAIRS:  Patricia A. Uber, PharmD and Andreas Zuckermann, MD

8:00 AM  Pre-Transplant Journey: Advanced Heart Failure with BTT MCS and Malfunction Due to Thrombosis, Paul E. Nolan, Jr., PharmD, University of Arizona, Tucson, AZ

8:20 AM  Early Post-Transplant Journey: Primary Graft Failure at 1 Week, David O. Taylor, MD, Cleveland Clinic Foundation, Cleveland, OH

8:40 AM  Late Post-Transplant Journey: Development of Skin Cancer and Pre-cancerous Colon Polyp, Michael Shullo, BS, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA

9:00 AM  Panel and Audience Questions and Answers

PANEL DISCUSSANTS:
Patricia A. Uber, PharmD, University of Maryland, Baltimore, MD
Andreas Zuckermann, MD, University of Vienna, Austria
Paul E. Nolan, Jr., PharmD, University of Arizona, Tucson
David O. Taylor, MD, Cleveland Clinic Foundation, Cleveland, OH
Michael Shullo, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA
Robert L. Page, II, PharmD, MSPH, University of Colorado, Denver, CO
Walter E. Uber, PharmD, Medical University of South Carolina, Charleston, SC

THURSDAY • APRIL 19

4:15 PM – 4:45 PM
COFFEE BREAK/VISIT EXHIBITS/VIEW POSTERS
(CONGRESS HALL FOYER)

4:45 PM – 7:00 PM
EXHIBIT HALL OPEN/POSTER VIEWING
(CONGRESS HALL FOYER)

4:45 PM – 6:00 PM

OPENING PLENARY SESSION  (CONGRESS HALL)
Overcoming Political Barriers

CHAIRS:  Jan Pirk, MD, John H. Dark, MB, FRCS and John B. O’Connell, MD

4:45 PM  Introduction and Welcome, Lori J. West, MD, DPhil, FRCP, ISHLT President, University of Alberta, Edmonton, Canada

4:50 PM  Welcome, Karel Schwarzenberg, Deputy Prime Minister and Minister of Foreign Affairs, Prague, Czech Republic

5:00 PM  Bringing Down the Walls: An Historical Perspective, Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT

5:15 PM  After the Iron Curtain: Successes of Regional Collaboration in Thoracic Transplantation, Walter Klepetko, MD, Medical University of Vienna, Austria

5:25 PM  Political Influence and Scientific Advancement, Lawrence Krauss, PhD, School of Earth and Space Exploration, Arizona State University, Tempe, AZ

6:00 PM – 7:00 PM
EXHIBIT HALL OPENING RECEPTION
AND POSTER VIEWING
(CONGRESS HALL FOYER)

6:00 PM – 7:00 PM
PULMONARY TRANSPLANT COUNCIL
QOL WORKFORCE MEETING
(CLUB D)
**CONCURRENT SESSION 7**

**The Dark Side of VADs**

**CHAIRS:** Tomoko S. Kato, MD, PhD and Nader Moazami, MD

**8:00 AM** (37) **Optimal Medical Management and Lowering LVAD Speed Prevents Progression of Aortic Insufficiency**; K. Hryniewicz, N. Moazami, M. Lilyblad, E.S. Shao, D. Feldman, C. Maxfield, B. Cabauy, E. Carter, B. Sun. Minneapolis Heart Institute, Minneapolis, MN.

**8:12 AM** (38) **Incidence and Impact of De Novo Aortic Insufficiency Following Continuous Flow LVADs Implantation**; A. Mang, J. Gorcsan, J.J. Teuteberg, C.A. Bermudez, J.K. Bhama, D.M. McNamara, R. Ramani, M.A. Simon, R.L. Kormos. Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.

**8:24 AM** (39) **Development of Aortic Insufficiency after Heart Mate II Left Ventricular Assist Device Implantation in 71 Patients**; A. Aggarwal, R. Raghuvir, G. Macaluso, R. Pant, C. Gallagher, A. Tatrooles, P. Pappas, G. Bhat. Center for Heart Transplant and Assist Devices, Advocate Christ Medical Center, Chicago; Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago; Cardiothoracic Surgery, Advocate Christ Medical Center, Chicago.

**8:36 AM** (40) **Clinician Attitudes toward Ventricular Assist Device Deactivation at Life’s End**; K.M. Swetz, K.E. Cook, A.L. Ottenberg, N. Chang, P.S. Mueller. Mayo Clinic, Rochester, MN; Augsburg College, Minneapolis, MN.


**9:00 AM** (42) **Predictors of Hospital Length of Stay Following Implantation of a Left Ventricular Assist Device: An Analysis of the INTERMACS Registry**; W.G. Cotts, K.L. Grady, E. McGee, D.C. Naftel, J.B. Young, J.K. Kirklin, F.D. Pagani. Cardiovascular Disease, Bluhm Cardiovascular Institute, Northwestern University, Chicago, IL; Surgery, University of Alabama, Birmingham, AL; Endocrinology and Metabolism Institute, Cleveland Clinic Foundation, Cleveland, OH; Cardiac Surgery, University of Michigan, Ann Arbor, MI.

**CONCURRENT SESSION 8**

**Heart Transplantation: Trends in Complications and Risk Factors**

**CHAIRS:** Maryl Johnson, MD and J. David Vega, MD

**8:00 AM** (43) **Have Risk Factors Changed over the Last 20 Years of Cardiac Transplantation?**; S.V. Pamboukian, R.N. Brown, J.K. Kirklin, J.A. Tallaj, J.F. George. Medicine, University of Alabama, Birmingham, AL; Surgery, University of Alabama, Birmingham, AL.


**8:24 AM** (45) **Application of Immunosuppression Clinical Trial Results in Reducing the Incidence of Heart Transplant Rejection – Bridging the New Millenium**; J. Patel, R. Shiozaki, M. Rafiei, L. Stern, M. Kittleson, D. Chang, L. Czer, F. Esmailian, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.


**9:00 AM** (48) **Consequences of First-Year Rejection after Heart Transplantation: Is the Worse yet To Come?**; L. Czer, T. Patel, M. Kittleson, M. Rafiei, L. Stern, D. Chang, D. Luthringer, F. Esmailian, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.
### CONCURRENT SESSION 9  (MEETING HALL 1)

**Lessons from Lung Transplant Database Analysis**

**CHAIRS:** Jason D. Christie, MD, MS and Leah B. Edwards, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>(49) Five Years of Lung Transplantation Since the Implementation of the Lung Allocation Score: A Comparative Analysis of Patient Characteristics and Outcomes; J.M. Schaffer,1 S.K. Singh,2 R.R. Sista,2 R.C. Robbins,1 H.R. Mallidi,4 1Cardiac Surgery, Stanford University Medical Centre, Palo Alto, CA; 2Cardiac Surgery, Hamilton General Hospital, McMaster University, Hamilton, ON, Canada; 3Pulmonary Medicine, Baylor School of Medicine, Houston, TX; 4Cardiac Surgery, Baylor School of Medicine, Houston, TX.</td>
<td></td>
</tr>
<tr>
<td>8:24 AM</td>
<td>(51) Branching out To Refine the Lung Allocation Score: Does Pre-Transplant Diagnosis Matter?; C.J. Gries,1 S.Y. Park,2 L.P. Douglas,2 S. Norihisa,3 J.M. Pilewski,1 1Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Pittsburgh, PA; 2Division of General Internal Medicine, Department Medicine, University of Pittsburgh, PA; 3Division of Cardiothoracic Transplant, Department of Cardiothoracic Surgery, University of Pittsburgh, PA.</td>
<td></td>
</tr>
<tr>
<td>8:36 AM</td>
<td>(52) Impact of Lung Transplantation in the US Lung Allocation Score System on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease; B. Mittler, K. Brown, R.D. Yusen, Medicine, Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO.</td>
<td></td>
</tr>
<tr>
<td>8:48 AM</td>
<td>(53) Geographic Disparities in Access to Lung Transplantation in the United States; D.J. Lederer1 D.L. Segev,2 E.R. Peterson,1 S. Ravichandran,1 J.R. Sonett,1 S.M. Arcasoy.1 1Columbia University Medical Center, New York, NY; 2Johns Hopkins University School of Medicine, Baltimore, ME.</td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td>(54) Institutional Volume Affects Ten-Year Survival in Lung Transplantation; A. Kilic,1 E.S. Weiss,1 J.V. Conte,1 C.A. Merlo,2 A.S. Shah.1 1Division of Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD; 2Division of Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD.</td>
<td></td>
</tr>
</tbody>
</table>

---

### CONCURRENT SESSION 10  (PANORAMA HALL)

**Pulmonary Hypertension: Advances in Diagnosis and Therapy**

**CHAIRS:** Evelyn Horn, MD and George Javoyrski, MBBS, FRACP, FCSANZ

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>(55) RePHerral Study: A Multi-Center Study on the Referral of Pulmonary Hypertension Patients; B.C. Dean,1 A. Frost,2 S. Viscovali,2 C. Glassner,1 V. McLaughlin,3 M. Rubenstein,3 M. Gomberg-Maitland.1 1Section of Cardiology, University of Chicago, IL; 2Pulmonary and Critical Care, Baylor College of Medicine, Houston, TX; 3Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI.</td>
<td></td>
</tr>
<tr>
<td>8:24 AM</td>
<td>(56) Velotri® and Flolan® (Epoprostenol Sodium) in the Treatment of Pulmonary Arterial Hypertension; K.M. Chin,1 D.B. Badescu,2 I.M. Robbins,3 V.F. Tapson,4 H. Palevsky,5 N.H. Kim,6 S.M. Kavut,7 A. Frost,7 W.W. Benton,8 J.C. Lemarie,9 F. Bodin,10 L.J. Rubin,5 V.V. McLaughlin,11 1UT Southwestern, Dallas, TX; 2University of Colorado, Denver, CO; 3Vanderbilt University Medical Center, Nashville, TN; 4Duke University Medical Center, Durham, NC; 5University of Pennsylvania Medical Center, Philadelphia, PA; 6University of California at San Diego, San Diego, CA; 7Baylor College of Medicine, Houston, TX; 8Actelion Pharmaceuticals US, Inc., South San Francisco, CA; 9Effi-Stat, Paris, France; 10Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; 11University of Michigan, Ann Arbor, MI.</td>
<td></td>
</tr>
<tr>
<td>8:36 AM</td>
<td>(57) ATHENA-1: Long Term Clinical Improvements Following the Addition of Ambisentan to Background PDE5i Therapy in Patients with Pulmonary Arterial Hypertension; S. Shapiro,1 H. Gillies,2 M. Allard,2 C. Blair,2 R.J. Oudiz,3 1West Los Angeles VA HealthCare UCLA School of Medicine, Los Angeles, CA; 2Gilead Sciences Inc., Foster City, CA; 3LA Biomedical Research Institute at Harbor-UCLA, Torrance, CA.</td>
<td></td>
</tr>
<tr>
<td>8:48 AM</td>
<td>(58) An Open Label Non-Randomized Pilot Study To Evaluate the Safety of the GeNO Nitrosyl Delivery System in Patients Being Evaluated for Heart Transplantation; A.J. Boyle,1 M.F. Tector,1 D.H. Fine,2 M.M. Miller,1 M.R. Rush,2 C.A. Zwicki,1 A.J. Tector.1 1Auburn Cardiovascular Services, Aurora St. Luke’s Medical Center, Milwaukee, WI; 2GeNO LLC, Cocoa, FL.</td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td>(59) Is There a Role for Cardiac Resynchronization Therapy in Pediatric Pulmonary Hypertension?; K.S. Motanakara, C.Y. Miyake, R. Punn, D.N. Rosenthal, J.A. Feinstein, A.M. Dubin. Pediatric Cardiology, Stanford University, Palo Alto, CA.</td>
<td></td>
</tr>
</tbody>
</table>
8:00 AM – 9:30 AM

**CONCURRENT SESSION 11**

**(MEETING HALL 5)**

**Tolerance: To the Bench and Back**

**CHAIRS:** Sangeeta Bhorade, MD and Sonja Schrepfer, MD, PhD

**8:00 AM**

Invited Lecture: Costimulation Blockade in Transplantation: Back to the Bench, Mohammad H. Sayegh, MD, Brigham and Women’s Hospital and Children’s Hospital Boston, MA.

**8:25 AM (61)**

PHD (Prolyl-Hydroxylase)-Inhibitor Activating Hypoxia-Inducible Transcription Factors (HIFs) Reduces Levels of Transplant Arteriosclerosis in a Murine Aortic Allograft Model; C. Heim,1 S. Aghayeva,1 Z. Wang,2 B. Motsch,1 N. Koch,1 N. Burzlaff,2 M. Weyand,1 W. Bernhardt,2 K.-U. Eckardt,2 S.M. Ensminger.11 Department of Nephrology, University Hospital, Erlangen, Germany; 2Department of Inorganic and Analytical Chemistry, University Hospital Erlangen, Germany.

**8:37 AM (62)**

T-bet Deficiency in Mouse Orthotopic Lung Transplant; E.A. Lendermon,1 J.M. Dodd-o,2 H.L. Miller,3 Q. Zhong,1 J.F. McDyer.31 Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD; 2Department of Medicine, Montefiore Medical Center, Bronx, NY; 3Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, PA.

**8:49 AM (63)**

Regulatory T Cells Correlate with Percent Predicted FEV1 after Lung Transplantation; J. Salmon,1 W. Sommer,1 A.-K. Knöfel,1 C. Kühn,1 M. Avsar,1 G. Buechler,1 T. Fuehner,2 J. Gottlieb,2 T. Welte,2 A. Havenich,1 G. Warnecke.1 Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany; 2Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany; 3Department of Gastroenterology, Hannover Medical School, Hannover.

**9:01 AM (64)**


---

8:00 AM – 9:30 AM

**CONCURRENT SESSION 12**

**(NORTH HALL)**

**Bad Bugs: Donors, Recipients and the Consequences**

**CHAIRS:** Erik AM Verschuuren, MD, PhD and Margaret Hannan, MD

**8:00 AM (65)**

Cardiac Transplantation from Bacteremic Donors: Is It Safe?; S.J. Forest,1 D. Goldstein,1 P. Friedmann,1 R. Bello,1 V. Muggia,2 D. D’Alessandro,1 Department of Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY; 2Department of Medicine, Montefiore Medical Center, Bronx, NY.

**8:12 AM (66)**

Donor-Derived Infections in Heart Transplantation; A. Ehsan,1 S. Taranto,2 S.H. Covington,3 R.A. Miller;1 K.H. Taylor,2 K.B. Parker,3 B.S. Friedman,7 M.D. Green,5 P. Ruiz,6 E.A. Blumberg.2 Surgery, Tufts Medical Center, Boston, MA; 1Medicine, University of Pennsylvania, Philadelphia, PA; 2United Network for Organ Sharing, Richmond, VA; 3Medicine, University of Iowa, Iowa City, IA; 5Pediatrics, University of Pittsburgh, PA; 6Pathology, University of Miami, FL; 7University of Minnesota, Minneapolis, MN.

**8:24 AM (67)**

Donor-Derived Infections in Lung Transplantation; A. Ehsan,1 S. Taranto,2 S.H. Covington,3 R.A. Miller;4 K.H. Taylor,3 K.B. Parker,3 B.S. Friedman,7 M.D. Green,5 P. Ruiz,6 E.A. Blumberg.2 Surgery, Tufts Medical Center, Boston, MA; 1Medicine, University of Pennsylvania, Philadelphia, PA; 2United Network for Organ Sharing, Richmond, VA; 3Medicine, University of Iowa, Iowa City, IA; 5Pediatrics, University of Pittsburgh, PA; 6Pathology, University of Miami, FL; 7University of Minnesota, Minneapolis, MN.

**8:36 AM (68)**

Distinct Microbial Signatures of Healthy and Failing Lung Allografts; D. Willner,1 P. Hugenholtz,1 M.E. Tan,6 S.T. Yerkovich,2,3 P.M. Hopkins,2,3 D.C. Chambers.2,3 Australian Centre for Ecogenomics, The University of Queensland, Brisbane, Australia; 2Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia; 3School of Medicine, The University of Queensland, Brisbane, Australia.

**8:48 AM (69)**

Impact of Cardiotropic Viruses on Alloimmune Response and Microvasculopathy in Cardiac Transplant Recipients; N.E. Hiemann,1 E. Wellnhofer,2 K. Klingel,3 R. Kandel,2 C. Proch,2 C. Knosalla,1 H. Lehmkuhl,1 R. Hetzer,1 R. Meyer.1 Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; 2Department of Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany; 3Department of Molecular Pathology, Institute for Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany.

**9:00 AM (70)**

Cardiac Allograft Vasculopathy and Survival after Heart Transplantation for Chagas’ Heart Disease; M. Diego,1 L. Favaloro,1 A. Bertolotti,1 C. Vigliano,1 M. Peradejordi,1 A. Schijman,2 R. Favaloro.1 Intrathoracic Transplant Unit, University Hospital Favaloro Foundation, Ciudad Autónoma de Buenos Aires, Argentina; 2Molecular Biology Laboratory of Chagas’ Disease, INGEBI-CONICET, Ciudad Autónoma de Buenos Aires, Argentina.
9:00 AM – 7:00 PM
EXHIBIT HALL OPEN
(CONGRESS HALL FOYER)

9:15 AM – 9:45 AM
COFFEE BREAK/VISIT EXHIBITS/VIEW POSTERS
(CONGRESS HALL FOYER)

9:45 AM – 11:30 AM
PLENARY SESSION
(CONGRESS HALL)

ISHLT Traditions
CHAIRS: Stuart C. Sweet, MD, PhD and Lori J. West, MD, DPhil

9:45 AM Welcome and Program Chair’s Report, Stuart C. Sweet, MD, PhD, St. Louis Children’s Hospital, St. Louis, MO

9:55 AM President’s Address, Lori J. West, MD, DPhil, FRCP, ISHLT President, University of Alberta, Edmonton, Canada

10:05 AM Thoracic Registry Report, Marshall I. Hertz, MD, University of Minnesota, Minneapolis, MN

10:25 AM MCS Registry Reports, James K. Kirklin, MD, University of Alabama at Birmingham, AL

10:35 AM The Responsibility of Transplantation Specialists in the World Health Assembly’s Vision for Transplantation, Luc Noel, MD, Coordinator of Clinical Procedures, World Health Organization, Geneva, Switzerland

10:55 AM Lifetime Achievement Award, Sharon Hunt, MD Stanford University, Palo Alto, CA

11:30 AM – NOON
COFFEE BREAK/VISIT EXHIBITS/VIEW POSTERS
(CONGRESS HALL FOYER)

NOON – 1:15 PM

CONCURRENT SYMPOSIUM 2
(MEETING HALL 5)

Focus on Caregivers: Investing in Our Patients’ Future
CHAIRS: Michael G. Petty, PhD, RN, CCNS, CNS and Sharon Beer, RN, MSc

NOON Family Caregivers of Mechanical Circulatory Support Patients, Judy A. Currey, PhD, Alfred/Deakin Nursing Research Center, Melbourne, Australia

12:12 PM Family Caregivers of Heart Transplant Candidates and Recipients, Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA

12:24 PM Family Caregivers of Lung Transplant Candidates and Recipients, Kevin C. Carney, MSN, CRNP, CCTC, Hospital of the University of Pennsylvania, Philadelphia, PA

12:36 PM Family Caregivers of Children with End Stage Heart and Lung Disease and Thoracic Transplant, Paula A. Kofflin, RN, BSN, CPTC, University of Minnesota Amplatz Children’s Hospital, Minneapolis, MN

12:48 PM Burdens of Family Caregivers as Surrogate Decision-Makers, Denise Dudzinski, PhD, MTS, University of Washington, Seattle, WA

1:00 PM Panel Discussion
CONCURRENT SESSION 13  
(MUNICH CONGRESS HALL)

MCS: Balancing on the Razor’s Edge

CHAIRS: Evgenij V. Potapov, MD, PhD and Josef Stehlik, MD, MPH

NOON  (71) Heparin May Not Be Needed as a Transition to Long Term Warfarin Therapy in LVAD Destination Therapy Patients; R.M. Adamson, 1 R. John, 2 D. Goldstein, 3 S.J. Park, 4 C.A. Milano, 5 A.J. Tatooles, 5 K.S. Sundareswaran, 6 D.J. Ferrara, 7 M.S. Slaughter; 5 Sharp Memorial Hospital, San Diego, CA; 2University of Minnesota, Minneapolis, MN; 3Montefiore Medical Center, New York, NY; 4Mayo Clinic, Rochester, MN; 7Duke University, Durham, NC; 7Advocate Christ Medical Center, Chicago, IL; Thoratec Corporation, Pleasanton, CA; 7University of Louisville, Louisville, KY.


12:24 PM (73) Gastrointestinal Bleeding and Subsequent Risk of Thromboembolic Events during Support with a Left Ventricular Assist Device; J.M. Szulak, D. Lee, M.A. Romano, J.W. Haft, J. Cowger, K.D. Aaronson, S.J. Park, L.D. Joyce, R.C. Daly, F.D. Pagani; Cardiovascular Surgery, Mayo Clinic College of Medicine, Rochester, MN; Cardio Surgery, University of Michigan Health System, Ann Arbor, MI.

12:36 PM (74) Gastrointestinal Bleeding Is Not Associated with Pump Speed and Aortic Valve Opening in Patients Supported with the HeartMate II LVAD; S.R. Patel, A. Rivera, J. Patel, O. Saeed, M. Camacho-Rivera, S. Maybaum, D. Goldstein, Montefiore Medical Center, Bronx, NY; Harvard School of Public Health, Boston, MA.

12:48 PM (75) von Willebrand Factor in Recipients of Different VAD Systems and Its Clinical Relevance; N. Dranishnikov, A. Stepnanko, A. Frumkin, J. Vierecke, E.V. Potapov, T. Krbatsch, R. Hetzer; Department of Cardiothoracic and Vascular Surgery, German Heart Institute Berlin, Berlin, Germany.

1:00 PM (76) Thrombus Formation at the Inflow Area in HeartMate II Patients; M.E.I. Schipper, A. Vink, H.F.J. Duflens, R.A. de Weger, N. de Jonge, J.R. Lahpor; Department of Pathology, University Medical Centre, Utrecht, Netherlands; Department of Cardiology, University Medical Centre, Utrecht, Netherlands; Department of Cardio-Thoracic Surgery, University Medical Centre, Utrecht, Netherlands.

NOON  (77) Impact of Time Post Transplant on Gene Expression Profile Scores, an Analysis of 34,567 Tests; B.A. Austin, E. Wang, P.J. Arnold, A. Kao; Cardiology, Saint Luke’s Mid America Heart Institute, Kansas City, MO; Expression Diagnostics, Brisbane, CA.

12:12 PM (78) Are Donor-Specific Antibodies Detected after Heart Transplant All Bad?; J. Patel, M. Kittleson, L. Czer, M. Rafiei, L. Stern, F. Esmalian, N. Reinsmoen, J. Kobashigawa; Cedars-Sinai Heart Institute, Los Angeles, CA.

12:24 PM (79) Intentional ABO-Incompatible Heart Transplantation; G. Tyden, I. Hagerman, K.-H. Grinnemo, P. Svensrud, R. van der Linden, G. Kumljen, A. Wernerson; Transplantation Surgery, Karolinska Institute, Stockholm, Sweden; Cardiology, Karolinska Institute, Stockholm, Sweden; Cardiothoracic Surgery and Anaesthesiology, Karolinska Institute, Stockholm, Sweden; Transfusion Medicine, Karolinska Institute, Stockholm, Sweden; Pathology, Karolinska Institute, Stockholm, Sweden.

12:36 PM (80) Clinical Relevance of Preformed Complement- and Non-Complement-Fixing HLA Allreactivity in Cardiac Transplantation; S.L. Mahr, M. Wahrmann, A. Zuckermann, G. Böhmg; Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria; Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.

12:48 PM (81) Prediction of Allograft Clinical Outcomes and Risk of Acute Cellular Rejection with a Non-Invasive Gene-Expression Profiling Test (AlloMap): Results from the Cargo 2 European-Based Multicenter Trial; M.G. Crespo-Leiro, U. Schulz, A. Zuckermann, C. Bara, P. Mohaci, R. Bogaev, A. Boyle, H. Ross, J. Parameshwar, M. Zalkicynski, R. Fiochi, J. Stypmann, D. Hoffer, H. Lehmkuhl, M.C. Deng, P. Lepinse, J.P. Yee, J. Vanhaecke; Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardioíaco, Hospital Universitario A Coruña, La Coruña, Spain; Heart Center North-Rhine-Westphalia, Department of Thoracic and Cardiovascular Surgery, Ruhr University of Bochum, Bad Oeynhausen, Germany; Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria; Department of Cardiac Surgery, Hannover Medical School, Hannover, Germany; Department of Cardiology, Swiss Cardiovascular Centre Bern, University Hospital Bern, Bern, Switzerland; Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN; Division of Cardiology and Heart Transplantation, Toronto General Hospital, Toronto, Canada; Papworth Hospital, Papworth Everard, Cambridge, United Kingdom; Department of Cardiac Surgery & Transplantation, Silesian Center for Heart Disease, Zabrze, Poland; Cardiovascular Department-Transplant Section, Ospedali Riuniti di Bergamo, Bergamo, Italy; Department of Cardiology and Angiology, University Hospital Muenster, Muenster, Germany; Department of Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria; Deutsches Herzzentrum, Berlin, Germany; College of Physicians and Surgeons, Columbia University Medical Center, New York, NY; Department of Cardiothoracic Surgery, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Texas Heart Institute, St. Luke’s Episcopal Hospital, Houston, TX.
**Blood-Based Biomarker Panels for Diagnosis of Acute Heart Allograft Rejection; J.E. Wilson-McManus,1 Z. Hollander,1,2 G. Cohen Freue,1,4 R. Balshaw,1,4 C. Borchers,3,6 R. Davies,7 D. Delgado,8 H. Haddad,7 A. Ignaszewski,2 D. Isaac,9 D. Kim,10 A. Mui,11 M. Rajda,12 L. West,13 M. White,14 S. Zieroth,15 P. Keown,3 R. McMaster,16 R. Ng,1,17 B. McManus.1,2 1PROOF Centre of Excellence, Vancouver, BC, Canada; 2Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; 3Medicine, University of British Columbia, Vancouver, BC, Canada; 4Statistics, University of British Columbia, Vancouver, BC, Canada; 5Biochemistry, University of Victoria, Victoria, BC, Canada; 6UVic Genome BC Proteomics Centre, Victoria, BC, Canada; 7Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada; 8Medicine, University of Victoria, Victoria, BC, Canada; 9Biochemistry, University of Victoria, Victoria, BC, Canada; 10Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada; 11Medicine, University of British Columbia, Vancouver, BC, Canada; 12Medicine, University of Calgary, Calgary, AB, Canada; 13Medicine, University of Alberta, Edmonton, AB, Canada; 14Surgery, University of British Columbia, Vancouver, BC, Canada; 15Medicine, Queen’s Health Sciences Centre, Dalhousie University, Halifax, NS, Canada; 16Pediatrics, Surgery and Immunology, University of Alberta, Edmonton, AB, Canada; 17Medicine, Montreal Heart Institute, Montreal, QC, Canada; 18Medicine, University of Manitoba, Winnipeg, MB, Canada; 19Medical Genetics, University of British Columbia, Vancouver, BC, Canada; 20Computer Science, University of British Columbia, Vancouver, BC, Canada.
NOON – 1:15 PM

CONCURRENT SESSION 16  (PANORAMA HALL)

Bringing Hearts Alive and Kicking

CHAIRS: Bart Meyns, MD and J. David Vega, MD


12:24 PM  (91) Equivalent Long Term Survival of Heart Transplant Patients Receiving Resuscitated Donor Hearts; S.R. Hosmane, M. Devbhandari, S. Williams, R. Venkateswaran, N. Yonan. Transplant Department, University Hospital of South Manchester, Manchester, United Kingdom.

12:36 PM  (92) Donor Treatment with Simvastatin and Methylprednisolone Targets Microvascular-Monocyte Interactions and Improves Cardiac Allograft Survival; R. Tuuminen, S. Syrjälä, R. Krebs, R. Arnaudova, E. Rouvinen, A.I. Nykänen, K.B. Lemström. Transplantation Laboratory, Heart Institute, University of Helsinki and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland; Department of Cardiothoracic Surgery, Helsinki University Central Hospital, Helsinki, Finland.

12:48 PM  (93) Activation of Aldehyde Dehydrogenase Type 2 (ALDH2) by Alda-1 Significantly Enhances the Function of the DCD Heart; F.J. Taghavi, P.K. Thanaporn, C.E. Woods, A. Ali, S.R. Large, D. Mochly-Rosen, E. Ashley, C. Chen. Department of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA; Department of Cardiothoracic Surgery, Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom.

1:00 PM  (94) Ex Vivo Assessment of DCD Hearts with STEEN Solution Is Associated with Less Myocardial Edema and Improved Cardiac Function; A. Ali, C. White, B. Xiang, S. Colah, P. Mundt, R. Arora, T. Lee, S. Tsui, S. Large, G. Tian, D. Freed. Surgery, University of Manitoba, Winnipeg, MB, Canada; Institute of Biodiagnostics, National Research Council of Canada, Winnipeg, MB, Canada; Cardiothoracic Surgery, Papworth Hospital, Cambridge, United Kingdom.

NOON – 1:15 PM

CONCURRENT SESSION 17  (MEETING HALL 4)

B-Cells, Antibodies and Graft Injury

CHAIRS: Lori J. West, MD, DPhil, FRCPC and Karl B. Lemstrom, MD, PhD

NOON  Invited Lecture: B-Cell Biology: A New Frontier in Understanding and Preventing Thoracic Transplant Injury, Richard N. Pierson, III, MD, University of Maryland, Baltimore, MD

12:24 PM  Antibodies to MHC Induce Autoimmunity Leading to Obliterative Airway Disease: Definition of Mechanisms; V. Tiriveedhi, M. Takenaka, V. Subramanian, A. Gelman, G.A. Patterson, T. Mohanakumar, Surgery, Washington University School of Medicine, St. Louis, MO; Pathology & Immunology, Washington University School of Medicine, St. Louis, MO; Cardiovascular Surgery, Washington University School of Medicine, St. Louis, MO.

12:36 PM  Spleen Tyrosine Kinase Modulates Obliterative Bronchiolitis Associated Lymphoid Neogenesis after Lung Transplantation; Y. Matsuda, M. Liu, M. Sato, X. Wang, G. Zehong, S. Keshavjee, C.-W. Chow. Department of Thoracic Surgery, University of Toronto, Toronto, ON, Canada; Division of Respirology, Department of Medicine, University of Toronto, Toronto, ON, Canada.


1:00 PM  Determining Developmental Immaturity in B-Cell Receptor Signaling; L.A. Ryan, L.J. West, S. Urschel. University of Alberta, Edmonton, AB, Canada.
NOON – 1:15 PM

CONCURRENT SESSION 18 (NORTH HALL)

AMR in Thoracic Transplantation: Are We Making Progress?

CHAIRS: Charles C. Marboe, MD and Dylan V. Miller, MD

NOON (99) Interpretation of C4d and C3d in the Diagnosis of Antibody Mediated Rejection in Hearts. Can Accommodation Be Diagnosed? A 51 Month Experience with 550 Patients; E.R. Rodriguez, C.D. Tan. Anatomic Pathology, Cleveland Clinic, Cleveland, OH.

12:12 PM (100) Intracapillary Macrophages in Cardiac Allograft Biopsies for Diagnosis of Antibody-Mediated Rejection (AMR); M. Fedrigo, G. Feltrin, E. Benazzi, F. Poli, A. Frigo, F. Tono, A. Cafarini, C. Castellani, G. Toscano, A. Gambino, G. Gerosa, G. Thiene, A. Angelini, Medico-Diagnostic and Special Therapies, University of Padua, Padua, Italy; Cardiac, Thoracic and Vascular Science, University of Padua, Padua, Italy; Regenerative Medicine Transplant Immunology, IRCCS Ca Granda, Policlinic Hospital, Milan, Italy; Environmental Medicine and Public Health, University of Padua, Padua, Italy.

12:24 PM (101) C4d Positive Biopsy without Dysfunction: Relevance and Outcome in Heart Transplant Recipients; C.D. Tan, E. Rene Rodriguez. Anatomic Pathology, Cleveland Clinic, Cleveland, OH.

12:36 PM (102) Macrophage Density of Cardiac Allograft Biopsies Reflects Complement Staining by C4d and Is Strongly Associated with Alloantibodies to HLA Antigens; L. Xu, C. Drachenberg, E. Feller, A. Burke. University of Maryland, Baltimore, MD.

12:48 PM (103) Pathologic Diagnosis of Antibody-Mediated Rejection of the Lung Allograft; M.M. DeNicola, S.S. Weigt, J.A. Belperio, D.J. Ross, W.D. Wallace. Pathology, University of California, Los Angeles, CA; Medical-Pulmonology/Critical Care, University of California, Los Angeles, CA.

1:00 PM (104) Evaluation of Antibody Mediated Rejection in Lung Transplant Recipients; M.L. Bissonnette, S. Marino, S. Bhorade, A. Husain. Pathology, University of Chicago; Pulmonary and Critical Care, University of Chicago.

1:15 PM – 1:45 PM
BOX LUNCH PICK-UP (BUFFET, 1ST FLOOR)

1:15 PM – 3:15 PM
LUNCH BREAK

1:15 PM – 3:15 PM
JUNIOR FACULTY MENTOR LUNCH (CLUB A)
1:45 PM (108) A New M-Mode Parameter To Assess Ventricular Unloading in the LVAD Patient: Slope of the Anterior Mitral Leaflet (SLAM); S.C. Martinez, E.A. Bradley, E.L. Novak, R. Rasalingam, S.C. Silvestry, G.A. Ewald, S.M. Joseph. 1Internal Medicine, Cardiovascular Division, Washington University School of Medicine, Saint Louis, MO; 2Surgery, Cardiothoracic Division, Washington University School of Medicine, Saint Louis, MO.


1:55 PM (110) Blood Urea Nitrogen to Creatinine Ratio Identifies Heart Failure Patients Likely To Experience Substantial Improvement in Right Ventricular Function Post-LVAD Placement: Insights from the INTERMACS Registry; M.A. Prisco, S.E. Kimmel, M. Jessup, J.M. Testani. 1Department of Medicine, Cardiovascular Division, University of Pennsylvania School of Medicine, Philadelphia, PA; 2Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA.

2:00 PM (111) Outcomes of Patients with Anthracycline Cardiomyopathy Treated with Mechanical Circulatory Support: Data from the INTERMACS Registry; S.H. Oliveira, D. Matthias, D.C. Naftel, Y. Yuan, S.L. Meyers, D. Schmuhl, M.M. Mountis, N. Smedira, W.W.H. Tang, G. Gonzalez-Stawinski, D.O. Taylor, R.C. Starling. 1Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH; 2Department of Biostatistics, University of Alabama, Birmingham, AL.


2:10 PM (113) Improvement in Functional Capacity after Left Ventricular Assist Device Therapy Can Be Limited by Preoperative Comorbidities; M.S. Kiernan, D.T. Pham, N.K. Kapur, N.L. Pereira, K.S. Sundareswaran, M. Maltby, D.J. Farrar, D. DeNofrio, J.G. Rogers. 1Cardiology, Tufts Medical Center; Boston, MA; 2Cardiology, Mayo Clinic, Rochester, MN; 3Thoratec Corporation, Pleasanton, CA; 4Cardiology, Duke University Medical Center; Durham, NC; 5Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.


2:20 PM (115) Bivalirudin Is A Safe and Effective Anticoagulant for Post-Operative Bridging to Warfarin in LVAD Patients; N. Mozami, L.B. Richardson, B. Sun, B. Cabuay, E. Shao, K.M. Hryniewicz, D. Feldman. 1Cardiothoracic Surgery, Minneapolis Heart Institute, Minneapolis, MN; 2Cardiology, Minneapolis Heart Institute, Minneapolis, MN.

2:25 PM (116) Gastrointestinal Bleeding Risk in Patients with Ventricular Assist Devices; J.B. French, S.V. Pambukian, G.B. Smallfield, S. Peter, J.A. Tallaj, R.N. Brown, M.C. Smallfield, J.K. Kirklin, J.F. George. 1Graduate Medical Education Department of Internal Medicine Residency Program, University of Alabama, Birmingham, AL; 2Department of Medicine: Division of Cardiovascular Disease, University of Alabama, Birmingham, AL; 3Department of Medicine: Division of Gastroenterology and Hepatology, University of Alabama, Birmingham, AL; 4Department of Surgery, Cardiovascular/Surgery, University of Alabama, Birmingham, AL.

2:30 PM (117) Patient Selection for Ventricular Assist Device Therapy in the Elderly: Application of the HeartMate II Risk Score; J.A. Cowper, K. Sundareswaran, J.G. Rogers, S.S. Kushwaha, F.D. Pagani, A. Tatooles, R.M. Adamson, M.S. Slaughter, D.J. Farrar. 1Univ. of Michigan Health System, Ann Arbor, MI; 2Thoratec Corporation, Pleasanton, CA; 3Duke University Medical Center, Durham, NC; 4Mayo Clinic, Rochester, MN; 5Advocate Christ Medical Center, Oak Lawn, IL; 6Sharp Memorial Hospital, San Diego, CA; 7Univ of Louisville, Jewish Hospital, and St. Mary's HealthCare, Louisville, KY.

2:35 PM (118) Effectiveness of Platelet Aggregation Inhibitor (Tirofiban) in Treating Continuous Flow Ventricular Assist Device (VAD) Thrombus; K.M. Lam, H. Hayes, J. Barber, G. Green, L. Dembo, G. O'Driscol. 1Advanced Heart Failure and Cardiac Transplant Unit, Royal Perth Hospital, Perth, WA, Australia; 2Cardiology, Royal Perth Hospital, Perth, WA, Australia; 3Notre Dame University, Fremante, WA, Australia.


2:45 PM (120)Derivation of IQ Flow Index as a Measure of LV Chamber Function in Patients Supported with Continuous Flow Centrifugal LVADs; K. Muthiah, D. Robson, R. Walker, P.S. MacDonald, A.M. Keogh, E. Kotlyar, S. O’Donnell, C.E. Granger, K. Dhital, P. Jansz, C.S. Hayward, J. Hill, L.M. Nelson, F. Gustafsson, K. Sander, H. Bruunsgaard, V. Rao, D. Delgado, H. Ross. 1Heart Failure and Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia; 2Cardiothoracic Surgery and Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia.

2:50 PM (121) Factors Associated with Anti-HLA Antibodies in Patients Supported with Continuous Flow Devices and Impact on Probability of Transplant; A.C. Alba, K. Tinkham, L.M. Nelson, F. Gustafsson, K. Sander, H. Bruunsgaard, V. Rao, D. Delgado, H. Ross. 1Toronto General Hospital, Toronto, ON, Canada; 2Rigshospitalet, Copenhagen, Denmark.

2:55 PM (122)Pre Implant Noncompliance Does Not Predict Social Success in LVAD Recipients; M. Maltby, M. Flattery, A. Barclay, V. Kasirajan, D. Tang, M. Hess, S. Barton, M.E. Olbinsch, K. Shah. 1Department of Social Work, Virginia Commonwealth University Health System, Richmond, VA; 2Pauley Heart Center, Virginia Commonwealth University Health System, Richmond, VA; 3Department of Psychiatry, Virginia Commonwealth University, Richmond, VA.
1:30 PM – 3:00 PM
MINI ORAL SESSION 2 (MEETING HALL 4)
Heart and Pediatric Transplantation

CHAIRS: Kimberly Gandy, MD, PhD and Randall C. Starling, MD, MPH


1:40 PM (125) Reduced Skinfold Thickness Is an Independent Predictor of Adverse Outcome in Patients with Advanced Heart Failure; V. Melenovsky, M. Kotrc, A. Jabor, I. Malek, J. Kautzner. Cardiology, Institute for Clinical and Experimental Medicine – IKEM, Prague, Czech Republic.

1:45 PM (126) Risk Stratification of Ambulatory Patients with Advanced Heart Failure Undergoing Evaluation for Heart Transplantation; G.R. Stevens, J. Jiang, P.C. Schulze, T. Kato, N. Gukasyan, A. Levin, D. Mancini, M. Farn. Center for Advanced Cardiac Therapy, Montefiore Medical Center, Bronx, NY. Center for Advanced Cardiac Care, Columbia University Medical Center, New York, NY. Tulane University Medical Center, New Orleans, LA. Columbia University College, New York, NY.

1:50 PM (127) Safety and Prognostic Value of Cerebral Oximetry Monitoring in Heart Failure Patients during Cardiopulmonary Exercise; L. Rifai, W. Taylor, K. Key, M.A. Silver. Department of Medicine, University of Illinois at Chicago/Advocate Christ Medical Center, Oak Lawn, IL. Heart Failure Institute, Advocate Christ Medical Center, Oak Lawn, IL.


2:00 PM (129) Familial Dilated Cardiomyopathy (FDCM) Prevalence in End-Stage Non-Ischemic Heart Failure (ESHF); D.L. Jacoby, E.C. DePasquale, O. Laur, P. Pomianowski, W.J. McKenna. Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT. Department of Genetics, Yale University School of Medicine, New Haven, CT. Institute of Cardiovascular Science, University College London and The Heart Hospital, UCLH NHS Trust, London, United Kingdom.

2:05 PM (130) Extended Criteria Cardiac Transplantation Versus Destination Therapy Left Ventricular Assist Device Therapy in the Continuous Flow Era; M.A. Daneshmand.

2:10 PM (131) Effects of Bosentan in Patients Considered Ineligible for Heart Transplantation Because of Severe Pulmonary Hypertension; L. Tatjer, M. Farrero, M. Cardona, D. Penela, A. Castel, F. Perez-Villa. Heart Transplantation Unit, Hospital Clinic, Barcelona, Spain.


2:20 PM (133) Cardiac Allograft Vasculopathy (CAV) in Children: An 18 Year Pediatric Heart Transplant Study (PHTS) Analysis in 3120 Patients; S.J. Kindel, C. Chin, Y. Law, M.M. Burch, J.K. Kirkin, D.C. Naftel, M.P. Carboni, A. Arens, A.M. Atz, W.J. Dryer, J. Pahl. Division of Cardiology, Department of Pediatrics, Children’s Memorial Hospital – Northwestern University Feinberg School of Medicine, Chicago, IL. The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH. The Heart Center, Seattle Children’s Hospital Medical Center, Seattle, WA. Cardiology, Great Ormond Street Hospital, London, United Kingdom. University of Alabama, Birmingham, AL. Pediatric Cardiology, Duke University Medical Center, Durham, NC. Department of Pediatrics, Division of Cardiology, Medical College of South Carolina, Charleston, SC. Department of Pediatrics, Baylor College of Medicine, Houston, TX.

2:25 PM (134) Geographic Variation in Mortality Rates Following Pediatric Heart Transplantation; R.R. Davies, S. Haldeman, C. Pizarro, Nemours Cardiac Center, A.I. duPont Hospital for Children, Wilmington, DE.


2:45 PM (138) Bortezomib for Management of Antibody-Mediated Rejection Following Pediatric Heart Transplantation; W.T. Mahle, H. Henderson, A.M. Berg, K.R. Kanter. Children’s Healthcare of Atlanta, Emory University, Atlanta, GA.

1:30 PM – 3:00 PM
MINI ORAL SESSION 3
(MEETING HALL 5)
Pulmonary Hypertension and Lung Transplantation

CHAIRS: Florian Wagner, MD and Tereza Martinu, MD

1:30 PM (141) Feasibility and Effectiveness of a Telehealth Clinic for Lung Transplant Recipients; L.G. Singer,1,2 M. Binnie,1,2 C. Chaparro,1,2 S. Chernenko,1 C.-W. Chow,1,2 M. Davies,1 J. Duerr,1 M.A. Hutcheon,1,2 S. Juvet,1,2 N. Marks,1 Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada; 2Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.


1:40 PM (143) A Web-Based Pilot Study of Judgment of the Transplant Benefit by Transplant Experts in Comparison to the Lung Allocation Score: The Eurotransplant Experience; J. Gottlieb,1 A. Rahmel,2 J. Smits.2 Pulmonary Medicine, Hannover Medical School, Hannover, Germany; 2Eurotransplant International Foundation, Leiden, Netherlands.

1:45 PM (144) Does Age Matter in Lung Transplantation?; W. Shermam,1 A. Chaudhry,1 D. Klarin,5 D. Ross,5 J. Belperio,2 J.P. Lynch,2 R. Sagar,2 C. Hunter,1 M. Kwon,1 D. Gjerston,3 A. Ardehali,1 Surgery, Division of Cardiothoracic Surgery, David Geffen School of Medicine at University of California – Los Angeles, CA; 2Medicine, Division of Pulmonary and Critical Care, David Geffen School of Medicine at University of California – Los Angeles, CA; 3Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California – Los Angeles, CA.

1:50 PM (145) Impact of Donor Weight on Lung Graft Survival in Multiorgan Transplantation; M.S. Khan,1 J.S. Heinle,1 B. Shirk,2 J.A. Goss,3 M.G. Schecter,4 D.L.S. Morales,1 Congenital Heart Surgery, Texas Children’s Hospital, Baylor College of Medicine, Houston, TX; 3Congenital Heart Surgery, Texas Children’s Hospital, Houston, TX; 4Department of Surgery, Texas Children’s Hospital, Baylor College of Medicine, Houston, TX.

2:00 PM (146) The High Yield of Transbronchial Cryo-Biopsy in Lung Transplantation Patients; M.R. Kramer,1 L. Fridel, R. Yael,1 D. Rosengarten, F. Oren. The Pulmonary Division, Rabin Medical Center; Petah Tikva, Israel.


2:10 PM (149) Ambulatory ECMO Provides a Superior Bridge to Lung Transplantation Compared to Conventional ECMO; M.G. Hartwig,1 G. Zanotti,1 K. Rehder,2 D.A. Turner,2 S.S. Lin,1 R.D. Davis,1 Surgery, Duke University Medical Center, Durham, NC; 2Pediatrics, Duke University Medical Center, Durham, NC.

2:15 PM (150) Impact of Health Literacy on Adherence after Lung Transplantation; C.J. Gries,1 M.A. Dew,1 A.J. DeVito Dabbas,3 J.M. Plewski,1 D.B. White.4 Division of Pulmonary Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, PA; 2Departments of Psychiatry, Psychology, Epidemiology, Biostatistics and Clinical and Translational Science, University of Pittsburgh, PA; 3School of Nursing, University of Pittsburgh, PA; 4Division of Critical Care, University of Pittsburgh, PA.

2:20 PM (151) Longitudinal Spirometry Progression and BOS Diagnosis Post Transplant: Impact of Reference Equation; P. Robinson,1,2 H. Spencer,2 P. Aurora.2 Department of Pediatric Respiratory Medicine, The Children’s Hospital at Westmead, Sydney, NSW, Australia; 2Department of Cardiothoracic Transplantation, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom.

2:25 PM (152) Post-Marketing Hepatic Safety Profile of Ambrisenat in Patients with Pulmonary Arterial Hypertension – 4 Year Update; D.B. Badessi,1 T. Peschel,1 D. Pizzuti,1 H. Gillies,1 M. Allard,2 C. Blair,2 M. Littman.2 Pulmonary Hypertension Center, University of Colorado, Denver, CO; 2Gilead Sciences, Inc., Foster City, CA.

2:30 PM (153) Systemic Endothelial Dysfunction in Children with Idiopathic Pulmonary Arterial Hypertension Correlates with Disease Severity; D. Friedman,1 J. Szmuszkovicz,2 M. Rabai,2 J.A. Detterich,2 J. Menteer,2 J.C. Wood.2 Pediatric Cardiology, Newark Beth Israel Medical Center; Newark, NJ; 2Pediatric Cardiology, Children’s Hospital Los Angeles, Los Angeles, CA.

2:35 PM (154) Exercise Testing: Influence of Pulmonary Hypertension in Patients with Interstitial Lung Disease Awaiting Lung Transplantation; H.F. Armstrong,1 J.C. Clancy, S.M. Bartsch, M.H. Nguyen, D.R. Stuckey, R.K. Shields, B.Y. Lee. University of Pittsburgh Medical Center, Pittsburgh, PA; 2Department of Rehabilitation and Regenerative Medicine, Columbia University Medical Center; New York, NY; 3Department of Medicine, Division of Cardiology,

2:45 PM (156) Identifying High Risk Patients with Pulmonary Arterial Hypertension Undergoing Six Minute Walk Test; H. Seale, J. Harris, K. Kathleen, F. Kermeen. Queensland Centre for Pulmonary Transplantation & Vascular Disease, The Prince Charles Hospital, Brisbane, QLD, Australia.


2:55 PM (158) Definition and Functional Correlates of Right Ventricular Reserve in a Model of Chronic Thromboembolic Pulmonary Hypertension; J. Guihaire, F. Hadad, O. Mercier, D. Boulate, D. Decante, E. Flecher, P. Dartevelle, E. Fadel. Laboratory of Surgical Research, Marie Lannelongue Hospital, Le Plessis Robinson, France.

3:15 PM – 4:30 PM
CONCURRENT SYMPOSIUM 3 (CONGRESS HALL)
Mechanical Circulatory Support – When is It Too Soon or Too Late?

CHAIRS: Jan Pirk, MD and Stuart D. Russell, MD

3:15 PM Ambulatory Heart Failure Patient – When has Medical Therapy Failed?; JoAnn Lindenfeld, MD, University of Colorado, Denver, CO

3:30 PM Patient Risk – Heart Failure and VAD Operation – Where is the ‘Sweet Spot’?; Garnick C. Stewart, MD, Brigham & Women’s Hospital, Boston, MA

3:45 PM MCS in the Less Sick Patients – Where will REVIVE-IT Fit?; Keith Aaronson, MD, MS, University of Michigan Health Systems, Ann Arbor, MI

4:00 PM DEBATE: MCS Should Be the First Choice for Patients with End-Stage Heart Failure, Not Transplant

PRO: Joseph Woo, MD, University of Pennsylvania Health System, Philadelphia, PA

CON: Andreas Zuckermann, MD, Medical University of Vienna, Austria

4:16 PM Discussion

3:15 PM – 4:30 PM
CONCURRENT SYMPOSIUM 4 (FORUM HALL)
Large and Small Vessels Disease in Heart Transplantation

CHAIRS: A. G. Kloury, MD and Javier Segovia, MD, PhD

3:15 PM Intimal Thickening vs. Remodeling: Clinical Significance of Volumetric Changes in Epicardial Coronary Arteries; Luciano Potena, MD, PhD, University of Bologna, Italy

3:30 PM Microvasculopathy from Artifact to Prognostic Factor; M. Elizabeth H. Hammond, MD, UTAH Cardiac Transplant Program, Intermountain Healthcare, Salt Lake City, UT

3:45 PM From Morphology to Function: Coronary Flow Reserve; Francesco Tona, MD, PhD, University of Padua, Padova, Italy

4:00 PM How Can We Ameliorate Microvasculopathy?; Nicola E. Hiemann, MD, FACC, Deutsches Herzzentrum, Berlin, Germany

4:15 PM Questions and Answers

3:15 PM – 4:30 PM
CONCURRENT SYMPOSIUM 5 (MEETING HALL 1)
Tough Situations in Cardiac Transplantation: Bring in the Experts

CHAIR: Mandeep R. Mehra, MD, MBBS, FACC, FACP

3:15 PM Case Presentation; Jennifer A. Cowger, MD, MS, University of Michigan Health Systems, Ann Arbor, MI

3:50 PM Case Presentation; Arezu Z. Aliabadi, MD, Medical University of Vienna, Austria

PANELISTS:
Juan F. Delgado Jimenez, PhD, “12 Octubre” University Hospital, Madrid, Spain
Roberto Fiocchi, MD, PhD, Ospedali Riuniti di Bergamo, Italy
Sharon A. Hunt, MD, Stanford University, Palo Alto, CA
Sudhir S. Kushwaha, MD, Mayo Clinic, Rochester, MN
Sean P. Pinney, MD, Mount Sinai Medical Center, New York, NY
Hermann Reichenspurner, MD, PhD, University Heart Centre Hamburg, Germany
Marc J. Semigran, MD, Massachusetts General Hospital, Boston, MA
### CONCURRENT SYMPOSIUM 6  (PANORAMA HALL)

**Lung Transplantation for Pulmonary Arterial Hypertension – A Review and Panel Discussion**

**CHAIRS:** Thomas K. Waddell, MD, MSc, PhD and Paul A. Corris, MB, FRCP

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:15 PM</td>
<td>Lung and Heart-Lung Transplantation for PAH: Universal and Regional Issues of Timing of Referral, Listing Status, and Organ Allocation,</td>
<td>Deborah J. Levine, MD, University of Texas Health Science Center, San Antonio, TX</td>
</tr>
<tr>
<td>3:30 PM</td>
<td>Bilateral Lung Versus Combined Heart-Lung Transplantation for PAH: What are the Considerations for the Type of Operation?,</td>
<td>Elie Fadel, MD, PhD, Marie Lannelongue, Paris-Sud University, Le Plessis Robinson, France</td>
</tr>
<tr>
<td>3:45 PM</td>
<td>Bridging Strategies for Lung Transplant Candidates with PAH: Atrial Septostomy, ECMO, RVAD, and Novalung,</td>
<td>Duane Davis, MD, MBA, Duke University Medical Center, Durham, NC</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Lung Transplantation for PAH: Panel Discussion with Transplant Physicians from Various Regions of The World – Learning from Each Other</td>
<td></td>
</tr>
<tr>
<td>4:15 PM</td>
<td>Discussion: Learning from Each Other – How We Do It Around the World</td>
<td></td>
</tr>
</tbody>
</table>

**PANELISTS:**
- Deborah J. Levine, MD, University of Texas Health Science Center, San Antonio, TX, USA
- Elie Fadel, MD, Marie Lannelongue Hospital, Paris-Sud, France
- Walter Klepetko, MD, Medical University of Vienna, Austria
- Phillip Spratt, St. Vincent’s Hospital, Sydney, Australia
- Duane Davis, MD, Duke University Medical Center, Durham, NC, USA

### CONCURRENT SYMPOSIUM 8  (MEETING HALL 5)

**Risky Business: Infectious Risk in Donors and Recipients**

**CHAIRS:** Valentina Stosor, MD and Kate Gould, FRCPath

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:15 PM</td>
<td>Hepatitis C: When is it a Contraindication?,</td>
<td>Minh-Hong T. Nguyen, MD, University of Pittsburgh, PA</td>
</tr>
<tr>
<td>3:35 PM</td>
<td>Opening the Door to Hepatitis B Core Donors,</td>
<td>Shirish Huprikar, MD, Mount Sinai Medical Center, New York, NY</td>
</tr>
<tr>
<td>3:55 PM</td>
<td>On the Horizon: Hepatitis E,</td>
<td>Erik A. M. Verschuuren, MD, University Medical Centre Groningen, The Netherlands</td>
</tr>
<tr>
<td>4:10 PM</td>
<td>The ‘Well-Travelled’ Donor: What Are The Risks?,</td>
<td>Camille N. Kotton, MD, FIDSA, Massachusetts General Hospital/Harvard Medical School, Boston, MA</td>
</tr>
</tbody>
</table>

### CONCURRENT SYMPOSIUM 9  (NORTH HALL)

**Coagulation and Transplantation – The Clot Thickens**

**CHAIRS:** Joren C. Madsen, MD, DPhil and Stephan M. Ensminger, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:15 PM</td>
<td>The Role of Platelets in the Development of Arteriosclerosis – Relevant Aspects for Transplantation,</td>
<td>Steffen Massberg, MD, PhD, German Heart Center, Munich, Germany</td>
</tr>
<tr>
<td>3:40 PM</td>
<td>Platelets and Leucocyte Adhesion,</td>
<td>Christian Weber, MD, Kreislaufinstitut, Munich, Germany</td>
</tr>
<tr>
<td>4:05 PM</td>
<td>Complement and T Cell Alloimmunity,</td>
<td>Steven Sacks, MD, PhD, MRC Centre for Transplantation, King’s College London, United Kingdom</td>
</tr>
</tbody>
</table>

### CONCURRENT SYMPOSIUM 7  (MEETING HALL 4)

**Special Considerations: Cystic Fibrosis and Lung Transplantation**

**CHAIRS:** Cecilia Chaparro, MD and Paul Aurora, MBBS, BSc(Hons), MSc, MRCP, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:15 PM</td>
<td>Surgical Issues in Lung Transplantation for Cystic Fibrosis,</td>
<td>John H. Dark, MB, FRCS, Newcastle Upon Tyne University, United Kingdom</td>
</tr>
<tr>
<td>3:40 PM</td>
<td>Microbiological Issues in Patients with Cystic Fibrosis Undergoing Lung Transplantation,</td>
<td>Shahid Husain, MD, MS, University Health Network, University of Toronto, Canada</td>
</tr>
<tr>
<td>4:05 PM</td>
<td>Medical Management of the Lung Transplant Recipient with Cystic Fibrosis,</td>
<td>Denis Hadjiilias, MD, MHS, University of Pennsylvania, Philadelphia, PA</td>
</tr>
</tbody>
</table>
### 5:00 PM – 6:15 PM

#### CONCURRENT SYMPOSIUM 10

**Joint ISHLT/IPTA Symposium**

**CHAIRS:** Shaf Keshavjee, FRCS(C) and Richard E. Chinnock, MD

**Part I: Cardiac Transplant in Infancy – A Window into the Immune System**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00 PM</td>
<td>Insights into Immunological Development and Tolerance Drawn from Recipients of Heart Transplantation in Infancy, Simon Urschel, MD, University of Alberta, Edmonton, Canada</td>
</tr>
<tr>
<td>5:15 PM</td>
<td>Challenges to Achieving Tolerance, Mohamad H. Sayegh, MD, Brigham and Women's Hospital &amp; Children's Hospital, Boston, MA</td>
</tr>
<tr>
<td>5:30 PM</td>
<td>Insights into Acquisition and Maintenance of Host Defense after Heart Transplantation in Infancy, Jeffrey L. Platt, MD, University of Michigan, Ann Arbor, MI</td>
</tr>
<tr>
<td>5:45 PM</td>
<td>Heart Transplantation Yields Insights into T Cell Dependent B Cell Responses to Infection, Vaccines and Regulation of Immunity, Marilia Cascalho, MD, PhD, University of Michigan, Ann Arbor, MI</td>
</tr>
</tbody>
</table>

**Part II: Update on ISHLT / IPTA Consensus Process**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 PM</td>
<td>Heart, Elfriede Pahl, MD, Children's Memorial Hospital, Chicago, IL</td>
</tr>
<tr>
<td>6:05 PM</td>
<td>Lung, Samuel B. Goldfarb, MD, The Children's Hospital of Pennsylvania, Philadelphia, PA</td>
</tr>
<tr>
<td>6:10 PM</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

### 5:00 PM – 6:15 PM

#### CONCURRENT SESSION 19

**MCS: Desired Outcomes – Can We Get There**

**CHAIRS:** Edwin C. McGee, MD and Paul Mohasci, MD, eMBA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00 PM</td>
<td>(159) Impact of Bridging with Ventricular Assist Devices on Long-Term Survival Following Heart Transplantation; A. Kilic, A.S. Shah, D.D. Yuh, V.A. Baumgartner, J.V. Conte, Division of Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD; Section of Cardiac Surgery, Yale University School of Medicine, New Haven, CT.</td>
</tr>
<tr>
<td>5:12 PM</td>
<td>(160) Trends in Utilization and Costs of Left Ventricular Assist Device Therapy for Advanced Heart Failure in US – Results from the Nationwide Inpatient Sample 2005-2008; A.R. Mahankali Sridhar, S. Parasa, W.B. Hilegass, G. Pranajt, Department of Medicine, Washington Hospital Center, Washington, DC; Division of Cardiology, University of Alabama, Birmingham, AL; Division of Cardiology, Johns Hopkins University, Baltimore, MD.</td>
</tr>
<tr>
<td>5:24 PM</td>
<td>(161) Patients with INTERMACS 4-7 Heart Failure Have Reduced Quality of Life; P.C. Patel, C.G. Stewart, M.M. Kittleson, J.A. Cowger, C.B. Patel, M.M. Mountis, F.L. Johnson, J.E. Rame, J. Testani, M.E. Guglin, J.J. Teuteberg, M.H. Drazner, University of Texas, Southwestern, Dallas, TX; Brigham and Women’s Hospital, Boston, MA; Cedars-Sinai Heart Institute, Los Angeles, CA; University of Michigan, Ann Arbor, MI; Duke University, Durham, NC; Cleveland Clinic, Cleveland, OH; University of Iowa, Iowa City, IA; University of Pennsylvania, Philadelphia, PA; University of South Florida, Tampa, FL; University of Pittsburgh, PA.</td>
</tr>
<tr>
<td>5:36 PM</td>
<td>(162) Prediction of Events in Patients with Advanced Heart Failure: Application of the Seattle Heart Failure Model to the MEDAMACs Population; J.J. Teuteberg, M. Kittleson, J. Cowger, C. Patel, G. Stewart, M. Mountis, F.L. Johnson, P. Patel, E. Rame, J. Testani, M. Guglin, L. Stevenson, R.L. Kormos, Heart and Vascular Institute, University of Pittsburgh, PA; Cardiology, Cedars Sinai, Los Angeles, CA; Cardiology, University of Michigan, Ann Arbor, MI; Cardiology, Duke University, Durham, NC; Cardiology, Brigham and Women’s, Boston, MA; Cardiology, Cleveland Clinic, Cleveland, OH; Cardiology, University of Iowa, Ames, IA; Cardiology, UT Southwestern, Dallas, TX; Cardiology, University of Pennsylvania, Philadelphia, PA; Cardiology, University of South Florida, Tampa, FL.</td>
</tr>
<tr>
<td>5:48 PM</td>
<td>(163) Increased LVAD Utilization Has Increased Waiting Time for Medically Bridged Patients; E.S. Shao, R. Garberich, K. Hryniewicz, B. Sun, N. Moazami, B. Cabuyay, D. Feldman, Minneapolis Heart Institute, Minneapolis, MN.</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>(164) Continuous Flow Mechanical Circulatory Support: Does It Really Improve Peak Oxygen Consumption (VO2); E.S. Leibner, C. Cysyk, K. Eleuteri, E. Stephenson, B. Soleimani, El-Banayosy, J.P. Boehmer, W.E. Pae, Heart and Vascular Institute, Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey, PA; Division of Artificial Organs, Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey, PA.</td>
</tr>
</tbody>
</table>
CONCURRENT SESSION 20
(Forum Hall)
Advanced Heart Failure: When is a Contraindication Not a Contraindication to Transplant

CHAIRS: Luciano Potena, MD, PhD and Allen Anderson, MD

5:00 PM (165) Analysis of over 1000 Patients Listed for Combined Heart-Kidney Transplant in the Modern Era; J.M. Schaffer, S.K. Singh, B.A. Reitz, P.E. Oyer, R.C. Robbins, H.R. Mallidi, Cardiac Surgery, Stanford University Medical Centre, Palo Alto, CA; 2Cardiac Surgery, Hamilton General Hospital, McMaster University, Hamilton, ON, Canada; 3Cardiac Surgery, Baylor School of Medicine, Houston, TX.

5:12 PM (166) High Transpulmonary Gradient Obtained at the Time of LVAD Implantation Is Associated with Worse Long Term 1 Year Survival after Cardiac Transplantation; N. Uriel, D.B. Sims, P.C. Colombo, H. Takayama, R. John, F.D. Pagani, Y. Naka, K.S. Sundareswaran, D.J. Ferran, U.P. Jorde, Medicine, Columbia University, New York, NY; 2Surgery, Columbia University, New York, NY; 3Surgery, University of Minnesota, Minneapolis, Mn; 4Surgery, University of Michigan, Ann Arbor, MI; 5Thoratec Corporation, Pleasanton, CA.

5:24 PM (167) Follow-Up of Lung and Heart Transplant Recipients with Pre-Transplant Malignancies; V. Siuwardadottir, O. Bjortuft, H. Eiskjær, H. Ekmehag, E. Gude, F. Gustafsson, I. Hagerman, M. Halme, L. Lommi, L. Mared, G.C. Riise, S. Simonsen, Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Respiratory Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Department of Cardiology, Skejby University Hospital, Aarhus, Denmark; Department of Cardiology, Skåne University Hospital, Lund, Sweden; Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Department of Cardiology, Rigshospitalet Copenhagen, Copenhagen, Denmark; Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden; Division of Respiratory Medicine, Helsinki University Central Hospital, Helsinki, Finland; Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland; Department of Respiratory Medicine, Skåne University Hospital, Lund, Sweden.

5:36 PM (168) Experience of Sequential Heart and Bone Marrow Transplant for AL Amyloidosis: What Is the Optimal Waiting Time for Bone Marrow Transplant; J.D. Estep, D.S. Medina, A.M. Cordero-Reyes, K. Youker, A. Bhimaraj, M. Loebe, G. Amione-Torres. The Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, TX.

5:48 PM (169) Interplay between Pulmonary Hypertension and Donor-Recipient Matching in the Risk for Early Graft Failure after Heart Transplantation; L. Potena, S. Martin-Suarez, V. Manfredini, M. Maselli, E. Pilato, G. Magnani, F. Fallani, F. Cocolo, A. Russo, F. Fallani, F. Grigioni, A. Branzi, G. Arpesella. Cardiovascular Department, University of Bologna, Bologna, Italy.

6:00 PM (170) Heart Transplantation in 11 Patients with End Stage Heart Failure Caused by Muscular Dystrophy; U. Fuchs, U. Schulz, B. Schulze, A. Zittermann, K. Hakim-Meibodi, J.F. Gummert. Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany.
### CONCURRENT SESSION 22 (PANORAMA HALL)

**Pulmonary Hypertension: Assessment and Prognosis**

**CHAIRS:** Srinivas Murali, MD and Dana McGlothlin, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00 PM</td>
<td>(177) ‘Notching’ of the Right Ventricular Outflow Tract Doppler Profile (DopplerRVOT) Is a Highly Sensitive and Specific Predictor of Pulmonary Vascular Disease among Patients with Systemic Sclerosis; R. Saggar, 1, R. Saggar, 2, A. Derhovanessian, 3, A. V. Fields, 4, D. Khanna, 5, P. R. Forfia, 3, 5 Heart-Lung Institute, St. Joseph Hospital &amp; Medical Center, Phoenix, AZ; 2Pulmonary &amp; Critical Care, University of California, Los Angeles, CA; 3Heart Failure/Transplant Cardiology, Univ of Penn, Philadelphia, PA; 4Division of Rheumatology, Scleroderma Program, University of Michigan Scleroderma Program, Ann Arbor, MI.</td>
</tr>
<tr>
<td>5:12 PM</td>
<td>(178) Reduced Resting Pulmonary Artery Compliance (CPa) in Exercise-Induced Pulmonary Arterial Hypertension (El-PAH) Associated with Systemic Sclerosis (SSc); R.E. Girgis, 1, R.J. Tedford, 2, S.C. Mathai, 1, D.A. Kass, 1, P.M. Hassoun, 1 Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD.</td>
</tr>
<tr>
<td>5:24 PM</td>
<td>(179) Exercise Determinates of Pulmonary Hypertension in Patients with Interstitial Lung Disease: Which Is Better?; H.F. Armstrong, 1, P.C. Schulze, 2, D.J. Lederer, 3, M.N. Bartels, 1 1Department of Rehabilitation and Regenerative Medicine, Columbia University Medical Center, New York, NY; 2Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY; 3Department of Surgery, Columbia University Medical Center, New York, NY.</td>
</tr>
<tr>
<td>5:36 PM</td>
<td>(180) Exercise Hemodynamics Can Predict Otherwise Undetectable Left Heart Failure in Patients Referred Due to Suspicion of Pulmonary Arterial Hypertension; P. Lesny, M. Luknar, I. Varga, P. Solik, E. Goncalvesova, National Cardiovascular Institute, Bratislava, Slovakia (Slovak Republic).</td>
</tr>
<tr>
<td>5:48 PM</td>
<td>(181) Hemodynamic Assessment of Pulmonary Hypertension in Grown-Up Congenital Heart Disease; M. Gerges, C. Gerges, M. Lang, I.M. Lang, Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>(182) Validation of the REVEAL Score for Pulmonary Arterial Hypertension and Application of the Model To Predict Long Term Survival; R. Cogswell, D. McGlothlin, R. Shaw, T. DeMarco. Cardiology, University of California, San Francisco, CA.</td>
</tr>
</tbody>
</table>

### CONCURRENT SESSION 23 (MEETING HALL 4)

**Clinical Case Dilemmas in Thoracic Transplantation**

**CHAIRS:** Pali D. Shah, MD and Geert M. Verleden, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00 PM</td>
<td>(183) Dyspnea, Dizziness and Weakness 5 Years after Heart Transplantation; K.J. Lindley, A.K. Ravichandran, J. Schilling, S.M. Joseph. Cardiology, Washington University in St. Louis, Saint Louis, MD.</td>
</tr>
<tr>
<td>5:07 PM</td>
<td>EXPERT DISCUSSANT: Gerald J. Berry, MD, Stanford University, Palo Alto, CA.</td>
</tr>
<tr>
<td>5:19 PM</td>
<td>EXPERT DISCUSSANT: Peter Hopkins, MBBS, FRACP, HONOURS, The Prince Charles Hospital Brisbane, Australia.</td>
</tr>
<tr>
<td>5:24 PM</td>
<td>(185) Renal Failure and Hemolysis 10 Days after Lung Transplantation; I. Sinapi, 1, P. Bulpa, 1, 2 M. Gonzalez, 2 M. Buche, 1, L. Delaunois, 1, I. Michaux, 2, A. Dive, 2, P. Eyraud, 1, 2 Transplant Center, CHU Mont-Godinne, Yvoir, Belgium; 2Intensive Care, CHU Mont-Godinne, Yvoir, Belgium.</td>
</tr>
<tr>
<td>5:31 PM</td>
<td>EXPERT DISCUSSANT: Allan Glanville, MBBS, FRACP, St. Vincent’s Hospital, Sydney, Australia.</td>
</tr>
<tr>
<td>5:36 PM</td>
<td>(186) Long Term Mechanical Circulatory Support: What Are the Final Options?; C.B. Patel, 1, M.L. Mackinnon, 1, A.D. Smith, 1, G.M. Felker, 1, D. Vikraman-Sushama, 1, D.L. Sudan, 1, P.B. Rosenberg, 1, A.F. Hernandez, 1, G.T. Delario, 2, C.A. Milano, 1, J.G. Rogers, 1 1Duke University Medical Center, Durham, NC; 2Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA.</td>
</tr>
<tr>
<td>5:43 PM</td>
<td>EXPERT DISCUSSANT: George M. Wieselthaler, MD, University of California San Francisco, CA.</td>
</tr>
<tr>
<td>5:48 PM</td>
<td>(187) Ventricular Dysfunction after Pediatric Heart Transplant: It’s Not Always Rejection; E.L. Albers, 1, D.P. Bichell, 1, D.A. Dodd, 1 1Pediatric Cardiology, Vanderbilt University, Nashville, TN; 2Pediatric Cardiothoracic Surgery, Vanderbilt University, Nashville, TN.</td>
</tr>
<tr>
<td>5:55 PM</td>
<td>EXPERT DISCUSSANT: Beth D. Kaufman, MD, Children’s Hospital of Philadelphia, PA.</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>(188) Is the Use of Remodulin Safe for Pregnant and Breastfeeding Patients with Pulmonary Arterial Hypertension (PAH)? A Case Report; V. Franco, J. Mueller, C.J. Daniels. Cardiovascular Medicine, The Ohio State University, Columbus, OH.</td>
</tr>
<tr>
<td>6:07 PM</td>
<td>EXPERT DISCUSSANT: Raymond Benza, MD, Allegheny General Hospital, Pittsburgh, PA.</td>
</tr>
</tbody>
</table>
CONCURRENT SESSION 24  (MEETING HALL 5)

Heart Failure: Back to Basics

CHAIRS: Lee R. Goldberg, MD, MPH and Eric Epailly, MD

5:00 PM (189) Regulation of the Mitochondrial Proteins Mitofilin and Porin in Explanted Failing Human Hearts; R.C. Gupta, S. Rastogi, M. Wang, P. Mohyi, H.N. Sabbah. Medicine, Henry Ford Hospital, Detroit, MI.

5:12 PM (190) Local Expression of Myocardial Galectin-3 Does Not Correlate with Its Serum Levels in Patients Undergoing Heart Transplantation; A. Beiras-Fernandez,1 J. Rothkopf,2 S. Reinwand,3 I. Kaczmarek,2 S. Kreth,3 F. Weis,3 1Thoracic and Cardiovascular Surgery, JW Goethe University, Frankfurt, Germany; 2Cardiac Surgery, LM-University, Munich, Germany; 3Anesthesiology, LM-University, Munich, Germany.

5:24 PM (191) Modulation of the Myocardial Expression of Neuregulin-1 and Its Receptor ErbB4 in Patients with Chronic Heart Failure; J. Rothkopf,1 F. Weis,2 I. Kaczmarek,1 S. Kreth,2 A. Beiras-Fernandez,3 1Cardiac Surgery, LM-University of Munich, Munich, Germany; 2Anesthesiology, LM-University of Munich, Munich, Germany; 3JW-Goethe University, Frankfurt, Germany.

5:36 PM (192) Safety and Efficacy of Ixmyelocel-T, an Expanded Patient-Specific Mixed Cell Product, in Dilated Cardiomyopathy (IMPACT-DCM); R.R. Bunge,1 A.N. Patel,2 B.L. Hamman,4 O.M. Lattouf,3 N.G. Smedira,5 R.L. Bartel,6 S. Watling,6 B.A. Bruckner,1 1Cardiovascular Surgery, The Methodist Hospital DeBakey Heart & Vascular Center, Houston, TX; 2Cardiothoracic Surgery, University of Utah, Salt Lake City, UT; 3Cardiothoracic Surgery, Emory Crawford Long Hospital, Atlanta, GA; 4Cardiothoracic Surgery, Baylor University Medical Center, Dallas, TX; 5Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH; 6Aastrom Biosciences Inc., Ann Arbor, MI.

5:48 PM (193) Biomarkers of Recovered Heart Function; Z. Hollander,1,2 M. Lazárová,2 A. Ignaszewski,2 V. Chen,1 R.T. Ng,1,5 J.E. Wilson-McManus,1,2 R. Balshaw,1,2 R.W. McMaster,1,2 P.A. Keown,1,2,4 B.M. McManus,1,2,4,8,9 PROOF Centre of Excellence, Vancouver, Canada; 2Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, Canada; 3Internal Medicine – Cardiology, University Hospital Olomouc, Olomouc, Czech Republic; 4Medicine, The University of British Columbia, Vancouver, Canada; 5Medical Genetics, The University of British Columbia, Vancouver, Canada; 6Computer Science, The University of British Columbia, Vancouver, Canada; 7Statistics, The University of British Columbia, Vancouver, Canada; 8Medical Genetics, The University of British Columbia, Vancouver, Canada; 9UBC James Hogg Research Centre, Vancouver, Canada; 10Institute for Heart + Lung Health, Vancouver, Canada.

6:00 PM (194) End-Stage Human Failing Hearts Increase Cardiac Progenitor Cells by Switching to a Developmental Program; S. Kaushal,1 D. Simpson,1 R. Mishra,2 S. Sharma,1 E. Pahl,2 1Cardiothoracic Surgery, University of Maryland, Baltimore, MD; 2Cardiology, Children's Memorial Hospital, Chicago, IL.

6:15 PM – 7:00 PM
PAST PRESIDENT’S COUNCIL MEETING AND RECEPTION
(CLUB B)

6:15 PM – 7:00 PM
EXHIBIT HALL RECEPTION AND POSTER VIEWING
(CONGRESS HALL FOYER)

FRIDAY, APRIL 20, 2012

7:00 AM – 6:00 PM
REGISTRATION DESK OPEN
(CONGRESS HALL FOYER)

7:00 AM – 6:30 PM
SPEAKER READY ROOM OPEN
(CLUB H)

8:00 AM – 7:00 PM
POSTER VIEWING
(CONGRESS HALL FOYER)

8:00 AM – 7:00 PM
PRESS OFFICE OPEN
(MEETING ROOM 2.4)

8:00 AM – 9:15 AM

CONCURRENT SYMPOSIUM 11  (MEETING HALL 4)
Management of the Failing Fontan Patient Across the Age Spectrum?

CHAIRS: W. Robert Morrow, MD and Aditya Kaza, MD

8:00 AM How and Why Does the Fontan Circuit Fail?, Anne I. Dipchand, MD, Hospital for Sick Children, Toronto, Canada

8:10 AM Is Fontan Conversion a Good Alternative to Transplantation?, Carl Lewis Backer, MD, Children's Memorial Hospital, Chicago, IL

8:20 AM When to list the Failing Fontan Patient for Transplantation?, Daniel Bernstein, MD, Stanford University and Packard Children's Hospital at Stanford, Palo Alto, CA

8:30 AM Plumbing Matters in the Failing Fontan Circulation!, Asif Hasan, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

8:40 AM Challenges in the ICU Post-Transplant, Jane V. Cassidy, MRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

8:50 AM What are the Post-transplant Outcomes for the Failing Fontan Patient?, Steven D. Zangwill, MD, Children's Hospital of Wisconsin, Milwaukee, WI
8:00 AM – 9:15 AM

**CONCURRENT SESSION 25**  
**(CONGRESS HALL)**

**VAD Future: Recovery and New Devices?**

**CHAIRS:** George M. Wiesethaler, MD and Michael McDonald, MD, FRCP(C)

8:00 AM (195) **A New Treatment Option for Intermacs Profile 4, 5 and 6 Patients with the Circuitite® Synergy® System;**  
B. Meyns,1 F. Rega,1 M. Strueber,2 A. Barbone,3 E. Vitali,3 D. Burkhoff,4 University Hospital Leuven, Leuven, Belgium; 4Hannover Medical School, Hannover, Germany; 1Instituto Clinico Humanitas, Milan, Italy; 2Circuitite, Inc., Saddle Brook, NJ.

8:12 AM (196) **The Role of ST-2 as a Novel Heart Failure Biomarker during Mechanical Unloading and Recovery in MCS Patients;**  

8:24 AM (197) **First Clinical Evaluation of a Novel Percutaneous Right Ventricular Assist Device: The Impella RP;**  
B. Meyns1, D. Freed2, D. Raess,4 P. Leprince,3 1University of British Columbia, Vancouver, Canada; 4University of Manitoba, Winnipeg, Canada; 4Ptitie Salpêtrière Hospital, Paris, France; 4Abiomed Inc, Danvers.

8:36 AM (198) **Cardiac Power Output Predicts Myocardial Recovery and Successful Explantation of Left Ventricular Assist Device;**  

8:48 AM (199) **Reverse Remodelling with the Use of the Circuitite® Synergy® Circulatory Assist System;**  
J. Geens,1 P. Claus,2 S. Jacobs,1 M. Martin,1 I. Van Tichelen,1 F. Rega,1 D. Burkhoff,3 B. Meyns1. 1Dept. of Cardio Surgery, University Hospitals Leuven, Leuven, Belgium; 2Dept. of Medical Imaging, University Hospitals Leuven, Leuven, Belgium; 3Circuitite, Inc., Saddle Brook, NJ.

9:00 AM (200) **Does Prolonged Continuous-Flow LVAD Unloading Induce Hypertrophy Regression to the Point of Atrophy in the Failing Human Heart?;**  
S.G. Drakos,1,2,4 N.A. Diakos,2,4 A.G. Kloury,1 C.H. Selzman,1 B.B. Reid,1 D.V. Miller,1 M.P. Revelo,1 D.R. Verma,1 D. Weaver-Pinson,1 K. Brunisholz,1 R. Alharethi,1 C. Myrick,3 M. Salama,2 E.M. Gilbert,1 E.H. Hammond,1 J. Stehlik,1 D.Y. Li,2 UTAH Cardiac Transplant Program, Salt Lake City, UT; 3University of Utah Molecular Medicine & ARUP, Salt Lake City, UT; 4Intermountain Donor Services, Salt Lake City, UT; 4Division of Cardiology, University of Athens, Athens, Greece.

8:00 AM – 9:15 AM

**CONCURRENT SESSION 26**  
**(FORUM HALL)**

**Heart Transplant Immunosuppression: What Can We Learn from Clinical Trials**

**CHAIRS:** Eulalia Roig, MD and Donna Mancini, MD

8:00 AM (201) **Multicenter Randomized Trial of Everolimus vs. Mycophenolate Mofetil in Heart Transplantation: Final 24 Month Analysis of Efficacy and Safety;**  
J. Kobashigawa,1 D. Pauly,2 A. Kloury,3 H. Ross,4 S.-S. Wang,5 B. Cantin,6 A. van Bakel,7 R.C. Stanley,2 S. Hirt,3 G. Gong,10 C. Paris,10 P. Lopez,11 H. Eisen.12 1 Cedars-Sinai Heart Institute, Los Angeles; 2University of Florida College of Medicine, Gainesville; 3Intermountain Medical Center, Salt Lake City; 4University Health Network, Toronto General Hospital, Toronto, Canada; 5National Taiwan University, Taipei, Taiwan; 6Quebec Heart Institute, Quebec, Canada; 7Medical University of South Carolina, Charleston; 8Cleveland Clinic Foundation, Cleveland; 9Universitätsklinikum Regensburg, Regensburg, Germany; 10Novartis Pharmaceuticals, East Hanover; 11Novartis Pharma AG, Basel, Switzerland; 12Drexel University College of Medicine/Hahnemann University Hospital, Philadelphia.

8:12 AM (202) **Alemtuzumab Induction Facilitates Steroid-Free Immunosuppression in Human Cardiac Transplantation: Four Year Outcomes;**  
J.J. Teuteberg,1 R. Zomak,1 C. Yost,1 C. Newman,1 M. Navoney,1 J.K. Bhama,1 D. McNamara,1 C. Bermudez,1 R.L. Kormos,1 M.A. Shullo,2 1 Heart and Vascular Institute, University of Pittsburgh, PA; 2Pharmacy and Therapeutics, University of Pittsburgh, PA.

8:24 AM (203) **Prospective Randomized 3-Arm Trial Comparing Tacrolimus with Mycophenolate Mofetil (MMF) or Sirolimus with Calcineurininhibitor-Free Immunosuppression (Sirolimus/MMF) after Heart Transplantation: 5-Year Results;**  
I. Kaczmarek,1 M.-M. Zaruba,2 S. Sadoni,3 A. Bigdeli,2 R. Schramm,1 B. Meisen.1 1Transplantation Center Ludwig-Maximilians-University, Munich, Germany; 2Cardiology, Ludwig-Maximilians-University, Munich, Germany; 3Cardio Surgery, Ludwig-Maximilians-University, Munich, Germany.

8:36 AM (204) **Long-Term Benefit of Tacrolimus over Cyclosporine Preventing Cardiac Allograft Vasculopathy (CAV) after Heart Transplantation: 10-Year Results of a Prospective Randomized Trial Comparing Tacrolimus Versus Cyclosporine Both in Combination with Mycophenolate Mofetil;**  
J. Segovia,1 M. Gómez-Bueno,1 J. Goicoeia,1 J. Elizaga,2 J. Fernández-Yáñez,2 J. Palomo,2 F. González-Vílchez,3 L. Alonso-Pulpo,1 1Hospital Puerta de Hierro, Madrid, Spain; 2Hospital Gregorio Marañón, Madrid, Spain; 3Hospital Marqués de Valdecilla, Santander, Spain.

8:48 AM (205) **A Survey of Current Practice for Antibody Mediated Rejection in Heart Transplant To Guide Treatment Standardization;**  
S. Chih,1 K. Tinckam,2 H.J. Ross.3 1Division of Cardiology and Cardiac Transplant, Toronto General Hospital-University Health Network, Toronto, ON, Canada; 2Division of Nephrology and Multi-Organ Transplant, Toronto General Hospital-University Health Network, Toronto, ON, Canada.

9:00 AM (206) **Effect of Everolimus in Patients with Established Cardiac Allograft Vasculopathy: Results of a Randomized, Multicenter Intravascular Ultrasound Study;**  
J. Segovia,1 M. Gómez-Bueno,1 J. Goicoeia,1 J. Elizaga,2 J. Fernández-Yáñez,2 J. Palomo,2 F. González-Vílchez,3 L. Alonso-Pulpo,1 1Hospital Puerta de Hierro, Madrid, Spain; 2Hospital Gregorio Marañón, Madrid, Spain; 3Hospital Marqués de Valdecilla, Santander, Spain.
8:00 AM – 9:15 AM

CONCURRENT SESSION 27
(MEETING HALL 1)
Basic Science of Lung Transplantation

CHAIRS:
Thomas Waddell, MD, MSc, PhD and
Daniel C. Chambers, MBBS, MRCP, FRACP, MD

8:00 AM (207) Plasma RAGE Levels Measured 24 Hours after Lung Transplantation Are Associated with Bronchiolitis Obliterans Syndrome (BOS); R.J. Shah,1 J.M. Diamond,1 S. Kawut,1 E. Cantu,3 N. Wickersham,2 L.B. Ware,2 J.D. Christie.1 1Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia; 2Division of Allergy, Pulmonary, and Critical Care, Vanderbilt University, Nashville; 3Division of Surgery, University of Pennsylvania, Philadelphia.

8:12 AM (208) IL-23R Polymorphism Is Associated with Higher Mortality, after Lung Transplantation; D. Ruttens,1 S.E. Verleden,1 E. Wauters,2 A. Vaneylen,1 V. Robin,1 D. Lambrechts,2 D. Van Raemdonck,1 G.M. Verleden,1 B.M. Vanaudenaerde,1 Lung Transplantation Unit, Lab of Pneumology, KULeuven, University Hospital Gasthuisberg Leuven, Belgium; 2Vesalius Research Centrum, University Hospital Gasthuisberg, Leuven, Belgium.

8:24 AM (209) Functional TLR4 Polymorphisms Are Associated with Lower Risk of Primary Graft Dysfunction (PGD) after Lung Transplantation; J.M. Diamond,1 R. Feng,1 N.J. Meyer,1 R. Shah,1 S.M. Kawut,1 D.J. Lederer,2 J.C. Lee,1 V. Ahya,1 E. Cantu,1 A. Weinacker,3 S. Bhorade,4 V.N. Lama,5 J.B. Orenes,6 J. Sonett,2 K.M. Wille,7 M. Crespo,8 D. Weill,3 B. Kohl,1 S.M. Arcasoy,2 A.S. Shah,6 P.D. Shah,9 E. Demissie,1 J.M. Reynolds,10 J.A. Belperio,11 D. Wilkes,11 L.B. Ware,9 S.M. Palmer;12 J.D. Christie.1 1University of Pennsylvania, Philadelphia, PA; 2Columbia University, New York, NY; 3Stanford University, Palo Alto, CA; 4University of Michigan, Ann Arbor; MI; 5University of Chicago, IL; 6Johns Hopkins University Hospital, Baltimore, MD; 7University of Alabama, Birmingham, AL; 8University of Pittsburgh, PA; 9Vanderbilt University Medical Center, Nashville, TN; 10Indiana University School of Medicine, Indianapolis, IN; 11David Geffen School of Medicine at UCLA, Los Angeles, CA; 12Duke University, Durham, NC.

8:36 AM (210) Toll-Like Receptor 4 Polymorphisms and the Risk of Primary Graft Dysfunction after Lung Transplantation; S. Wauters,1 E. Wauters,2 D. Ruttens,3 J. Somers,1 S.E. Verleden,2 B.M. Vanaudenaerde,3 D. Lambrechts,2 J. van Loon,4 G.M. Verleden,3,5 D.E. Van Raemdonck,1,6 Laboratory for Experimental Thoracic Surgery, KULeuven, Leuven, Belgium; 2Vesalius Research Center, KULeuven, Leuven, Belgium; 3Laboratory of Pneumology, KULeuven, Leuven, Belgium; 4Division of Neurosurgery, UZLeuven, Leuven, Belgium; 5Division of Thoracic Surgery, UZLeuven, Leuven, Belgium.

8:48 AM (211) WITHDRAWN

9:00 AM (212) Direct Evidence of Chronic Epithelial Injury and Dysregulated Repair in the Lung Allograft; B. Banerjee,1,5 M. Muskh,2 P. Hopkins,4 S.M. Stick,1,3,5 D.C. Chambers,4 A. Kicic,1,5 Telethon Institute for Child Health Research, SIBiaco, WA, Australia; 2Western Australia Lung Transplant Program, Royal Perth Hospital, Perth, WA, Australia; 3Department of Respiratory Medicine, Princess Margaret Hospital for Children, Perth, WA, Australia; 4Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, QLD, Australia; 5School of Paediatrics and Child Health, University of Western Australia, Nedlands, WA, Australia.

8:00 AM – 9:15 AM

CONCURRENT SESSION 28
(PANORAMA HALL)
Right Ventricle Function

CHAIRS:
Marc de Perrot, MD and Veronica Franco, MD, MSPH

8:00 AM (213) The Relationship between Right Ventricular Pulmonary Arterial Coupling and Right Ventricular Structure and Function in a Porcine Model of Pulmonary Hypertension; J. Guihaire, F. Haddad, O. Mercier; B. Decante, E. Fletcher; P. Dartevelle, E. Fadel. Laboratory of Surgical Research, Marie Lannelongue Hospital, Le Plessis Robinson, France.

8:12 AM (214) Improvement in Right Ventricular Function after Surgical Treatment of Chronic Thromboembolic Pulmonary Hypertension in a Porcine Model; J. Guihaire, O. Mercier; F. Haddad, D. Boulão, B. Decante, P. Dormrul, S. Eddahibi, E. Fletcher, F. Fadel. Laboratory of Surgical Research, INSERM U999, Marie Lannelongue Hospital, Le Plessis Robinson, France.

8:24 AM (215) Independent Determinants of Septal Curvature in Patients with Pulmonary Arterial Hypertension; J. Haddad,1 A.Y. Denault,2 M. Shkiri,1 J. Guihaire,3 O. Mercier; F. Gomani,1 E. Ashley,1 E. Fadel,2 R. Zamanian;1 I. Schnitter;1 Medicine, Stanford University, Stanford, CA; 2Intensive Care Medicine and Anesthesia, Montreal University, Montreal, QC, Canada; 3Surgery, Marie-Lannelongue Surgical Center, Paris, France.

8:36 AM (216) Right Ventricular Size and Function and Its Change over Time Independently Predict Survival in Pulmonary Hypertension; K.A. Stackhouse,1 G. Devendra,1 S. Hart,1 W. Elmallah,1 J. Lee,1 T.M. Bashore,2 R. Dweik,3 R.A. Krasuski;1 Cardiovascular Medicine, The Cleveland Clinic, Cleveland, OH; 2Cardiovascular Medicine, Duke University Medical Center, Durham, NC; 3Pulmonary Medicine, The Cleveland Clinic, Cleveland, OH.

8:48 AM (217) Echocardiographic Mortality Predictors in Idiopathic Pulmonary Fibrosis; B.N. Rivera-Lebron,1 P.R. Forfia,2 J. Holmes,3 M. Kreider,1 J. Lee,1 S.M. Kawut,1,3 Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA; 2Department of Medicine, Division of Cardiology, University of Pennsylvania, Philadelphia, PA; 3Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA.

9:00 AM (218) Not the Right, but the Left Ventricle Causes the Problem after Lung Transplantation for Pulmonary Artery Hypertension – Awake ECMO for Postoperative LV Remodelling; I. Tudorache,1 C. Kühn,1 O. Wiesen,2 K. Olsson,2 J. Hadem,3 W. Sommer,1 C. Bara,1 T. Welte,2 J. Gottlieb,2 M. Hoepen,2 A. Havenich,1 G. Warnecke,1 Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany; 2Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany; 3Department of Gastroenterology, Hannover Medical School, Hannover, Germany.
**CONCURRENT SESSION 29**  
**MEETING HALL 5**  
**Role of Physical Activity in the Pre and Post-Transplant Setting**  
**CHAIRS:** Fabienne Dobbels, PhD and Katherine Hoercher, RN, FAHA  
(219) WITHDRAWN

8:00 AM (220) **Comparison between Supervised and Unsupervised Exercise Program after Lung Transplantation;** A. Rozanski,1 F.A. Ferrante,1 P.H.B. Alves,1 R.T.B. Ribas,1 M.L. Caramori,3 P.M. Peço-Fernandes,2 M.I.Z. Feltrim.1 1Department of Physical Therapy, Heart Institute (InCor), Hospital das Clínicas da Universidade de São Paulo, São Paulo, SP, Brazil; 2Department of Thoracic Surgery, Heart Institute (InCor), Hospital das Clínicas da Universidade de São Paulo, São Paulo, SP, Brazil; 3Department of Pneumology, Heart Institute (InCor), Hospital das Clínicas da Universidade de São Paulo, São Paulo, SP, Brazil.

8:12 AM (221) **Better Event-Free Survival in Ambulatory Heart Transplant (HTx) Candidates Who Are Physically Active and in Good Mood;** H. Spaderna,1 G. Weidner,2 V. Bunnym.1 1Psychology, Johannes Gutenberg-University, Mainz, Germany; 2Biology, San Francisco State University, San Francisco, CA.

8:24 AM (222) **Effects of Exercise Training on Exercise Capacity and Quality of Life in Patients with a Left Ventricular Assist Device (LVAD): A Randomised Controlled Trial;** K. Hayes,1 A.S. Leet,1,2 S.J. Bradley,1 A.E. Holland.1,3 1 Alfred Health, Melbourne, VIC, Australia; 2Baker Heart Institute, Melbourne, Australia; 3La Trobe University, Melbourne, Australia.

8:36 AM (223) **Evaluation of a Family Camp Intervention in Pediatric Heart Transplant;** S. Urschel,1 D. Nicholas,2 B. Dodd,1 K. Simard,1 F. Dicke,2 L.J. West.1 1Pediatric Cardiology, University of Alberta, Edmonton, AB, Canada; 2Faculty of Social Work, University of Calgary, Calgary, AB, Canada.

8:48 AM (224) **Physical Capacity and Health Related Quality of Life before and One Year after Lung Transplantation;** K. Heimburg, I. Skog, L. Hansson. Dept of Respiratory Medicine and Allergology, Skane University Hospital, Lund, Sweden.

---

**CONCURRENT SESSION 30**  
**NORTH HALL**  
**Innate Immunity and Ischemia Reperfusion Injury**  
**CHAIRS:** Daniel Kreisel, MD, PhD and David S. Wilkes, MD

8:00 AM (225) **Protective Effect of Anti-High-Mobility Group Box-1 (HMGB1) Antibody on Pulmonary Ischemia-Reperfusion Injury (IRI) in Miniature Swine;** H. Sahara, A. Shimizu, M. Sekijima, K. Setoyama, M. Oku, H. Nishimura, K. Yamada. Xenotransplantation Surgery Section, Frontier Science Research Center, Kagoshima University, Kagoshima, Japan.

8:12 AM (226) **Toll-Like Receptor-4 (TLR-4) Signaling in Alveolar Macrophages Undergoing Hypoxia and Reoxygenation;** H.E. Merry, P.J. Phelan, M.S. Mulligan. Division of Cardiothoracic Surgery, University of Washington, Seattle, WA.

8:24 AM (227) **Neutrophils Are Necessary and Sufficient To Exacerbate Allograft Vasculopathy in Murine Aortic Allografts Exposed to Prolonged Cold Ischemia;** C.L. Hancock Friesen,1 M. So,2 T.D.G. Lee,2,3 1Department of Pathology, Dalhousie University, Halifax, NS, Canada; 2Department of Surgery, Dalhousie University, Halifax, NS, Canada; 3Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.

8:36 AM (228) **Therapeutic Effect of Surfactant Inhalation on Lungs Donated after Cardiac Death in a Canine Lung Transplantation Model;** A. Ohsumi, F. Chen, J. Sakamoto, D. Nakajima, K. Hijiya, H. Mutoyama, K. Okita, K. Horita, R. Kikuchi, T. Yamada, H. Sakai, T. Bando, H. Date. Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

8:48 AM (229) **Lipopolysaccharide Preconditioning in Lung Ischemia-Reperfusion Injury Is TRAM Dependent;** A. Shimamoto, H. Fujii, M. Tomita, Y. Yajima, M. Takao, H. Shimpo. Thoracic and Cardiovascular Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan.

---

9:00 AM – 5:00 PM  
**EXHIBIT HALL OPEN**  
(CONGRESS HALL FOYER)

9:15 AM – 9:45 AM  
**ANNUAL BUSINESS MEETING**  
(CONGRESS HALL)

9:15 AM – 9:45 AM  
**COFFEE BREAK/VISIT EXHIBITS/POSTER VIEWING**  
(CONGRESS HALL FOYER)
**PLENARY SESSION**

**The Aging Imperative: Ethics, Economics and Resource Allocation**

**CHAIRS:** Robert L. Kormos, MD, FRCS(C) and Sharon A. Hunt, MD

**9:45 AM**

**Featured Abstract Presentation (231) Ventricular Assist Device Implantation in the Elderly: Nationwide Outcomes;** A. Kilic,1 D.D. Yuh,2 A.S. Shah,1 J.V. Conte.1 1Division of Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD; 2Section of Cardiac Surgery, Yale University School of Medicine, New Haven, CT.

**10:30 AM**

**The Impact of an Aging Population on Resources for Healthcare and Transplant,** Axel Rahmel, MD, Eurotransplant International Foundation, Leiden, The Netherlands

**10:45 AM**

**Immunobiology – The Immune System from Birth Through End of Life,** Daniel R. Goldstein, MD, Yale New Haven Hospital, New Haven, CT

**11:00 AM**

**How to Incorporate Measures of Frailty in Assessment for Cardiothoracic Surgery,** David J. Lederer, MD, MS, Columbia University, New York, NY

**11:15 AM**

**Shared Decision Making in the Aging Population – How to Help Patient Make Decision Right for Them,** Mi-Kyung Song, RN, PhD, University of North Carolina at Chapel Hill, NC

**11:30 AM**

**‘Accountability for Reasonableness’ as an Ethical Framework for Scarc Resource Allocation,** Heather J. Ross, MD, MHSc, FRCP(c), Toronto General Hospital, Toronto, Canada

**CONCURRENT SYMPOSIUM 12**

**MCS Recovery – How Do We Get There**

**CHAIRS:** Joseph G. Rogers, MD and Hans B. Lehmkuhl, MD

**11:45 AM**

**Effects of LVAD Unloading on the Myocardial Function and Structure,** Stavros G. Drakos, MD, Utah Cardiac Transplant Program, Salt Lake City, UT

**NOON**

**Targeted Adjuvant Therapies to Enhance LVAD-Induced Reverse Remodeling,** Emma Birks, MD, PhD, FRCP, University of Louisville, KY

**12:15 PM**

**How to Monitor the Heart During LVAD Unloading,** Simon Maybaum, MD, Montefiore Medical Center; Albert Einstein College of Medicine, New York, NY

**12:30 PM**

**Predictors of LVAD-Induced Sustained Myocardial Recovery,** Michael Dandel, MD, PhD, German Heart Institute, Berlin, Germany

**12:45 PM**

**Panel Discussion**

**CONCURRENT SYMPOSIUM 13**

**The Leading Edge of Immunosuppression in Heart Transplantation: Evidence, Perspectives and Clinical Practice**

**CHAIRS:** Eulalia Roig, MD and Guatam V. Ramani, MD

**11:45 AM**

**Recent Trials in Immunosuppression – 2, 3 or 1 Drugs?,** David A. Baran, MD, Newark Beth Israel Medical Center, Newark, NJ

**12:05 PM**

**mTOR Inhibitors as Rescue or First Line Strategy: A Balancing Act,** Luciano Potena, MD, PhD, University of Bologna, Italy

**12:25 PM**

**Emerging Immunosuppression: Novel Molecules,** Marisa G. Crespo Leiro, MD, Hospital Universitario A Coruña, La Coruña, Spain

**12:45 PM**

**Putting it Together: A Case Based Moderated Discussion**

**MODERATOR:** Howard J. Eisen, MD, Drexel University Medical Center, Philadelphia, PA

**PANELISTS AND AUDIENCE QUESTIONS AND ANSWERS:**

Eulalia Roig, MD, Hospital Sant Pau, Barcelona, Spain

Guatam V. Ramani, MD, University of Maryland, Baltimore, MD

David A. Baran, MD, Newark Beth Israel Medical Center, Newark, NJ

Luciano Potena, MD, PhD, University of Bologna, Italy

Marisa G. Crespo Leiro, MD, Hospital Universitario A Coruña, La Coruña, Spain

**CONCURRENT SYMPOSIUM 14**

**Following the RV Through Thick and Thin**

**CHAIRS:** Felix Perez-Villa, MD, PhD and Lynne W. Stevenson, MD

**11:45 AM**

**Bi-ventricular Failure and Pulmonary Hypertension: A Unique Pathophysiology,** Robert P. Frantz, MD, Mayo Clinic, Rochester, MD

**NOON**

**Drugs in PH with Left Heart Failure: Role for PH Specific Novel Therapies,** Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium

**12:15 PM**

**Treatment of RV Failure After LVAD or Transplant,** Mauro Rinaldi, MD, University of Turin, San Giovanni Battista “Molinette” Hospital, Torino, Italy

**12:30 PM**

**Assessment of CRV Function During RV Support,** Marc A. Simon, MD, MS, University of Pittsburgh, PA

**12:45 PM**

**Panel Discussion**
**CONCURRENT SYMPOSIUM 15** (PANORAMA HALL)

**Solving the Enigmatic: Cases in Heart and Lung Transplantation**

**CHAIRS:** Lianne G. Singer, MD, FRCPC and Gerald J. Berry, MD

**11:45 AM** *Cardiac Case #1*, Robert F. Padera, MD, PhD, Brigham & Women's Hospital, Boston, MA

**12:05 PM** *Lung Case #1*, Alexandra Rice, FRCP, Royal Brompton and Harefield Hospitals, London, United Kingdom

**12:25 PM** *Lung Case #2*, Joseph J. Maleszewski, MD, Mayo Clinic, Rochester, MN

**12:40 PM** *Cardiac Case #2*, Marny Fedrigo, MD, University of Padua, Italy

---

**CONCURRENT SYMPOSIUM 16** (MEETING HALL 4)

**Bad Bugs – What Can We Do?**

**CHAIRS:** Shimon Kusne, MD and Stanley I. Martin, MD

**11:45 AM** *Multi-Drug Resistant Gram Negative Infections: What Are The Options?*, Amparo sole, MD, PhD, Hospital Universitario y Politecnico le Fè, Valencia, Spain

**NOON** *VRE & MRSA: Can They Be Defeated?*, Stanley I. Martin, MD, The Ohio State University Medical Center, Columbus, OH

**12:15 PM** *C. difficile: Can We Keep Our Patients Off the Toilet?*, Michele Estabrook, MD, Washington University School of Medicine, St. Louis, MO

**12:30 PM** *Infection Prevention: Get The Bugs Before They Get You!*, Frauke Mattner, PhD, Kliniken der Stadt Köln gGmbH, Cologne, Germany

**12:45 PM** Panel Discussion

---

**CONCURRENT SYMPOSIUM 17** (MEETING HALL 5)

**Pulmonary Hypertension in Chronic Parenchymal Lung Diseases: Does it Matter?**

**CHAIRS:** Marion Delcroix, MD, PhD and Reda Girgis, MB, BCh

**11:45 AM** *Cor Pulmonale in COPD: Not Just Blue Bloaters*, Omar A. Minai, MD, Cleveland Clinic Foundation, Cleveland, OH

**NOON** *Importance of Pulmonary Hypertension in ILD*, Oksana Anatolia Shlobin, MD, Inova Fairfax Hospital, Heart and Vascular Institute, Falls Church, VA

**12:15 PM** *The Impact of PH in the Lung Transplant Recipient*, Marc De Perrot, MD, Toronto General Hospital, Toronto, Canada

**12:30 PM** *Therapy for PH Associated with Lung Disease: What Is The Evidence?*, Pavel Jansa, MD, General University Hospital, Prague, Czech Republic

**12:45 PM** Panel Discussion

---

**CONCURRENT SYMPOSIUM 18** (NORTH HALL)

**Challenges in Pediatric Lung Transplant**

**CHAIRS:** Bart L. Rottier, MD and Melinda P. Solomon, MD, MSC, FRCP(C)

**11:45 AM** *Small But Not Forgotten*, Stuart C. Sweet, MD, PhD, St. Louis Children's Hospital, St. Louis, MO

**NOON** *Second Chances: Re-Transplantation in Pediatric Lung Transplantation*, Christian Benden, MD, St. Vincent's Hospital, Sydney, Australia

**12:15 PM** *Bridging to Lung Transplantation in Children*, Charles B. Huddleston, MD, Cardinal Glennon Hospital, St. Louis University School of Medicine, St. Louis, MO

**12:30 PM** *Transition to Adult Care: What Could Pediatricians Do Better?*, Joseph M. Pilewski, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

**12:45 PM** Panel Discussion

---

**1:00 PM – 1:30 PM**

**BOX LUNCH PICK-UP**

(BUFFET, 1ST FLOOR)

**1:00 PM – 3:00 PM**

**LUNCH BREAK**
SCIENTIFIC PROGRAM

1:00 PM – 3:00 PM
JHLT EDITORIAL BOARD MEETING AND LUNCH
(CLUB B)

1:00 PM – 3:00 PM
BASIC SCIENCE AND TRANSLATIONAL RESEARCH COUNCIL MEETING
(CLUB C)

1:00 PM – 3:00 PM
JUNIOR FACULTY AND TRAINEE COUNCIL MEETING
(CLUB D)

1:00 PM – 3:00 PM
COUNCIL CHAIRS LUNCH MEETING
(MEETING HALL 2)

1:15 PM – 2:15 PM

CONCURRENT SYMPOSIUM 19  (MEETING HALL 1)

Joint ISHLT/ESOT Symposium

CHAIRS:  David O. Taylor, MD (ISHLT) and Rutger J. Ploeg, MD (ESOT)

1:15 PM  Impact of DCD Donors for Thoracic Donation, Darren H. Freed, MD, PhD, FRCSC, University of Manitoba, Winnipeg, Canada

1:30 PM  Are TRegs Ready for the Clinic?, Carla C. Baan, PhD, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

1:45 PM  Clinical Experience with Belatacept: A Balanced View, Josep M. Grinyó, MD, Hospital Universitari de Bellvitge, Barcelona, Spain

2:00 PM  The Impact of ABO Incompatibility on De Novo HLA Ab Production, Simon Urschel, MD, University of Alberta, Edmonton, Canada
1:15 PM – 2:45 PM
MINI ORAL SESSION 4 (PANORAMA HALL)
Mechanical Circulatory Support II

**CHAIRS:** Cumara Sivathasan, FRCS and Martin Schweiger, MD

1:15 PM  **(232)** Improvement in Blood Sugar Control and Insulin Requirements in Patients with a Ventricular Assist Device; K.L. Eleuteri, C.D. Kline, A. El-Banayosy, W. Pae, S. Behzad, E. Stephenson. Penn State Milton S. Hershey Medical Center, Hershey, PA.


1:45 PM  **(238)** Driveline Staging System; Help in Managing Acute and Chronic Driveline Infections; K.L. Eleuteri, A. El-Banayosy, W. Suzanne. Mechanical Circulatory Support, Heart and Vascular Institute, Penn State Milton S. Hershey Medical Center, Hershey, PA.

1:50 PM  **(239)** Hospital Readmissions Are a Common Occurrence in the Current Era with Continuous Flow (CF) LVADs; F. Kamdar, J. Rasmussen, P. Eckman, K. Liao, B. Millowitz, M. Colvin-Adams, R. John. University of Minnesota, Minneapolis, MN; Fairview Health, Minneapolis, MN.


2:00 PM  **(241)** Impact of Malnutrition on Early Outcomes Following Implantation of Continuous Flow Left Ventricular Assist Devices; D.J. Goldstein, W. Holman, N. Moazami, R. John, D. Naftel, F. Pagani. Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY; Cardiothoracic Surgery, University of Alabama, Birmingham, AL; Cardiothoracic Surgery, Minneapolis Heart Institute, Minneapolis; Cardiothoracic Surgery, University of Minnesota, Minneapolis; Cardiothoracic Surgery, University of Michigan, Ann Arbor.


2:10 PM  **(243)** Comparison of Outcomes for Heart Transplantation Following Continuous Versus Pulsatile Flow Ventricular Assist Device Bridging; A. Kilic, J.V. Conte, D.D. Yuh, A.S. Shah. Division of Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD; Section of Cardiac Surgery, Yale University School of Medicine, New Haven, CT.

2:15 PM  **(244)** VLAD: A Novel Approach to EMS Education Utilizing an Interactive VAD Medical Simulator; J.A. Gluck, B. Mendes, T. Devoe, J. Radjevic, D. Wierczen. Center for Advanced Heart Failure and Transplant, Hartford Hospital, Hartford, CT.

2:20 PM  **(245)** Translatable Performance with the Total Artificial Heart: The U.S. Post-Market Study; M.J. Slepijan, R.G. Smith, D. Covington, M. Acker, F.A. Arabia, S. Clayson, J.G. Copeland, P.A. DeValencia, G.V. Gonzalez-Stawinski, I.D. Gregoric, J.W. Long, R. Morris, W.E. Pae, F.D. Pagani, N.G. Smedira, C. Smith, V. Kasirajan. Server Heart Center, University of Arizona, Tucson, AZ; Cardiothoracic Surgery, University of Pennsylvania, Philadelphia, PA; Cardiothoracic Surgery, The Mayo Clinic Scottsdale, Scottsdale, AZ; Cardiothoracic Surgery, Intermountain Medical Center, Salt Lake City, UT; Cardiothoracic Surgery, The Cleveland Clinic Foundation, Cleveland, OH; Cardiothoracic Surgery, The Texas Heart Institute, Houston, TX; Cardiothoracic Surgery, Integris Baptist Medical Center, Oklahoma City, OK; Cardiothoracic Surgery, Penn State Hershey Medical Center, Hershey, PA; Cardiothoracic Surgery, The University of Michigan Medical Center, Ann Arbor, MI; Cardiothoracic Surgery, Virginia Commonwealth Medical Center, Richmond, VA.

2:25 PM  **(246)** BiVACOR® – A Magnetically Levitated Rotatory Total Artificial Heart; B. Thomson, J. Choudhary, N. Greatrex, S. Gregory, M. Stevens, S. Diab, C. McDonald, K. Dunster, N. Kurita, Cardiothoracic Surgery, The Prince Charles Hospital, Brisbane, Australia; Critical Care Research Group, The Prince Charles Hospital, Brisbane, Australia; Graduate School of Biomedical Engineering, University of New South Wales, Sydney, Australia; Mechanical Engineering, Gunma University, Kiryu, Japan.


1:15 PM – 2:45 PM
MINI ORAL SESSION 5
Heart Transplantation

CHAIRS: Nicholas Banner, FRCP and Stephan Schueler, MD, PhD, FRCS

1:15 PM (249) Living with a Total Artificial Heart; L.S. Savage, M.P. Flattery, J. Salyer, Department of Nursing, Pauley Heart Center; Virginia Commonwealth University Health System, Richmond, VA; Adult Health and Nursing Systems, School of Nursing, Virginia Commonwealth University, Richmond, VA.

1:20 PM (251) Incidence, Determinants and Clinical Consequences of Acute Rejection after Conversion from Calcineurin-Inhibitor to Proliferation Signal Inhibitor in Maintenance Heart Transplant Recipients; J.A. Vázquez de Prada, J. Delgado, M. Gómez-Bueno, M.J. Paniagua, F. Perez-Villa, S. Mirabet, J.M. Arizon, L. Almenar, F. Gonzalez-Vilchez, Cardiology Service, University Hospital Marqués de Valdecilla, Santander, Cantabria, Spain; Cardiology Service, University Hospital Puerta de Hierro, Majadahonda, Madrid, Spain; Cardiology Service, University Hospital A Coruña, A Coruña, Galicia, Spain; Cardiology Service, Hospital Clinic, Barcelona, Cataluña, Spain; Cardiology Service, University Hospital Santa Creu i Sant Pau, Barcelona, Cataluña, Spain; Cardiology Service, University Hospital Reina Sofia, Cordoba, Andalucia, Spain; Cardiology Service, University Hospital Central de Asturias, Oviedo, Asturias, Spain; Cardiology Service, University Hospital La Fe, Valencia, Spain.

1:25 PM (252) Sirolimus Based Immunosuppression Attenuates Cardiac Allograft Vasculopathy Progression by Decreasing Fibrotic Component of Coronary Atherosclerotic Plaque; E. Rachlin, Y. Matsu, N.L. Pereira, B.S. Edwards, R.P. Frantz, A.L. Clavell, R.J. Rodheffer, B.A. Bolson, J.A. Schirger, A. Lerman, S.S. Kushwa, William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN; Center for Coronary Physiology and Imaging, Mayo Clinic, Rochester, MN; Division of Cardiology, University of Nebraska Medcicar Center, Omaha, NE.

1:30 PM (253) Long-Term Renal Function in the TICTAC Trial: Outcomes beyond 5 Years; D.A. Baran, C. Guerrero-Miranda, J. Pieretti, N. Hochbaum, M.E. Goldschmidt, S. Pardi, M. Camacho, M.J. Zucker: Transplant Center, Newark Beth Israel Medical Center, Newark, NJ.


1:40 PM (255) Predictors of Acute Rejection or Renal Function Improvement in Cardiac Transplant Patients with Renal Insufficiency; A. Zuiker, H. Eisen, S. See Tai, H. Li, C. Hahn, M.G. Crespo-Leiro, AKH Wien, Vienna, Austria; Drexel University College of Medicine, Philadelphia, PA; Wyeth Pharmaceuticals (now Pfizer), Collegeville, PA; Hospital Universitari i Politècnic La Fe, Valencia, Spain.

1:45 PM (256) Use of Thymoglobulin after Heart Transplantation: Is There a Role in African American Patients?; B. Coleman, J. Patel, L. Czer, J. Mirocha, J. Kobashigawa, Cedars Sinai Heart Institute, Los Angeles, CA.


2:00 PM (259) The Clinical Outcomes of Prolonged Donor Ischemic Time in Adult Patients Undergoing Heart Transplantation. A Single Center Experiences in Canada; M. Mutsuga, S. Wang, R. MacArthur, J. Mullen, D. Modry, D. Ross, S. Meyer; Cardiac Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; Division of Cardiac Surgery, University of Alberta, Edmonton, AB, Canada.

2:05 PM (260) Is Metabolic Syndrome Important in the Development of Cardiac Allograft Vasculopathy in Heart Transplant Patients?; I. Sanchez-Lazaro, J.M. Sanchez-Gomez, L. Martinez-Dolz, L. Almenar-Bonet, R. Cortes-Vergaz, F. Buendia Fuentes, E. Rosello-Lleti, M. Portoles-Sanz, M. Rivera-Otero, A. Salvador-Sanz; 1Heart Failure and Transplantation Unit, Cardiology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain; 2Research Center, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

2:10 PM (261) Optical Coherence Tomography for Detection of Cardiac Allograft Vasculopathy (OCTCAY Study); S.J. Khandhar, H. Yamamoto, J.J. Teuteberg, M.A. Shullo, H.G. Bezerra, M.A. Costa, M. Ramratnam, J.S. Lee, O.C. Marroquin, S.R. Mulukutla, C. Toma; 1Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; 2Harrington-McLaughlin Heart and Vascular Institute, University Hospitals Case Medical Center, Cleveland, OH; 3Department of Pharmacy and Therapeutics, University of Pittsburgh, PA.

2:20 PM **(263)** Multicentric Validation of RADIAL Score for Primary Graft Failure Prediction; M.D.G. Cosio,¹ J. Segovia,¹ M. Gómez Bueno,¹ L. Almenar,² J. Delgado,³ J.M. Arizón,⁴ F. González-Vilchez,⁵ M.G. Crespo-Leiro,⁶ S. Mirabet,¹ M.G. Alonso-Vilchez,⁵ M.G. Crespo-Leiro,⁶ S. Mirabet,¹ M.G. Alonso-Vilchez,⁵ M.G. Crespo-Leiro,⁶ S. Mirabet,¹ M.G. Alonso-Vilchez,⁵ M.G. Crespo-Leiro,⁶ S. Mirabet,¹ M.G. Alonso-Vilchez,⁵ M.G. Crespo-Leiro,⁶ S. Mirabet,¹ ¹Heart Transplant Unit, Hospital Puerta de Hierro, Madrid, Spain; ²Hospital La Fe, Valencia, Spain; ³Hospital 10 de Octubre, Madrid, Spain; ⁴Hospital Reina Sofia, Córdoba, Spain; ⁵Hospital Valdecilla, Santander, Spain; ⁶Complejo Hospitalario Universitario A Coruña, La Coruña, Spain; ⁷Hospital Clínico, Barcelona, Spain; ⁸Hospital Universitario Gregorio Marañón, Madrid, Spain; ⁹Hospital Universitario Central de Asturias, Oviedo, Spain; ¹⁰Hospital de Bellvitge, Hospital de Llobregat, Barcelona, Spain; ¹¹Hospital Universitario de Valladolid, Valladolid, Spain; ¹²Hospital Miguel Servet, Zaragoza, Spain; ¹³Hospital La Amnyma, Múrcia, Spain; ¹⁴Hospital Sant Pau, Barcelona, Spain; ¹⁵Clínica Universitaria de Navarra, Navarra, Spain.

2:25 PM **(264)** Five-Year Survival Trends in Heart Transplantation Based on Recipient Age over Two Decades of Multinstitutional Experience; J.F. George,¹ S.V. Pamboukian,² R.N. Brown,¹ J.K. Kirklin,¹ J.A. Tallaj.² ¹Surgery, University of Alabama, Birmingham, AL; ²Medicine, University of Alabama, Birmingham, AL.

2:30 PM **(265)** Tricuspid Regurgitation and Surgical Technique Influences Outcome after Heart Transplantation; M. Carlström,¹ S. Dahlin,¹ J. Gåbel,¹ R. Doanh,¹ J. Hörlinge,¹ A. Jeppsson,¹ V. Sigurdardottir,² G. Dellgren,¹ ¹Cardiothoracic Surgery and Anesthesia, Sahlgrenska University Hospital, Gothenburg, Sweden; ²Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.

2:35 PM **(266)** High Intensity Interval Training Improves Muscle Strength and VO2 peak in Heart Transplant Recipients; K. Nytrøyen,¹ L.A. Rustad,² I. Holm,³ S. Aakhus,¹ L. Gullestad,¹ ¹Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; ²Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway; ³Division of Surgery and Clinical Neuroscience, Oslo University Hospital, Rikshospitalet, Oslo, Norway; ⁴Faculty of Medicine, University of Oslo, Norway.

2:40 PM **(267)** Health Behaviors as Correlates of Quality of Life in the Waiting for a New Heart Study; V. Bunyamin,¹ H. Spaderna,¹ G. Weidner,² For the Waiting for a New Heart Study Group. ¹Health Psychology, Institute of Psychology – Johannes Gutenberg-University Mainz, Mainz, Rheinland Pfalz, Germany; ²Department of Biology, San Francisco State University, Tiburon, CA.

**1:15 PM – 2:45 PM**
**MINI ORAL SESSION 6**
**Lung Transplantation, Infectious Diseases and Donor Management**

**CHAIRS:** Kenneth R. McCurry, MD and Vincent G. Valentine, MD

1:15 PM **(268)** Older Donor Lungs: A Neglected Source of Transplantable Organs; G.I. Snell, L.E. Mitchell, A.P. Griffiths, H.M.

1:20 PM **(269)** The Utilization of Donors Aged 65 and Older Is Associated with Decreased Survival Following Lung Transplantation; G.J. Bittle, P.G. Sanchez, Z.N. Kon, A.C. Watkins, J.P. Garcia, B.P. Griffith. Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD.

1:25 PM **(270)** Ex Vivo Treatment of Infection in Human Donor Lungs; R. Bonato,¹ T.N. Machuca,¹ M. Cypel,³ J.C. Yeung,¹ T. Satô,¹ M. Liu,¹ D.M. Hwang,² S. Husain,² G. Keshavjee.¹ ¹Latter Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada; ²Department of Pathology, University Health Network, Toronto, ON, Canada; ³Division of Infectious Diseases and Multi-Organ Transplantation, University Health Network, Toronto, ON, Canada.

1:30 PM **(271)** Non Heparinisation Does Not Impact Outcome of Lung Transplantation from Maastricht Category III Donation after Circulatory Death (DCD) Donors; A. Iyer,¹ M. Harkess,¹ A. Havryk, M. Plitt, M. Malouf, P. Janisz, E. Granger, K. Dhill, P. Spratt, A.R. Glanville. Lung Transplant Unit, St Vincent’s Hospital, Sydney, Australia.

1:35 PM **(272)** Ex Vivo Perfusion and Transplantation of Initially Rejected Donor Lungs; A. Wallinder,¹ S.-E. Ricksten,² C. Hansson,² G.C. Riise,² M. Silverbom,¹ H. Liden,² G. Dellgren.⁶ ¹Department of Cardiothoracic Surgery, Sahlgrens University Hospital, Gothenburg, Sweden; ²Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden; ³Cardiothoracic Anaesthesia and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden.

1:40 PM **(273)** Seroconversion and Safety of H1N1 Vaccination in Lung Transplant Recipients: Data from the Brussels Lung Transplant Group; A. Hombrouck,¹ A. Lemy,² M. Dumonceaux,² M. Estenne,³ A. Belhaj,⁴ B. Rondelet,⁴ I. Thomas,¹ C. Knoop.³ ¹Section Viral Diseases, Scientific Institute of Public Health, Brussels, Belgium; ²Nephrology, Erasme University Hospital, Brussels, Belgium; ³Chest Medicine, Erasme University Hospital, Brussels, Belgium; ⁴Heart and Lung Transplantation Surgical Clinic, Erasme University Hospital, Brussels, Belgium.

1:45 PM **(274)** Extensive- and Pandrug-Resistant (XDR/PDR) Acinetobacter baumannii (Ab) and KPC-Producing Klebsiella pneumoniae (KPC) Primarily Cause Pneumonia (PNA) among Lung and Heart Transplant (LTR, HTR) Recipients, and Outcomes May Be Improved by Treatment with a Carbapenem + Colistin (CBM+COL); R.K. Shields, M.H. Nguyen, E.J. Kwak, F.P. Silveira, R.C. Abdel-Massih, J. Pilewski, M. Crespo, Y. Toyoda, C. Bermudez, J.K. Bhama, C.J. Clancy. University of Pittsburgh Medical Center; Pittsburgh, PA.


1:55 PM **(276)** Paired Donor Lung Expression Suggest Key Effectors in Primary Graft Dysfunction; E. Cantin.¹ L. Erhunmwunsee,² R. Feng,² N.J. Meyer,³ J.M. Diamond,³ R.J. Shah,² S. Rao,² S.S. Lin,² R.D. Davis,² J.D. Christie.³ ¹Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; ²Department of Surgery, Duke University Medical Center; Durham, NC; ³Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; 4Pulmonary, Allergy, and Critical Care Division, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; 5Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; 6Penn Molecular Profiling Facility Bioinformatics Group, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

2:00 PM (277) Lung Transplant Surgery on Cardiac Electrical Support: Extracorporeal Membrane Oxygenation Outperforms Cardiopulmonary Bypass; F. Ius, C. Kühn, I. Tu-dorache, W. Sommer, M. Avsan, T. Fuehner, T. Welte, J. Gottlieb, A. Havercik, G. Warnecke. 1Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany; 2Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.


2:10 PM (279) Renal Function Preservation with Everolimus after Lung Transplant; S. Schneer, Y. Raiv, D. Rosengarten, B. Medallion, M.R. Kramer. 1Pulmonary Institute, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel; 2Thoracic Surgery Unit, Rabin Medical Center (RMC), Beilinson Campus, Petah Tiqwa, Israel.

2:15 PM (280) Pharmacokinetic Study of the Conversion from Tacrolimus to Tacrolimus Retard in Stable Lung Transplantation; A. Méndez, C. Berastegui, M. López-Meseguer, V. Monforte, C. Bravo, A. Blanco, S. Camós, L. Pau, A. Roman. 1Pneumology, Hospital Universitari Vall d’Hebron, CIBERES, Barcelona, Spain; 2Pharmacy, Hospital Universitari Vall d’Hebron, CIBERES, Barcelona, Spain.


2:25 PM (282) Alemtuzumab Minimizes Airway Ischemic Reperfusion Injury (aIRI), Which Is Associated with Graft Damage and Deaths Post-Lung Transplant (LT); M.M. Crespo, J.M. Pilewski, C.J. Clancy, B. Johnson, C. Bermudez, J. Bham, Y. Toyoada, S.S. Haider, M. Morrell, N. Shigemura, M.H. Nguyen. 1Division of Pulmonary, Allergy and Critical Care, University of Pittsburgh Medical Center, Pittsburgh, PA; 2Division of Infectious Disease, University of Pittsburgh Medical Center, Pittsburgh, PA; 3Division of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; 4Cardiothoracic, Temple University Hospital, Philadelphia, PA.


2:40 PM (285) A Panel of Lung Injury Biomarkers Enhances the Definition of Primary Graft Dysfunction (PGD) after Lung Transplantation for Early Clinical Studies; R.J. Shah, J.M. Diamond, S.M. Kawut, J.C. Lee, D.J. Lederer, S. Bhorade, M. Crespo, E.J. Demissie, J.A. Belperio, V.N. Llama, J.B. Dren, S.M. Palmer, J. Reynolds, A. Shah, P. Sheh, K.M. Wille, A. Weinacker, D.S. Weill, D. Wilkes, L.B. Ware, J.D. Christie. 1Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia, PA; 2Columbia University, New York City; 3University of Chicago; 4University of Pittsburgh; 5University of California, Los Angeles; 6University of Michigan, Ann Arbor; 7Johns Hopkins University, Baltimore; 8Duke University, Durham; 9Indiana University, Indianapolis; 10Vanderbilt University, Nashville; 11University of Alabama, Birmingham; 12Stanford University, Palo Alto.

1:15 PM – 2:45 PM MINI ORAL SESSION 7 Basic Science and Immunobiology, Heart Transplantation and Infectious Diseases

CHAIRS: Roland G. Nador, MD and Bruce R. Rosengard, MD, FRCS

1:15 PM (286) Altered Naive and Effector FOXP3+ T-Cell Frequencies after Thymectomy and Heart Transplantation (HTx) in Infants; E. Dike, S. Urschel, I. Larsen, K. Matthews, E. Pahl, R. Chinmuk, L. West. 1Pediatrics, University of Alberta, Edmonton, AB, Canada; 2Pediatrics, Children’s Memorial Hospital, Chicago, IL; 3Pediatrics, Loma Linda University and Children’s Hospital, Loma Linda, CA.

1:20 PM (287) Xenotransplant Immunology: Impact on Bioprosthetic Materials; C.G.A. McGregor, H. Kogelberg, G.W. Byrne. 1Institute of Cardiovascular Sciences, University College London, London, Westminster, United Kingdom; 2Department of Surgery, Mayo Clinic, Rochester, MN.

1:25 PM (288) Non-HLA Antibodies and Risk of Rejection after Heart Transplantation: Profiling with Antigen Microarrays; A. Chruscinski, F. Huang, K. Tincak, V. Rao, G. Levy, H. Ross. 1Multi Organ Transplant, UHN-Toronto General Hospital, Toronto, ON, Canada; 2Cardiovascular Surgery, UHN-Toronto General Hospital, Toronto, ON, Canada.

1:30 PM (289) In Situ Imaging of Neonatal Tolerance Induction: Donor Bone Marrow and Spleen Cells Home Differently and Induce Tolerance by Distinct/Overlapping Mechanisms; R.A. Bascom, K. Taz, S.L. Tolleen, L.J. West. Pediatrics, Surgery and Immunology, University of Alberta, Edmonton, Canada.


1:40 PM (291) Immunogenicity of Umbilical Cord Lining-Derived Mesenchymal Stromal Cells; M. Stubbendorff, J. Kawalkowska, T. Deuse, T.T. Phan, K. Bieback, K. Atkinson, T.H. Eiermann, H. Reichenspurner, R.C. Robbins, S. Schreper. 1TSI-Lab, Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; 2Surgery, Yong Lin University, Singapore, China; 3Transfusion Medicine, University Mannheim, Mannheim, Germany; 4University Queensland, St.
1:45 PM (292) Physiologic and Biochemical Profile of Clinically Rejected Lungs on a Normothermic Ex Vivo Lung Perfusion Platform; T.J. George, G.J. Arnaoutakis, C.A. Beatty, S.K. Jandu, D.E. Berkowitz, L. Santhanam, A.S. Shah. The Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD; The Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD.

1:50 PM (293) Novel Nebulized Arginase Inhibitor Increases Human Lung Compliance during Normothermic Ex Vivo Lung Perfusion; T.J. George, G.J. Arnaoutakis, C.A. Beatty, S.K. Jandu, D.E. Berkowitz, L. Santhanam, A.S. Shah. The Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD; The Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD.

1:55 PM (630) Donor Pharmacologically Induced Hypothermia with DADLE Abolishes Rat Cardiac Allograft Ischemia/Reperfusion Injury through Akt, ERK1/2 Signaling; A. Rungatscher, A. Giacomazzi, D. Linardi, A. Mazzucco, G. Faggian. Department of Surgery, Section of Cardiac Surgery, University of Verona, Verona, Italy.


2:10 PM (297) Non-HLA Antibody Screening after Heart Transplantation Identifies High Risk for Cardiac Allograft Vasculopathy; M.J. Barten, D. Dragun, M.-T. Dieterlen, S. von Salisich, J. Garbade, S. Klein, S. Dhein, F.W. Mohr, H.B. Bittner. Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany; Clinic for Nephrology and Intensive Care Medicine, Charité Campus Virchow Clinic, Berlin, Germany.

2:15 PM (298) Pre-Transplant Non-Cytotoxic Anti-HLA Antibodies Predict Multiple Adverse Events after Heart Transplantation; L. Potena, A. Bontadini, F. Frueu, S. Iannelli, F. Barberini, M. Nardozza, V. Manfredini, M. Masetti, G. Magnani, F. Grigioni, A. Branzi. Cardiovascular Department, University of Bologna, Bologna, Italy; Immunogenetics Unit, Academic Hospital S. Orsola-Malpighi, Bologna, Italy.

2:20 PM (299) Cardiac Allograft Remodeling Is Associated with Increased Inflammatory Burden of Coronary Atherosclerotic Plaque; E. Raichlin, Y. Matsuo, A.L. Clavell, R.P. Frantz, R.J. Rodlheffer, B.S. Edwards, B.A. Boilson, J.A. Schinger, A. Lerman, N.I. Pereira, W.J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN; Division of Cardiovascular Diseases, Center for Coronary Physiology and Imaging, Mayo Clinic, Rochester, MN; Division of Cardiovascular Diseases, University of Nebraska Medical Center, Omaha, NE.

2:25 PM (300) Low Absolute Lymphocyte Count at Six Months Post-Heart Transplantation Predictive of Late-Onset CMV; T. Kuw, R. Cheng, A.S. Baas, D. Cruz, A. Nsair. 1Heart Transplant, University of California, Los Angeles, CA; 2Medicine, Division of Cardiology, University of California, Los Angeles, CA; 3Medicine, Division of Infectious Disease, University of California, Los Angeles, CA; 4Surgery, Division of Cardiothoracic Surgery, University of California, Los Angeles, CA.
5:00 PM – 11:59 PM
EXHIBIT HALL TEAR DOWN
(CONGRESS HALL FOYER)

5:00 PM – 11:59 PM
POSTER HALL TEAR DOWN
(CONGRESS HALL FOYER)

5:00 PM – 6:15 PM
CONCURRENT SYMPOSIUM 20
(MEETING HALL 5)
Self-Management in End Stage Heart and Lung Disease and Transplantation

CHAIRS: Bronwyn J. Lewey, RN, BEd Stu Grad Dip Clin Epi and Nancy P. Blumenthal, CRNP

5:00 PM Self-Management as Part of Chronic Illness Management (CIM), Christiane Kugler, PhD, University Witten, Witten, Germany

5:15 PM Health Care System Factors Related to Self Management, Luu Berben, PhD, RN, Institute for Nursing Science, University of Basel, Switzerland

5:30 PM Management of New Life Roles, Michael G. Petty, PhD, RN, CCNS, CNS, University of Minnesota Medical Center-Fairview, Minneapolis, MN

5:45 PM Self-Management in Pediatrics, Samantha Anthony, PhD, MSW, RSW, Hospital for Sick Children/McMaster University, Toronto, Canada

6:00 PM Self-Management via the Virtual Heart Clinic, Annermarie Kaan, MCN, RN, St. Paul’s Hospital, Vancouver, Canada

5:00 PM – 6:15 PM
CONCURRENT SESSION 31
(Forum Hall)
Right Ventricle – Staying Alive

CHAIRS: Benjamin Sun and Antonio Loforte, MD

5:00 PM (304) Clinical Use of the HeartWare HVAD for Biventricular Support; M. Schmitto, C. Fegbeutel, K. Chorpenning, M. Avsar, D. Tarnez, A. Havenich, Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Lower Saxony, Germany; HeartWare Inc., Miami Lakes.

5:12 PM (305) Bridge to Transplant Using BiVAD or Total Artificial Heart: Is There a Survival Difference?; A. Nouwen, M. Pozi, C. Mastroianni, P. leprince, P. Alain, P. Léger, M. Kirsch, Department of Cardiothoracic Surgery, La Pitié-Salpêtrière Hospital, Paris, France.

5:24 PM (306) Concomitant Tricuspid Valve Procedure Reduces Right Ventricular Failure after Continuous Flow Left Ventricular Assist Device (LVAD) Implantation; V. Piacentino III, A.M. Ganapathi, M. Stafford-Smith, C.B. Patel, A. Barbosa, A.J. Lodge, A.A. Simeone, J.G. Rogers, C.A. Milano, Cardiac and Thoracic Surgery, Duke University Medical Center, Durham, NC; Cardiothoracic Anesthesia, Duke University Medical Center, Durham, NC; Cardiology, Duke University Medical Center, Durham, NC.

5:36 PM (307) Mechanical Circulatory Support for Right Ventricle Failure: The Tandem Heart in Right Ventricular Support (THRV) Registry; N.K. Kapur, V. Paruchuri, A. Jagannathan, J. Finley, A.K. Chakrabarti, D. Steinberg, N.M. Orr, M. Tempelhof, M.S. Kiernan, D.T. Pham, D. DeNofrio, The Cardiovascular Center, Tufts Medical Center, Boston, MA; Interventional Cardiology, Thomas Jefferson University, Philadelphia, PA; Interventional Cardiology, Beth Israel Deaconess Medical Center, Boston, MA; Interventional Cardiology, Medical University of South Carolina, Charleston, SC; Cardiology, St. Francis Hospital, Roslyn, NY; Interventional Cardiology, Northwestern University, Chicago, IL.

5:48 PM (308) Right Ventricular Failure in Patients with Continuous-Flow Left Ventricular Assist Devices: Incidence and Risk Factors from INTERMACS; M.S. Kiernan, N.K. Kapur, D.T. Pham, J.K. Kirkin, D.C. Naftel, F.D. Pagani, R.L. Kormos, D. DeNofrio, Cardiovascular Center, Tufts Medical Center, Boston, MA; Cardiovascular Division, University of Alabama, Birmingham, AL; Cardiovascular Surgery, University of Michigan, Ann Arbor; Cardiovascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.

6:00 PM (309) The Bad Oeynhausen Experience with Temporary Right Ventricular Assist Device; N. Aissaouai, M. Morshuis, J. Börgermann, K. Hakim, J. Gummert, Department of Thoracic and Cardiovascular Surgery, Heart & Diabetes Center North Rhine-Westphalia, Bad Oeynhausen, Germany.
CONCURRENT SESSION 32  
(MEETING HALL 1)
End Stage Congenital Heart Disease: Opportunities and Challenges

CHAIRS: Daphne T. Hsu, MD and Michael P. Carboni, MD

5:00 PM  (310) Heart Transplantation for Adults with Congenital Heart Disease: Results in the Modern Era; J.K. Bhatia,1 J. Shulman,1 C.A. Bermudez,2 A. Bansal,1 D. Zaldonis,1 R. Ramani,1 J.J. Teuteberg,1 M. Shullo,1 D.M. McNamara,1 R.L. Kormos,1 Y. Toyoda,2 1Heart & Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; 2Department of Cardiothoracic Surgery, Temple University Hospital, Philadelphia, PA.

5:12 PM  (311) Late Mortality after Heart Transplantation in Adults with Congenital Heart Disease; L.J. Burchill,1 L.B. Edwards,2 M.B. Hertz,2 J.J. Stohlik,2 A.I. Dipchand,4 H.J. Ross,1 1Division of Cardiology, University Health Network, Toronto, ON, Canada; 2International Society of Heart and Lung Transplantation, Addison, TX, Australia; 3Cardiology Division, University of Utah School of Medicine, Salt Lake City, UT, Australia; 4Cardiology, Hospital for Sick Children, Toronto, ON, Canada; 5Pediatric Medicine, University of Minnesota, Minneapolis, MN.

5:24 PM  (312) Predicting 1-Year Survival in Pediatric Heart Transplant Candidates With Congenital Heart Disease: An Analysis of the PHTS Database; K.R. Schumacher,1 D. Naffet,2 M. Tresler,2 R. Kirk,3 C. Almond,4 T.P. Singh,5 R. Spicer,5 T.M. Hoffman,6 D. Hsu,7 C. Caner,9 M. Zamberlan,1 R.J. Gajarski,1 1Congenital Heart Center, University of Michigan, Ann Arbor, MI; 2University of Alabama, Birmingham, AL; 3Pediatric Cardiology, Children's Memorial Hospital, Chicago, IL; 4Pediatric Cardiology, Children's Hospital Boston, Boston, MA; 5Pediatric Cardiology, Siragusa Transplant Center, Children's Memorial Hospital, Chicago, IL; 6Pediatric Cardiology, Children's Hospital, St. Louis, MO; 7The Children's Hospital at Montefiore, New York, NY; 8St. Louis Children's Hospital, St. Louis, MO.

5:36 PM  (313) The Fontan Outcomes Need To Be Assessed in Adults Now (FONTAN) Study: A Prospective Study; L.J. Burchill,1 A.H. Kovacs, R.M. Welld, A. Soufi, E.N. Oechslin, H.J. Ross, Toronto Congenital Cardiac Centre for Adults/Toronto General Hospital, University Health Network, Toronto, ON, Canada.

5:48 PM  (314) Combined Heart-Liver Transplantation (HLT) for Failed Single Ventricle/Fontan Physiology; P. Vallabhapu-rosula,1 C. Kornik,1 M. Molina,2 L. Roche,1 Y. Kim,2 L. Goldberg,7 A. Pochettino,1 1Cardiovascular Surgery, Hospital of University of Pennsylvania, Philadelphia, PA; 2Cardiology, Hospital of University of Pennsylvania, Philadelphia, PA.

6:00 PM  (315) Outcomes of Cardiac Transplantation in Single Ventricle Patients with Plastic Bronchitis – A Multi-Center Report; J.G. Gossett,1 C. Almond,2 R. Kirk,3 S. Zangwill,4 M.E. Richmond,5 P.F. Kantor,6 M.A. Tresler,7 S.M. Lenderman,7 D.C. Naffet,7 D.C. Naffet,7 D.C. Naffet,7 K.L. Matthews,1 E. Pahl,1 1Pediatric Cardiology, Siragusa Transplant Center, Children's Memorial Hospital, Chicago, IL; 2Pediatric Cardiology, Children's Hospital Boston, Boston, MA; 3Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom; 4Pediatric Cardiology, Children's Hospital of Wisconsin, Milwaukee, WI; 5Pediatric Cardiology, Columbia University, Morgan Stanley Children's Hospital of New York, New York, NY; 6Pediatric Cardiology, Hospital for Sick Children, Toronto, ON, Canada; 7University of Arizona, Birmingham, AL.
5:00 PM – 6:15 PM

CONCURRENT SESSION 34

(MEETING HALL 4)

Fishing Lungs from the Donor Pool

CHAIRS: Matthew G. Hartwig, MD and Florian Wagner, MD

5:00 PM

(322) The INSPIRE International Lung Trial with the Organ Care System Technology (OCS™); G. Warnecke,1 A. Haverich,1 G. Massard,2 N. Santelmo,2 F. Rea,2 C. Knosalla,4 R. Hetzer,4 G. Leseche,5 A. Arehelali,6 A.R. Simon,7 J. Kukreja,8 K. McCurry,9 1Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; 2Hopitaux Universitaires de Strasbourg, Strasbourg, France; 3University of Padua, Padua, Italy; 4German Heart Center, Berlin, Germany; 5Hospital Bichat, Paris, France; 6UCLA, Los Angeles; 7Hereford Trust, London, United Kingdom; 8UCSF, San Francisco; 9Cleveland Clinic, Cleveland.

5:12 PM

(323) Successful Transplantation of Unusable Donor Lungs Using Ex-Vivo Lung Perfusion: The Newcastle Experience; J.H. Dark,1,2 D. Karanamanou,1 S. Clark,1 P. Mahesh,1 B. Watson,1 P.A. Corris,1,2 A.J. Fisher,1,2 1Institute of Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom; 2Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom.

5:24 PM


5:36 PM

(325) 5 Years Experience with Lung Donation after Cardiac Death; M. Cypel,1 A. Pierre, K. Yasufuku, M. DéPénot, V. Leist, L.G. Singer, T.K. Waddell, S. Keshavjee. University of Toronto, Toronto, ON, Canada.

5:48 PM

(326) A Randomized Trial of Nebulized Albuterol To Enhance Resolution of Pulmonary Edema in 506 Brain Dead Organ Donors; L.B. Ware1, M. Landeck,2 T. Koyama,1 E. Johnson,2 G.R. Bernard,1 J.W. Lee,3 M.A. Matthay.31 Van-HaarlemTrust, London, United Kingdom; 2Biomedical Research Center, Korea University, Seoul, South Korea; 3Department of Thoracic Surgery, Helsinki University Central Hospital, Helsinki, Finland; 4Biomedical Research Center, Korea University, Guro, Seoul, South Korea; 5Cardiopulmonary Research Group, Transplantation Laboratory, Haartman Institute, University of Helsinki, Helsinki, Finland; 6Department of Thoracic Surgery, Helsinki University Central Hospital, Helsinki, Finland; 7Biomedical Research Center, Korea Advanced Institute of Science and Technology, Daejeon, Korea; 8Molecular/Cancer Biology Program, Institute for Molecular Medicine Finland, Biomedicum Helsinki University, Helsinki, Helsinki, Finland.

6:00 PM

(327) Good Lungs for Bad Recipients and Bad Lungs for Good Recipients – Follow Up on Eurotransplant Rescue Offers; W. Sommer,1 C. Kuehn,1 I. Tudorache,1 M. Avsan,1 J. Salman,1 J. Gottlieb,2 A. Haverich,1 G. Warnecke,1 1Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany; 2Respiratory Medicine, Hannover Medical School, Hannover, Germany.
CONCURRENT SESSION 36  
(Forum Hall)
Pediatric Mechanical Circulatory Support

CHAIRS: David L.S. Morales, MD and Jennifer Conway, MD, FRCPC

8:00 AM  (333) Congenital Heart Disease Patients Have Disproportionately Lower Use of Ventricular Assist Devices Prior to Transplantation: Impact on Organ Allocation; J.M. Below,¹ J.O. Mudd,¹ H.K. Song,² C.S. Borberg,¹ Department of Medicine, Division of Cardiovascular Medicine, Oregon Health and Science University, Portland, OR; ²Department of Surgery, Oregon Health and Science University, Portland, OR.

8:12 AM  (334) The Use of Short-Term Ventricular Assist Devices in Children; I. Adachi,¹ J.S. Heinle,¹ E.D. McKenzie,¹ M.C. Mccarthy,³ A.G. Cabrera,² A. Jeewa,² C.D. Fraser, Jr.,¹ D.L.S. Morales,¹ Michael E. DeBakey Department of Surgery, Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX; ²Pediatrics-Cardiology, Baylor College of Medicine, Houston, TX; ³Cardiovascular Surgery, Texas Children's Hospital, Houston, TX.

8:24 AM  (335) Hospital Costs for Supporting Children with Ventricular Assist Device in the United States; A.X. Samaya,¹ B.S. Moffett,² M.S. Khan,¹ C.M. Mery,¹ J.S. Heinle,¹ D.L.S. Morales,¹ Congenital Heart Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX; ²Pharmacy, Texas Children's Hospital, Houston, TX.


8:48 AM  (337) Mechanical Circulatory Support (MCS) as a Bridge to Paediatric Heart Transplant: Does the End Justify the Means?; J.V. Cassidy,¹ A. Wagh, S. Haynes, R. Kirk, L. Ferguson, J. Smith, M. Guillen, Y. Thiru, M. Griselli, A. Hasan, Paediatric Intensive Care Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

9:00 AM  (338) Outcomes of Pediatric Patients Supported by the Heartmate II LVAD in the USA; A.G. Cabrera,¹ K. Sundareswaran,² A.X. Samaya,² D.J. Farrar,² O.H. Frazier,² D.L.S. Morales,³ ¹Pediatrics, Division of Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX; ²Thoratec Corporation, Pleasanton, CA; ³Congenital Heart Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX; ⁴Texas Heart Institute, St. Luke's Episcopal Hospital, Houston, TX.

8:00 AM – 9:15 AM

CONCURRENT SESSION 37  
(Meeting Hall 1)
Heart Transplantation: Outcomes with Patients with CAV and/or Alloantibody

CHAIRS: Joren C. Madsen, MD, DPhil and Bruce R. Rosengard, MD, FRCS

8:00 AM  (339) Clinical Effects of Introducing Everolimus in the Immunosuppressive Regimen of Patients with Established Cardiac Allograft Vasculopathy (CAV): Efficacy Analysis of a Randomized, Multicenter Study; J. Segovia,¹ J. Fernández-Yáñez,² F.J. González-Vilchez,³ J. Delgado,⁴ S. Mirabet,⁵ N. Manito,⁶ E. Roig,⁶ G. Rábago,⁷ M. Gómez-Bueno,¹ L. Alonso-Pulpón,¹ Heart Transplant Units, Hospital Puerta de Hierro, Madrid, Spain; ²Hospital Gregorio Marañón, Madrid, Spain; ³Hospital Marqués de Valdecilla, Santander, Spain; ⁴Hospital de Octubre, Madrid, Spain; ⁵Hospital Sant Pau, Barcelona, Spain; ⁶Hospital Bellvitge, Barcelona, Spain; ⁷Clinica Universitaria de Navarra, Pamplona, Spain.

8:12 AM  (340) Outcomes Validation of the New ISHLT Cardiac Allograft Vasculopathy Coronary Angiogram Grading Scale; J. Patel, M. Kittleson, P. Kansara, M. Rafiei, L. Stern, D. Chang, B. Azarbal, L. Czer, F. Esmailian, J. Kobashigawa, Cedars-Sinai Heart Institute, Los Angeles, CA.

8:24 AM  (341) Distal Pruning as an Important Factor for Outcome in the New ISHLT Cardiac Allograft Vasculopathy Grading Scale; J. Czer, J. Patel, M. Kittleson, M. Rafiei, L. Stern, D. Chang, B. Azarbal, A. Trento, J. Kobashigawa, Cedars-Sinai Heart Institute, Los Angeles, CA.

8:36 AM  (342) Non-Stenotic Coronary Vasculopathy Is Associated with Reduced Survival after Heart Transplantation; N.E. Hiemann,¹ E. Wellnhofer,² C. Chistian,¹ S. Kretschmer,¹ R. Meyer,¹ H. Valantine,³ R. Hetzer,¹ K.K. Khush.¹ ¹Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Department of Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany; ³Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford.

8:48 AM  (343) First-Year Brain Natriuretic Peptide (BNP) as a Biomarker after Heart Transplant To Predict Severity of Cardiac Allograft Vasculopathy (CAV) as Per the New ISHLT CAV Scale; J. Patel, M. Kittleson, R. Shiozaki, M. Rafiei, L. Stern, B. Azarbal, L. Czer, F. Esmailian, J. Kobashigawa, Cedars-Sinai Heart Institute, Los Angeles, CA.

**CONCURRENT SESSION 38**  
(PANORAMA HALL)

**From BOS to CLAD and Beyond!**

**CHAIRS:** Keith C. Meyer, MD, MS and Daniel Dilling, MD

---

8:00 AM (345) *Evaluation of FVC and FEV1 in Both Cohorts Previously Included in a Randomized Controlled Trial of Azithromycin To Prevent Bronchiolitis Obliterans Syndrome after Lung Transplantation;* R. Vog, B.M. Vanaudenaerde, S.E. Verleden, L.J. Dupont, D.E. Van Raemdonck, G.M. Verleden. Lung Transplant Unit, KULeuven and UZLeuven, Leuven, Belgium.

8:12 AM (346) *Risk of Patient Death after CLAD Onset: BOS and RAS as Time-Dependent Covariates in a Cox Model;* M. Sato, 1 K. Ohmori-Matsuda, 2 L.G. Singer, 3 S. Keshavjee, 3 Thoracic Surgery, Kyoto University, Kyoto-city, Japan; 3Centre for Research on Inner City Health, St. Michael’s Hospital, Toronto, ON, Canada; 2The Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada.

8:24 AM (347) *Running Out of Air: CLAD Phenotypes Post Lung Transplant;* M. Paraskeva, 1 M. Bailey, 2 T. Williams, 1 B. Lev-Ari, 1 G. Snell, 1 G. Westall, 1 Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, VIC, Australia; 2ANZIC-RC, Department of Epidemiology and Preventative Medicine, Monash University, Alfred Hospital, Melbourne, VIC, Australia.

8:36 AM (348) *Inter-Observer Variability on Diagnosing Bronchiolitis Obliterans Syndrome;* S. Bhorade, 1 A. Kápri, 1 V. Valentine, 2 M. Baz, 2 On Behalf of the AIRSAC Investigators. 1Medicine, University of Chicago Medical Center, Chicago, IL; 2Medicine, University of Texas, Galveston, TX; 3Medicine.

8:48 AM (349) *Air Pollution and the Development of Post-Transplant Bronchiolitis Obliterans Syndrome;* S. Bhinder, 1 H. Chen, 2 M. Sato, 4 R. Copes, 7 G.J. Evans, 4 C.-W. Chow, 1 L.G. Singer. 1Department of Medicine, University of Toronto, Toronto, ON, Canada; 2Public Health Ontario, Toronto, ON, Canada; 3Southern Ontario Centre for Atmospheric Aerosol Research, University of Toronto, Toronto, ON, Canada; 4Thoracic Surgery, Kyoto University, Kyoto, Japan.

---

**CONCURRENT SESSION 39**  
(MEETING HALL 4)

**‘Hitting the Right Spot’ – New Targets in Immunosuppression**

**CHAIRS:** Richard N. Pierson, III, MD and Carla C. Baan, PhD

8:00 AM (351) *The JAK1/3-Inhibitor R507 Diminishes Acute and Chronic Rejection While Demonstrating Immune Cell Specificity;* T. Deuse, 1 X. Hua, 1 M. Stubbendorf, 1 T. Gossler, 1 J. Velden, 2 V. Taylor, 3 G. Park, 3 Y. Chen, 3 H. Reichenspurner, 1 R.C. Robbins, 4 S. Schrepfer, 1, 4 TSI-Lab, Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; 2Pathology, University Hospital Hamburg, Hamburg, Germany; 3Rigel Pharmaceuticals, San Francisco; 4CT Surgery, Stanford University School of Medicine, Stanford.

8:12 AM (352) *Role of Mitochondrial Activity in the Development of Chronic Allograft Vasculopathy;* X. Hua, 1 T. Deuse, 1 M. Stubbendorf, 1 T. Gossler, 1 J. Velden, 2 R.C. Robbins, 3 E. Michelakis, 4 S. Schrepfer, 1, 3 TSI-Lab, Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; 2Pathology, University Hospital Hamburg, Hamburg, Germany; 3CT Surgery, Stanford University, Stanford; 4CV Medicine, University of Alberta, Edmonton, Canada.

8:24 AM (353) *Clopidogrel Alone and Combined with Everolimus or Tacrolimus Substantially Reduces Obliterative Bronchiolitis (OB) in an Experimental Mouse Model;* R. Preidl, 1 S. Eckl, M. Ramsperger-Gleixner, N. Koch, M. Weyand, S.M. Ensminger. Department of Cardiac Surgery, University Hospital, Erlangen-Nürnberg, Germany.

8:36 AM (354) *Blocking VEGF Receptors 1 and 2 Prevents Inflammatory Response and Experimental Obliterative Airway Disease;* A. Krebs, 1 J. Tikkanen, 1 M. Hollmén, 1 Y. Wu, 2 B. Pytowski, 3 K. Lernström, 1 Transplantation Laboratory, University of Helsinki, Helsinki, Finland; 2Department of Experimental Therapeutics, ImClone Systems, New York, NY.

8:48 AM (355) *In Vivo Expansion of Regulatory T Cells with ATG and Inhibition of IL-6 Prolongs Non-Human Primate Lung Allografts Survival;* A. Aoyama, 1 M. Tonsho, 1 Y. Yamada, 1 T.M. Millington, 1 S. Boskovic, 1 S. Lee, 1 R.-N. Smith, 2 J.C. Madsen, 3 T. Kawai, 3 J.S. Allan, 4 Transplant Surgery, Massachusetts General Hospital, Boston, MA; 3Pathology, Massachusetts General Hospital, Boston, MA; 2Transplant Center, Massachusetts General Hospital, Boston, MA; 4Thoracic Surgery, Massachusetts General Hospital, Boston, MA.

---

**Biologic Subtyping of Human Chronic Lung Allograft Dysfunction;** T. Saito, 1 M. Sato, 2 S. Azad, 1 M. Binnie, 3 S.E. Gilpin, 1 T. Machuca, 1 R. Bonato, 1 Y. Matsuda, 1 C.-W. Chow, 1 M. Cypel, 1 M. Liu, 1 T.K. Waddell, 1 S. Keshavjee, 1 Latner Thoracic Surgery Research Laboratories, University Health Network, University of Toronto, Toronto, ON, Canada; 2Department of Thoracic Surgery, Kyoto University, Kyoto, Japan; 3Division of Respiriology, University of Toronto, Toronto, ON, Canada.

**Pyruvate Dehydrogenase Kinase 2 Controls Vascular Remodeling;** T. Deuse, 1 X. Hua, 1 F. Längen, 2 T. Gossler, 1 M. Stubbendorf, 1 A. Rakovic, 3 C. Klein, 3 G. Sutendra, 4 P. Drompanis, 4 L. Maegdefessel, 5 P.S. Tsao, 3 J. Velden, 5 H. Reichenspurner, 1 R.C. Robbins, 5 F. Haddad, 5 E. Michelakis, 4 S. Schrepfer, 1, 7 1TSI-Lab, Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; 2Pathology, University Hospital Hamburg, Hamburg, Germany; 3Rigel Pharmaceuticals, San Francisco; 4CT Surgery, Stanford University School of Medicine, Stanford.
8:00 AM – 9:15 AM

CONCURRENT SESSION 40

(MEETING HALL 5)

Secondary (Non-PAH) Pulmonary Hypertension

CHAIRS: Joren Carlsen, MD, DMSC and J. Eduardo Rame, MD, MPhil

8:00 AM (357) Comparative Effects of the Drugs Used for Pulmonary Hypertension Reversibility Testing: A Meta-Analysis; M. Guclu,1 S. Mehra,2 T. Mason,2 1Cardiology, University of South Florida, Tampa, FL; 2College of Public Health, University of South Florida, Tampa, FL.

8:12 AM (358) Pulmonary Vascular Gradient: A Predictor of Prognosis in Pulmonary Hypertension Due to Left Heart Disease; C. Gerges,1 M. Gerges,1 M. Lang,1 H. Heinzl,2 P. Probst,1 G. Maurer,1 I. Lang,1 1Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria; 2Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.

8:24 AM (359) Long-Term Sildenafil Therapy in Advanced HF Patients with Severe PH Improves Hemodynamics and Prevents Weight Loss; A. Reichenbach, V. Melenovsky, H. Al-Hiti, I. Malek, J. Kautzner. Cardiology, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.

8:36 AM (360) Echo-Doppler Profile of Abnormal Right Ventricular-Pulmonary Arterial Interaction Is Associated with Beneficial Response to Sildenafil in Heart Transplant Recipients with Pulmonary Hypertension; M.R. Molina,1 E.H. Ticehurst,2 L. Goldberg,1 D. Chojnowski,1 N. Hornsby,1 P. Forfia,2 1Heart Transplant & Heart Failure, Hosp of the Univ of Penn, Philadelphia, PA; 2Pharmacy, Hosp of the Univ of Penn, Philadelphia, PA.

8:48 AM (361) The REVEAL Score Predicts Prognosis in Patients with Multifactorial and Non-WHO Group I Pulmonary Hypertension; R. Cogswell, D. McGlothlin, R. Shaw, T. DeMarco. Cardiology, University of California San Francisco, CA.

9:00 AM (362) Pulmonary Arterial Lesions in Explanted Lungs after Transplantation Correlate with Severity of Pulmonary Hypertension in End-Stage Chronic Obstructive Pulmonary Disease; J. Carlsen,1 K.H. Andersen,1 S. Boesgaard,1 M. Iversen,1 D. Steinbrüchel,2 C.B. Andersen,3 1Department of Cardiology, Pulmonary Vascular Program, National University Hospital, Rigshospitalet, Copenhagen, Denmark; 2Department of Cardiothoracic Surgery, National University Hospital, Rigshospitalet, Copenhagen, Denmark; 3Department of Pathology, National University Hospital, Rigshospitalet, Copenhagen, Denmark.

8:00 AM – 9:15 AM

CONCURRENT SESSION 41

(NORTH HALL)

Getting Back To Basics

CHAIRS: Filo Billia, MD, PhD and Takeshi Nakatani, MD, PhD

8:00 AM (363) Apoptosis Occurs in Late Stages of Unloading Related Ventricular Remodeling; H.L. Brinks,1 T.P. Carrel,1 W.J. Koch,2 H.T. Tveaerai,3 M.-N. Giraud,1 1Cardiac and Vascular Surgery, Inselspital University Hospital Bern, Bern, Switzerland; 2Center for Translational Medicine, Thomas Jefferson University, Philadelphia.

8:12 AM (364) Increased Vascular Expression of the Proinflammatory Adhesion Molecules VCAM and E-Selectin and Endothelial Depletion of vWF Following Continuous Flow Left Ventricular Assist Device Placement; T. Kato,2 H. Takayama,1 E. Collado,2 H. Akashi,2 S. Yi,2 C.J. Chung,2 D. Mancini,1 Y. Naka,1 P.C. Schulze,2 1Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; 2Center for Advanced Cardiac Care, Columbia University Medical Center, New York, NY.

8:24 AM (365) Improved LVAD Haemocompatibility of Sintered Inflow Cannula by Endothelialization with Human Endothelial Cells; B. Wiegmann,1 I. Birschmann,2 A. Havenich,1 M. Strüber,1 1Department for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; 2Clinic for Haematology, Haemostaseology and Oncology, Hannover Medical School, Hannover, Germany.

8:36 AM (366) Plasma NOx Decreases Following Continuous Flow Left Ventricular Assist Device Despite Lack of Change in Shear Stress; S. Hozayen,1 A. Somani,2 S. Nair,2 D. Dengel,3 R. John,4 A. Hamel,1 P.M. Eckman.1 1Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, MN; 2Department of Pediatric Medicine, Critical Care Division, University of Minnesota, Minneapolis, MN; 3School of Kinesiology, University of Minnesota, Minneapolis, MN; 4Division of Cardiac Surgery, University of Minnesota, Minneapolis, MN.

8:48 AM (367) Augmentation of LV Wall Thickness by Selective Regional Injections of Alginate Hydrogel into Epivascular Cardiac Veins Improves LV Function and Reverses Chamber Remodeling in Dogs with Chronic Heart Failure; H.N. Sabbah,1 M. Wang,1 R.C. Gupta,1 S. Rastogi,1 S. Hegerman.2 1Medicine, Henry Ford Hospital, Detroit, MI; 2Lonestar Heart, Inc., Laguna Hills, CA.

9:00 AM (368) Developing a Biohybrid Lung – Gas Exchange Membranes Endothelialized with Allogeneic MHC-Silenced Endothelial Cells To Prevent Transplant Rejection; B. Wiegmann,1 C. Figueiredo,2 V. Dewor,1 S. Vahlsing,2 R. Blaszczyk,2 A. Havenich,1 1Department for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; 2Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany.
PLENARY SESSION (FORUM HALL)
Incorporating Information Technology into Pre and Post-Transplant Care
CHAIRS: Allan R. Glanville, MD, FRACP and David O. Taylor, MD

9:30 AM Awards Presentations
9:45 AM Integrating Information Technology into Care: Challenges and Opportunities, C. Martin Harris, MD, MBA, Cleveland Clinic Foundation, Cleveland, OH

10:15 AM Featured Abstract (369) Initial Experience of Cardiac Transplant Recipient Follow Up Using Telehealth; S.C. McKenzie, J. Maddicks-Law, R. Gururajän, M. Brown, D. Platts, A. Hickey, G. Javorsky, The Advanced Heart Failure and Cardiac Transplant Unit, The Prince Charles Hospital, Brisbane, QLD, Australia; School of Information Systems Faculty of Business, The University of Southern Queensland, Toowoomba, QLD, Australia.

10:30 AM Remote Hemodynamic Monitoring, W. H. Wilson Tang, MD, Cleveland Clinic Foundation, Cleveland, OH

10:45 AM Using Technology to Promote Self-Monitoring and Health Outcomes after Transplant, Annette J. DeVito-Dabbs, RN, PhD, University of Pittsburgh School of Nursing, Pittsburgh, PA

11:00 AM Remote Monitoring of Mechanical Circulatory Support Devices, Jan F. Gummert, MD, PhD, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany

11:15 AM – 11:30 AM COFFEE BREAK (CONGRESS HALL FOYER)

11:30 AM – 12:45 PM CONCURRENT SESSION 42 (FORUM HALL)
Featured Abstracts
CHAIRS: Jack Copeland, MD and Jon Kobashigawa, MD

11:30 AM (370) Prognostic Indications of Serial Risk Score Assessments: A REVEAL Analysis; R.L. Benza, D.P. Miller, A.J. Foreman, A.E. Frost, D.B. Badesch, L.A. Meltzer, M.D. McGoon, Allegheny General Hospital, Pittsburgh, PA; ICON Late Phase & Outcomes Research, San Francisco, CA; Baylor College of Medicine, Houston, TX; University of Colorado Denver; Aurora, CO; Actelion Pharmaceuticals US, Inc., South San Francisco, CA; Mayo Clinic, Rochester, MN.


12:06 PM (373) First-in-Man Experience with a Superficial, Synchronous Partial Circulatory Support Device for Chronic Heart Failure Patients; R. Cecere, N. Giannetti, R. Dowling, D. Raess, E. Gratz, A. Cheung, McGill University Health System, Montreal, Canada; DCI, Louisville, KY; Abiomed, Danvers; University of British Columbia, Vancouver, Canada.

12:18 PM (374) Psychiatric Predictors of 10-Year Outcomes after Lung Transplantation; E.M. Rosenberger, A.F. DiMartini, Y. Toyoda, J.M. Pilewski, C.A. Bermudez, A. DeVito Dabbs, M.A. Dew, Clinical and Translational Sciences, University of Pittsburgh, PA; Psychiatry, Western Psychiatric Institute and Clinic, Pittsburgh, PA; Transplantation Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; Surgery, Temple University, Philadelphia, PA; Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; Cell Biology and Physiology, University of Pittsburgh, PA; Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; School of Nursing, University of Pittsburgh, PA; Biostatistics, University of Pittsburgh, PA; Psychology, University of Pittsburgh, PA; Epidemiology, University of Pittsburgh, PA.

12:30 PM (375) The Impact of High Recipient Acuity on Outcomes after Lung Transplantation; T.J. George, C.A. Beatty, J.V. Conte, A.S. Shah. The Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD.
11:30 AM – 12:45 PM

CONCURRENT SESSION 43  
(MEETING HALL 1)
Bad VADs

CHAIRS: Thomas Krabatsch, MD, PhD and TBD

11:30 AM (376) Durability of Left Ventricular Assist Devices (LVADs): INTERMACS 2006-2011; W.L. Holman,1 D.C. Naftel,1 C.E. Eckert,2 R.L. Kornos,3 D.J. Goldstein,2 Y. Yuan,1 J.K. Kirklin.1 1Surgery, University of Alabama, Birmingham, AL; 2Surgery, Montefiore-Einstein Medical Center, Bronx, NY; 3Bioengineering and Surgery, University of Pittsburgh, PA.

11:42 AM (377) Survival to Transplant in Patients Undergoing Mechanical Circulatory Support as Bridge: Retrospective Analysis of LVAD, BiVAD and TAH Strategies; O.E. Paiao,1 A.V. Kalya,2 R.S. Gopalan,2 L.L. Staley,1 K.L. Diane,1 J.M. Spadafore,1 C.N. Pierce,1 B.N. Noble,2 C. Krishnasamy,2 R.L. Scott,2 F.A. Arabia.1 1Cardiovascular and Thoracic Surgery, Mayo Clinic, Phoenix, AZ; 2Cardiovascular Diseases, Mayo Clinic, Phoenix, AZ; 3Department of Biostatistics, Mayo Clinic, Phoenix, AZ.

11:54 AM (378) Adverse Events and Complications Profile after HVAD LVAD Implantations in Adult Patients; T. Krabatsch,1 M. Schweiger,1,2 J. Vierecke,1 A. Stepanenko,1 E. Potapov,1 M. Hübler,1 M. Kukuczu,1 R. Hetzen.1 1German Heart Institute Berlin, Clinic for Heart, Thoracic and Vascular Surgery, Berlin, Germany; 2Medical University Graz, Division for Transplantations Surgery, Graz, Austria.

12:06 PM (379) Early Results from the SoundMate Study, Acoustic Analysis of a Thromboembolic Event in a Patient Treated with HeartMate II™, Mechanical Circulatory Support; L. Hubbert,1 U.P. Jorde,1 B. Peterzén,1 H. Grenfeldt,1 B. Kornhall,2 K. Morrison,1 H. Ahn.1 1Heart Centre at Linkoping University, Linkoping, Sweden; 2Division of Heart failure and Cardiac Valves, Skane University Hospital, Lund, Sweden; 3Columbia University Medical Center, New York Presbyterian Hospital, New York.

12:18 PM (380) Changes in Sexual Function Following Left Ventricular Assist Device (LVAD); V. Dhungel,1 S.A. Mandras,2 M.A. Brisco,2 S. Ermani,4 J. Lindenfeld,5 N. Sulemanjee,6 G. Sokos,7 J.L. Feldman,8 P.M. Eckman.1 1Cardiology Division, University of Minnesota, Minneapolis, MN; 2Cardiology Division, Ochsner Medical Center, New Orleans, LA; 3Cardiology Division, University of Pennsylvania, Philadelphia, PA; 4Cardiology Division, The Ohio State University Medical Center, Columbus, OH; 5Cardiology Division, University of Colorado, Aurora, CO; 6Transplant and Cardiology Clinics, Aurora Medical Group, Milwaukee, WI; 7The Gerald McGinnis Cardiovascular Institute, Allegacy General Hospital, Pittsburgh, PA; 8Department of Family Medicine, University of Minnesota, Minneapolis, MN.


11:30 AM – 12:45 PM

CONCURRENT SESSION 44  
(PANORAMA HALL)
Heart Transplantation: What Can We Learn from Registry Data

CHAIRS: Finn Gustafsson, MD, PhD, DMSc and Gregory A. Ewald, MD

11:30 AM (382) Outcomes of Adults with Restrictive Cardiomyopathy (RCM) Post Heart Transplant (HT): UNOS Registry Analysis; E.C. DePasquale.1 K. Nasir,1 L. Bellumkonda,1 A. Mangi,2 D. Dries,1 D.L. Jacoby.1 1Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT; 2Section of Cardiac Surgery, Yale University School of Medicine, New Haven, CT.

11:42 AM (383) ABO Blood Type Matching and Survival after Heart Transplantation: Analyze of the ISHLT Registry; J. Nilsson,1 M. Ohlsson,2 P. Höglund,3 B. Ekmehag,4 B. Koul,1 B. Andersson.5 1Clinical Sciences in Lund, Cardiothoracic Surgery, Lund University and Skåne University Hospital, Lund, Sweden; 2Computational Biology and Biological Physics, Lund University, Lund, Sweden; 3Competence Centre for Clinical Research, Lund University and Skåne University Hospital, Lund, Sweden; 4Clinical Sciences in Lund, Cardiology, Lund University and Skåne University Hospital, Lund, Sweden; 5Clinical Sciences in Lund, Surgery, Lund University and Skåne University Hospital, Lund, Sweden.

11:54 AM (384) Pre-Transplant Malignancy: An Analysis of Outcomes after Thoracic Organ Transplantation; C.A. Beatty, T.J. George, A. Kilic, J.V. Conte, A.S. Shah. The Division of Cardiac Surgery, Johns Hopkins Medical Institutions, Baltimore, MD.

12:06 PM (385) Predictors of Graft Survival in Heart Transplant Recipients with Peripartum Cardiomyopathy: Insights from the United Network for Organ Sharing (UNOS) Database; K. Rasmussen,1 K. Brunisholz,1 M. Labeled,1 S. Knight,1 D. Budge,1 J. Stehlik,2 R. Alharethi,1 J. Nixon,1 S. Frampton,1 A. Kfoury.1 1UTAH Cardiac Transplant Program, Intermountain Medical Center, Salt Lake City, UT; 2University of Utah, Salt Lake City, UT.

12:18 PM (386) Outcomes of Familial Dilated Cardiomyopathy (FDCM) Post Heart Transplant (HT); E.C. DePasquale,1 D. Dries,1 W.J. McKenna,2 D.L. Jacoby.1 1Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT; 2Institute of Cardiovascular Science, University College London and The Heart Hospital, UCLH NHS Trust, London, United Kingdom.

12:30 PM (387) Post-Transplant Survival of Patients in Need of Biventricular and Right-Ventricular Mechanical Bridge to Heart Transplantation. A Comparative Analysis of the ISHLT Transplant Registry, [Transplant Registry Early Career Award]; J.N. Nativi,1 S.G. Drakos,1 L.B. Edwards,2 A.Y. Kucheryavyaya,2 C. Selzman,1 A.G. Kfoury,2 F. Baden,1 R. Alharethi,2 O. Wever-Pinzone,1 S. Kushwaha,2 M.I. Hertz,2 J. Stehlik.1 1University of Utah, Salt Lake City, UT; 2International Society for Heart and Lung Transplantation, Addison, TX; 3University of Minnesota, Minneapolis, MN; 4Intermountain Medical Center; Salt Lake City, UT; 5Mayo Clinic, Rochester, MN.
CONCURRENT SESSION 45  (MEETING HALL 4)
Growing Up with a Heart Transplant: Adolescence, Antibodies and Pharmacogenetics

CHAIRS: Richard Kirk, MA, FRCP, FRCPCH and Robert E. Shaddy, MD


11:54 AM (390) Infant Heart Transplantation: 10 Years and Beyond; V. Krishnamurthy, L. Zaytsev, K. Freier Randall, R. Chinnock. Pediatrics, Loma Linda University Health Care, Loma Linda, CA.


12:18 PM (392) Complement Fixation by C1q vs MFI: Detection of Clinically Relevant Antibodies; C. D. Castleberry, C. Chin, D. Rosenthal, D. Bernstein, S. A. Hollander, D. Tyas. 1Pediatric Cardiology, Stanford University School of Medicine, Palo Alto, CA; 2Pediatric Cardiology, Cincinnati Children's Hospital, Cincinnati, OH; 3Pathology, Stanford University School of Medicine, Palo Alto, CA.

12:30 PM (393) Donor Specific HLA Antibodies Arising after Pediatric Cardiac Transplantation; C. Irving, V. Carter, A. Gennery, G. Parry, A. Hasan, M. Griselli, M. Howell, R. Kirk. 1Transplant Institute, Freeman Hospital, Newcastle upon Tyne, United Kingdom; 2National Health Service Blood and Transplant, Newcastle upon Tyne, United Kingdom.

CONCURRENT SESSION 46  (MEETING HALL 5)
Mechanisms of Acute Injury and Organ Preservation

CHAIRS: Tobias Deuse, MD, PhD and James George, PhD

11:30 AM (394) Control of Cardiac Metabolism and Growth by DJ-1; F. Billia, L. Hauck, D. Grothe, F. Konechy, V. Rao, T.W. Mak. 1Research, Campbell Family Institute for Cancer Research, Toronto, ON, Canada; 2Medicine/Cardiac Surgery, University Health Network, Toronto, ON, Canada; 3Research, Toronto General Research Institute, Toronto, Canada.

11:42 AM (395) Secretome of Apoptotic Peripheral Blood Cells (APOSEC) Attenuates Area at Risk in a Porcine Closed Chest Reperfused Acute Myocardial Infarction Model: Role of Platelet Aggregation In Vitro and In Vivo; K. Hoetzenecker, A. Assinger, M. Lichtenauer, M. Mildner, T. Schweiger, A. Mitterbauer, P. Starlinger, M. Ernstbrunner, B. Steinlechner, M. Gyoergyosi, I. Volf, H.J. Ankersmit. 1Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria; 2Institute of Physiology, Medical University of Vienna, Vienna, Austria; 3Department of Dermatology, Medical University of Vienna, Vienna, Austria; 4Department of Surgery, Medical University of Vienna, Vienna, Austria; 5Department of Anaesthesia, General Intensive Care and Pain Management, Medical University of Vienna, Vienna, Austria; 6Department of Cardiology, Medical University of Vienna, Vienna, Austria.


12:18 PM (398) Successful 24-Hour Ex-Vivo Maintenance of Swine Lungs Using the Organ Care System (OCS™); M. Avsar, G. Warnecke, F. Ius, A. Haverich, I. Abdel fattah, A. Hasebanein, M. Irianiha, H. O’Connor. 1Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany; 2Thoracic and Cardiovascular Surgery, Cairo University Medical School, Cairo, Egypt; 3Thoracic and Cardiovascular Surgery, Ain Shams University School of Medicine, Cairo, Egypt; 4Department of Clinical Development, TransMedics, Inc., Andover, MA.

CONCURRENT SESSION 47
(NORTH HALL)
Evolving Infections in a New Era

CHAIRS:
Glen P. Westall, FRACP, PhD and Frauke Mattner, PhD


11:42 AM (401) Differential Distribution and Functional Quality of CMV-Specific T Cell Effector Memory in High-Risk Lung Transplant Recipients; J.A. Akulian, M.R. Pipeling, E.R. John, J.F. McDyer. Johns Hopkins University School of Medicine, Baltimore, MD; PACCM, University of Pittsburgh School of Medicine, Pittsburgh, PA.

11:54 AM (402) Reconstitution of CMV-Specific Immunity after Heart Transplantation Is Modulated by mTOR Inhibition, but Not by Antiviral Strategy; E. Petrisi, L. Potena, I.G. Bianchi, A. Chiereghin, P. Prescinti, F. Barberini, F. Angeli, G. Magnani, T. Lazzarotto, F. Grigioni, A. Branzi. Cardiovascular Department, University of Bologna, Bologna, Italy; Clinical Microbiology, University of Bologna, Bologna, Italy.

12:06 PM (403) Chronic Hepatitis E Virus Infection in Lung Transplant Recipients; H.Y. van der Weide, E.B. Haagsma, B.G.M. Nieters, A. Riezbos-Bhiman, E.A.M. Verschuuren. Gastro-enterology & Hepatology, University Medical Centre Groningen, Groningen, Netherlands; Medical Microbiology & Virology, University Medical Centre Groningen, Groningen, Netherlands; Pulmonary Diseases & Tuberculosis, University Medical Centre Groningen, Groningen, Netherlands.

12:18 PM (404) Impact of Deep-Sequencing for the Identification of Viruses in Pediatric Lung Transplant Recipients; L. Danziger-Isakov, D. Wang, R. Buller, S. Mason, C. Conrad, A. Faro, S. Goldfarb, D. Hayes, Jr., M. Schecter, H. Spencer, G. Visner, G. Storch, S. Sweet, Cleveland Clinic, Cleveland; Washington University, St. Louis; Lucile Packard Children's Hospital, Palo Alto; Children's Hospital of Philadelphia, Philadelphia; Nationwide Children's Hospital, Columbus; Texas Children's Hospital, Houston; Great Ormond Street Hospital, London, United Kingdom; Children's Hospital Boston, Boston.

12:30 PM (405) Risk Factors for Invasive Fungal Infection after Lung Transplantation; D.C. Chambers, S.T. Yerkovich, V. Maloyasena, M. Menon, P.M. Hopkins, Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, QLD, Australia; School of Medicine, The University of Queensland, Brisbane, QLD, Australia.
SESSION 1
(CONGRESS HALL FOYER)

Presenters will be available on Wednesday from 6pm-7pm to discuss their posters and answer any questions.

(406) Translational Models: A Humanized Model To Study the Development of Obliterative Airway Disease; X. Hua,1 T. Deuse,1 M. Stubben-dorff,1 J. Velden,2 H. Reichenspurner,1 R.C. Robbins,3 S. Schrepfer,1,3 1TSI-Lab, Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; 2Pathology, University Hospital Hamburg, Hamburg, Germany; 3CT Surgery, Stanford University, Stanford, Germany.

(407) Regulatory T Cells in Transbronchial Biopsies Compared with FoxP3 mRNA Level in Bronchoalveolar Lavage Fluid; D. Krusstrup,1 C.B. Madsen,2 M. Iversen,3 C.B. Andersen,1 1Department of Pathology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; 2The Tissue Type Laboratory, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; 3The Heart and Lung Transplantation Unit, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

(408) The Importance of DC (Dendritic Cell) – T Cell Interplay in Cardiac Transplantation; T. Ueno,1,2 M.Y. Yeung,2 K. Jung,2 P. Dutta,1 M. Nahren-dorf,1 S.H. Yun,2 R. Weissleder,1 1Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; 2Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

(409) Dynamic Changes in the Immunophenotypic Maturation Status of CD19 B Lymphocytes in Patients with Acute Cellular Rejection after Heart Transplantation; J. Carbone,1 N. Lanio,1 A. Gallego,1 J. Navarro,1 J. Paizmo,2 J. Fernandez-Yañez,2 E. Sarmiento,1 1Clinical Immunology, Gregorio Marañon Hospital, Madrid, Spain; 2Cardiology, Gregorio Marañon Hospital, Madrid, Spain.

(410) Can Cross-Reactive Anti-Viral T Cells to CMV Influence Alloreactivity in Lung Transplant Recipients?; O. Nguyen,1,2 G.P. Westall,1,2 T.C. Kotsimbos,1,3 N.A. Mifsud.1,2 1Medicine, Central Clinical School, Monash University, Melbourne, VIC, Australia; 2Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, VIC, Australia.

(411) Epigenetic Analysis Demonstrates That Natural Treg Only Infiltrate the Cardiac Allograft during an Acute Rejection Episode; K. Boer,1 A.M.A. Peeters,1 A.P.W.M. Meat,2 K. Caliskan,3 A.H.M.M. Balk,2 W. Weimar,1 C.C. Baan,1 1Internal Medicine – Transplantation, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands; 2Thoracic Surgery, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands; 3Cardiology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands.

(412) CMV Reactivation Rather Than Persistent Alloantigen Drives a Specific Cross- Reactive T Cell Receptor Repertoire; O. Nguyen,1,2 K. Kedzierska,3 N. Bird,3 G.P. Westall,1,2 T.C. Kotsimbos,1,3 N.A. Mifsud.1,2 1Medicine, Monash University, Melbourne, VIC, Australia; 2Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, VIC, Australia; 3Microbiology and Immunology, The University of Melbourne, Parkville, VIC, Australia.

(413) Impact of CD14+CD5+ B-Cells on T-Dependent and T-Independent Immune Responses in Early Childhood; Y. Ling,1,3 E. Dijke,1 L.J. West,1,3 S. Urschel,1,3 1Pediatrics, University of Alberta, Edmonton, AB, Canada; 2Surgery, University of Alberta, Edmonton, AB, Canada; 3Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada.

(414) Differential Gene Regulation between Brain and Cardiac Death Donor Lungs during Ex Vivo Lung Perfusion; R. Zamel, X.-H. Bai, J.C.

Attila V. Salice,1 M. Pizzocri,3 S. Gatti,3 L. Santambrogio,2 L. Gattinnoni,11 Anestesia, Terapia Intensiva e Subintensiva e Terapia del Dolore, Fondazione IRCCS Ca’ Granda – Ospedale Maggiore Policlinico, Milano, Italy; 2Department of Surgery, Columbia University Medical Center, New York, NY; 3Centro di Ricerche Chirurgiche Precliniche, Strasbourg, France; 4Cardiology, University of Arizona, Tucson, AZ; 5Division of Cardiovascular Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN; 6Giner Inc, Newton, MA; 7Division of Cardiothoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN.

P.M. Eckman,5 L.A. Tempelman,6 R. John,7 N. Chronos,3 K.K. Papas,1 Division of Transplantation, Department of Surgery, University of Minnesota, Minneapolis, MN; 2Institute for Cellular Transplantation, Department of Surgery, University of Arizona, Tucson, AZ; 3Saint Joseph’s Translational Research Institute, Atlanta, GA; 4Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX; 5Division of Cardiovascular Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN; 6Giner Inc, Newton, MA; 7Division of Cardiothoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN.

Evaluating Transplantation Survival Following Orthotopic Heart Transplantation; A. Kilic, J.V. Conte,1 A.S. Shah,1 W.A. Baumgartner,1 D.D. Yuh,6 Division of Cardiovascular Medicine, Johns Hopkins Hospital, Baltimore, MD; 2Section of Cardiovascular Surgery, Yale University School of Medicine, New Haven, CT.

Evaluation of Patients with Dyspnea with Utilization of Submaximal Exercise Study with SHAPE-HF™ Test Shows Benefits of Cost Saving and Better Patient Care; B. Czereska, A. Pelaez. Transplantation, Florida Hospital, Orlando, FL.

Chagas Cardiomyopathy: The Economic Burden of an Expensive, Neglected Disease, and Cause for Heart Failure; A. Abubak, E. Trindade, S.M. Fujii, E.A. Bocchi, F. Bacal. Heart Failure, Heart Institute, Sao Paulo, SP, Brazil.

Health Economic Evaluation of Predictive and Diagnostic Biomarkers of Acute Cardiac Rejection; Z. Holland,1,2 T.H.G. Mohammadi,3 M. Co,1 J.E. Wilson-McManus,1 R.T. Ng,1,4 R. Balshaw,1,5 R.W. McMaster,1,6 P.A. Keown,1,2,7 B.M. McManus,1,2,7,8,9 G. Marra,1,10,11,12 1PROOF Centre of Excellence, Vancouver, BC, Canada; 2Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada; 3Collaboration for Outcomes Research and Evaluation, Vancouver, Canada; 4Computer Science, The University of British Columbia, Vancouver, Canada; 5Statistics, The University of British Columbia, Vancouver, Canada; 6Medical Genetics, The University of British Columbia, Vancouver, Canada; 7Medicine, The University of British Columbia, Vancouver, Canada; 8UBC James Hogg Research Centre, Vancouver, Canada; 9Institute for Heart + Lung Health, Vancouver, Canada; 10Collaboration for Outcomes Research and Evaluation, The University of British Columbia, Vancouver, Canada; 11Centre for Health Evaluation and Outcome Sciences, Providence Health Care Research Institute, Vancouver, Canada; 12Arthritis Research Centre of Canada, Vancouver, Canada.

Diffusion Tensor Magnetic Resonance Imaging: A New Tool To Evaluate Cardiac Remodeling Changes in the Failing Human Heart; S.G. Drakos,1,2 O. Abdullah,1 J. Stehlik,2 N. Diakos,1 K. Brunisholz,2 B.H. Reid,2 C.H. Selzman,2 D. Verma,2 O. Wever-Pinzon,2 C. Mlynch,3 G. Russel,3 R. Alharethi,4 E. M. Gilbert,5 D. Budge,5 E. Hsu,1 D.Y. Li,1 A.G. Kloufy.3 1University of Utah Department of Bioengineering & Molecular Medicine, Salt Lake City, UT; 2UtAH Cardiac Transplant Program, Salt Lake City, UT; 3Intermountain Donor Services, Salt Lake City, UT.

Impact of the Severity of End-Stage Liver Disease in Cardiac Remodeling; O.M. Silvestre,1 F. Bacal,1 A.Q. Farias,2 J.L. Andrade,1 M. Furtado,2 V. Pugliese,2 W. Andraus,2 D.S. Ramos,2 E. Belleti,2 L.A.C. Albuquerque,2 F.J. Carnilho,2 Cardiology, University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil; 3Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil; 4Radiology, University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil.

The Role of Cardiac Biomarkers in Takotsubo Cardiomyopathy; A. Lahoti,1 M. Badri,1 M. Iqbal,2 K.S. Mohammadi,1 J.M. Saeed,2 E. Gnall,1 R. Zolt,3 M.R. Sardar.1 1Department of Cardiology, Lankenau Medical Center, Wynnewood, PA; 2Department of Cardiology, Montefiore Medical Center, New York, NY.

Is Improvement in Pulmonary Vascular Hemodynamics in Patients Supported with Continuous-Flow Left Ventricular Assist Devices;

(432) Transmural Heterogeneity and Depressed Function in the Mechanical Properties of Ventricular Tissue from Patients with End-Stage Heart Failure; P. Shekar,1 M.I. Mitov,2 L.F. Ferreira,4 S.G. Campbell,1 S.A. Stanuso,1 A.M. Jarrells,1 B.A. Lawson,1 M.B. Reid,1 C.W. Hoopes,3 M.R. Bonnell,5 K.S. Campbell,1 Physiology, University of Kentucky, Lexington, KY; 2Chemistry, University of Kentucky, Lexington, KY; 3Division of Cardiothoracic Surgery, University of Kentucky, Lexington, KY; 4Applied Physiology and Kinesiology, University of Florida, Gainesville, FL; 5Toledo Medical Center; University of Toledo, Toledo, OH.

(433) Relationship between Lead Location and Left Ventricular Remodeling with Peri-Infarct Pacing; C.M. Stolen,1 L.M. Thackery,1 E.S. Chung,2 1Boston Scientific, St. Paul, MN; 2The Christ Hospital, Cincinnati, OH.

(434) Rest Cerebral Oxygenation Is a Biomarker in Heart Failure Patients; L. Rifa,1 W. Taylor,1 K. Key,1 M.A. Silver,1,2 1Department of Medicine, University of Illinois at Chicago/Advocate Christ Medical Center, Oak Lawn, IL; 2Heart Failure Institute, Advocate Christ Medical Center, Oak Lawn, IL.

(435) Use of Vitamin K and Prothrombin Complex Concentrate as Warfarin Reversal Prior to Heart Transplant; T. Mathia,1 K.E. Puca,2 F. Downey,3 A.J. Boyle,3 1Pharmacy, Aurora St. Luke’s Medical Center of Aurora Health Care, Inc, Milwaukee, WI; 2Transfusion Medicine, Blood Center of Wisconsin, Milwaukee, WI; 3Cardiothoracic Transplant, Aurora St. Luke’s Medical Center of Aurora Health Care Metro, Inc, Milwaukee, WI.

(436) Effect of CYP3A5, CYP3A5 and ABCB1 Genotypes in Tacrolimus Dose-Monitoring and Clinical Outcomes after Heart Transplantation; B. Tavira,1 B. Díaz-Molina,2 J.L. Lambert,2 M.J. Bernardo,2 C. Morís,2 V. Álvarez,1 C. López-Larrea,3 E. Coto,1 1Molecular Genetics, Laboratory of Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain; 2Cardiology, Hospital Universitario Central de Asturias, Oviedo, Spain; 3Inmunology, Hospital Universitario Central de Asturias, Oviedo, Spain.

(437) Outcomes in Patients Removed from the Heart Transplant Waitlist Prior to Transplant; C.J. VanderPluym, D. Graham, C. Almond, C. Millein, T.P. Singh. Children’s Hospital Boston, Boston, MA.

(438) Cardiac Transplantation for Chemotherapy Induced Cardiomyopathy: Demographics and Long Term Follow-Up; S.C. McKenzie,1,2 A. Sharma,1 K.-W. Chee,1 D. Platts,1 G. Javorskky,1 M. Brown,1,2 1Advanced Heart Failure and Cardiac Transplant Unit, The Prince Charles Hospital, Brisbane, Queensland, Australia; 2School of Medicine, University of Queensland, Brisbane, QLD, Australia.

(439) Remodeling Risk Prediction with Chronic Heart Rate Variability: Secondary Results from the Myocardial Enlargement and Dilatation Post Myocardial Infarction (MENDMI) Study; D. Dan,2 A. Patangay,1 C.M. Stolen,1 1Cardiology, Rhythm and Vascular; Boston Scientific, St. Paul, MN; 2Piedmont Hospital, Atlanta, GA.

(440) Uric Acid Elevation Is Associated with Severity of Congestion in Advanced Heart Failure; M. Guqlin,1 G. Stewart,2 M.M. Kittleson,2 J.A. Cowger,3 C.B. Patel,5 J.E. Rame,3 M.M. Mountis,3 P. Patel,6 F. Johnson,9 J. Teuteberg,10 J. Testani,6 L.W. Miller.1 Cardiology, University of South Florida, Tampa, FL; 2Medicine, Brigham and Women’s Hospital, Boston, MA; 3Sedar Sinai Hospital, Los Angeles; 4University of Michigan, Ann Arbor; 5Duke University, Durham; 6University of Pennsylvania, Philadelphia; 7Cleveland Clinic, Cleveland; 8UT Southwestern, Dallas; 9University of Iowa, Iowa City; 10University of Pittsburgh, PA.


(442) Reoperative Sternotomy Is Associated with Increased Mortality after Heart Transplantation; T.J. George,1 C.A. Beatty,1 G.A. Ewald,2 A.S. Shah,1 S.D. Russell,2 J.V. Conte,1 G.J. Whitman,1 S.C. Silvestry.4 1The Division of Cardio Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD; 2The Division of Cardiovascular Diseases, Washington University School of Medicine, St. Louis, MO; 3The Division of Cardiology, The Johns Hopkins Medical Institutions, Baltimore, MD; 4The Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO.

(443) Is Heart Transplantation a Reasonable Concept in Patients with Severe Cardiac Amyloidosis?; N. Reiss,1 A. Krsten,2 S. Schoenland,2 U. Hegenbart,2 S. Buss,2 F.-U. Sack,1 P. Schnabel,4 C. Roeck en,2 T. Denger,2 A. Ho,2 A. Ruhiparwar,2 M. Kark,2 H. Katus,2 1Department of Cardio Surgery, University of Heidelberg, Heidelberg, Germany; 2Department of Cardiology, Angiology and Respiratory Medicine, University of Heidelberg, Heidelberg, Germany; 3Department of Hematology, University of Heidelberg, Heidelberg, Germany; 4Department of Pathology, University of Heidelberg, Heidelberg, Germany; 5Department of Pathology, University of Kiel, Kiel, Germany.

(444) Use of Continuous Home Infusion Milrinone (HIM) in Inotrope Dependent (ID) Patients as a Bridge to Recovery; P. Muthusamy,1,2 S. Madan,3 K. Movers,3 D.E. Langholz,1 J.D. Call,1 M.B. Hanrahan,1,2 A.T. Devis,2,3 M.G. Dickinson.1 1Cardiology, Fredrik Meijer Heart & Vascular Institute/Spectrum Health, Grand Rapids, MI; 2Grand Rapids Medical Education Partners, Grand Rapids, MI; 3Michigan State University/College of Human Medicine, Grand Rapids, MI; 4Coram Home Infusion Group, Grand Rapids, MI.

(445) Increased Mortality Following Cardiac Transplantation in Patients with Peripheral Vascular Disease; J.S. Enciso,1 T.S. Kato,1 C.J. Chung,1 J. Yang,2 P.C. Schulze.1 1Center for Advanced Cardiac Care, Columbia University Medical Center; New York, NY; 2Division of Cardiothoracic Surgery, Columbia University Medical Center; New York, NY.


(447) Late Response to Desensitization Therapy; J. Kobashi gawa, J. Patel, M. Rafiei, L. Stern, M. Kittleson, L. Czer, F. Esmailian. Cedars-Sinai Heart Institute, Los Angeles, CA.

(448) Heart Transplantation for End-Stage Valvular Cardiomyopathy: A 26-Year Single-Center Experience; C. Pellegrini,1 S. Nicolardi,2 D. Di Perma,1 P. Totaro,1 C. Tinelli,2 F. Pagani,1 A. D’Armini,1 M. Viganò.1 1Department of Surgical Sciences, Section of Cardiac Surgery and Thoracic Transplantation, Fondation IRCCS Policlinico “San Matteo” – University of Pavia, Pavia, Italy; 2Department of Surgical Sciences, Section of Surgery, Fondation IRCCS Policlinico “San Matteo” – University of Pavia, Pavia, Italy; 3Clinical Epidemiology and Biometry Service, Fondation IRCCS Policlinico “San Matteo”, Pavia, Italy.

(449) The Outcome of Patients with Idiopathic Non-Dilated Hypertrophic Cardiomyopathy Following Cardiac Transplantation; T.S. Kato,1 M. Maurer,1 Y. Naka,2 M. Fan,1 D. Mancini,1 P.C. Schulze,1 H. Takayama.1,2 1Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY; 2Department of Surgery, Division of Cardiothoracic Surgery, Columbia University Medical Center; New York, NY.

(450) Palliative Care in End Stage Heart Failure: A Single Center Observational Study; M.J. Owen, B.D. DeMoss, D. Gupta. Emory University Hospital, Atlanta, GA.

(451) Kidney Biopsies on Patients With Awaiting Heart Transplant: Glomerulomegaly as a Feature; C. Panikh,1 S. Sandilya,1 J. Pullman,2 J.J.
(452) Right Ventricle Impact on Functional Capacity, Cardio Pulmonary Exercise Test and BNP in Chronic Heart Failure; D. Murnikas, A.C. Alba, H.J. Ross. Toronto General Hospital, Toronto, ON, Canada.

(453) The Prevalence of Chronic Kidney Disease before and after Orthotopic Heart Transplant: Does the Degree of eGFR Decline Proportionally Translate into Poorer Patient Outcomes; J. Jiang, A. Almehimi, M. Ji, H. Yerebakian, M.A. Farn, M. Argenziano, C.R. Smith, H. Takayama, D.M. Mancini, Y. Naka, P.C. Schulze, F.H. Cheema. Department of Cardiothoracic Surgery, Columbia University Medical Center; New York, NY; Department of Cardiology, Columbia University Medical Center; New York, NY; Division of Nephrology, University of Tennessee College of Medicine, Memphis, TN.

(454) Milrinone in Advanced Heart Failure: A Potential Role for Therapeutic Drug Monitoring; D. Charisopoulou, N. Leaver, N.R. Banner. Heart Failure and Transplant, Royal Brompton and Harefield Hospitals NHS Trust; London, United Kingdom; Heart Failure and Transplant, Royal Brompton and Harefield Hospitals NHS Trust; London, United Kingdom; Heart Failure and Transplant, Royal Brompton and Harefield Hospitals NHS Trust; London, United Kingdom.

(455) U.S. Heart Transplant Rates Vary by Holiday; J.L. Grodin, J.T. Thibodeau, J.O. Mishkin, P.P.A. Mammen, D.W. Markham, M.H. Drazner, P.C. Patel. Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX.

(456) Regional Distribution of End-Stage Heart Failure Patients in a Single Heart Transplant Center Country; P. Soos, Eva Belicza, D. Becker, L. Kiss, K. Karlocai, Z. Szabolcs, F. Horkay, B. Mérkely. Semmelweis University, Budapest, Hungary.

(457) Desensitization Therapy with Immunoglobulin (IVIG) and Rituximab for Patients Awaiting Heart Transplantation; J. Patel, M. Kittleson, M. Rafiei, L. Stern, D. Chang, L. Czer, A. Trento, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(458) Endothelial Progenitor Cells Independently Predict Functional Capacity in Heart Failure Patients; A.C. Alba, V. Rao, S. Walter, G. Guyatt, H. Ross. Toronto General Hospital, Toronto, ON, Canada; McMaster University, Hamilton, ON, Canada.

(459) Monitoring of Respiratory Rate Derived from an Implantable Right Ventricular Pressure Sensor in Patients with Heart Failure; E. Chung, M. Erickson, V. Torres, G. Haas, A. Magalski, P. Adamson, M.R. Costanzo, J. Murillo. The Christ Hospital, Cincinnati, OH; Medtronic, Inc., Mounds View, MN; Loma Linda University, Loma Linda, CA; The Ohio State University Medical Center, Columbus, OH; Mid America Heart Institute, Kansas City, MO; Oklahoma Heart Hospital, Oklahoma City, OK; Midwest Heart Specialists, Naperville, IL; Sentara Cardiovascular Research Institute, Norfolk, VA.

(460) Characterization and Functional Implications of Heart Rate Increase at the Onset of Exercise Testing and Heart Rate Recovery in Patients with Advanced Heart Failure; M. White, J. Myers, M.C. Guertin, M. Cossette, A. Durham, F. Harel, E. O’Meara, G. Gravel, B. Thibault. Research Center, Montreal Heart Institute/Université de Montréal, Montreal, QC, Canada; Research Center, Stanford University, Palo Alto, CA; Biostatistics, Montreal Heart Institute Coordinating Center; Montreal, QC, Canada.


(462) Effect of Preoperative Dental Foci on Event-Free Survival Post Heart Transplantation; S. Meyer, S. Ohdah, A. von Stritzky, C. Ivanov, T. Deuse, H. Reichenspurner, A. Costard-Jacqué. Department of General and Interventional Cardiology, University Heart Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Cardiovascular Surgery, University Heart Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

(463) Anti-Angiotensin Type 1 Receptor (AT1R) Antibodies Together with Anti-HLA Donor Specific Antibodies (HLA-DSA) Identify Patients at Risk for Immune Complication in Heart Transplant; K. Cao, C.-H. Lai, S.V. Flores, M. Rafiei, J. Mirocha, M. Haas, G. Ong, M. Naim, G. Wang, L. Constanza, J. Patel, N.L. Reinsmoen, J. Kobashigawa. HLA Laboratory, Cedars-Sinai Medical Center; Los Angeles, CA; Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center; Los Angeles, CA; Biostatistics Core, Research Institute, Cedars-Sinai Medical Center; Los Angeles, CA; Pathology and Laboratory Medicine, Cedars-Sinai Medical Center; Los Angeles, CA.

(464) Preoperative Anti-HLA Antibodies Predict Antibody-Mediated Rejection in Heart Transplant Recipients; T. Gzadic, E. Slimackova, I. Malek, A. Slavcev, M. Kubejak, J. Pink. Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

(465) A Multivariate Analysis of Clinical Parameters That Affect Gene Expression Profile Assessment of Immune Activation; B. Patterson, B. Springfield, J.A. Hill, J.M. Aranda, R.S. Schofield, P.K. Humphlett, D.F. Pealy. Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, FL.

(466) The Combination of Left Ventricular Torsion and Global Strain Based on Two-Dimensional Speckle Tracking Echocardiography Could Detect Treatment-Required Rejection in Heart Transplant Recipients; S. Hashimoto, T.S. Kato, Y. Surnita, N. Tanaka, I. Nakasone, M. Sano, H. Kanzaki, T. Dhara, M. Kitakaze. Department of Clinical Physiology, National Cerebral and Cardiovascular Center; Saitama, Japan; Department of Organ Transplantation, National Cerebral and Cardiovascular Center; Saitama, Japan; Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center; Saitama, Japan.

(467) Serological Characterization of Cardiac Transplant Patient with Evidence of Antibody Mediated Rejection and Those Without; L.F. Xu, E. Feller, A.P. Burke, C.I. Drachenberg. Pathology, University of Maryland Medical Center, Baltimore, MD; Cardiology, University of Maryland Medical Center, Baltimore, MD.

(468) Are the Levels of Serum CXCL10 Significant for Prediction of Cardiac Allograft Rejection?; L. Kolessar, E. Slimackova, T. Gzadic, E. Honsová, I. Netuka, A. Slavcev, I. Malek, J. Pink. Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Clinical Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

(469) Correlation of Cytomegalovirus (CMV) Serologic Status of Heart Transplant Recipients to Gene-Expression Profiling Scores and Clinical Outcomes: Results from the IMAGE Multicenter Study; W.G. Cotts, M.C. Deng, B. Elashoff, M.X. Pham, J.J. Teuteberg, A.G. Kfoury, R.C. Starling, T.P. Cappola, A. Kao, A.S. Anderson, G.A. Ewald, D.A. Baran, R.C. Bogaev, V. Stoson, J.P. Yee, H.A. Valentine. Northwestern University, Chicago, IL; Columbia University Medical Center, New York, NY; XDX Inc., Brisbane, CA; Stanford University Medical Center; Palo Alto, CA; University of Pittsburgh Medical Center; Pittsburgh, PA; Intermountain Medical Center, Salt Lake City, UT; Cleveland Clinic, Cleveland, OH; Hospital of the University of Pennsylvania, Philadelphia, PA; America Heart Institute, Saint Luke’s Hospital, Kansas City, MO; University of Chicago Medical Center, Chicago, IL; Washington University School of Medicine, St. Louis, MO; Newark Beth Israel Medical Center; Newark, NJ.


(472) Younger Age and Female Gender Are Associated with Higher Gene Expression Profile Values: B.A. Austin, E. Wang, P.J. Arnold, A. Kao. Cardiology, Saint Luke’s Mid America Heart Institute, Kansas City, MO.


(475) Correlation of Immunological Markers with Graft Vasculopathy Development in Heart Transplantation: C. Gei, C. Roldan, S. Mirabet, V. Brocca, L. Lopez, A. Mendez, J.M. Pedro, E. Roig. Immunology, Hospital Sant Pau, Barcelona, Spain; Immunology, Hospital Sant Pau, Barcelona, Spain; Cardiology, Hospital Sant Pau, Barcelona, Spain; Cardiology, Hospital Sant Pau, Barcelona, Spain; Cardiology, Hospital Sant Pau, Barcelona, Spain; Cardiology, Hospital Sant Pau, Barcelona, Spain; Cardiology, Hospital Sant Pau, Barcelona, Spain; Cardiology, Hospital Sant Pau, Barcelona, Spain; Cardiology, Hospital Sant Pau, Barcelona, Spain; Cardiology, Hospital Sant Pau, Barcelona, Spain; Cardiology, Hospital Sant Pau, Barcelona, Spain.

(476) Identification of Immune Profiles That Are Associated with Development of Severe Infection in Heart Recipients: J. Carbon, N. Del Pozo, A. Gallego, N. Lanio, J. Rodriguez-Molina, J. Navarro, J. Palomo, J. Fernandez-Yañez, A. Villa, P. Muñoz, M. Ruiz, J. Hortal, C. Rodríguez, E. Fernandez-Cruz, K. Kotsch, E. Sarmiento. Immunology, Gregorio Marañon Hospital, Madrid, Spain; Cardiology, Gregorio Marañon Hospital, Madrid, Spain; Microbiology, Gregorio Marañon Hospital, Madrid, Spain; Cardiovascular Surgery, Gregorio Marañon Hospital, Madrid, Spain; Anesthesiology, Gregorio Marañon Hospital, Madrid, Spain; Biochemistry, Gregorio Marañon Hospital, Madrid, Spain; Visceral, Transplant and Thoracic Surgery, Medical University Innsbruck, Innsbruck, Austria.


(478) TNF-α and IL-8 Predict Cardiac Vasculopathy after Cardiac Transplantation: N. Heikal, H. Hill, T. Martins, I. Pavlov, A. Wilson, J. Stehlík, A. Kfouri, J. Delgado, F. Bader. ARUP Institute for Clinical and Experimental Pathology, SLC, UT; Department of Pathology, SLC; Pediatrics and Medicine, SLC; Division of Cardiology, University of Utah School of Medicine, SLC.


(480) Donor Specific Anti-HLA Antibody Detection in Heart Transplantation: Comparison of a Donor-Specific Bead-Based Crossmatch Technique with Flow-Crossmatch and Single-Antigen Bead Methodology: A. Chaijaroenkul, A. Skoura, A. Goziuma, D. Degiannis. Molecular Immunopathology and Histocompatibility Laboratory, Onassis Cardiac Surgery Center, Athens, Greece; 2nd Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece.


(482) Cellular Rejection on a Non-Routine Biopsy Predicts Poor Long Term Outcome: S.S. Panag Nash, T. George, S.D. Russell, R.J. Tedford, C. Steenbergen, J. Scheel, D.V. Skoje, M.K. Halushka. Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD; Division of Cardiovascular Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; Division of Pediatric Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD.

(483) Iron Deficiency in Hospitalized Heart Failure Patients: P. Mutusamy, K. Mowers, S. Madan, A. Bhopalwala, M. Khan, C.R. Smith, A. Shoemaker, A.T. Davis, M.G. Dickinson. Cardiology, Fredrick Meijer Heart & Vascular Institute/Spectrum Health, Grand Rapids, MI; Grand Rapids Medical Education Partners, Grand Rapids, MI; Michigan State University/College of Human Medicine, Grand Rapids, MI.

(484) Combined Heart and Liver Transplant Attenuates Cardiac Allograft Vasculopathy with Decreased Coronary Related Cardiac Events Compared to Isolated Heart Transplantation: Y. Topolsky, E. Raichlin, T. Hasin, B.A. Boilson, J.A. Schirger, N.L. Pereira, B.S. Edwards, A.L. Claywell, R.J. Rodeheffer, R.P. Frantz, M.J. Gandhi, S. Maltais, S.J. Park, R.C. Daly, A. Lerman, S.S. Kushwaha. Cardiology, Mayo Clinic, Rochester, MN; Cardiology, University of Nebraska Medical Center; Omaha, NE; Cardiac Surgery, Mayo Clinic, Rochester, MN.

(485) Do Significant Daily, Monthly and Seasonal Variations in Thoracic Organ Transplantation Exist?: B. K. Khan, I.A. Samayoa, B. Adachi, B. Shirley, J.S. Heinle, D.L.S. Morales. Congenital Heart Surgery, Baylor Children's Hospital, Baylor College of Medicine, Houston, TX; Congenital Heart Surgery, Texas Children's Hospital, Houston, TX.

(486) Thoracic Transplantation Increases during Holidays: Reality or Myth?: A.X. Samayoa, M.S. Khan, B.A. Shirley, B. Adachi, W.J. Dreyer, J.S. Heinle, D.L.S. Morales. Congenital Heart Surgery, Baylor College of Medicine, Houston, TX; Pediatric Cardiology, Baylor College of Medicine, Houston, TX.

(487) Oral Sildenafil: A Safe and Effective Treatment of Persistent Pulmonary Hypertension after Heart Transplantation: R. Marzoa, M.J. Paniagua-Martín, E. Barge-Caballero, Z. Grille-Cancela, J. Balea-Filgueiras, A. Aldama-Lopez, M. García-Guimarães, E. Mendez-Eirin, J.J. Cuenca-Castillo, A. Castro-Beiras, M.G. Crespo-Leiro. Advanced Heart Failure and Heart Transplant Unit, University Hospital of A Coruña, A Coruña, Spain; Hemodynamic Unit, University Hospital of A Coruña, A Coruña, Spain; Cardiac Surgery Service, University Hospital of A Coruña, A Coruña, Spain; Pharmacy Service, University Hospital of A Coruña, A Coruña, Spain.

(489) Metabolic Syndrome Is Significantly Associated with Cardiac Allograft Vasculopathy: The Influence of Modifiable Risk Factors on Mortality in Patients Undergoing Orthotopic Heart Transplantation; J. Jiang,1 O.T. Siddiqui,1 M. Ji,1 K. Schaeffer,1 H. Yerebakan,1 M.A. Farr,2 H. Takayama,1 C.R. Smith,1 D.M. Mancini,2 M. Angenziano,1 Y. Naka,1 P.C. Schulze,2 F.H. Cheema,11 Department of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; 2Department of Cardiology, Columbia University Medical Center, New York, NY.

(490) Can Strain Echocardiography Be Used as a Noninvasive Method To Predict Cardiac Allograft Stage 3 Vasculopathy in HTx Recipients with Normal Ejection Fraction; L.J.F. Estofan, H.R. Villarraga, B.S. Edwards, F.A. Miller, P.A. Pellikka. Cardiovascular, Mayo Clinic, Rochester, MN.

(491) Differential Effect of Everolimus and Metabolic Risk Factors on Early vs. Late Progression of Allograft Vasculopathy: Dissecting Two Faces of the Same Disease; M. Masetti, L. Potena, M. Nardozza, P. Prestinzeni, V. Pece, N. Taglioni, F. Saia, G. Magnani, F. Cuccolo, F. Fellani, F. Gregioni, A. Branzi. Cardiovascular Department, University of Bologna, Bologna, Italy.


(494) Tetroxenectin Is Associated with Cardiac Allograft Vasculopathy in Heart Transplant Recipients; S. Aharinejad, M. Salarna, R. Susanne, A. Zueckermann, G. Laufer. Medical University of Vienna, Vienna, Austria.

(495) A Strong Thigh Can Make VO2 Go High – Predictors of VO2 peak in Heart Transplant Patients; K. Nyvøen,1 L.A. Rusted,1,2 E. Gude,1 A.E. Fiane,1,3 K. Rold,1 I. Holm,4 S. Aakhus,1 L. Gullesstad,1,5 Department of Cardiology, Oslo University Hospital HF Rikshospitalet, Oslo, Norway; 2Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway; 3Norwegian School of Sport Sciences, Oslo, Norway; 4Department of Cardiothoracic Surgery, Oslo University Hospital HF Rikshospitalet, Oslo, Norway; 5Division of Surgery and Clinical Neuroscience, Oslo University Hospital HF Rikshospitalet, Oslo, Norway; 6Faculty of Medicine, University of Oslo, Oslo, Norway.

(496) Risk Factors for Nosocomial Infection in the Post-Operative Period after Heart Transplantation; P. Fernández-Ugidos,1 R. Gómez-López,1 M.J. Paniagua-Martín,2 R. Marzoa-Rivas,2 E. Barge-Caballero,2 J. Muñiz,2 J.J. Cuenca,2 M.T. Bouza-Vieyro,2 S. Fojo-Polanco,2 Z. Grille-Cancela,2 A. Castro-Beiras,2 M.G. Crespo-Leiro,21 Intensive Care, Complexo Hospitalario Universitario de Ourense, Ourense, Spain; 2Cardiology, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain; 3Instituto Universitario de Ciencias de la Salud, Universidade de A Coruña, A Coruña, Spain; 4Cardiac Surgery, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain; 5Intensive Care, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain.

(497) Rates of CMV Viremia and Treated CMV in Patients Receiving Alemtuzumab Induction Prior to Cardiac Transplantation; M.A. Shullo,1 R. Zomak2 C. Grubowski,2 M. Navoney,2 D. McNamara,2 C. Bermudez,2 R.L. Komos,2 J.J. Teuteberg,2 Pharmacy and Therapeutics, University of Pittsburgh, PA; 3Heart and Vascular Institute, University of Pittsburgh, PA.

(498) Combined Prophylactic and Pre-Empitve CMV Strategy with Valganciclovir in Heart Transplant Patients Is Efficacious and Safe; M. Eriksson,1 J.J. Jokinen,2 P. Hammainen,2 J. Lommi,2 K. Lemstrom,2 Infectious Diseases, Helsinki University Central Hospital, Helsinki, Finland; 3Heart and Lung Transplantation Program, Helsinki University Central Hospital, Helsinki, Finland; 4Cardiology, Helsinki University Central Hospital, Helsinki, Finland.

(499) First Documented Case of Transmission of Mycobacterium Tuberculosis from a Multi-Organ Donor to a Heart Transplant Recipient; J. Welle,1 U. Fuchs,2 H. Eckmeyer,2 J.W. Wittenke,3 S. Ruesch-Gerdes,4 J.F. Gummert,5 C. Knabe,6 U. Schulz,7 Institute for Laboratory and Transfusion Medicine, Heart- and Diabetes Center NRW, Bad Oeynhausen, Germany; 8Thoracic and Cardiovascular Surgery, Heart- and Diabetes Center NRW, Bad Oeynhausen, Germany; 9Medical Laboratory of Bremen, Bremen, Germany; 10Research Center Borstel, German Reference Center for Mycobacteria; Leibniz Center for Medicine and Biosciences, Borstel, Germany.

(500) Non-Invasive Mycoses after Heart Transplantation: Outcome and Long-Term Prognosis; T. Haberl,1 D. Hutschalla,2 C. Pelanek,1 A.Z. Aliabadi,1 G. Laufer,1 A. Zuckermann,11 Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria; 12Department of Anaesthesiology, Medical University of Vienna, Vienna, Austria.

(501) Low Infection Rates in Jarvik 2000 LVAD. Are Post-Auricular Cable and Pump Configuration Playing a Positive Effect?; V. Tarzia,1 U. Livi,2 G. Di Giannmarco,2 G. Sani,4 M. Macchionni,5 M. Rinaldi,6 F. Alamanni,7 M. De Bonis,8 F. Gazzoli,9 A. Renzulli,10 G. Mazzei,11 G. Arpesella,12 G. Di Credico,13 M. Zogno,14 A. Costantino,10 G. Gerosa,16 Cardiovascular Surgery University of Padova, Padova, Italy; 2Cardiac Surgery University of Udine, Udine, Italy; 3Cardiac Surgery University of Chieti, Chieti, Italy; 4Cardiac Surgery University of Florence, Florence, Italy; 5Cardiac Surgery University of Siena, Siena, Italy; 6Cardiac Surgery University of Turin, Turin, Italy; 7Cardiac Surgery CCFM University of Milan, Milan, Italy; 8Cardiac Surgery San Raffaele Hospital, Milan, Italy; 9Cardiac Surgery Policlinico San Matteo, Pavia, Italy; 10Cardiac Surgery Magna Grecia University, Catanzaro, Italy; 11Cardiac Surgery La Sapienza University, Rome, Italy; 12Cardiac Surgery University of Bologna, Bologna, Italy; 13Cardiac Surgery Civil Hospital, Legnano, Italy; 14Cardiac Surgery Carlo Poma Hospital, Mantova, Italy; 15Cardiac Surgery S. Filippo Neri Hospital, Roma, Italy; 16Cardiac Surgery University of Padova, Padova, Italy.

(502) Spectrum and Etiologies of Ventricular Assist Device Infections: A Single Center Study; V. Stosor,1,2 K. Meehan,3,4 R. Gordon,3,4 E. McGee,3,4 1Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL; 2Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL; 3Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine, Chicago, IL; 4Northwestern Memorial Hospital, Chicago, IL; 5Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL.

(503) RSV Prevention and Treatment in Pediatric Lung Transplant Patients: A Survey of Current Practices among the International Pediatric Lung Transplant Collaborative (IPLTC); L.A. Danziger-Ilsakow,1 D. Arslan,1 S. Sweet,3 C. Benden,3 S. Goldfarb,4 J. Wong,5 Cleveland Clinic, Cleveland, OH; 2St. Louis Children’s Hospital, St. Louis; 3University Hospital Zurich, Zurich, Switzerland; 4Children’s Hospital of Philadelphia, Philadelphia; 5University of Alberta, Alberta, Canada.

(504) Change in Disability Is a Determinant of Quality of Life in Persons Undergoing Lung Transplant; J.P. Singer,1,2 P.P. Katz,3 J. Chen,3 T. Golden,4 L.E. Leard,1 S.R. Hays,1 J. Kukreja,2 D. Sayeh,1,3 P.D. Blanc.1,2 1Pulmonary and Critical Care Medicine, UC San Francisco, San Francisco, CA; 2Occupational and Environmental Medicine, UC San Francisco, San Francisco, CA; 3Cardiovascular Research Institute, UC San Francisco, San Francisco, CA; 4Health Policy Studies, UC San Francisco, San Francisco, CA; 5Cardiothoracic Surgery, UC San Francisco, San Francisco, CA.

(505) Overcoming the Tyranny of Distance: Ensuring Equity of Access and Outcome in Lung Transplant; J. Harris, D.T. Keating, S. Hacker, G.I.
(506) The Transbronchial Brush Test Circumvents Sampling Limitation Associated with Transbronchial Biopsy and Has Superior Reproducibility for Assessment of Lymphocytic Bronchiolitis; D.C. Chambers,¹,² S.T. Yerkovich,¹,² M.E. Tan,¹ K.A. Sinclair,³ F.D. Kermeen,¹ A. Fiene,¹ P.M. Hopkins,¹,² Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia; ²School of Medicine, The University of Queensland, Brisbane, Australia.

(507) IgM Depletion Discovers Undetected Donor Specific Antibodies Associated with Antibody Mediated Rejection after Lung Transplantation; H.W. Ainge Allen,¹ A.P. Havdy,¹ M.A. Malouf,¹ M. Pilt,⁷ C. Benden,⁷ N. Watson,² A.R. Glanville,¹ Department of Cardiopulmonary Transplant, St. Vincent’s Hospital, Sydney, NSW, Australia; ²NSW Transplantation and Immunogenetics Laboratory, Australian Red Cross Blood Service, Sydney, NSW, Australia.

(508) Experience with Cylex Immune Cell Function Assay in Clinical Immune Monitoring of Lung Transplant Recipients; F. Bini,¹ S. Misener,¹ M. Morosini,¹ A. Grasso,¹ E. Cova,¹ C. Pellegrini,² A.M. D’Armi,³ F. Meloni.¹ Clinic Respiratory Diseases, San Matteo Foundation and University of Pavia, Pavia, Italy; ²Department of Surgery, Section of Cardiac Surgery, University of Pavia and San Matteo Foundation, Pavia, Italy.

(509) Prospective Surveillance and Treatment of De Novo Donor Specific Antibodies after Lung Transplantation Ameliorates 1-Year Risk of BOS; H.W. Ainge Allen,¹ A.P. Havdy,¹ M.A. Malouf,¹ M. Pilt,⁷ C. Benden,⁷ N. Watson,² A.R. Glanville,¹ Department of Cardiopulmonary Transplant, St. Vincent’s Hospital, Sydney, NSW, Australia; ²NSW Transplantation and Immunogenetics Laboratory, Australian Red Cross Blood Service, Sydney, NSW, Australia.


(511) Prospective Surveillance and Treatment of Pre-Existing Donor Specific Antibodies Ameliorates 1-Year Risk of BOS after Lung Transplantation; H.W. Ainge Allen,¹ A.P. Havdy,¹ M.A. Malouf,¹ M. Pilt,⁷ C. Benden,⁷ N. Watson,² A.R. Glanville,¹ Department of Cardiopulmonary Transplant, St. Vincent’s Hospital, Sydney, NSW, Australia; ²NSW Transplantation and Immunogenetics Laboratory, Australian Red Cross Blood Service, Sydney, NSW, Australia.

(512) Lessons from the Lung: 186 Autopsies after Lung Transplantation; M. Malouf, A. Havryk, M. Pilt, C. Benden, S. Rainer; A. Glanville. The Lung Transplant Unit, St. Vincent’s Hospital, Darlinghurst, NSW, Australia.

(513) Extracorporeal Treatment of Antibody Mediated Heart or Lung Transplant Rejection; S. Rummier,¹ K. Maier,¹ M. Breuer,² T. Sandhaus,² T. Pauli,² T. Steinke,² T. Doenst,² D. Barz,¹ University of Jena, Institute of Transfusion Medicine, Jena, Germany; ²University of Jena, Department of Cardiothoracic Surgery, Jena, Germany.

(514) Biopsy-Proven Acute Rejection after Combined Heart and Lung Transplantation; K.L. Dawson,¹ V.P. Doan,² J. Estep,¹ H. Seetharamaju.¹ The Methodist Hospital, Houston, TX; ²University of Houston, Houston, TX.

(515) Everolimus for Calcineurin Inhibitor Minimization in Lung Transplant Recipients with Chronic Renal Insufficiency; K. Scheepjers,¹ D. Lyu,² I. Kim,¹ T. Grazia,² J. Crossno,² U. Christians,³ M.R. Zamora.² Pharmacy, University of Colorado Hospital, Aurora, CO; ²Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Aurora, CO; ³Anesthesiology, University of Colorado Health Sciences Center, Aurora, CO.

(516) Plasma Surfactant Protein D Concentrations in Lung Transplant Recipients during Infection and Rejection Events; I. Beijl,¹ L. Wesselingh,¹ R. Strassl,² P. Jaksh,³ M. Kundi,³ W. Klepetko,² E. Pudhammer-Stöckl.¹ Department of Virology, Medical University of Vienna, Vienna, Austria; ²Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria; ³Institute of Environmental Health, Medical University of Vienna, Vienna, Austria.

(517) Monitoring Warm Ischemic Time Helps Improve Surgeons’ Technical Performance; Y. Toyoda,¹ J.K. Bhma,² N. Shigemura,² A. Bansal,² M. Crespo,² J. Pilewski,² C. Bermudez.² Temple University School of Medicine, Philadelphia, PA; ²UPMC, Pittsburgh, PA.

(518) Incidence and Clinical Course of Barrett’s Esophagus Pre- and Post-Lung Transplantation; R. Waliya, T.N. Hodges, J.L. Huang, K.A. Varsch, R. Saggar; P.M. Naik, E.Y. Kuo, R.M. Bremner, M.A. Smith. Heart Lung Institute, St. Joseph’s Hospital & Medical Center, Phoenix, AZ.

(519) Pulmonary Re-Transplantation in the Nordic Countries; P. Wierup,¹ M. Iversen,² G. Riise,² P. Håmmäinen,² I. Skog,² S. Lindstedt,¹ A. Fiane,² G. Dellgren,³ Department of Cardiothoracic Surgery, Lund University Hospital, Lund, Sweden; ²Department of Pulmonary Medicine, Rigshospitalet, Copenhagen, Denmark; ³Department of Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden; ⁴Department of Pulmonary Medicine, Rikshospitalet, Oslo, Norway; ⁵Department of Cardiothoracic Surgery, Mesihi University Hospital, Helsinki, Finland; ⁶Department of Pulmonary Medicine, Lund University Hospital, Lund, Sweden; ⁷Department of Cardiothoracic Surgery, Rikshospitalet, Oslo, Norway; ⁸Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.


(521) Does Pulmonary Hypertension Preclude or Impact Outcomes in Single Lung Transplantations for Pulmonary Fibrosis in the Older Recipients; S.L.C. Reddy, M. Hartwig, Z. Hashmi, S. Lin, D.R. Davis. Cardiothoracic Transplant Division, Duke University Medical Center, Durham, NC.

(522) Down-Regulation of CD28 and Up-Regulation of 4-1BB on Peripheral Blood Pro-Inflammatory CD8+ T Cells Is Associated with BOS; G. Hodge,¹,² S. Hodge,¹,² C.L. Holmes-Liew,¹,²,³ P.N. Reynolds,¹,² M. Holmes,¹,²,³ Lung Research and Department of Thoracic Medicine, Hans Institute and Royal Adelaide Hospital, Adelaide, SA, Australia; ²Medicine, University of Adelaide, Adelaide, SA, Australia; ³South Australian Lung Transplant Service, Royal Adelaide Hospital, Adelaide, SA, Australia.

(523) BOS Is Associated with Increased Peripheral Blood NK1.1 Like and NK Cell Granymes, Perforin and Th1 Pro-Inflammatory Cytokines; S. Hodge,¹,² G. Hodge,¹,² C.L. Holmes-Liew,¹,²,³ P.N. Reynolds,¹,²,³ M. Holmes,¹,²,³ Lung Research and Department of Thoracic Medicine, Hans Institute and Royal Adelaide Hospital, Adelaide, SA, Australia; ²Medicine, University of Adelaide, Adelaide, SA, Australia; ³South Australian Lung Transplant Service, Royal Adelaide Hospital, Adelaide, SA, Australia.


(525) The Fibroproliferative Chemokine, Eotaxin/CCL11, Is Upregulated in Lung Transplant Recipients Colonized with Aspergillus – A Link to BOS; S.S. Weigt,¹ S. Wang,² C.-H. Tseng,¹ A. Derhovanessian,¹ A. Gregson,¹ R. Saggar; D.J. Ross,¹ A. Ardehali,² M. Holter,³ J.P. Lynch III,¹ R.M. Elashoff,² J.A. Belperio.¹ Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, CA; ³Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.
**General Poster • Session 1**

(526) Chronic Allograft Dysfunction after Lung Transplantation. A Comparison of RAS vs. BOS; C.H. Möller, M. Jørgensen, M. Perch, C.B. Andersen, J. Carlsen, D.A. Steinbrüchel, M. Iversen. 1 Cardiointensive Care Surgery, Rigshospitalet, Copenhagen, Denmark; 2Nephrology, Rigshospitalet, Copenhagen, Denmark; 3Cardiology, Section for Lungtransplantation, Rigshospitalet, Copenhagen, Denmark; 4Pathology, Rigshospitalet, Copenhagen, Denmark.


(531) Bone-Marrow Derived CCSP+ Epithelial Cells Reside in the Airway Epithelium after Lung Transplantation; S.T. Yerkovich, S. Gilpin, K.A. Sinclair, M.E. Tan, A. Fiene, P.M. Hopkins, T. Waddell, D.C. Chambers. 1 Queensland Lung Transplant Program, The Prince Charles Hospital, Brisbane, Australia; 2School of Medicine, The University of Queensland, Brisbane, Australia; 3Latner Thoracic Surgery Research Laboratories, University of Toronto, Toronto, Canada.

(532) Remote Ischemic Pre-Conditioning (RIPC) to Improve Lung Transplant (Ltx) Outcomes: A Randomized, Placebo-Controlled, Clinical and Mechanistic Trial; E. Lin, G.I. Snell, B.J. Levy, L. Mitchell, S. Marasco, T. Kotsiminos, N. Mifsud, A. Sharland, P. Myles. 1 Lung Transplant Service, Alfred Hospital, Melbourne, VIC, Australia; 2Anaestheis, Alfred Hospital, Melbourne, VIC, Australia; 3Medicine, Monash University, Melbourne, VIC, Australia; 4Central Clinical School, University of Sydney, Sydney, NSW, Australia.

(533) Methylprednisolone Regulation of Human Donor Lung Surfactant Protein A (SP-A) Expression Is Dependent on the SP-A Polymorphism; B. Aramini, C. Kim, D. Lederer, J. Costa, S. DiAngelo, J. Flores, S. Arcasoy, J. Sonett, F. D’Ovidio. 1 Columbia University Medical Center, New York; 2The Pennsylvania State University College of Medicine, Hershey.


(535) Clinical Predictors and Risks Factors for Left Ventricular Assist Device Thrombosis in HeartMate II Supported Patients; M.R. Labedi, D. Weyer-Pinzon, F. Gaqa, R. Alharethi, C. Selzman, S.G. Grakos, E. Gilbert, D. Budge, A. Saidi, B. Ried, A.G. Kloury, J. Stathlik, F. Bader. 1 Cardiology/UTAH Heart Transplant Program, University of Utah, Salt Lake City, UT; 2Heart Transplant Program, Intermountain Medical Center, Salt Lake City, UT.


(537) Non-Cardiac Surgery in Patients with a Ventricular Assist Device; J. Vieroecke, M. Schweiger, T. Krabatsch, A. Stepananko, B. Jurmann, N. Dranishnikov, E. Potapov, R. Herzel. 1 Deutsches Herz Zentrum Berlin, Berlin, Germany; 2Universität Graz, Graz, Austria.


(539) Higher Incidence of Class II Human Leukocyte Antigen (HLA)-Allosensitization in Patients Supported with Pulsatile Ventricular Assist Devices (VAD); M. Askar, A. Zhang, L. Klingman, M. Mastroianni, A. Nowacki, P. Reville, J. Gatto, S. Bakdash, N. Smedira, R. Starling, G. Gonzalez-Stawinski. 1 Allogen Laboratoires, Cleveland Clinic; 2Doisy College of Health Sciences, St. Louis University; 3Department of Quantitative Health Sciences, Cleveland Clinic; 4College of Arts and Sciences, The Ohio State University; 5Clinical Pathology, Cleveland Clinic; 6Cardiothoracic Surgery, Cleveland Clinic; 7Cardiovascular Medicine, Cleveland Clinic.


(541) Novel Assessment of Hemolytic Anemia in Patients with Continuous Flow Left Ventricular Assist Devices; W.A. Kay, S. Emami, Y. Ravi, V. Franco, E. Abol, J. Crestanello, A. Kili, C.B. Sai-Sudhaker. 1 Internal Medicine, The Ohio State University, Columbus, OH; 2Surgery, The Ohio State University, Columbus, OH.

(542) Recovery of Right Heart Function with Temporary Right Ventricular Assist Using a Centrifugal Pump in Patients with Severe Biventricular Failure; S. Saito, T. Sakaguchi, S. Miyagawa, H. Nishi, Y. Yoshikawa, S. Fukushima, T. Ueno, T. Kuratani, Y. Sawa. Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.


(545) Changes in Anti-Human Leukocyte Antigen Antibodies after Continuous Flow Left Ventricular Assist Device Implantation; S.S. Desai, M.S. Lefell, C.M. Rosner, K.P. Schilling, L.G. Edwards, P. Shah, C.W. May, A.J. Rongione, N.A. Burton. 1 Heart Failure/Transplant Program, Inova Fairfax Hospital, Falls Church, VA; 2Immunogenetics Laboratory, Johns Hopkins University, Baltimore, MD; 3Division of Cardiology, George Washington University, Washington, DC.

(546) Platelet Glycoprotein Ibα Shedding: A Novel Marker To Determine the Risk of Bleeding in Recipients of Continuous-Flow Left Ventricular Assist Device (CF-LVAD); J. Hu, E.N. Sorensen, L. Romar, N.J. Hirvila, L. Dees, E. Feller, A.C. Watkins, J.C. Gayden, B.P. Griffith, Z.J. Wu. 1 Surgery Department, University of Maryland, Baltimore, MD; 2University of Maryland Medical Center, Baltimore, MD.


[550] 0 to 60 in under 3 Years: Creating a Regional Referral Network To Grow a New VAD Center; W.H. Perry, K.E. Nelson, J.W. Long, N.M. Cheilkan, S.R. Clements, T.A. Snyder, B.V. Bogomilov, A.M. Kaneshige, H. Farhoud, D. Simpson, D.A. Horstmanhoff. 1Mechanical Circulatory Support, Integris Baptist Medical Center, Oklahoma City, OK; 2Walker Heart Institute Cardiovascular Clinic, Fayetteville, AR; 3Oklahoma Heart Institute at Hillcrest Medical Center, Tulsa, OK; 4Kansas Medical Center, Andover, KS; 5Mercy Heart and Vascular Center, Rogers, AR.

[551] Initial Experience – Cost Adjusted Quality of Life Years for Patients Supported by Ventricular Assist Devices for Destination Therapy Indication; T.B. Icenogle, D. Sandler, A.A. Schmitt, D. Sato, J. Bjelkengren, S.A. Schaefer, S. Lewey. Inland Northwest Thoracic Organ Transplant Program, Providence Sacred Heart Medical Center; Spokane, WA; Northwest Cardiothoracic & Transplant Surgeons, Spokane, WA.


[553] Temporal Leukocyte Profiles and Granulocyte Activation in IVAD Recipients; B.L. Kormos, J.R. Woolley, K.L. Lockard, C. Bermudez, J.K. Bhama, J.J. Teuteberg, W.R. Wagner. 1Heart and Vascular Institute, University of Pittsburgh Medical Center; Pittsburgh, PA; 2McGowan Institute for Regenerative Medicine, University of Pittsburgh, PA.


[559] Increased Blood Pressure Variability in Patients Supported by Continuous Flow Left Ventricular Assist Devices: A Novel Vascular Phenomena in the Absence of Pulsatility?; P.C. Schulte, M.N. Bartels, C.J. Chung, H. Armstrong, A. Chokshi, M. Jones, Y. Zhao, D. Shimbo, H. Takayama, Y. Nak, D.M. Mancini, R.P. Sloan. 1Center for Advanced Cardiac Care, Columbia University Medical Center; New York, NY; 2Department of Rehabilitation and Regenerative Medicine, Columbia University Medical Center; New York, NY; 3Department of Psychiatry, Columbia University Medical Center; New York, NY; 4Department of Medicine, Columbia University Medical Center; New York, NY; 5Department of Surgery, Columbia University Medical Center; New York, NY.

[560] Institutional Experience with Low Molecular Weight Heparin as an Alternative to Unfractionated Heparin in the Immediate Postoperative Period after Left Ventricular Assist Device Implantation; F. Eckandary, G. Wiesethal, S. Schima, S. Mahr, Z. Hartner, S. Sander, J. Gökler, G. Laufer, D. Zimpfer. 1Cardiac Surgery, Medical University of Vienna, Vienna, Austria; 2Center of Med. Physics and Biomed. Engineering, Medical University of Vienna, Vienna, Austria; 3Ludwig Boltzmann Cluster of Cardiovascular Research, Medical University of Vienna, Vienna, Austria.

[561] Maintaining Pulsatility or Not with Intermittent Aortic Valve Opening Does Not Appear To Contribute to Formation of AV Malformation in Patients with Continuous-Flow Left Ventricular Assist Devices; A. Bhimaraj, D. Hall, R. Vivo, A.M. Cordero-Reyes, M. Aldieri, G. Torre-Amione, M. Loeb, B. Bruckner, R. Lamla, S. Scheinin, J.D. Estep. 1The Methodist DeBakey Heart and Vascular Center; The Methodist Hospital, Houston, TX; 2Cardiology, Hospital San Jose Tec de Monterrey, Monterrey, NL, Mexico.


[567] Renal Dysfunction Following Syncardia Total Artificial Heart Implantation Does Not Affect Survival Following Heart Transplantation; A. Kalya, K. Boyle, R. Goel, F. Arabia, O. Pajaro, R. Scott, R.S. Gopalan, D. Jaroszewski, D. Kasper, G. Wu, L. Staley, C. Pierce, Cardiovascular Dis-

Preliminary Study: Increased Levels of cGMP in Recipients of Continuous Flow LVADs, Implications for Gastrointestinal Bleeding; L. Grusman-Rimon, D.Z.I. Cherney, S. Pollock Bar-Ziv, M.A. McDonald, L. Turniati, V. Rao. Exercise Sciences, University of Toronto, Toronto, ON, Canada; Medicine, Toronto General Hospital, Toronto, ON, Canada; Heart Transplant, Hospital for Sick Children, Toronto, ON, Canada; Department of Medicine, Division of Cardiology, Toronto General Hospital, Toronto, ON, Canada; Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada; Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada.


Development and Animal Test of the Novel Infection-Resistant Skin-Button for Long-Term VAD Support; T. Mizuno, Y. Nemoto, T. Tsujiya, Y. Takawa, Y. Taenaka, E. Tatsumi. Artificial Organs, National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka, Japan.

Preoperative Risk Factors for Postoperative Infection after Left Ventricular Assist Device Implantation; A. Raina, M. Kanwar, G.G. Sokos, A. Hopwood, N. Bhanot, R.J. Moraca, S. Bailey, S. Murail, R.L. Benza. Gerald McGinnis Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA; Division of Infectious Disease, Allegheny General Hospital, Pittsburgh, PA.

Improved Surgical Technique of Left Ventricular Assist Device Drive Line Placement; S.M. Youssafzai, T. Butt, F. Oezalp, N. Wrightson, R. Nicola, P. Thasee, M. Guy, G. Parry, A. Siddique, S. Schueler. Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne Hospitals Foundation Trust, Newcastle upon Tyne, Tyne & Wear, United Kingdom.


Left Ventricular Assist Devices for Treatment of Severe Pulmonary Hypertension in Heart Transplant Candidates; Z. Dorozilova, J. Kettner, I. Netuka, M. Hegarova, I. Malek, J. Pirk. Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Hemodynamic Efficacy of a Catheter-Deployed Intra-Aortic Micro-Axial Entrapment Pump in Porcine Acute Heart Failure: A Novel Approach for an Old Problem; F. Raissi Shabari, J.K. George, M. Cuchiara, J.J. Heuring, B.A. Hertzog, R.M. Delgado. Texas Heart Institute, Houston, TX; Procynion, Houston, TX.


Blood Pressure Measurement in Patients with Continuous Flow LVADs: Comparing the Doppler Sphygmomanometer, the NExfin Device, and the Arterial Line; K.K. Rap, G.J. Haro, C.R. Ayers, P.C. Patel, J. Mishkin, J.T. Thibodeau, B.T. Botha, D.M. Meyer, P.P.A. Mammen, M.H. Drazner, B.D. Levine, D.W. Markham. Cardiology, University of Texas Southwestern Medical Center, Dallas, TX; Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX; Donald W. Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX; Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Dallas, Dallas, TX.


Veno-Pulmonary Arterial ECMO as Temporary Right Ventricular Support in Patients Undergoing Left Ventricular Assist Device Implantation; E.K. Simi, C. Sato, R. Pye, E. Granger, D. Robson, P.S. Macdonald, A.M. Keogh, E. Kotlyar, K. Dhillen, P. Spratt, C.S. Hayward, P. Jansz. Department of Cardiothoracic Surgery Heart and Lung Transplantation, Saint Vincent's Hospital, Darlinghurst, NSW, Australia; Department of Clinical Perfusion, Saint Vincent's Hospital, Darlinghurst, NSW, Australia; Department of Intensive Care, Department of Anaesthesia, Saint Vincent's Hospital, Darlinghurst, NSW, Australia; Heart Failure and Transplant Unit, Saint Vincent's Hospital, Darlinghurst, NSW, Australia.


Predictors of Recovery during Combined Pharmacological and Mechanical Unloading with the Heart Mate II Continuous Flow (CF) LVAD; O. Saeed, S. Patel, S. Ravishankar, J. Patel, N. Fida, P. Edwards, J. Pullman, D. Goldstein, S. Maybaum. Department of Internal Medicine, Montefiore Medical Center; Albert Einstein College of Medicine, Bronx, NY; Department of Pathology, Montefiore Medical Center; Albert Einstein College of Medicine, Bronx, NY; Department of Surgery, Montefiore Medical Center; Albert Einstein College of Medicine, Bronx, NY.


(588) Does Level of Education Affect Outcome after Heart Transplantation; B. Kearney, W. Chai, J. Patel, M. Kittleson, M. Rafei, L. Stern, L. Czer; J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(589) A Participatory Approach to Online Education and Support Curriculum Development for Parents of a Child with a Heart Transplant; D.B. Nicholas; 1 L.J. West,2 S. Urschel,2 B. Dodd. 3Faculty of Social Work, Central and Northern Alberta Region, University of Calgary, Edmonton, AB, Canada; University of Alberta, Edmonton, AB, Canada; 3Alberta Health Services, Edmonton, AB, Canada.

(590) Long-Term Outcome of Pediatric Heart Transplant Patients with Incidental Subclinical Cellular Rejection during Annual Study; M.A. Kuhn,1 D.D. Deming,1 J. Fitts,1 L.L. Bailey,2 R.E. Chinneck.1 1Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA; 2Cardiothoracic Surgery, Loma Linda University Children's Hospital, Loma Linda, CA.

(591) Waiting List Risk Factors in Pediatric Heart Transplant Center in the Developing Country; A.S. Cauduro, L.F.P. Moreira, C. Tanamati, L.F. Caneo, J. Penha, M.B. Jatene. Pediatric Cardiac Surgery Unit, Heart Institute of Sao Paulo University School of Medicine, Sao Paulo, SP, Brazil.

(592) Utility of Routine C4d Staining in the First Year after Pediatric Heart Transplantation; Y. Xu,1 M. Reyes-Múgica,2 C. Galambos,2 A. Zeevi,3 S.A. Miller,1 S.A. Webber,1 B. Feingold,1 1Pediatric Cardiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA; 2Pathology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA; 3Pathology, University of Pittsburgh, PA.

(593) Non-PTLD Malignancy in Pediatric Heart Transplantation; H.T. Henderson, K. Laporte, W.T. Mahle. Department of Pediatrics, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA.

(594) A New Glomerular Filtration Rate Estimation Formula Derived from a Pediatric Heart Transplant Population; P. Herrmann,1 T. Shankel,2 S. Sahney,3 F. James,3 D. Cutler,2 R. Chinneck,2 1Pathology, Loma Linda University Medical Center, Loma Linda, CA; 2Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA.

(595) Relationship of 2D Echocardiographic Strain Imaging in Pediatric Heart Transplant Patients and Healthy Children; L. Wilmot,1 S. Cupp,1 T.P. Nguyen,1 G.H. Dadlani,1 S.R. Ghazarian.3 1All Children's Hospital, St. Petersburg, FL; 2Department of Pediatrics, University of South Florida, Tampa, FL; 3Pediatrics, Johns Hopkins Medicine, Johns Hopkins University, Baltimore, MD.

(596) The Change in B-Type Natriuretic Peptide Levels over Time Predicts Significant Rejection in Pediatric Cardiac Transplant Recipients; D.V. Skojec,1 S.D. Russell,1 M.K. Halushka,1 J. Wang,1 J.N. Scheel,3 1Medicine, Johns Hopkins Hospital, Baltimore, MD; 2Pathology, Johns Hopkins Hospital, Baltimore, MD; 3Pediatrics, Johns Hopkins Hospital, Baltimore, MD.

(597) Persistence of Human Leukocyte Antibodies in Congenital Heart Disease Late Following Surgery Utilizing Allograft and Whole Blood; M.J. O'Connor,1 C. Lind,2 D. Monos,2 J. Weber,1 R.E. Shaddy.1 1Division of Cardiology, The Children's Hospital of Philadelphia, Philadelphia, PA; 2Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, PA.

(598) Outcomes in Children Removed from the Heart Transplant Wait-List before Receiving a Transplant; C.J. VanderPluym, D. Graham, C. Almond, C. Milliren, T.P. Singh. Cardiology, Children's Hospital Boston, Boston, MA.

(599) NTproBNP as a Marker of Rejection in Pediatric Heart Transplant Recipients; K.R. Knecht,1 M.L. Alexander,6 C.J. Swearingen,6 E.A. Fra-
(609) Steroid Avoidance in Pediatric Heart Transplantation Results in Excellent Graft Survival; S.R. Auerbach, J. Gralla, D.N. Campbell, S.D. Miyamoto, B.A. Pietra, Pediatrics, Division of Pediatric Cardiology, University of Colorado Denver School of Medicine, Aurora, CO; Epidemiatics, Children’s Hospital Research Institute, University of Colorado Denver School of Medicine, Aurora, CO; Pediatric Cardiac Surgery, University of Colorado Denver School of Medicine, Aurora, CO.


(611) Eosinophilic Esophagitis (EoE) Is a Cause of Morbidity after Pediatric Heart Transplant and Is Associated with Increased Rates of Post-Transplant Lymphoproliferative Disease (PTLD); S.J. Kindel, B.F. Joy, E. Pahl, E.L. Wald, Department of Cardiology, Department of Pediatrics, Children’s Memorial Hospital – Northwestern University Fienberg School of Medicine, Chicago, IL; Division of Critical Care, Department of Pediatrics, Children’s Memorial Hospital – Northwestern Fienberg School of Medicine, Chicago, IL.

(612) Treatment of Non-Group 1 Pulmonary Hypertension: Results of a Survey of Pulmonary Hypertension Centers in the United States; M.E. Pugh, A.R. Hemnes, J.H. Newman, J.M. Robbins, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center; Nashville, TN.

(613) Lung and Heart-Lung Transplantation in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Results from the Spanish Registry; M. López-Meseguer, J. Segovia, P. Morales, J. Ciftrán, J.A. Barbera, A. Roman, P. Escolano, Respiratory Medicine, H. U. Vall d’Hebron, Barcelona, Spain; Cardiology, H. 12 de Octubre, Madrid, Spain; Respiratory Medicine, H. Clinic, Barcelona, Spain; Respiratory Medicine, H. La Fe, Valencia, Spain; Respiratory Medicine, H. Marqués de Valdecilla, Santander, Spain; Cardiology, H. Puerta de Hierro, Madrid, Spain.

(614) Simple Echo-Doppler Tool Powerfully Predicts Response to Pulmonary Hypertension Specific Therapy in WHO Group 3 Pulmonary Hypertension; A.V. Fields, S.S. Sinha, R. Sagar, R. Sagar, P.R. Forfia; Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; Pulmonary & Critical Care, University of California, Los Angeles, CA; Heart-Lung Institute, St. Joseph Hospital, Phoenix, AZ.

(615) Efficacy of Imatinib Mesylate on Scleroderma Associated Pulmonary Arterial Hypertension; H. Maji, M. Hatano, A. Yao, T. Imamura, K. Asada, T. Inaba, T. Shiga, K. Kinugawa, R. Nagai, Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

(616) Bradykinin Targeted Therapy Decreases Mortality in Pulmonary Hypertension; J.N. Salamon, R. Zolty; Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronz, NY; Medicine, Division of Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY.

(617) Differences in the Baseline Right Ventricular-Pulmonary Artery Interaction Provides Insight into 'Responders' vs. 'Non-Responders' to PH Specific Therapy in WHO Group 3 Pulmonary Hypertension; S.S. Sinha, A.V. Fields, P.R. Forfia; Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA.

(618) Characteristics and Early Outcomes of Patients Requiring Extra Corporeal Life Support after Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension; D. Boulate, O. Mercier, E. Fadel, S. Mussot, D. Fabre, F. Stephan, D. Marteauville; Department of Thoracic and Vascular Surgery, Hopital Marie Lannelongue, Le Plessis- Robinson, France; Adult Intensive Care Unit, Hopital Marie Lannelongue, Le Plessis- Robinson, France.

(619) PTEN Is a Therapeutic Target in Pulmonary Hypertension; Y. Ray, K. Selvendiran, S. Emami, B.K. Rivera, P. Kuppusamy, C.B. Sai-Sudhakar; Surgery, The Ohio State University, Columbus, OH; Obstetrics and Gynecology, The Ohio State University, Columbus, OH; Internal Medicine, The Ohio State University, Columbus, OH.

(620) Increase in the Adenosine A2B Receptor in Association with Pulmonary Hypertension Secondary to Pulmonary Fibrosis; L.J. Garcia-Morales, H. Karmouty-Quintana, T. Weng, B.A. Bruckner, S. LaFrancesca, M. Loebe, B. Ramlawi, M.R. Blackburn, H. Seethamrajnu; Cardiovascular Surgery, Methodist DeBakey Heart & Vascular Center; Houston, TX; Pulmonary, Methodist J.C. Walter Jr. Transplant Center; Houston, TX; Department of Biochemistry and Molecular Biology, The University of Texas-Houston Medical School, Houston, TX.

(621) Endothelin-1 Levels in Pulmonary Hypertension: A Comparison between Pulmonary Arterial Hypertension and Diastolic Heart Failure-Induced Pulmonary Hypertension; J.A. Mazurek, J.N. Salamon, I. Kelesidis, W. Saeed, R. Zolty; Department of Medicine, Jacobi Medical Center; Albert Einstein College of Medicine, Bronx, NY; Department of Medicine, Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

SEASON 2

(CONGRESS HALL FOYER)

Presenters will be available on Thursday from 6:15 pm-7 pm to discuss their posters and answer any questions.

11:45 AM (622) Preoperative Irradiation and Donor Splenocyte Infusion Induce Tolerance in Lung, but Not Heart Allografts in a Minipig Model – Role of Passenger Leukocytes; G. Bucheler, G. Wannecke, M. Avar, A.-K. Kniefel, K. Dreckmann, W. Sommer, J. Gottlieb, F. Laenger, J. Karstens, A. Havenich, M. Strubner; Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; Clinic for Pneumology, Hannover Medical School, Hannover, Germany; Institute for Pathology, Hannover Medical School, Hannover, Germany; Institute for Radiation Therapy and Special Oncology, Hannover Medical School, Hannover, Germany.

(623) WITHDRAWN

(624) Acute Ethanol Exposure Increases the Susceptibility of the Donor Hearts to Ischemia/Reperfusion Injury after Transplantation in Rats; S. Li, S. Korkmaz, Z. S. Loganathan, T. Radovits, P. E. Barnes, K. Hirschberg, P. Hegeduš, S. Pali, G. Veres, M. Karck, G. Szabó; Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; Heart Center, Semmelweis University, Budapest, Hungary; Heart Surgery, Semmelweis University, Budapest, Hungary.

(625) Dual Blockade of the Renin-Angiotensin System (RAS) Prevents Tacrolimus-Induced Nephrotoxicity in Normotensive and Hypertensive Rats; L. Hoskova, L. Kopkan, E. Hansova, I. Malek, J. Prik, L. Cervenka; Cardio Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

(626) Vascular Biology: Dichloroacetate Inhibits the Development of Intimal Hyperplasia, but Not Atherosclerotic Lesions; X. Hua, T. Deuse, M. Stubbendorff, F. Haddad, H. Reinenspurner, R.C. Robbins, E. Michalakis, S. Schreper; TTS-Lab, Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; CV Medicine, Stanford University, Stanford, Germany; CT Surgery, Stanford University, Stanford, Germany; Cardiology, University of Alberta, Edmonton, Canada.

(627) Acute Inflammatory Response and Cell Death in Human Epithelial Cells Induced by Hypothermic and Hypoxic Ischemia Followed
(628) A Single-Dose Recombinant Glutathione S-Transferase P1-1 Improves Cardiac Function Post Myocardial Infarction in Rats; S. Ahammer,1 M. Salama,1 O. Andrukhova,2 D. Wiedermann,1 M. Kress,1 L. El-Husseiny,1 A. Kocher,1 G. Laufer.1 Medical University of Vienna, Vienna, Austria; University of Witten/Herdecke, Witten, Germany.

(629) Development of an Experimental Perfusion Model in the Human Placenta; A. Beiras-Fernandez,1 L. Conradi,1 X. Hua,1 L. Peters,1 T. Deuse,1 A. Hansen,2 A. Edén,2 H. Reichenspurner,2 R. C. Robbins,3 T. Eschenhagen,2 S. Schreper1,2,3 TSI-Lab, Cardiovascular Surgery, University of Zurich, Zurich, Switzerland; Stanford Cardiovascular Institute, Stanford School of Medicine, Palo Alto, CA.

(630) Improved Red Cell Distribution Width Predicts Poor Stem Cell Mobilization in Advanced Chronic Heart Failure Patients; G. Puglisi,1 R. Okrajšek,1 M. Sedešťen,2 F. Haddad,1 B. Vrtovec.1 Advanced Heart Failure and Transplantation Center, Dept. of Cardiology, University Medical Center Ljubljana, Ljubljana, Slovenia; Stanford Cardiovascular Institute, Stanford School of Medicine, Palo Alto, CA.

(631) Clinical Aspects in Regenerative Medicine: Immunobiology of Engineered Heart Tissue; S. Schmidt,1 L. Conradi,1 X. Hua,1 L. Peters,1 T. Deuse,1 A. Hansen,2 A. Edén,2 H. Reichenspurner,2 R. C. Robbins,3 T. Eschenhagen,2 S. Schreper1,2,3 TSI-Lab, Cardiovascular Surgery, University of Zurich, Zurich, Switzerland; Stanford Cardiovascular Institute, Stanford School of Medicine, Palo Alto, CA.

(632) Use of the Oto Lung Donor Score To Analyze the 2010 Donor Pool of the Nord Italia Transplant Program; G. Porro,1 F. Valenza,1 S. Coppola,1 S. Froio,1 E. Benazzi,2 N. De Fazio,2 L. Santambrogio,2 A. D’Armini,4 M. Loy,5 M. Ravini,6 A. Lucianetti,7 M. P. Moretti,8 S. Vesconi,9 M. Scalamogna,2 L. Gatti,1 M. Salama,1 O. Andrukhova,2 D. Wiedermann,1 M. Krssak,1 L. El-Husseiny,1 A. Kocher,1 G. Laufer.1 Medical University of Vienna, Vienna, Austria; University of Witten/Herdecke, Witten, Germany.

(633) Ex Vivo Evaluation of Brain Dead Donor Lungs: PO2 Is Not Enough; J.C. Yeung,1 M. Cypel,1 T. Machuca,1 T. Kolke,1 F. Cook,1 R. Bonato,1 M. Chen,1 M. Sato,1 T.K. Waddell,1 M. Liu,1 A.S. Slutsy,1 S. Keshavjee.1 University of Toronto, Toronto, Canada.

(634) Ex Vivo Evaluation of Brain Dead Donor Lungs: PO2 Is Not Enough; J.C. Yeung,1 M. Cypel,1 T. Machuca,1 T. Kolke,1 F. Cook,1 R. Bonato,1 M. Chen,1 M. Sato,1 T.K. Waddell,1 M. Liu,1 A.S. Slutsy,1 S. Keshavjee.1 University of Toronto, Toronto, Canada.

(635) Ex-Vivo Lung Evaluation of Pre-Arrest Heparinization in Donor Lung: A Single-Dose Recombinant Glutathione S-Transferase P1-1 Improves Cardiac Function Post Myocardial Infarction in Rats; S. Ahammer,1 M. Salama,1 O. Andrukhova,2 D. Wiedermann,1 M. Kress,1 L. El-Husseiny,1 A. Kocher,1 G. Laufer.1 Medical University of Vienna, Vienna, Austria; University of Witten/Herdecke, Witten, Germany.

(636) The 4G/4G Genotype of the Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G Polymorphism Is Associated with Decreased Lung Allograft Utilization and Decreased Overall Organ Utilization; A. Sapru,1 J. Zaroff,2 L. Pawlikowska,2 L.A. Baxter-Lowe,2 K.K. Krush,2 V. Lo,2 J. Kukreja,2 M.A. Matheny,3 Pediatrics, University of California, San Francisco, CA; Cardiology, University of California, San Francisco, CA.

(637) Procedure for Solid Organ Recovery Leads to Systemic Inflammatory Response; H. Auranen,1,2 T.E. Molinnes,1,4 J. Kongerud,1,2 B. Bjertnæs,2 O. Geiran,1,3 A. E. Fiane,1,3 A. M. Holm,1,2 Faculty of Medicine, University of Oslo, Oslo, Norway; Dept. of Respiratory Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Dept. of Cardiothoracic Surgery, Oslo University Hospital Rikshospitalet, Oslo, Norway; Dept. of Immunology, University of Oslo, Oslo, Norway.

(638) The Effect of Cocaine Use in Donors for Lung Transplant; T.J. Lee, M.P. Fox, J. Trivedi, V. van Berkel.1 Department of Surgery, University of Louisville, Louisville, KY.

(639) Extended Criteria Donor in Lung Transplantation: Older Donor’s Selection; C. Berutto,1 T. Krueger,2 M. Gonzalez,3 M.-F. Derkenne,1 J. Wellinger,3 H.-B. Ris,1 J. H. Roberts,4 P. Soccol,4 T. Rochat,4 L.P. Nicod,5 J.-D. Aubert.1,6 Organ Transplantation Centre, CHUV, Lausanne, Switzerland; Pneumology, CHUV, Lausanne, Switzerland; Thoracic Surgery, CHUV, Lausanne, Switzerland; Pneumology, HUG, Geneva, Switzerland; Thoracic Surgery, HUG, Geneva, Switzerland.

(640) The Administration of Exogenous Surfactant during Cold Preservation Can Improve Pulmonary Function after Lung Transplantation in a Swine Model of Prolonged Ischemia; A. Bertani,1 L. DeMonte,1 P. Vitalulo,2 S. Sonesi,2 A. Callan,3 F. Tuzzolino,3 G. Di Paola,2 A. Arcadipane,2 B. Girdelli.1 Thoracic Surgery and Lung Transplantation, ISMETT-UPMC Italy, Palermo, Italy; Pneumology, ISMETT-UPMC Italy, Palermo, Italy; Statistics, ISMETT-UPMC Italy, Palermo, Italy; Anesthesia and CCM, ISMETT-UPMC Italy, Palermo, Italy.

(641) The Donor Bithermia Preservation: Clinical Experience in Lung Transplantation from Uncontrolled NHBD; P. Gámez,2 A. Mariscal,1 I. Martínez,1 V. Díaz Hellín,1 C. Marrón,1 J.C. Méneses,1 E. López,2 F. Hermoso,1 Á. Ávila,1 J.L. Martín de Nicolás,1 O. González,2 A. de Pablo,3 Thoracic Surgery, Hospital Universitario 12 de Octubre, Madrid, Spain; Anesthesia, Hospital Universitario 12 de Octubre, Madrid, Spain; Pulmonology, Hospital Universitario 12 de Octubre, Madrid, Spain; Rehabilitation, Hospital Universitario 12 de Octubre, Madrid, Spain.


(643) Correlation of Differently Defined Warm Ischemic Time in Controlled Donation after Circulatory Death (DCD) with Early Outcome of Lung Transplantation (LTX); B. Zych,1 P. Mohite,1 A.F. Popov,1 A. Moza,1 A. Wypych-Zych,3 N. Crouch,1 H. Krueger,1 M. Carby,1 A.R. Simon.1 Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; Department of Pulmonary Medicine, Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; Intensive Care Unit, Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom.

(644) The Smoking Donor – Benefit or Hazard to the Potential Lung Transplant Recipient; R.S. Bonser,1,2,3,4 R. Taylor,6 D. Collett,1,2 H.L. Thomas,1,5 J.H. Dark,5 J. Neuberger.3 UK Cardiothoracic Transplant Audit, Clinical Effectiveness Unit, London, United Kingdom; Statistics and Clinical Audit, NHS Blood and Transplant, Bristol, United Kingdom; University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; University of Birmingham, Birmingham, United Kingdom; Newcastle University, Newcastle Upon Tyne, United Kingdom.

(645) Reconditioning of an Injured Lung Graft from Donor after Cardiac Death (DCD) Donor before Transplantation: Utilization of Ex...
(646) Donor History of Cigarette Smoking Does Not Adversely Affect Lung Transplant Mortality: A Single Center Experience; R. Hussain,1 H. Seetharamaju,2 M. Loeb,2 S. Scheinin,2 B. Bruckner,2 S. LaFrancesca,2 S. Jothula,2 A.D. Parulekar.1 Division of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, TX; 2Methodist J.C. Walter Jr. Transplant Center, The Methodist Hospital, Houston, TX.

(647) High Prevalence of Hypertensive Nephropathy in Cardiac Transplant Recipients Selected for Sirolimus Immunoprophylaxis; M. White,1 A. Boucher,2 R. Dandavino,3 A. Fortier,2 G.B. Pelletier,1 N. Racine,1 A. Ducharme,2 S. de Deneus,1 M. Carrien,1 S. Collette,3 Research Center, Montreal Heart Institute/Université de Montréal, Montreal, QC, Canada; 2Biosystatistics, Montreal Heart Institute Coordinating Center, Montreal, QC, Canada; 3Nephrology, Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada.

(648) Resurgence of Photopheresis for Recalcitrant Cellular and Antibody-Mediated Cardiac Allograft Rejection; J. Patel,1 M. Kittleson,1 M. Rafiei,1 L. Stern,1 N. Patel,1 L. Czer,1 F. Esmailian,1 J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(649) Study Design and Preliminary Results of the Italian Everolimus Registry CERTIÇ; F. Paniz,1 A. Branzi,2 R. Fiocchi,2 M. Frigerio,4 G. Gerosa,5 G. Leonardi,6 U. Livi,7 M. Macchini,2 C. Maello,8 M. Rinaldi,10 M. Viganò,11 D. Colombo,12 R. Brusa,12 L. Potena.2 Research Center, University of Padova – Università degli Studi, Padova, Italy; 2Presidio Ospedaliero Ferrarotto, Catania, Italy; 3Osp. Univ. di Udine – A.O. Santa Maria della Misericordia, Udine, Italy; 4O.A. Univ. Senese – Policlinico Santa Maria alle Scotte, Siena, Italy; 5ADRN Monaldi – II Università di Napoli, Napoli, Italy; 6A.D.U. S. Giovanni Battista di Torino, Torino, Italy; 11Policlinico San Matteo – Fondazione IRCCS, Pavia, Italy; 12Novartis Farma, Origgio, VA, Italy.

(650) High Rate of Discontinuation of a Mammalian Target of Rapamycin Inhibitor Based Regime during Long-Term Follow-Up of Cardiac Transplant Recipients; J. González-Castello, E. Kaplinsky, N. Manito, J. Rocca, M. Nebot, M.J. Barbosa, P. Mañas, J. Sáenzbar, A. Miralles, A. Cecquier. Cardiology, Hospital Universitari de Bellvitge, Hospital de Llobregat, Barcelona, Spain.


(652) Use of m-TOR Inhibitors in Maintenance Heart Transplant Recipients with Renal Failure: Conversion or CNI Minimization? A Propensity Study; F. González-Vilchez,1 J.A. Vázquez de Prada,1 M.J. Paniagua,2 M. Gómez Bueno,2 J.M. Arizón,4 J.M. Arizón,4 L. Almenar,5 S. Mirabet,6 J. Delgado,7 J.L. Lambert,8 F. Pérez-Villa,9 M.L. Sanz-Juvé,10 Cardiology Service, University Hospital Marqués de Valdecilla, Santander, Cantabria, Spain; 2Cardiology Service, Complejo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain; 3Cardiology Service, University Hospital Puerta de Hierro, Majadahonda, Madrid, Spain; 4Cardiology Service, University Hospital Reina Sofia, Córdoba, Andalucia, Spain; 5Cardiology Service, University Hospital La Fe, Valencia, Spain; 6Cardiology Service, Hospital Sant Joan de Déu, Bellvitge, Barcelona, Spain; 7Cardiology Service, University Hospital Hospital General Universitario de Badajoz, Badajoz, Spain; 8Cardiology Service, Hospital Clinico, Barcelona, Catalunya, Spain; 9Cardiology Service, University Hospital Miguel Servet, Zaragoza, Aragon, Spain.

(653) Heart Rate Reduction for 36 Months with Ivabradine Reduces Left Ventricular Mass in Cardiac Allograft Recipients; A.O. Doesch,1 C. Erbel,1 A. Ruhparwar,2 P. Ehlermann,1 T.J. Dengler,1 C. Zugck,1 H.A. Katus.1 Department of Cardiology, University of Heidelberg, Heidelberg, Germany; 2Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany.

(654) Cardiac Transplantation without Induction Therapy Despite Renal Dysfunction: A Report from the TICTAC Trial; D.A. Baran, C.Y. Guerrero-Miranda, J. Pieretti, N. Hochbaum, M.E. Goldschmidt, M. Camacho, S. Pardi, M.J. Zucker. Transplant Department, Newark Beth Israel Medical Center, Newark, NJ.

(655) Short-Term Outcomes in Heart Transplant Recipients Treated with Generic Tacrolimus; V. Dhungel, M. Colvin-Adams, P.M. Eckman. Department of Medicine, Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN.

(656) Similar Survival in Patients Following Heart Transplantation Receiving Induction Therapy Using Daclizumab Versus Basiliximab; S. Martin,1 T.S. Kato,1 M. Fan1, F. Cheema,2 M. Ji,2 A. Ross,2 H. Yerebakan,2 Y. Naka,2 D.M. Mancini,1 P.C. Schulze.1 Center for Advanced Cardiac Care, Columbia University Medical Center, New York, NY; 2Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

(657) Effects of Heart Rate Reduction with Ivabradine on Cardio-Pulmonary Capacity in Heart Transplant Recipients; U. Radunski,1 M. Schlützer,1 S. Ohdah,1 A. von Stritzky,1 T. Deuse,2 H. Reichenspurner,1 A. Costard-Jäckle.1 Department of General and Interventional Cardiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2Department of Cardiovascular Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

(658) Lower Lp-PLA2-Activity in Heart Transplanted Patients Treated with Calcineurin Inhibitor Free Therapy Including Everolimus; K. Rosing,1 J. Stoymann,1 M. Fobker,1 J.-R. Nofer.1 Center for Laboratory Medicine, University Hospital Münster, Münster, Germany; 2Department for Cardiology and Angiology, University Hospital Münster, Münster.

(659) Perioperative Levosimendan Therapy Affects Short-Term Outcome after Heart Transplantation; G. Poplajen,1 R. Okrajšek,1 M. Šebestjen,1 I. Knežević,1 F. Haddad,2 B. Vrtovček,1 Advanced Heart Failure and Transplantation Center, Dept. of Cardiology, University Medical Center Ljubljana, Ljubljana, Slovenia; 2Stanford Cardiovascular Institute, Stanford School of Medicine, Palo Alto, CA.

(660) Safety Aspects of the Introduction of Everolimus in Cardiac Recipients with Established Allograft Vasculopathy: Results of a Randomized, Multicenter Study; J. Segovia,1 J. Palomo,2 F. González-Vílchez,3 J. Delgado,4 V. Brossa,5 N. Manito,5 F. Pérez-Villa,7 G. Rébago,8 M. Gómez-Bueno,1 L. Alonso-Pulpón,1 Hospital Puerta de Hierro, Madrid, Solonon Islands; 2Hospital Gregorio Marañón, Madrid, Spain; 3Hospital Marqués de Valdecilla, Santander, Spain; 4Hospital 12 de Octubre, Madrid, Spain; 5Hospital Sant Pau, Barcelona, Spain; 6Hospital de Bellvitge, Barcelona, Spain; 7Hospital Clinic, Barcelona, Spain; 8Clínica Universitaria de Navarra, Pamplona, Spain.

(661) Virus-Derived Immunomodulatory Therapeutics for Heart Transplantation; M.M.C. Dorotan-Guevara,1 M. Bartee,2 J. Davids,2 H. Chen,2 D. Zheng,2 C. McGinn,3 S. Conrad,2 J. Hill,2 D. Pauly,2 J. Aranda, Jr.,2 F.J. Fricker,2 A.R. Lucas.2 Pediatric Cardiology, University of Florida, Gainesville, FL; 1Advanced Heart Failure and Transplantation Center, Dept. of Cardiology, University Medical Center Ljubljana, Ljubljana, Slovenia; 2Stanford Cardiovascular Institute, Stanford School of Medicine, Palo Alto, CA.

(662) Incidence of Rejection after Conversion to Proliferation Signal Inhibitors after Heart Transplantation. Is There any Difference between CNI-Free vs CNI Minimization Regimens?; M.G. Crespo-Leiro,1 M.J. Paniagua-Martín,1 R. Marzoa-Rivas,1 E. Barge-Caballero,1 Z. Grille-Carcel,1 J. Pombó-Otero,2 C. Naya-Leira,1 P. Fainas-Garrido,1 M. García-Guimeras,1 E. Mendez-Eirin,1 A. Castro-Beiras,1 Advanced Heart Failure and Heart Transplant Unit, University Hospital of A Coruña, A Coruña, Spain; 2Anatomy Pathology Unit, University Hospital of A Coruña, A Coruña, Spain.
(663) Cardiac Allograft Hypertrophy: An Important Prognostic Marker for Cardiac Allograft Vasculopathy; H. Yerebakyan,1 M. Ji,1 A. Ross,1 J. Jiang,2 S. Jones,1 L. Soni,1 M. Argenziano,1 C.R. Smith,1 H. Takayama,1 Y. Naka,1 P.C. Schulze,2 F.H. Cheema.1 1Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; 2Division of Cardiology, Columbia University Medical Center, New York, NJ.

(664) Secular Trends of Renal Dysfunction and Its Risk Factors in Heart Transplantation; K. Lachance,1,2 M. Carner,1,2 A. Ducharme,1,3 N. Racine,1,3 M. White,1,2 S. Denus,1,2 1Montreal Heart Institute, Montreal, QC, Canada; 2Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada; 3Faculty of Medicine, Université de Montréal, Montréal, QC, Canada.


(666) Prostate Cancer after Heart Transplantation: Incidence and Prognosis. Data from the Spanish Post-Heart-Transplant Tumour Registry; B. Díaz-Molina,1 V. Brossa,2 G. Rábago,2 L. Alonso-Pulpón,2 F. Vilchez,3 J. Palomo,4 N. Manito,5 L. Almenar,6 J. Delgado,6 J.M. Argenziano,7 E. Lage,7 J.L. Lambert,7 F. Pérez-Villa,8 T. Blasco,9 D. Pascual,10 L. Fuente,11 M. Crespo-Leiro,11 1Hospital Universitario Central de Asturias, Oviedo, Spain; 2Hospital Puerta de Hierro, Madrid, Spain; 3Hospital Universitario Marqués de Valdecilla, Santander, Spain; 4Hospital General Universitario Gregorio Marañon, Madrid, Spain; 5Hospital Universitario de Bellvitge, Barcelona, Spain; 6Hospital Universitario La Fe, Valencia, Spain; 7Hospital Universitario 12 de Octubre, Madrid, Spain; 8Hospital Reina Sofia, Córdoba, Spain; 9Hospital Universitario Miguel Servet, Zaragoza, Spain; 10Hospital Clinico, Valladolid, Valladolid, Spain; 11Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.

(667) Development of Serum Lipids in Everolimus Treated Heart Recipients; H. Lehmkuhl,1 C. Bara, A. Zuckermann, P. Lopez, G. Dong, S. Hirt, A2310 Study Group, Basel, Switzerland.

(668) Primary Graft Failure in Heart Transplantation: Current Characteristics in a Nationwide Cohort; J. Segovia,1 M.D.G. Cosio,1 M. Gómez Bueno,1 L. Almenar,2 J. Delgado,2 J.M. Argenziano,4 F. Gonzalez-Vilchez,3 M.G. Crespo-Leiro,5 S. Mirabet,6 F. Perez Villa,7 J. Fernández-Yañez,8 J.L. Lambert,9 N. Manito,10 L. Fuente,11 M.L. Sanz Julve,12 D. Pascual,13 G. Rábago,15 L.A.A. Pulpolín,17 1Heart Transplant Unit, Hospital Puerta de Hierro, Madrid, Spain; 2Hospital Universitario de Bellvitge, Barcelona, Spain; 3Hospital La Fe, Valencia, Spain; 4Hospital 12 de Octubre, Madrid, Spain; 5Hospital Reina Sofia, Córdoba, Spain; 6Hospital Virgen del Rocio, Sevilla, Spain; 7Hospital Clinico and Provincial, Barcelona, Spain; 8Hospital Universitario Miguel Servet, Zaragoza, Spain; 9Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; 10Hospital Clinico de Valladolid, Valladolid, Spain; 11Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.

(669) The Possibility of Tumor Markers as a Screening Method for De-Novo Malignancies in Heart Transplants; Y. Schneeburger,1 A. Aliabadi,2 D. Dunkler,2 H. Reichenspurner,1 A. Zuckermann,1 1University Heart Center Hamburg, Hamburg, Germany; 2Medical University of Vienna, Vienna, Austria.

(670) Urinary Biomarkers in Heart Allograft Recipients in Relation to Kidney Function; P. Przybylowski,1 J. Malyzsko,2 J.S. Malyzsko,2 E. Koczorawska,4 M. Myśliwiec.2 Cardiovascular Surgery and Transplantology, Jagiellonian University, Krakow, Poland; 2Nephrology and Transplantology, Medical University, Białystok, Krakow, Poland.

(671) Pre-Existing Neoplasms and Risk for Malignancy after Heart Transplantation. Data from the Spanish Post-Heart Transplant Tumors Registry; J.F. Delgado,1 L. Alonso-Pulpón,2 S. Mirabet,6 F. Perez,4 L. Almenar,5 F. Gonzalez,6 A. Villa,7 M. Sanz,8 M.J. Ruiz,9 N. Manito,10 L. de la Fuente,11 G. Rábago,12 E. Lage,13 D.A. Pascual,14 B. Díaz-Molina,15 J.L. Lambert,16 T. Blasco,17 D. Pascual,18 L. Fuente,19 M. Crespo-Leiro,11 1Hospital La Fe, Valencia, Spain; 2Hospital 12 de Octubre, Madrid, Spain; 3Hospital Clinico, Valladolid, Valladolid, Spain; 4Hospital La Fe, Valencia, Spain; 5Hospital Virgen del Rocio, Sevilla, Spain; 6Hospital Clinico de Valladolid, Valladolid, Spain; 7Hospital Puerta de Hierro, Madrid, Spain; 8Hospital Cronicas, Santander, Spain; 9Hospital Gregorio Marañon, Madrid, Spain; 10Hospital Miguel Servet, Zaragoza, Spain; 11Hospital Hospitalet de Llobregat, Barcelona, Spain; 12Hospital Santa Creu i Sant Pau, Barcelona, Spain; 13Hospital Clinic i Provincial de Barcelona, Barcelona; 14Hospital La Fe Fe, Valencia, Spain; 15Hospital Marqués de Valdecilla, Santander, Spain; 16Hospital Virgen de la Arrixaca, Murcia, Spain; 17Hospital Central de Asturias, Oviedo, Spain; 18Hospital Reina Sofia, Córdoba, Spain; 19Hospital Universitario Miguel Servet, Zaragoza, Spain; 20University Heart Center Hamburg, Hamburg, Germany; 21Department of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.


(673) Outcomes with Mechanical Support for Early Primary Graft Dysfunction in Heart Transplantation; C.A. Bermudez, R.V. Rocha, D.B. Zaladonis, J.K. Bhamra, R.N. Ramani, J.J. Teutemberg, D.M. McNamara, M.A. Simon, R.L. Kormos. Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.

(674) Acute Renal Failure Does Not Predict Long-Term Outcome after Heart Transplantation; D. Kolsrud,1 S.-E. Ricksten,2 V. Sigurdardottir,3 H. Liden,1 S.-E. Bartfay,4 N. Selimovic,4 G. Dellgren,3 Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden; 2Cardiothoracic Anesthesiology, Sahlgrenska University Hospital, Gothenburg; 3Transplant Institute, Sahlgrenska University Hospital, Gothenburg; 4Cardiology, Sahlgrenska University Hospital, Gothenburg.

(675) CD19 Monitoring after Rituxamab in Patients with Cardiac Transplant Antibody Mediated Rejection (AMR); F. Kandlar,1 M. Caccamo, C. Martin, C. Masri, P. Eckman, M. Colvin-Adams. Cardiology, University of Minnesota, Minneapolis, MN.

(676) New Onset Atrial Fibrillation and Atrial Flutter after Cardiac Transplant Is Associated with High Mortality and Cardiac Allograft Vasculopathy; L.K. Soni,1 J. Jiang,1 M. Ji,1 S. Cheung,1 E. Heng,1 H. Yerebakyan,1 C.R. Smith,1 M.A. Farr,2 H. Takayama,1 M. Argenziano,1 D.M. Mancini,2 Y. Naka,1 P.C. Schulze,2 F.H. Cheema.1 1Department of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; 2Department of Cardiology, Columbia University Medical Center, New York, NY.


(678) Renalase and Endothelium Function in Heart Transplant Recipients; P. Przybylowski,1 J. Malyzsko,2 J.S. Malyzsko,2 E. Koczorawska,4 M. Myśliwiec.2 Cardiovascular Surgery and Transplantology, Jagiellonian University, Krakow, Poland; 2Nephrology and Transplantology, Medical University, Białystok, Krakow, Poland.
(700) The Clinical and Histological Characteristics of End-Stage Sarcoidosis Requiring Lung Transplantation; a Three Center Experience; H. Shigemitsu,1 M. Drent,2 B. van den Blink,3 O. Sharma,1 R.J. van Suylen,4 M.A. den Bakker,5 M.N. Koss.1 1Pulmonary & Critical Care Medicine, University of Southern California Keck School of Medicine, Los Angeles; 2Idiopathic Care Center, Maastricht University Medical Center; Maastricht, Netherlands; 3Pathology, Erasmus MC University Medical Center, Rotterdam, Netherlands; 4Pathology, Maastricht University Medical Center, Maastricht, Netherlands; 5Pathology, Erasmus MC University Medical Center, Rotterdam, Netherlands; 6Pathology, University of Southern California Keck School of Medicine, Los Angeles.

(701) Rapid Decline in Six Minute Walk Distance Is Associated with Lower Survival to Transplant in the Idiopathic Pulmonary Fibrosis Patient; J.R. Walsh,1,2 D.C. Chambers,1,2 S.T. Yerkovich,1,2 N.R. Morris,1,2 P.M.A. Hopkins.1,2 1Queensland Centre for Pulmonary Transplantation and Vascular Disease, The Prince Charles Hospital, Brisbane, QLD, Australia; 2School of Medicine, The University of Queensland, Brisbane, QLD, Australia; 3Griffith Health Institute, Griffith University, Gold Coast, QLD, Australia.

(702) Growing Single Center Experience with ECMO as a Bridge to Lung Transplantation; N. Vevel,1 D.P. Mason,1 S. Murthy,1 M.M. Budde,2 J.J. Yun,2 D.R. Johnston,1 K.R. McCurry,1 G.B. Pottersson,1 1Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH; 2Pulmonary, Allergy and Critical Care Medicine, Cleveland Clinic, Cleveland, OH.


(705) Pre-Operative Cardiac Variables and Clinical Outcomes in Patients with Bilateral Lung Transplants; A. Yadlapati, J. Aboulhosn, J. Belpario,2 D. Ross,2 A. Andehali,2 R. Saggard,2 1Cardiology, UCLA, Los Angeles, CA; 2Pulmonary, UCLA, Los Angeles, CA; 3CT Surgery, UCLA, Los Angeles, CA.

(706) 100% 3-Year Survival after Extracorporeal Membrane Oxygenation (ECMO) Bridge to Lung Transplantation (N=10); M.B. Connellan,1 Y. Om,1 R. Pye,2 E. Granger,1 K. Dhiital,1 C. Soto,1 M.A. Malouf,1 P. Spratt,1 A.R. Glanville,1 R. Pansu,1 1Cardiopulmonary Transplant Unit, St. Vincent’s Hospital, Sydney, NSW, Australia; 2Department of Anaesthetics and Intensive Care, St. Vincent’s Hospital, Sydney, NSW, Australia.

(707) Pre-Transplant Allosensitization Increases Time to Transplant and Waitlist Mortality in Lung Transplantation; H. Gureshi,1 H. Seetharamaju,2 M. Loebe,3 S. Scheinin,2 B. Bruckner,2 S. LaFrancesca,2 S. Jyothula,2 A.D. Parulekar.1 1Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, TX; 2Methodist J.C. Walter Jr. Transplant Center, The Methodist Hospital, Houston, TX.

(708) Percutaneous Coronary Intervention Improves Outcomes in Patients with Coronary Artery Disease Undergoing Lung Transplantation; R.R. Bunje,1 H. Seetharamaju,2 S. Scheinin,1 J. Estep,2 T. Motomura,1 S. LaFrancesca,2 W. Fischer,1 A.D. Perulekar,1 M. Loebe,1 B.A. Bruckner.1 1Cardiovascular Surgery & Thoracic Transplant, The Methodist Hospital DeBakey Heart & Vascular Center, Houston, TX; 2Internal Medicine/Division of Pulmonary Transplant, The Methodist Hospital, Houston, TX; 3Internal Medicine/Division of Cardiology, The Methodist Hospital DeBakey Heart & Vascular Center, Houston, TX.

(709) Single Versus Double-Lung Transplantation in Emphysema; M. Delgado,1 J.M. Borro,1 D. González,1 R. Fernández,1 S. Campainha,2 J.A. García,1 E. Feira,1 L. Mendez,1 M. De LaTorre,1 Thoracic Surgery, University Hospital A Coruña, A Coruña, Spain; 2Pulmonology, Centro Hospitalar de Gaia/Espinho, Vila Nova de Gaia, Portugal.

(710) Survival Stratification in Scleroderma Patients by DeMeester Score; J.P. Gagermeier,1 P. Patel,1 J. Joseph,3 P.M. Fischella,2 C.S. Davis,2 C.G. Alex,1 R.B. Love.4 1Pulmonary and Critical Care Medicine, Loyola University Medical Center, Maywood, IL; 2Medicine, Loyola University Medical Center, Maywood, IL; 3General Surgery, Loyola University Medical Center, Maywood, IL; 4Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL.

(711) Changes in Pulmonary Volumes in Patients Who Underwent Lung Transplantation for Pulmonary Fibrosis; A. Bertani,1 P. Vitulo,2 S. Sioresi,2 L. DeMonte,1 F. Tuzzolino,1 A. Callani,2 B. Gridelli.1 1Thoracic Surgery and Lung Transplantation, ISMETT-UPMC Italy, Palermo, Italy; 2Pulmonology, ISMETT-UPMC Italy, Palermo, Italy.


(713) CT Scores Are Predictive of Survival in CF Patients Awaiting Lung Transplant; M. Leoni,1 W.C.J. Hop,3 M. de Bruijne,2 P.Th.W. van Hal,9 P. Robinson,5 M.L. Attken,7 J.D. Dodd,8 H.A.W.M. Tiddens.1 2Pediatric Pulmonology, Erasmus MC Sophia Children’s Hospital, Rotterdam, Zuid Holland, Netherlands; 3Pediatric Pulmonology, Erasmus MC Rotterdam, Zuid Holland, Netherlands; 4Biostatistics, Erasmus MC, Rotterdam, Zuid Holland, Netherlands; 5Medical Informatics, Erasmus MC, Rotterdam, Zuid Holland, Netherlands; 6Respiratory Medicine, Erasmus MC, Rotterdam, Zuid Holland, Netherlands; 7Pediatric Pulmonology, Royal Children’s Hospital Melbourne, Melbourne, VIC, Australia; 8Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA; 9Radiology, Sint Vincent’s Hospital, Dublin, Ireland.

(714) Fluid Balance and Immediate Post Operative Outcomes Following Lung Transplant; L. Munshi,1 L.G. Singer,5 M. Cypel,2 S. Keshavjee,2 M. Binnie,3 N.D. Ferguson.1 1Critical Care, Toronto General Hospital, University of Toronto, Toronto, ON, Canada; 2Thoracic Surgery, Toronto General Hospital, University of Toronto, Toronto, ON, Canada; 3Respirology, Toronto General Hospital, University of Toronto, Toronto, ON, Canada.

(715) Right Ventricular Stroke Work Index as a Predictor of One-Year Mortality and Initial Hospital Stay after Lung Transplantation; H.F. Armstrong,1 P.C. Schulze,2 W. Thirapatarapon,3 M.N. Bartels.1 1Department of Rehabilitation and Regenerative Medicine, Columbia University Medical Center, New York, NY; 2Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY; 3Department of Rehabilitation Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

(716) Risk Factors for the Development of Cutaneous Squamous Cell Carcinoma after Lung Transplantation; T. Tse,4 Z. Klyza,4 S.T. Yerkovich,3 P.A. Hopkins,3 D.C. Chambers.4 1Pharmacy Department, The Prince Charles Hospital, Brisbane, QLD, Australia; 2The School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia; 3Queensland Centre for Pulmonary Transplantation and Vascular Disease, The Prince Charles Hospital, Brisbane, QLD, Australia; 4The Queensland Lung Transplant Service, Brisbane, QLD, Australia.

(717) Increased Distal Airway Nitric Oxide (NO) Release during Acute Complications in Lung Transplant Recipients (L TxR); M.A. Gashoula,1 Z. Cao,1 M.R. Pipeling,1 J.P. McDyer,1 C.A. Merlo,1 A.A. Shah,2 J.B. Orens,1 R.E. Girgis.1 1Medicine, Johns Hopkins University, Baltimore, MD; 2Cardiac Surgery, Johns Hopkins University, Baltimore, MD.
(718) Delayed Recovery in Exercise Capacity Post Lung Transplantation Bears No Association with Age or Preoperative Functional Status; J.R. Walsh,1,2 D.C. Chambers,1,2 S.T. Yerkovich,1,2 N.R. Morrisey,1,3 H.E. Seale,1 P.M.A. Hopkins,1,2 1Queensland Centre for Pulmonary Transplantation and Vascular Disease, The Prince Charles Hospital, Brisbane, QLD, Australia; 2School of Medicine, The University of Queensland, Brisbane, QLD, Australia; 3Department of Medicine, Lung Transplant Program, Keck School of Medicine, University of Southern California, Los Angeles, CA.


(721) Pepsin Concentrations Are Elevated in the Bronchoalveolar Lavage Fluid of Patients with Idiopathic Pulmonary Fibrosis after Lung Transplantation; C.S. Davis,1 D.V. Flint,1 K. Pelletiere,2 E. Lowery,2 L. Ramirez,1 R.B. Lowe,2 E.J. Kovacs,1 P.M. Fischella,1 Department of Surgery, Loyola University Chicago, Health Sciences Campus, Maywood, IL; 2Department of Medicine, Division of Pulmonary and Critical Care Medicine, Loyola University Chicago, Health Sciences Campus, Maywood, IL; 3Department of Thoracic and Cardiovascular Surgery, Loyola University Chicago, Health Sciences Campus, Maywood, IL.

(722) Mycophenolate Mofetil (MMF) as a Cause of Colonic Ischemia Requiring Colectomy in Lung Transplant Recipients (LTR); A. Bansal,7 Y. Toyoda,8 N. Shigemura,1 J.K. Bhama,1 D.J. Hartman,4 C.J. Clancy,2 R. Shields,3 M. Crespo,3 J. Pilewski,3 C. Bermudez,7 M.H.T. Nguyen,2 Department of Cardiothoracic Transplant, University of Pittsburgh Medical Center, Pittsburgh, PA; 2Department of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, PA; 3Department of Pulmonary Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; 4Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA; 5Department of Pharmacology, University of Pittsburgh Medical Center, Pittsburgh, PA; 6Cardiothoracic Surgery, Temple University School of Medicine, Philadelphia, PA; 7Ochsner Clinic Foundation, New Orleans, LA.

(723) Aspiration after Lung Transplantation: Incidence, Risk Factors, and Accuracy of the Bedside Swallow Evaluation; J.K. Bhama,1 B.M. Baumann,2 S. Byers,3 T. Wasserman,2 R. Zomak,2 A. Bansal,2 N. Shigemura,1 J.M. Pilewski,3 M. Crespo,3 D. Zaldonis,1 C.A. Bermudez,1 Y. Toyoda,4 Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; 2Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA; 3Department of Pulmonary Allergy & Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; 4Department of Cardiothoracic Surgery, Temple University Hospital, Philadelphia, PA.

(724) Primary Graft Dysfunction (PGD) vs Transfusion-Related Lung Injury (TRLI) in Lung Transplantation (LT): Can These Entities Be Differentiated Based on the Current ISHLT PGD Definition?; M.M. Crespo,1 C.J. Clancy,2 J.M. Pilewski,1 C. Bermudez,2 V. Jarido,1 A. Shiose,1 A. Ali,1 H. Kanemitsu,1 C. Gries,2 M. Crespo,2 B. Johnson,1 J. Pilewski,2 C. Bermudez,1 Cardiothoracic Transplant, University of Pittsburgh Medical Center, Pittsburgh, PA; 2Division of Pulmonary Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; 3Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; 4Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA; 5Department of Pharmacology, University of Pittsburgh Medical Center, Pittsburgh, PA; 6Cardiothoracic Surgery, Temple University School of Medicine, Philadelphia, PA; 7Ochsner Clinic Foundation, New Orleans, LA.

(725) The Importance of Risk-Factor Adjustment When Assessing the Relationship between Voriconazole Utilization and the Development of Non-Melanoma Skin Cancer among Lung and Heart/Lung Transplant Patients, 2002-2009; J.M. McLoughlin,1 O. Equils,1 K.T. Somerville,1 J. Aram,1 H. Schlamm,1 V. Welch,1 J. Manekian,2 R.G. Barbers,2 Pfizer Inc., New York, NY; 2Adult Asthma and Allergy Center, Lung Transplantation Program, Keck School of Medicine, University of Southern California, Los Angeles, CA.

(726) Endoscopic Treatment of Native Lung Hyperinflation with One-Way Valves in Single Lung Transplant Patients: A Multinational Experience; M. Perch,1 D.K. Hogarth,2 S.C. Springmeyer,2 G.C. Risie,4 A.L. Musani,5 X. Gonzalez,3 M. Iversen.1 1Cardiology, Section for Lungtransplantation, Rigshospitalet, Copenhagen, Denmark; 2University of Chicago, IL; 3Spiration, Redmond, WA; 4Sahlgrenska University Hospital, Göteborg, Sweden; 5National Jewish Health and University of Colorado, Denver, CO.

(727) Negative Clinical Outcomes Associated with Postoperative Atrial Arrhythmias after Lung Transplantation; K.R. Branch,1 B.R. Parmar,1 M.S. Mulligan,4 K.M. Koprivcic,3 G. Raghu,3 R.W. Rho,4 1Internal Medicine/Cardiology, University of Washington, Seattle, WA; 2Thoracic Surgery, University of Washington, Seattle, WA; 3Internal Medicine/Pulmonology and Critical Care, University of Washington, Seattle, WA; 4Cardiology, Sutter Pacific Medical Foundation, San Francisco, CA; 5Biostatistics, University of Washington, Seattle, WA.

(728) The Crossed Wiring Technique, Especially the Parasternal Technique, Is Associated with Less Sternal Dehiscence after Bilateral Lung Transplantation; T.D. Koster,1 F.Z. Ramjanikh,2 E.A. van de Graaf,1 H.D. Luijk,1 J.C. Grutters,1 R.C.A. Meijer,2 D.A. van Kessel,1 J.M. Kwakkel-van Erp,1 1Division of Respiratory Medicine, University Medical Centre Utrecht, Utrecht, Netherlands; 2Division of Cardio-Thoracic Surgery, University Medical Centre Utrecht, Utrecht, Netherlands; 3Division of Respiratory Medicine, St. Antonius Hospital, Nieuwegein, Netherlands.

(729) Abnormalities of Esophageal Motor Activity Are Highly Prevalent in Lung Transplanted Patients; M. Di Stefano,1 F. Meloni,4 T. Oggoni,2 C. Mengoli,1 F. Briganti,2 M. Bergonzi,1 A. Zanaboni,1 E. Pagani,1 E. Miceli,1 M. Luissetti,1 G.R. Corazza,1 11st Department of Internal Medicine, University of Pavia and IRCCS San Matteo Foundation, Pavia, Italy; 2Haematological Pneumology and Cardiovascular Sciences, Section of Pneumology, University of Pavia and IRCCS San Matteo Foundation, Pavia, Italy.

(730) Early Major Neurologic Complications after Lung Transplantation: Prevalence, Risk Factors and Outcome; N. Shigemura,1 J. Bhama,1 K. Fujimoto,1 A. Shiose,1 A. Ali,1 H. Kanemitsu,1 C. Gries,2 M. Crespo,2 B. Johnson,1 J. Pilewski,2 C. Bermudez,1 Cardiothoracic Transplant, University of Pittsburgh Medical Center, Pittsburgh, PA; 2Medicine, Division of Pulmonary Allergy and Critical Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.

(731) Acoustic Analysis of a Mechanical Circulatory Support; L. Hubbert, B. Peterzén, H. Granfeldt, H. Ahn. Heart Centre, University Hospital, Departments of Medicine & Health at Linkoping University, Linkoping, Sweden.

(732) Preoperative Hypoalbuninemia Predicts Poor Prognosis in Patients Undergoing Left Ventricular Assist Device Implantation; T.S. Kato,1 Y. Kawano,1 J. Yang,2 H. Akashi,2 H. Takayama,2 Y. Naka,2 M. Farr,1 D. Mancini,1 P.C. Schulze.1 1Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY; 2Department of Surgery, Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

(733) A Retrospective Study of Transcutaneous Energy Transmission in the LionHeart LVAD with Application to Future Wireless Circulatory Support Devices; W.J. Weiss, W.E. Pae, A. El-Banayosy, G. Rosenberg. Department of Surgery, Penn State Hershey Medical Center, Hershey, PA.

(734) Blood Pressure Control in Continuous Flow Left Ventricular Assist Devices – Efficacy and Impact on Adverse Events; B. Lampert,4 S. Weaver,1 A. Scanlon,1 K. Lockard,4 C. Allen,1 N. Kunz,1 C. Bermudez,1 J.K. Bhama,1 M. Shullo,2 R.L. Kormos,1 J.J. Teuteberg.1 1Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, PA; 2Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA.

(735) Left Ventricular Assist Device as a Bridge to Transplantation, Comparison of Quality of Life; E. Yilikelkili,1 R. Gustafsson,1 F. Nielsen,2 B. Koul,1 B. Andersson,2 J. Nilsson.1 1Clinical Sciences in Lund, Cardiothoracic Surgery, Lund University and Skåne University Hospital, Lund, Sweden; 2Chemical Engi-
neening, Lund University, LTH, Lund, Sweden; 2Clinical Sciences in Lund, Surgery, Lund University and Skåne University Hospital, Sweden.

(736) Hemodynamic Efficacy of a Novel Catheter-Deployed Intra-Aortic Micro-Axial Entrainment Pump in a Porcine Acute HF Model; E. Raisi Shaban, 1 M.P. Cuchiara, 2 J.H. Heuring, 2 B.A. Hertzog, 2 J.K. George, 1 R.M. Delgado, 1 Texas Heart Institute, Houston, TX; 2Procynion, Houston, TX.

(737) WITHDRAWN

(738) WITHDRAWN

(739) Integrating Palliative Care in the Management of Patients Considered for Mechanical Circulatory Support; Y. Ravi, 1 S. Emani, 2 S. Wismann, 1 A.K. Hasan, 2 E.F. Gafford, 2 C.B. Sai-Sudhakar. 1 Surgery, The Ohio State University, Columbus, OH; 2Internal Medicine, The Ohio State University, Columbus, OH.

(740) Impact of Reverse Remodeling Following LVAD Implantation on Predicting Long-Term Prognosis during LVAD Support Period; H. Yoksukura, 1 O. Seguchi, 2 T. Sato, 2 H. Sunami, 1 Y. Murata, 2 M. Yanase, 2 T. Fujita, 2 K. Toda, 2 T. Nakatani. 2 Division of Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan; 1 Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan; 2 Adult Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan.

(741) Endocardial Catheter Based Ablation of Ventricular Tachycardia in Patients with Ventricular Assist Devices; M.W. Winner, 1 E.G. Daoud, 1 Y. Ravi, 2 J. Ackers, 1 S. Emani, 1 M. Firstenberg, 2 D.B. Sai-Sudhakar. 1 Cardiovascular Medicine, The Ohio State University, Columbus, OH; 2Cardiac Surgery, The Ohio State University, Columbus, OH.

(742) Surgical Management of the Inlet Orifice in Explantation of Continuous-Flow LVADs; O.H. Frazier, J.K. Ho, W. Cohn, I. Gregoric. Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston, TX.

(743) Role of Echocardiographic Assessment in Staged Weaning and Elective Removal of the HeartMate II LVAD; O.H. Frazier; R. Radovancevic, Z. Demirozu, A.M. Segura, R. Bogaev, W. Cohn, I. Gregoric. Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston, TX.

(744) Variability in Fibrosis of Tissue Samples Obtained after Diaphragmatic and Apical LVAD Implantation; A.M. Segura, I. Gregoric, R. Radovancevic, A. Aguayo, L.M. Buja, O.H. Frazier. Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston, TX.

(745) Initial Report of Japanese Registry for Mechanically Assisted Circulatory Support (J-MACS); T. Nakatani, 1 K. Sase, 2 H. Oshiyama. 3 Department of Transplantation, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; 2Clinical Pharmacology, Juntendo University, Tokyo, Japan; 3Japan Medical Devices Manufacturers Association, Tokyo, Japan.

(746) Speed Adjustment and Thrombosis Detection in Continuous Flow Pumps: Utility of Ramp Studies; N. Uniel, 1 P.C. Colombo, 1 K.A. Morisson, 1 T. Kato, 1 S.W. Restaino, 1 M. Yuzefpolskaya, 2 H. Takayama. 2 Y. Naka, 2 U.P. Jorde, 1 1Medicine, Columbia University, New York, NY; 2Surgery, Columbia University, New York, NY.

(747) Long-Term Support with a Bi-Ventricular Assist Device – A Single Center Experience; A. Gkouziouta, A. Manginas, D. Zarkalis, A. Thanopoulos, S. Adamopoulos. Heart Transplant Unit, Onassis Cardiac Surgery Centre, Athens, Greece.

(748) Treatment of Advanced Heart Failure in Cardiac Amyloidosis with Left Ventricular Assist Device Therapy; P.L. Swieciok, 1 B. Edwards, 2 S. Kushwaha, 2 A. Dispenzieri, 1 S. Park, 3 M.A. Gertz, 1 Division of Hematology, Mayo Clinic, Rochester, MN; 3Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; 2Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN.

(749) Support Structure Impacts Outcomes after VAD Implantation; J.W. Entwistle, 1 C. Cassano, 2 T. Rowe, 2 S.C. Feitell, 2 P. Boaeng, 1 S.R. Hankins, 4 H.J. Eisen, 2 R.J. Petrucci, 5 Department of Cardiothoracic Surgery, Drexel University College of Medicine, Philadelphia, PA; 2Center for Advanced Heart Failure Care, Hahnemann University Hospital, Philadelphia, PA; 3Department of Medicine, Drexel University College of Medicine, Philadelphia, PA; 4Department of Medicine, Division of Cardiology, Drexel University College of Medicine, Philadelphia, PA; 5Department of Psychiatry, Drexel University College of Medicine, Philadelphia, PA.


(751) Tricuspid Regurgitation Is a Measure of Right Heart Dysfunction and Is Associated with Event Free Survival in Stage D Heart Failure: Analysis from MEDAMACS; J. Testani, 1 G.C. Stewart, 2 M.M. Kottkes, 2 J.A. Cowger; 1C.B. Patel, 2 M.M. Mountis, 2 F.L. Johnson, 2 M.E. Gulgin, 2 P.C. Patel, 2 J.J. Teuteberg, 2 J.E. Rame, 1 University of Pennsylvania, Philadelphia; 2Brigham and Women’s Hospital, Boston; 3Cedars Sinai Heart Institute, Los Angeles; 4University of Michigan, Ann Arbor; 5Duke University, Durham; 6Cleveland Clinic, Cleveland; 7University of Iowa, Iowa City; 8University of South Florida, Tampa; 9University of Texas Southwestern Medical Center, Dallas; 10University of Pittsburgh.

(752) Should Advanced Age Be a Contra-Indication to LVAD Implant: A Community Hospital Experience; R.M. Adamson, 1 P. Hoagland, 2 B. Jaski, 2 M. Stahovich, 3 S. Chillcott, 2 W.P. Dembitsky, 1 Cardiothoracic Surgery, Sharp Memorial Hospital, San Diego, CA; 3Cardiology, Sharp Memorial Hospital, San Diego, CA; 2Nursing, Sharp Memorial Hospital, San Diego, CA.

(753) Low Psychosocial and Financial Assessment Scores Are Not Predictive of Poor Outcomes among Ventricular Assist Device Patients: D.S. Medina, 2 A.M. Cordero-Reyes, 3 B. Mosele, 2 K. Fry, 2 J.D. Estepe, 1 A. Bhirajaraj, 1 M. Loeb, 1 G. Torre-Amione, 1 1The Methodist DeBakey Heart & Vascular, The Methodist Hospital, Houston, TX; 2Methodist J.C. Walter Jr. Transplant Center; 3Cardiology, Methodist Hospital, Houston, TX; 2Cardiology, Hospital San Jose Tec de Monterrey, Monterrey, NL, Mexico.

(754) An Estimate of the Potential Candidates for Mechanical Circulatory Support Based on the Analysis of Heart Failure Hospitalizations; G. Binaghi, 1,2 C. Vitton, 2 E. Parravincini, 3 L. Martinelli, 2 R. Paino, 2 F. Oliva, 2 M. Cipriani, 2 G. Masciocco, 2 F. Turrarza, 2 A. Garascia, 2 G. Foti, 2 A. Verde, 2 E. Ammirati, 2 M. Frigerio, 2 Dipartimento Patologia Cardio-Toraco-Vascolare, Azienda Ospedaliera Brotzu, Cagliari, Italy; 1Dipartimento “De Gasperi”, Azienda Ospedaliera – Ospedale Niguarda Ca’ Granda, Milano, Italy; 2Dipartimento Direzione – Qualità e Sicurezza Clinica, Azienda Ospedaliera – Ospedale Niguarda Ca’ Granda, Milano, Italy.

(755) Reduced Handgrip Strength as a Marker of Patient Frailty Predicts Worse Survival after Implantation of a Left Ventricular Assist Device; C.J. Chung, 1 O. Ferreira, 1 C. Wu, 1 H. Akashi, 1 T.S. Kato, 1 H. Takayama, 2 Y. Naka, 2 D.M. Mancini, 2 P.C. Schulze, 1 W.M. Winner, 1 B. Jaski, 2 M. Stahovich, 3 S. Chillcott, 2 W.P. Dembitsky, 1 Cardiothoracic Surgery, Sharp Memorial Hospital, San Diego, CA; 2Cardiology, Sharp Memorial Hospital, San Diego, CA; 3Cardiology, Hospital San Jose Tec de Monterrey, Monterrey, NL, Mexico.

(756) Can Right Ventricular Failure Associated with LVAD Insertion Be Avoided?; R.M. Adamson, 1 J. Channas, 1 V. Norman, 1 B. Jaski, 1 P. Hoagland, 2 S. Chillcott, 2 M. Stahovich, 3 W.P. Dembitsky, 1 Cardiothoracic Surgery, Sharp Memorial Hospital, San Diego, CA; 2Cardiology, Sharp Memorial Hospital, San Diego, CA; 3Nursing, Sharp Memorial Hospital, San Diego, CA.


(759) Safety Evaluation of the HeartWare MVAD Pump in the Pericardial Position in an Ovine Model; E. McGee, D. Tamez, A. Dierlam, M. Brown, N. Nunez. Bluhm Cardiovascular Institute Northwestern Memorial Hospital, Northwestern University's Feinberg School of Medicine, Chicago, IL; Clinical Research Division, HeartWare, Inc, Framingham, MA.


(761) Two CircuLite Pumps as Bi-Ventricular Assist Device (BVAD) in an Ovine Animal Model; J.D. Schimmo, D. Burkhoff, M. Avsar, O. Fey, P. Ziehm, G. Buechler, A. Havenich, M. Strueber. Dept. of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; Dept. of Cardiology, Columbia University, New York, NY; CircuLite Inc., Aachen, Germany.

(762) Use of Sealed Grafts in the HeartMate II Inflow and Outflow Conduits; I. Gregoire, R. Radovancevic, M. Patel, L. Fenik, W. Cohn, O.H. Frazier. Center for Cardiac Support, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX.

(763) Extracorporeal Membrane Oxygenation Support after Pediatric Heart Transplantation: Predictors of Survival to Hospital Discharge; J.A. Su, R.B. Kelly, J. Alejos. Pediatrics, Mattel Children's Hospital UCLA, Los Angeles, CA.

(764) Is There Adequate Knowledge about LVAD Patients among First Responders? A Survey from North Western Italy; A. Municino, A. Torriglia, On Behalf of Rete per l'Emergenza-Urgenza. Dept. of Cardiology, Ospedale A. Gallino ASL, Genovese, Genova, Italy.

(765) Can a Registry Match the Data Quality of a Clinical Trial? Lessons Learned from INTERMACS; D.C. Nafte, J.K. Kirklin, S.L. Myers, M.L. Clark, K.A. Hollifield, S.C. Collum, M.A. Miller. Surgery, University of Alabama, Birmingham, AL, United Kingdom; Cardiovascular Sciences, National Heart, Lung and Blood Institute, NIH, Bethesda, MD.

(766) Echocardiographic and Pathological Correlates of Aortic Regurgitation in Continuous-Flow LVAD Support; S. Murphy, R. Bello, S. Casazza, S. Maybaum, D. Goldstein. Cardiology, Montefiore Medical Center; Bronx, NY; Cardiothoracic Surgery, Montefiore Medical Center; Bronx, NY.

(767) Impact of Left Ventricular Assist Device Implantation upon Native Aortic Valve Regurgitation; K. Rajagopalan, M.A. Daneshmand, M.A. Schechtman, A.M. Ganapathi, C.B. Patel, J.C. Rogers, B.A. Bottiger, M. Swaminathan, C.A. Milano. Surgery – Division of Cardiovascular and Thoracic Surgery, Duke University Medical Center; Durham, NC; Medicine – Division of Cardiology, Duke University Medical Center; Durham, NC; Anesthesiology – Division of Cardiothoracic Anesthesia, Duke University Medical Center; Durham, NC.

(768) Transcranial Doppler Findings in Heart Failure Patients with Left Ventricular Assist Devices (LVADs); Z. Garami, K. Livia, B. Brian, T. Motomura, A. Lumsden, G. Noon, M. Loebe. Cardiovascular Surgery, The Methodist Hospital, Houston, TX.

(769) No Change in Endothelium Dependent Flow-Mediated Dilation Following Continuous Flow Ventricular Assist Device; P.M. Eckman, D. Templeton, S. Hozeyen, B. Baker, R. John, M. Colvin-Adams, D. Dengel. Department of Medicine, Division of Cardiovascular Medicine, University of Minnesota, Minneapolis, MN; Integrative Vascular Biology Lab, University of Colorado, Boulder, CO; Clinical and Translational Science Institute, Masonic Clinical Research Unit, University of Minnesota, Minneapolis, MN; Division of Cardiac Surgery, University of Minnesota, Minneapolis, MN; School of Kinesiology, University of Minnesota, Minneapolis, MN.


(771) Non Invasive Blood Pressure (BP) Measurement with the Terumo Elemano™ Is More Reliable during Return of Pulsatile Flow in Patients on Continuous Flow (CF) LVAD Support; O. Saeed, J. Patel, C. Nucci, S. Patel, D. Goldstein, S. Maybaum. Department of Internal Medicine, Montefiore Medical Center; Albert Einstein College of Medicine, Bronx, NY; Department of Surgery, Montefiore Medical Center; Albert Einstein College of Medicine, Bronx, NY.

(772) Normalization of Pulmonary Vascular Resistance after Bridging to Heart Transplantation with the Total Artificial Heart; S.L. Rennyson, M.P. Flattery, G.A. Meninari, D.G. Tang, G.J. Katlaps, R.H. Cooke, M.L. Hess, V. Kasirajan, K.B. Shah. Heart Failure and Transplantation, Virginia Commonwealth University, Richmond, VA.


(774) Inflammatory Markers and Cardiopulmonary Exercise Testing in Continuous Flow LVAD Recipients; L. Grosman-Rimon, D.Z.I. Cherney, S. Pollock Bar-Ziv, L. Tumiati, M.A. McDonald, I. Jacob, V. Rao. Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada; Medicine, Toronto General Hospital, Toronto, ON, Canada; Cardiopulmonary, Heart for Sick Children, Toronto, ON, Canada; Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada; Department of Medicine, Toronto General Hospital, Toronto, ON, Canada; Exercise Sciences, University of Toronto, Toronto, ON, Canada; Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada.

(775) Axial Flow Left Ventricular Assist Device (LVAD) Support Leads to Progressive Left Ventricular Enlargement and Functional Decline in Normal Hearts; P. Kloepfer, C.C. Del Rio, B. Youngblood, Y. Ueyama, P.I. McConnell. Cardiac Surgery, Nationwide Children's Hospital, Columbus, OH; Qtest Labs, Columbus, OH.

(776) Incidence and Clinical Significance of Atrial Fibrillation under Mechanical Circulatory Support Systems. Role of Catheter Ablation?; H.A. Welp, R. A. Rukosujev, A. Hoffmeier, R.V. Lichtenberg, L. Eckardt, J. Stypmann, H. H. Scheld, G. Mönnig, Department of Thoracic and Cardiovascular Surgery, University Hospital Münster, Münster, Germany; Department of Cardiology, University Hospital Münster, Münster, Germany.

(777) Left Ventricular Assist Device Implantation Significantly Improves Everyday Physical Activity and Quality of Life in Patients with Chronic Heart Failure; A. McDiarmid, G.A. MacGowan, G. Parry, S. Schuler, M.I.I. Trenew, D.G. Jakovljevic, Cardiotherapy and Cardiovascular Surgery and Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom; Institutes for Aging and Health, Genetic Medicine and Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Centre for Brain Aging and Vitality, Newcastle University, Newcastle upon Tyne, United Kingdom.

(778) Monitoring of Heart Rate Variability in Rotary Blood Pump Recipients Is Possible Using the Pump Flow Only; P. Moscati, M. Graninger, M. Edelmayer, D. Zimpfer, G. Wieselthaler, H. Schima, On Behalf of Rete per l’Emergenza-Urgenza. Dept. of Cardiology, Ospedale A. Marzà, Bologna, Italy; Dept. of Cardiac Surgery, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria.


(781) Performance of the Right Ventricular Failure Risk Score in Patients Supported with a Left Ventricular Assist Device; S. Lee, L. Vargas, S. Rao, C. Hallay, Z. Sun, M.M. Mountis, G. Gonzalez-Stawinski, N.G. Smedira, K. Fukumachi, R.C. Stanley. Section of Heart Failure and Cardiac Transplant Medicine, Cleveland Clinic Foundation, Cleveland, OH; Vascular Surgery, Cleveland Clinic Foundation, Cleveland, OH; Cardiovascular Medicine, SUNY Upstate Medical University, Syracuse, NY; Cardiovascular Medicine, Mather Misericordiae University Hospital, Dublin, Ireland; Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH; Thoracic & Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH; Biomedical Engineering, Cleveland Clinic Foundation, Cleveland, OH.

(782) Aggressive Preoperative Optimization Is a Better Determinant of Survival Than Current Risk Models for Acute Cardiogenic Shock; N. Moazami, D. Feldman, K. Hrynewicz, M. Lillyblad, B. Cabuay, E. Shao, B. Sun. Cardiothoracic Surgery, Minneapolis Heart Institute, Minneapolis, MN; Cardiology, Minneapolis Heart Institute, Minneapolis, MN.


(784) Clinical Experience with Patients over Age 65 Who Undergo HeartMate II LVAD Placement for Destination Therapy; B.A. Bruckner, M. Loeb, J.D. Estep, T. Motomura, I. Gregorich, W.E. Cohn, R. Radovancevic, R.R. Bunge, O.H. Frazier, D.H. Frazier. Cardiovascular Surgery, The Methodist Hospital DeBakey Heart & Vascular Center, Houston, TX; Cardiothoracic Surgery, Texas Heart Institute, Houston, TX; Cardiology, The Methodist Hospital DeBakey Heart & Vascular Center, Houston, TX.


(786) Isolated Right Ventricular Assist Device Support Does Not Predict Better Survival over Biventricular Support for Primary Graft Failure after Orthotopic Heart Transplant; J.A. Yang, Y. Naka, M.S. Koeckert, B.P. Shulman, J. Jiang, T. Horai, T. Ota, N. Uriel, P. Colombo, U.P. Jorde, D.M. Mancini, H. Takayama. Division of Cardiac Surgery, Dept of Surgery, Columbia University Medical Center; New York, NY; Division of Cardiology, Dept of Medicine, Columbia University Medical Center; New York, NY.

(787) Clinical Utility of Percutaneous Mechanical Support Devices in the Bridge to Decision Population; N.K. Kapur, M. Esposito, D.T. Pham, V. Paruchuri, A. Jagannath, M.S. Kiernan, M. Schecht, A. Weintraub, A. Majithia, D. DeNofrio. The Cardiovascular Center, Tufts Medical Center; Boston, MA.

(788) Preoperative Optimization Contributes to Sustained Improvement in Renal Function with LVAD Therapy; H.-S. Chiew, B.S. Edwards, S.J. Park, J. Geske, D.R. Fermin, S.S. Kushwaha, W.K. Kremer, P.A. Geerdes, J.A. Schirger. Faculty of Medicine and Dentistry, Charles University at Hradec Kralove, Hradec Kralove, Czech Republic; Cardiovascular Diseases, Mayo Clinic, Rochester, MN; Cardiovascular Surgery, Mayo Clinic, Rochester, MN; Department of Biostatistics, Mayo Clinic, Rochester, MN.


(790) Experience with Total Artificial Heart Bridge to Transplantation in 15 Women; H. Copeland, J. Copeland. Surgery, University of California San Diego, CA.

(791) Avoiding RVADs: Pre-Operative Optimization Is the Best Predictor of Need for RVADs; K. Hrynewicz, M. Lillyblad, E.S. Shao, D.S. Feldman, B. Cabuay, B. Sun, N. Moazami. Minneapolis Heart Institute, Minneapolis, MN.


(793) Addition of Mitral Valve Repair to Left Ventricular Assist Device Implantation; S. Taghavi, E. Hamad, L. Wilson, R. Clark, S.J. Jayaraj, N. Uriel, D. Goldstein, H. Takayama, Y. Naka, A.A. Mangi. Department of Surgery, Temple University Hospital, Philadelphia, PA; Department of Surgery, Montefiore Medical Center; Bronx, NY; Department of Cardiac Surgery, Yale University School of Medicine, New Haven, CT; Temple University School of Medicine, Philadelphia, PA; Department of Surgery, NewYork-Presbyterian Hospital/Columbia, New York, NY.

(794) Application of Destination Therapy Risk Score (DTRS) in Recipients of Continuous Flow LVADs; M. Kanwar, S. Bailey, R.J. Moraca, S. Murali, A. Raina, G. Sokos, A. Hopwood, R.L. Benza. Advanced Heart Failure and Transplant Cardiology, Allegheny General Hospital, Pittsburgh, PA; Cardiothoracic Surgery, Allegheny General Hospital, Pittsburgh, PA.

(795) Evidence for Restoration of Glucose Metabolism in Failing Myocardium Following Prolonged Mechanical Circulatory Support; A.M. Cordero-Reyes, A. Gupte, K.A. Youker, J.D. Estep, M. Loeb, D.J. Hamilton, W. Hsu, G. Torre-Amione. The Methodist DeBakey Heart & Vascular Center, Houston, TX; Hospital San Jose TEC de Monterrey, Monterrey, NL, Mexico; Center for Diabetic Research, The Methodist Hospital Research Institute, Houston, TX.

(796) Acoustic Monitoring Demonstrates Left Ventricular Systole Is Associated with Transient Speed Reduction of Implanted Rotary Left Ventricular Assist Devices (LVADs); M.R. Noon, S. Morad, C.T. Bowles, M.E. Hedger, N.R. Banner, K.H. Parker, A. Simon. Transplantation and Mechanical Circulatory Support, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom; National Heart and Lung Institute, Imperial College London, London, United Kingdom; Department of Bioengineering, Imperial College London, London, United Kingdom.

(797) Transcutaneous Energy Transfer with Bidirectional Data Flow for Powering a Novel Partial Circulatory Support Device; J.J. Heuning, M.P. Cuchiaro, B.A. Hertzog, R.M. Delgado, Procyrion, Houston, TX; Texas Heart Institute, Houston, TX.

(798) Extracorporeal Membrane Oxygenation Support after Pediatric Heart Transplantation: Long-Term Survival Trends; J.A. Su, R.B. Kelly. Pediatrics, Mattel Children's Hospital UCLA, Los Angeles, CA.

(799) VAD Competent or VAD Aware?; J.H. Webster, S. Merali, L. Adcock, N.Y. Raval, D.A. Dean. Advanced Heart Failure Center; Piedmont Heart Institute, Atlanta, GA.

(800) Poorer Immediate Memory Predicts Better Self Confidence in Managing Heart Failure; C.M. Murks, M. Gulnick, S. Penckofer, S.E. Fedson. Cardiology, University of Chicago, IL; Nursing, Loyola University, Chicago, IL.
[801] Improving Community Emergency Medical Services/Emergency Rooms Ability To Care for Mechanical Circulatory Device Patients; M.A. Murray,1 M.R. Johnson,2 J. Blabaum,1 L. Lozonschi,1 W. Biedermann,4 N. Robinson,3 T. Kohmoto,1 Cardiothoracic Surgery and Transplant, University of Wisconsin Hospital and Clinics, Madison, WI; 2Medicine, University of Wisconsin Hospital and Clinics, Madison, WI; 3Department of Cardiothoracic Surgery and Transplantation, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; 4Department of Cardiothoracic and Vascular Surgery, Children's Mercy Hospital and Clinics, Kansas City, MO; 5Department of Developmental and Behavioral Sciences, Children's Mercy Hospital and Clinics, Kansas City, MO; 6Information Systems, Children's Mercy Hospital and Clinics, Kansas City, MO; 7Adult Medicine Department, Children's Mercy Hospitals and Clinics, Kansas City, MO; 8Neophthalmology Department, Children's Mercy Hospitals and Clinics, Kansas City, MO.


[803] Guidelines for Withdrawal of VAD Therapy at End of Life; N. Wrightson, S. Louw, C. Regnard, S. Clark. Cardiothoracic Surgery and Transplantation, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom.

[804] WITHDRAWN

[805] LVAD Patient Pack; a Potential Reservoir for Pathogenic Organisms; J. Collins,1 C. Winter,2 N. Wrightson,3 G. MacGowan,2 T. Pillay,2 F.K. Gould,3 S. Schueler;1 Microbiology, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; 2Infection Prevention and Control, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; 3Cardiothoracic Transplantation, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

[806] Novel Use of Simulation Lab To Educate ' Rapid Response Teams' about Differences in (ACLS) Advanced Cardiac Life Support Algorithms in Patients with HeartMate II Left Ventricular Assist Devices (LVAD); D.H. Karia,1 G. Gould,2 A.J. Fisher,1 Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

[807] Outpatient Milrinone Therapy in Young Children with Advanced Heart Failure; E. Liu,1 A. Lin,1 M. Ogawa,1 D. Rosenthal,2 Pediatric Cardiology, Lucile Packard Children’s Hospital, Palo Alto, CA; 2Stanford University, Palo Alto, CA.

[808] Antibody-Mediated Rejection in Cardiac Transplant Recipients Is a Seasonal Disease; N.E. Hiemann,1 K. Wassilew,2 D. Kemper,1 R. Hetzer, Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

[809] Intraplaque Haemorrhage as a Trigger of Lesion Progression in Cardiac Allograft Vasculopathy; C. Castellani,1 A. Angelini,1 O. de Boer,2 C. van der Loos,3 M. Fedrigo,1 A. Gambino,3 F. Tona,3 G. Feltrin,3 G. Gerosa,3 G. Thiene,1 A.C. van der Waal,2 Medical-Diagnostic Sciences and Special Therapies, University of Padua, Padua, Italy; 3Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; 4Cardio-Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

[810] A Prognostic Role for C4d in Surveillance Endomyocardial Biopsies after Heart Transplantation; A.N. Husain,1 M.K. Mirza,1 S.R. Marino,1 S.E. Fedson,1 Pathology, University of Chicago Medical Center, Chicago, IL; 2Medicine, University of Chicago Medical Center, Chicago, IL.

[811] Study of Necropsies of Patients Submitted to Heart Transplantation: NEHTS-Necropsy Heart Transplant Study; S.M. Ayub-Ferreira, T.N. Valette, L.A. Benvenuti, E.A. Bocchi. Heart Failure Unit, Heart Institute, University of Sao Paulo Medical School, Sao Paulo, SP, Brazil.

[812] Prospective Evaluation of Alveolar and Bronchiolar C4d Expression in Transbronchial Biopsies from Lung Transplanted Recipients; J. Majo,1 R. Mahida,2 N. Thampy,1 F. Black,1 G. Meachery,1 J.L. Lordan,1 P.A. Corris,1 A.J. Fisher,1 Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, England, United Kingdom; 2Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, England, United Kingdom.

[813] Design of a Smart-Phone App with the Potential To Improve Adherence in Organ Transplantation; B. Kevern,7 J. Marshall,1 M. Herzer,2 T. Apodaca,3 R. Johnson,2 D. Lynch,1 B. Warady,1 J. Domen,1 K. Gandy,1 Cardiovascular Surgery, Children’s Mercy Hospitals and Clinics, Kansas City, MO; 2Developmental and Behavioral Sciences, Children’s Mercy Hospitals and Clinics, Kansas City, MO; 3Information Systems, Children’s Mercy Hospitals and Clinics, Kansas City, MO; 4Adolescent Medicine Department, Children’s Mercy Hospitals and Clinics, Kansas City, MO; 5Nephrology Department, Children’s Mercy Hospitals and Clinics, Kansas City, MO.

[814] Pulmonary Vein Stenosis as a Complication of Infant Lung Transplantation; P.H. Michelson,1 R.M. Grady,2 F.V. White,2 P. Eghtesady,1 C.B. Huddleston,3 A. Faro,4 S.C. Sweet,5 Pediatrics, Washington University School of Medicine, St. Louis, MO; 6Pathology and Immunology, Washington University School of Medicine, St. Louis, MO; 7Pediatric Cardiothoracic Surgery, Cardinal Glennon Children's Medical Center, St. Louis, MO.

[815] Lung Transplantation for Children in Europe: A 10-Year Multi-Center Austrian-German Experience; N. Schwark,1 C. Mueller,1 G. Wernacke,2 M. Giiese,3 J. Ripper,3 S. Gruber,4 A. Haverich,2 R. Hatz,5 W. Klepetko,6 T. Frischer,4 Department of Pediatrics Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany; 7Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany; 8Children's Hospital, University of Munich, Munich, Germany; 9Department of Pediatric and Adolescent Medicine, University of Vienna, Vienna, Austria; 10Department of Surgery, Grosshadern Medical Center Ludwig-Maximilians-University, Munich, Germany; 11Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.

[816] Changes in Body Composition after Lung Transplant in Children; U.G. Kyle,1 R.A. Orellana,1 J.K. Johnson,2 G.B. Mallory,2 M.G. Schecter;2 J.A. Coss-Bu,1 Critical Care Medicine, Baylor College of Medicine/TCH, Houston, TX; 3Pulmonary Diseases, Baylor College of Medicine/TCH, Houston, TX.

[817] ECMO Use in Pediatric Lung Transplantation – The Zurich Experience; A.J. Zuucher,1 I. Inci,2 G. Fretz,1 W. Wider,2 A. Boehler;1 C. Benden;1 Division of Pulmonary Medicine, University Hospital Zurich, Zurich, Switzerland; 2Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.

[818] ABO Blood Group Antigen Sensitization of Infants Exposed to Mechanical Circulatory Support (MCS); A. Guynes,2 M. Delaney,3 D. Townsend,1 M. Kemna,1 D.M. McMullan,4 R. Boucek,1 Y.M. Law,1 Pediatrics, Seattle Children’s Hospital, Seattle, WA; 2School of Medicine, University of Washington, Seattle, WA; 3Blood Bank and Pathology, Puget Sound Blood Center and Seattle Children’s Hospital, Seattle, WA; 4Surgery, Seattle Children’s Hospital, Seattle, WA.

[819] Human Leukocyte Antibody Production Is Uncommon in a Large Series of Pediatric Patients Supported with the Berlin Heart EXCOR Ventricular Assist Device; M.J. O’Conne,1 T.O. Harville,2 S.E. Pyle,1 K.R. Knecht,1 E.A. Fraizer,3 M. Imamura,3 W.R. Morrow,1 Cardiology, University of Arkansas for Medical Sciences/Arkansas Children’s Hospital, Little Rock, AR; 2Pathology and Laboratory Services, University of Arkansas for Medical Sciences, Little Rock, AR; 3Pediatric Cardiothoracic Surgery, University of Arkansas for Medical Sciences/Arkansas Children’s Hospital, Little Rock, AR.


[821] Heparin Free VADs: Can It Be Done?; J.V. Cassidy,1 L. Ferguson,1 M. Guiffen,1 S.R. Haynes,1 J.H. Smith,1 Y. Thiru,1 R. Kirk,1 P. Kesteven,2 M. Griselli,1 J.V. Cassidy,1 Critical Care Medicine, Baylor College of Medicine/TCH, Houston, TX; 2Division of Thoracic Surgery, Children’s Mercy Hospitals and Clinics, Kansas City, MO; 3Blood Bank and Pathology, Puget Sound Blood Center and Seattle Children’s Hospital, Seattle, WA; 4Surgery, Seattle Children’s Hospital, Seattle, WA.

[822] HLA Sensitization in Pediatric Patients Exposed to Mechanical Circulatory Support; B. Hong,1 M. Delaney,2 A. Guynes,4 G. Cohen,2 R.
(823) Impact of Pulmonary Venous Hypertension on Prognosis and Outcome after Lung Transplantation for End-Stage Chronic Obstructive Pulmonary Disease; K.H. Andersen,1,2 M. Iversen,1, J. Kjaergaard,1 J. Mortensen,2 J.-E. Nielsen-Kudsk,3 E. Bendstrup,4 R. Videbaek,1 J. Carlsen.11 Department of Cardiology, Rigshospitalet, Copenhagen, Denmark; 2Department of Cardiology, University Hospital of Aarhus, Skejby, Aarhus, Denmark; 3Department of Pulmonary Medicine, University Hospital of Aarhus, Aarhus, Denmark.

(824) WITHDRAWN

(825) Predictors of Six-Minute Walk Distance in Patients with Systemic Sclerosis Associated Pulmonary Hypertension; M.P. Tuppin,1,2 D. Chambers,1,2 R. Slaughter,3 O. Mohammed,2 F. Kermeen,2 School of Medicine, University of Queensland, Brisbane, QLD, Australia; 3Queensland Centre for Pulmonary Transplantation and Vascular Disease, Prince Charles Hospital, Brisbane, QLD, Australia; 4Medical Imaging, Prince Charles Hospital, Brisbane, QLD, Australia.

(826) RePHerral Study: A Multi-Center Study on the Referrals for Pulmonary Hypertension (PH); Left Heart Disease and PH; R.C. Deaño,4 M. Gomberg-Maitland1, S. Visovatti,2 C. Glassner1, V. McLaughlin2, M. Rubenfire3, A. Frost,3 Section of Cardiology, University of Chicago, IL; 2Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI; 3Pulmonary and Critical Care, Baylor College of Medicine, Houston, TX.

(827) Diastolic Pulmonary Artery Pressure – Pulmonary Artery Occlusion Pressure Difference Is a Good Predictor of Pulmonary Hypertension World Health Organization Group 2; L.R. Preston, K.E. Roberts, S.E. Richter, N.S. Hill. Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center/Tufts University School of Medicine, Boston, MA.

(828) Exercise Testing as a Predictor of Pulmonary Hypertension at Time of Lung Transplant; M.N. Bartels,1 C.P. Aaron,2 H.F. Armstrong,1 M. Bacchetta.1 Rehabilitation and Regenerative Medicine, Columbia University Medical Center, New York, NY; 2Medicine – Pulmonary, Allergy & Critical Care, Columbia University Medical Center, New York, NY; 3Department of Surgery, Columbia University Medical Center, New York, NY.

(829) Care Organisation for Pulmonary Arterial Hypertension in Developed Countries: A Survey; M. Delcroix,1 Y. Adir,2 A. Andreassen,3 A. Boonstra,4 B. Ekmehag,5 P. Escobedo,6 S. Gaine,7 N. Galie,8 S. Gibbs,8 M. Halm,10 M. Hoepfer,11 P. Jansa,12 I. Lang,13 S. Orfanos,14 A. Reis,15 I. Simkova,16 O. Sitbon,17 R. Speich,18 A. Torbicki,19 Center for Vascular Pulmonary Diseases, Université Ziekenhuizen Leuven, Leuven, Belgium; 2Pulmonary Division, Carmel Medical Center, Haifa, Israel; 3Cardiovascular & Pulmonary Disease, Osu University Hospital, Oslo, Norway; 4Respiratory Diseases, VU Medisch Centrum, Amsterdam, Netherlands; 5Heart and Lung Division, Skane University Hospital and Lund University, Lund, Sweden; 6Servicio de Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain; 7Miter Misericordiae University Hospital, Dublin, Ireland; 8Institute of Cardiology, University of Bologna, Bologna, Italy; 9National Heart and Lung Institute, Imperial College of Science, London, United Kingdom; 10Respiratory Medicine, Helsinki University Central Hospital, Helsinki, Finland; 11Department of Respiratory Medicine, Hannover Medical School, Hanover, Germany; 12Department of Cardiology and Angiology, Charles University, Prague, Czech Republic; 13Department of Cardiology, Medical University of Vienna, Vienna, Austria; 14Critical Care & Pulmonary Hypertension Clinic, Attkon Hospital, Athens, Greece; 15Hospital Santo António, Porto, Portugal; 16Slovak Medical University and National Institute of Cardiovascular Diseases, Bratislava, Slovakia; 17Service de Pneumologie et Réanimation, Hôpital Antoine Béclère, Clamart, France; 18Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland; 19Department of Chest Medicine, Institute of Tuberculosis and Lung Diseases, Warszawa, Poland.


(832) Determining Clinical Usefulness of the CAMPHOR Questionnaire; C. Glassner, S. Watson, M. Gomberg-Maitland. University of Chicago, Chicago, IL.

(833) WITHDRAWN

(834) Circulating Levels of the Stromal Derived Factor 1 in Patients with Pulmonary Arterial Hypertension; N. Selimovic,1 B. Andersen,1 N. Bergh,1 L. Mattsson Hulten,2 E. Sakinie,3 B. Rundqvist,4 5Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; 2Department of Molecular Clinical Medicine, Sahlgrenska Academy, Gothenburg, Sweden; 6Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden.

(835) Neovascularity in Patients with Idiopathic Pulmonary Arterial Hypertension; M.P. Tuppin,1,2 D. Chambers,1,2 R. Slaughter,3 O. Mohammed,2 F. Kermeen,2 School of Medicine, University of Queensland, Brisbane, QLD, Australia; 3Queensland Centre for Pulmonary Transplantation and Vascular Disease, Prince Charles Hospital, Brisbane, QLD, Australia; 4Medical Imaging, Prince Charles Hospital, Brisbane, QLD, Australia.

(836) Pulmonary Arterial Hypertension in Sweden: First Data from a National Registry; N. Selimovic,1 B. Lövgren Ekmejag,1 K. Jansson,1 F. Larsen,2 S. Söderberg,2 G. Wikström,4 5Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; 6Department of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden; 7Department of Cardiology, University Hospital Linköping, Linköping, Sweden; 8Department of Cardiology, Akademiska Hospital University of Uppsala, Uppsala, Sweden; 9Department of Cardiology, Umeå University Hospital, Umeå, Sweden; 10Norrtälje Hospital, Norrtälje, Stockholm, Sweden.

(837) Echocardiographic and Clinical Predictors of Outcome in Patients with Pulmonary Arterial Hypertension; E. Haddad,1 R. Doyle,1 A.Y. Deenault,2 M. Skhiri,1 E. Spierekotter,1 V. de Jesus Perez,1 K. Kudelko,1 I. Schnitter,1 R. Zamanian,1 1Medicine, Stanford University, Palo Alto, CA; 2Anesthesiology and Critical Care Medicine, Montreal Heart Institute, Montreal, QC, Canada.

(838) Differences in Mortality and Morbidity in Pulmonary Hypertension Secondary to Systolic vs. Diastolic Heart Failure; J.N. Salamon,1 R. Zolt,2 1Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY; 2Medicine, Division of Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY.
[839] Successful Cardiac Transplantation with Takotsubo Cardiomyopathy Donor; A.P. Nair,1 L. Murphy,1 S. Pinney.1 1Mount Sinai Medical Center, New York, NY; 4Mount Sinai Medical Center, New York, NY; 3Mount Sinai Medical Center, New York, NY.

[840] Successful Use of ECMO in a Jehovah’s Witness after Complicated Heart Retransplantation; M.J. Russo,1 P.J. Patel,1 R. Malysa,1 S. Fedson,2 A. Anderson,3 A. Shah,4 D. Eton,1 V. Jeewanandam.1 1Section of Cardiac and Thoracic Surgery, Department of Surgery, University of Chicago Medical Center, Chicago, IL; 2Section of Vascular Surgery, Department of Surgery, University of Chicago Medical Center, Chicago, IL; 3Section of Cardiology, Department of Medicine, University of Chicago Medical Center, Chicago, IL.

[841] Pomegranate-Induced Alterations in Tacrolimus Concentration; T. Khud1,2 A.S. Baas,2 R. Cheng,2 D. Cruz,2 A. Hickey,2 B. Kubak,2 A. Naair,2 C. Holt,2 M.C. Deng.2 1Heart Transplant, University of California, Los Angeles, CA; 2Medicine, Division of Cardiology, University of California, Los Angeles, CA.

[842] Severe Hyperacute Rejection after Cardiac Transplantation Despite Recent Negative Panel of Reactive Antibodies (PRA) Successfully Ameliorated by Utilization of CentriMag Ventricular Assist Devices (VADs) for Biventricular Support and Treatment with Rituximab, Intravenous Immunoglobulin (IVIG), and Plasmapheresis Resulting in Complete Functional Recovery; D.J. Kaczorowski,1 J. Datta,2 M. Kamoun,3 T.A. Mickler,4 Y.J. Woo.1 1Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA; 2Department of Surgery, University of Pennsylvania, Philadelphia, PA; 3Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA; 4Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA.

[843] Successful Heart Transplantation in a Patient with Common Variable Immunodeficiency; M. Sramko,1 M. Kubanej, J. Vrbiska, I. Malek, J. Pik. Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

[844] Early Recurrence of Cardiac Sarcoidosis 8 Weeks Post-Heart Transplantation; S.S. Cowen,1 A. Cheung,2 S. Virani,1 J. Bashir1,2 A. Kana,4 A. Ostry,3 M. Allard,3 A. Ignaszewski,1 M. Toma.1 1Department of Medicine, Division of Cardiology, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada; 2Department of Cardiovascular Surgery, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada; 3Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; 4Department of Nursing, St. Paul’s Hospital, Vancouver, Canada.


[846] Atrial Masses Post Cardiac Transplantation: Diagnostic and Treatment Dilemmas; J. Baumwol,1 D.H. Delgado,1 R.J. Cusimano,2 V. Rao,2 S. Kozuszko,1 J. Butany,1 H.J. Ross.1 1Division of Cardiology and Heart Transplantation, Toronto General Hospital, Toronto, ON, Canada; 2Division of Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada; 3Division of Pathology, Toronto General Hospital, Toronto, ON, Canada.

[847] Two Young Women with a Soft Tissue Tumor of the Heart; S.J. Lok1 M.E.I. Schipper,2 J.W.J. Hinrichs,2 P.J. van Diest,3 J.A.C. Post,3 I.O. Baas,4 R.A. de Weger,2 N. de Jonge,1 J.R. Lahpor.3 1Cardiology, Universitair Medical Center Utrecht, Utrecht, Netherlands; 2Pathology, Universitair Medical Center Utrecht, Utrecht, Netherlands; 3University Utrecht, Utrecht, Netherlands; 4Internal Medicine, Universitair Medical Center Utrecht, Utrecht, Netherlands; 5Cardiothoracic Surgery, Universitair Medical Center Utrecht, Utrecht, Netherlands.

[848] Sinotubular Junctional Remodeling Aortic Valve Repair Technique To Eliminate Aortic Regurgitation in Donor Cardiac Allograft; D.J. Kaczorowski,1 Y.J. Woo. Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA.

[849] Aborted Sudden Cardiac Death in a Long-Term Survivor after Orthotopic Heart Transplantation; G. Podlaja,1 M. Fister, R. Okrajesk, M. Sebestjen, B. Vrtovec. Advanced Heart Failure and Transplantation Center, Dept. of Cardiology, University Medical Center Ljubljana, Ljubljana, Slovenia.

[850] Cardiac Transplant Outcomes of 3 Cases with Behcet’s Disease; J. Huang,1 S.S. Hu,1 H.Y. Song,2 W. Wang,2 K.Z. Liao.1 1State Key Laboratory of Translational Cardiovascular Medicine, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 2Cardiovascular Surgery, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

[851] Donor-Derived Toxoplasma Infection in a Post-Transplant Patient; K.K. Rao,1 L.B. Cooper,2 P.C. Patel,1 S.Y. Wada.2 1Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX; 2Division of Infectious Diseases, University of Texas Southwestern Medical Center, Dallas, TX.

[852] Scopulariopsis Infection Following Lung Transplant: Lessons of Organ Procurement; J.L. Castilho,1 G.G. Miller,1 E.L. Grogan,2 E.S. Lambert,2 J.S. Dummer,1 J.E. Loyd,3 J. Fosnot,4 D.N. Cohen,5 L.M. Robbins,3 1Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN; 2Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN; 3Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN; 4Transplant Center, Vanderbilt University Medical Center, Nashville, TN; 5Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.

[853] Chagas Disease in a Heart Transplant Patient; E. Blodget,1 M. Bowdish,2 M. Barr3 G. Zeger.4 1Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA; 2Surgery, University of California Keck School of Medicine, Los Angeles, CA; 3Pathology, University of California Keck School of Medicine, Los Angeles, CA.


[856] Utopregulation of Matrix Metalloproteinases and No Evidence of Chromosomal Changes in Mounier-Kuhn Syndrome: Report of a Case; K. Hoetzelecker,1 A. Mitterbauer,1 P. Birner,2 M. Mildner,3 H. Prosch,4 B. Streubel,2 S. Taghavi,1 W. Klepetko,1 H.J. Ankersmit.1 1Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria; 2Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; 3Department of Dermatology, Medical University of Vienna, Vienna, Austria; 4Department of Radiology, Medical University of Vienna, Vienna, Austria.


(859) Mycobacterium genavense Infection in a Lung Transplant Recipient; V.L. Lorenzen, S. Öndahl, A. Costard-Jackle, T. Deuse, H.C. Reichenspurner. Department of Cardiology, Electrophysiology, University Heart Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of General and Interventional Cardiology, University Heart Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Cardiovascular Surgery, University Heart Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

(860) Rapidly Fatal Disseminated Acanthamoebiasis in a Single Lung Transplant Recipient; A. BoydKing, P.M. McFadden, S. Ganesh, C. Herrington, K. Alshar. Pulmonary and Critical Care, University of Southern California, Keck School of Medicine, Los Angeles, CA; Cardiotoracic Surgery, University of Southern California, Keck School of Medicine, Los Angeles, CA.

(861) Eculizumab for Treatment of Hyperacute Antibody-Mediated Lung Allograft Rejection; K.L. Dawson, A.S. Kirumaki, G.R. Honeycutt, A. Parulekar, H. Seethamraju. The Methodist Hospital, Houston, TX; Baylor College of Medicine, Houston, TX.

(862) Novel Approach for Treatment of Bronchial Dehiscence; E.V. Pinelis, N. Arora, P.S. Patel, C. Migliore, N. Shariati. Lung Transplant and Advanced Lung Diseases, Newark Beth Israel Medical Center, Newark, NJ.

(863) Lung Transplant Utilizing Cardiopulmonary Bypass in the Setting of Acute Heparin Induced Thrombocytopenia (HIT); H. Shah, S.R. Knoper, Y. Raz, J.C. Daniel, P.E. Nolan, M.J. Moulton. Division of Cardiothoracic Surgery, University of Arizona, Tucson, AZ; Division of Pulmonary and Critical Care, University of Arizona, Tucson, AZ; Pharmacy Practice and Science, University of Arizona, Tucson, AZ.

(864) Long-Term Follow-Up of Living-Donor Lobar Lung Transplantation for Diffuse Panbronchiolitis; S. Sugimoto, T. Oto, K. Miyoshi, M. Yamane, A. Nakatani, K. Goto, S. Miyoshi. Thoracic Surgery, Okayama University Hospital, Okayama, Japan; Anesthesiology, Okayama University Hospital, Okayama, Japan.

(865) Combined RV Outflow Tract (RVOT)-Single Lung Transplant: A Novel Approach for the Treatment of Chronic Pulmonary Valve (PV) Disease and Pulmonary Fibrosis (PF); G. Zanotti, M.G. Hartwig, R.D. Davis. Surgery, Duke University Medical Center, Durham, NC.


(868) Lung Transplant Recipients with a History of Treated Prostate Cancer: A Cedars-Sinai Lung Transplant Program Experience; D.I. Naim, E. Chaux. Pulmonary & Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.


(871) Small Arteriovenous Fistula Causing Persistent Right Heart Failure Symptoms Post Continuous Flow Left Ventricular Assist Device; M.A. Bowman, B. Rosen, M.N. Walsh, C.T. Salerno. Cardiology, St. Vincent Medical Center, Indianapolis, IN.

(872) HeartMate II as a Bridge to Weight Loss; B.C. Lampert, J.J. Teuteberg, R.L. Kormos. University of Pittsburgh Medical Center, Pittsburgh, PA.

(873) Novel Technique for Implanting a HeartMate II Left Ventricular Assist Device in the Presence of a Hostile Ventricle; P. Aturi, D.J. Dymond, Y.J. Woo. Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA.

(874) Percutaneous Transcatheter Closure of the Aortic Valve To Treat Cardiogenic Shock in a Left Ventricular Assist Device Patient with Severe Aortic Insufficiency; M.J. Russo, B.H. Freed, V. Jeevanandam, M. Hashimi, J. Paul, A. Anderson, R.M. Lang, A.P. Shah. Section of Cardiac and Thoracic Surgery, Department of Surgery, University of Chicago, IL; Section of Cardiology, Department of Medicine, University of Chicago, IL; Center for Aortic Diseases, University of Chicago, IL.

(875) Long Term Efficacy of Long-Acting Octreotide for Recurrent Gastro-Intestinal Bleeding Due to Gastric Angiodysplasia in a Jarvik 2000 Recipient; G. Coutance, V. Saplanac, A. Belin, A. Pellissier, R. Sabatier, M. Massetti. Cardiology, University Hospital Center of Caen, Normandy, France; Cardiac Surgery and Heart Transplantation, University Hospital Center of Caen, Normandy, France.

(876) Transapical Edge-to-Edge Mitral Valve Repair during Insertion of a Left Ventricular Assist Device; M.J. Russo, A.E. Merlo, E.M. Johnson, S.A. Akhtar, A. Anderson, V. Jeevanandam, J. Steinman, S. McCarthy. Section of Cardiac and Thoracic Surgery, Section of Surgery, University of Chicago Medical Center, Chicago, IL; Section of Cardiology, Department of Medicine, University of Chicago Medical Center, Chicago, IL; Center for Valve Disease, University of Chicago Medical Center, Chicago, IL; Department of Anesthesiology and Critical Care, University of Chicago Medical Center, Chicago, IL; Department of General Surgery, Division of Surgery, University of Chicago Medical Center, Chicago, IL.

(877) Improved Systemic Desaturation in Decompensated D-TGA Patient with Fontan Post LVAD Implantation; A.H. Abdul Jabbar, W.J. Franklin, R. Delgado, O.H. Frazier, L. Simpson, A. Civitello. Advanced Heart Failure and Cardiac Transplant Unit, Texas Heart Institute at St. Luke’s Episcopal Hospital/Baylor College of Medicine, Houston, TX; Adult Congenital Cardiology, Texas Children’s Hospital/Baylor College of Medicine, Houston, TX.


(879) Expplantation of a Temporary Implanted Right Ventricular Assist Device without Necessitating Resternotomy; D. Saeed, A. Albert, H. Kamiya, R. Westenfeld, A. Lichtenberg. Clinic for Cardiovascular Surgery,
(880) WITHDRAWN

(881) Catheter Ablation of Atrial Flutter in Patients with HeartMate II Left Ventricular Assist Device Improves Symptoms of Right Ventricular Dysfunction; R.U. Hottigoudar,1 A.G. Deam,1 E.J. Barks,1 K.C. McCants,1 M.S. Slaughter,2 R. Gopinathanannair,1 Division of Cardiovascular Medicine, University of Louisville, Louisville, KY; Division of Cardiothoracic Surgery, University of Louisville, Louisville, KY.

(882) Minimally Invasive Insertion of CentriMag Left Ventricular Assist Devices Via a Right Mini-Thoracotomy; D.J. Kaczorowski, Y.J. Woo, Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA.

(883) A Rare Disorder Requiring a Left Ventricular Assist Device; R. Hasan, K.D. Aaronson, F.D. Pagani, T.M. Koelling, Department of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI.

(884) Extended “Temporary” Use of Levitronix CentriMag Right Ventricular Assist Device; D. Saeed, A. Albert, H. Kamiya, A. Lichtenberg. Clinic for Cardiovascular Surgery, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.

(885) Berlin Heart EXCOR® Use in Pediatric Restrictive Cardiomyopathy: A Case Report; C.R. Pickett, J.M. Rutledge, D.B. Ross, H. Buchholz. Stollery Children's Hospital, Edmonton, AB, Canada.

(886) Extracorporeal Life Support (ECLS): The Silver Bullet; E.L. Bush,1 C.W. Hoopes,2 L. Martin,1 M. Brzezinski,1 J. Kukreja.1 Department of Cardiothoracic Surgery, University of California San Francisco, CA; Department of Cardiopulmonary Transplantation, University of Kentucky, Lexington, KY; Department of Anesthesiology, University of California San Francisco, CA.

(887) Hemolysis as a Marker for Thrombosis in Centrifugal Flow LVAD and the Role of Thrombolytic Therapy; A.H. Abdul Jabbar,1 R. Yau,2 D.H. Frazier,1 R. Delgado.1 Advanced Heart Failure and Cardiac Transplant Unit, Texas Heart Institute at St. Luke's Episcopal Hospital/Baylor College of Medicine, Houston, TX; Cardiology, Baylor College of Medicine, Houston, TX.

(888) Management of Excessive Menorrhagia in a Young Female on the Cardiowest Total Artificial Heart; C. Piercechi, J. Swan, P. Nolan, R. Smith, M.C. Smith. Cardiothoracic Surgery, University of Arizona, Tucson, AZ.

(889) A Heart Transplant Candidate of Severe Pulmonary Hypertension with Extremely High Pulmonary Vascular Resistance; N. Morikawa,1 O. Seguchi,2 T. Satou,2 H. Sunami,2 M. Yanase,2 T. Fujita,2 K. Toda,3 T. Nakatani.2 Division of Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan; Division of Cardiovascular Medicine, University of Arizona, Tucson, AZ; Adult Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan.

(890) First Report of Bilateral Epicardial Pulmonary Vein Isolation during Heartmate II Left Ventricular Assist Device Implantation; E.M. Hoenicke,1 M.B. Cishek,2 O.S. Gigliotti,2 J. Sanchez.2 Cardiothoracic & Vascular Surgeons, Seton Medical Center, Austin, TX; Seton Heart Institute, Seton Medical Center, Austin, TX.

(891) Oncologic Challenges in a Patient Supported by Left Ventricular Assist Device (LVAD); E. Ammirati, S. Cantoni, M. Cipriani, A. Garascia, F. Oliva, C. Russo, A. Verde, C. Vitton, F. Milazzo, L. Martirelli, M. Frigerio. Cardiovascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.

(892) Implantation of a Left Ventricular Assist Device in a Patient with a Concomitant Subcutaneous Implantable Cardioverter Defibrillator; D. Saeed, A. Albert, A. Lichtenberg. J. Winter. Clinic for Cardiovascular Surgery, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.

(893) LVAD Outflow Graft Pseudoaneurysm Masquerading as Sepsis; A. Aggarwal,1 G. Patel,2 A. Tatooles,3 P.S. Pappas,3 G. Bhat.1 Center for Heart Transplant and Assist Devices, Advocate Christ Medical Center, Oak Lawn; Cardiology, Advocate Christ Medical Center, Oak Lawn; Cardiothoracic Surgery, Advocate Christ Medical Center, Oak Lawn.


(895) Use of BIVAD and ECMO for the Treatment of Peripartum Cardiomyopathy; S. Kumar,1 D. Jacoby,2 A.A. Mangi.1 Section of Cardiac Surgery, Yale University School of Medicine, New Haven, CT; Section of Cardiology, Yale University School of Medicine, New Haven, CT.

(896) Dor Ventriculoplasty with Transventricular Mitral Valve Repair; D.J. Kaczorowski, M. Blank, Y.J. Woo. Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA.

(897) A Novel Way To Identify Donor Specific Antibody in Pediatric Heart Transplant; R.K. Ameduri. Pediatric Cardiology, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN.

(898) WITHDRAWN

(899) Life-Saving Single Living-Donor Lobar Lung Transplantation for Rapidly Deteriorating Pulmonary Veno-Occlusive Disease; K. Takahashi,1 F. Chen,1 H. Kayawake,2 T. Ikeda,2 H. Ishii,3 D. Nakajima,1 J. Sakamoto,1 A. Ohsumi,1 H. Motoyama,1 K. Okita,1 K. Hijiyama,1 H. Doi,4 A. Aoyama,1 M. Sato,1 T. Bando,1 H. Data,1 Thoracic Surgery, Kyoto University, Kyoto, Japan; Cardiovascular Surgery, Kyoto University, Kyoto, Japan; Anesthesiology, Kyoto University, Kyoto, Japan; Pediatrics, Kyoto University, Kyoto, Japan.

(900) A Three Month Course of Pre-Operative Extracorporeal Membrane Oxygenation Culminating in Pediatric Lung Transplantation; Y. Raz,1 J.C. Daniel,2 H. Shah,2 P.E. Nolan,3 S.R. Knoper,1 M.J. Moulton,2 Division of Pulmonary and Critical Medicine, University of Arizona, Tucson, AZ; Division of Cardiothoracic Surgery, University of Arizona, Tucson, AZ; Pharmacy Practice & Science, University of Arizona, Tucson, AZ.

(901) An Apparent Case of Undiagnosed Donor Kawasaki Disease Manifesting as Coronary Artery Aneurysms in a Pediatric Heart Transplant Recipient; J.M. Friedland-Little, R. Aiyagari, K.R. Schumacher. Division of Pediatric Cardiology, University of Michigan, Ann Arbor, MI.

(902) Massive Hemoptysis as a Marker of Treprostinil Induced Platelet Dysfunction in a Pulmonary Hypertension Patient; F. Rischard,1 K. Knox,1 L. Hanson,1 S. Knoper,1 P. Nolan.2 Pulmonary and Critical Care Medicine, University of Arizona, Tucson, AZ; Department of Pharmacology, University of Arizona, Tucson, AZ.

(903) Tadalafil Therapy in Exercise Induced Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction; D.C. Ishizawar, M.A. Simon. Cardiology, University of Pittsburgh, School of Medicine, Pittsburgh, PA.
# EXHIBITING COMPANIES

## Alphabetical List of Exhibitors

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avalon Laboratories</td>
<td>9</td>
</tr>
<tr>
<td>Bayer Pharma AG</td>
<td>12</td>
</tr>
<tr>
<td>Berlin Heart</td>
<td>19</td>
</tr>
<tr>
<td>CardiacAssist, Inc.</td>
<td>7</td>
</tr>
<tr>
<td>CircuLite GmbH</td>
<td>26</td>
</tr>
<tr>
<td>CorMatrix Cardiovascular, Inc.</td>
<td>10</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>31</td>
</tr>
<tr>
<td>Cylex, Inc.</td>
<td>23</td>
</tr>
<tr>
<td>Elsevier</td>
<td>6</td>
</tr>
<tr>
<td>Euromacs</td>
<td>32</td>
</tr>
<tr>
<td>HeartWare</td>
<td>2</td>
</tr>
<tr>
<td>IMACS Registry</td>
<td>22</td>
</tr>
<tr>
<td>ISHLT Thoracic Transplant Registry</td>
<td>29</td>
</tr>
<tr>
<td>Jarvik Heart, Inc.</td>
<td>20</td>
</tr>
<tr>
<td>MicroMed CV</td>
<td>24</td>
</tr>
<tr>
<td>Montreal Convention Bureau</td>
<td>13</td>
</tr>
<tr>
<td>Novartis Pharma AG</td>
<td>4</td>
</tr>
<tr>
<td>One Lambda, Inc.</td>
<td>17</td>
</tr>
<tr>
<td>Scanlan International, Inc.</td>
<td>25</td>
</tr>
<tr>
<td>Sunshine Heart</td>
<td>16</td>
</tr>
<tr>
<td>SynCardia Systems, Inc.</td>
<td>14</td>
</tr>
<tr>
<td>Therakos</td>
<td>11</td>
</tr>
<tr>
<td>Thoratec Corporation</td>
<td>5</td>
</tr>
<tr>
<td>TransMedics, Inc.</td>
<td>1</td>
</tr>
<tr>
<td>United Therapeutics Europe LTD</td>
<td>3</td>
</tr>
<tr>
<td>Vivoline Medical AB</td>
<td>28</td>
</tr>
<tr>
<td>XDx</td>
<td>8</td>
</tr>
<tr>
<td>XVIVO Perfusion AB</td>
<td>21</td>
</tr>
</tbody>
</table>
The Junior Faculty Case Report Posters are located on the 3rd floor of Prague Congress Centre.

LIST OF EXHIBITORS

1. TransMedics, Inc.
2. HeartWare
3. United Therapeutics Europe LTD
4. Novartis Pharma AG
5. Thoratec Corporation
6. Elsevier
7. CardiacAssist, Inc.
8. XDx
9. Avalon Laboratories
10. CorMatrix Cardiovascular, Inc.
11. Therakos
12. Bayer Pharma AG
13. Montreal Convention Bureau
15. Sunshine Heart
16. One Lambda, Inc.
17. Berlin Heart
18. Jarvik Heart, Inc.
19. XVIVO Perfusion AB
20. IMACS Registry
21. Cylex, Inc.
22. MicroMed CV
24. CircuLite GmbH
25. Vivaline Medical AB
26. ISHLT Thoracic Transplant Registry
27. CSL Behring
28. Euromacs
**Avalon Laboratories, LLC**
801 Michigan St. NE, Ste 500  
Grand Rapids, MI 49503  
Web address: www.avalonlabs.com

**BOOTH NUMBER: 9**

Avalon Laboratories is a leading manufacturer of wire-reinforced cardiopulmonary vascular cannula. Avalon Elite® is the company’s premium line of advanced catheters providing important solutions for patients receiving extracorporeal support. With a wide range of sizes, the Avalon Elite Bi-Caval Dual Lumen Catheter is the world’s first minimally invasive, kink resistant, veno-venous catheter available for both pediatrics and adults.

---

**Bayer Pharma AG**
Müllerstrasse 178  
13353 Berlin Germany  
Web address: www.bayerpharma.com

**BOOTH NUMBER: 12**

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of more than EUR 16.913 Billion (2010), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

---

**Berlin Heart**
Wiesenweg 10  
12247 Berlin  
Germany  
Web address: www.berlinheart.com

**BOOTH NUMBER: 19**

Berlin Heart is the only company worldwide that develops, produces and distributes implantable and paracorporeal ventricular assist devices for patients of every age and body size.

EXCOR® is a paracorporeal pulsatile VAD for uni- or biventricular support in newborns, children, adolescents, and adults. EXCOR® Pediatric is leading the worldwide market of pediatric VADs.

INCOR® is an implantable axial-flow IVAD for adults. INCOR® is the only 3rd generation axial flow pump with CE-mark approval.

The Berlin Heart EXCOR® Pediatric Ventricular Assist Device (EXCOR® Pediatric) is approved for use by the FDA under a Humanitarian Device Exemption. All other products are not FDA approved.

---

**CardiacAssist, Inc.**
240 Aopha Dr.  
Pittsburgh, PA, 15238  
Web address: www.tandemheart.com

**BOOTH NUMBER: 7**

CardiacAssist’s TandemHeart System is used by both Cardiologists and Cardiac Surgeons to initiate high flow extracorporeal circulatory support in minutes. Utilizing a femoral venous approach and transseptal cannulation of the left atrium, the TandemHeart system unloads the left ventricle and allows the heart to rest. The system maintains end organ perfusion with flow rates up to 5.0 L/min when placed percutaneously and up to 8.0 L/min with direct surgical cannulation.

---

**Circulite GmbH**
250 Pehle Ave.  
Park 80 West, Suite 403  
Saddle Brook, NJ 07663  
Web address: www.circulite.net

**BOOTH NUMBER: 26**

CircuLite, Inc. (Saddle Brook, NJ and Aachen, Germany) is transforming heart failure treatment with the development of a platform of minimally-invasive, long term partial circulatory support devices. By enabling a proactive and lower-risk treatment approach through supplementing a patient’s native cardiac pumping capacity, CircuLite has the potential to improve the quality of life for millions of chronic heart failure patients.

CircuLite’s Synergy® Micro-Pump, the world’s smallest implantable blood pump, weighs 25g and provides up to 4.25 L/min flow.

For more information on CircuLite and the Synergy Micro-pump devices, visit our website at www.CircuLite.net.
CorMatrix Cardiovascular, Inc.
286 S. Main St, Ste 200
Alpharetta, GA 30009
Web address: www.cormatrix.com

**BOOTH NUMBER: 10**

CorMatrix® Cardiovascular markets its ECM® Technology biomaterial devices for pericardial closure, cardiac tissue repair and carotid repair and is currently conducting preclinical studies to evaluate future applications in heart failure as well as other cardiovascular applications.

CSL Behring
1020 First Ave
King of Prussia, PA 19406
Web Address: cslbehring-us.com

**BOOTH NUMBER: 31**

CSL Behring is a global leader in the plasma protein biotherapeutics industry. CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company’s products are used for organ transplantation, inherited emphysema, in the prevention of hemolytic diseases in the newborn, in cardiac surgery and in the treatment of burns and shock. Additional therapies are used in the treatment of hemophilia, von Willebrand disease, other bleeding disorders and immune deficiency disorders. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring-us.com.

Cylex, Inc.
8980-l Old Annapolis Road
Columbia, MD 21045
Web address: www.cylex.net

**BOOTH NUMBER: 23**

Cylex™ is a global life sciences company developing and manufacturing in vitro diagnostic products that illuminate immunity. Its patented technology provides an innovative platform to assess immune cell function – providing insight for individualized patient management and opportunities for developing additional assays for diseases, and companion diagnostics for treatments affecting the immune system.

ImmuKnow®, Cylex’s FDA-cleared product, is a noninvasive biomarker of immune function used by clinicians to manage and optimize immunosuppression in transplant patients.

Elsevier
32 Jamestown Road, London, NW1 7BY, UK
Web address: www.elsevier.com

**BOOTH NUMBER: 6**

ELSEVIER, a premier worldwide health science publishing company, presents *The Journal of Heart and Lung Transplantation*, the official journal of The International Society for Heart & Lung Transplantation. Please stop by our booth to view the latest issue of the journal and browse our selection of publications in the field of Transplantation.

EUROMACS (European Registry for Patients with Mechanical Circulatory Support)
Augustenburger Platz 1
Berlin, Germany 13353
Web Address: www.euromacs.org

**BOOTH NUMBER: 32**

EUROMACS unites individual medical professionals and institutions with the goal of running a European registry for data from patients with mechanical circulatory support (MCS) systems. The data collected will be made available for research purposes and facilitate medical studies that will serve to improve the care of patients with MCS. Further, the registry will allow comparison between European and international MCS data.

HeartWare
205 Newbury Street, Suite 101
Framingham, MA 01701
Web address: www.heartwareinc.com.au

**BOOTH NUMBER: 2**

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB/IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia. The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.
IMACS (ISHLT Mechanically Assisted Circulatory Support) Registry
701 19th St. S., LHRB 790
Birmingham, AL 35294
Web Address: www.ishlt.org/registries/mcsdDatabase.asp

**BOOTH NUMBER: 22**

Launched on April 1, 2012, the ISHLT Mechanically Assisted Circulatory Support (IMACS) Registry is a new mechanical circulatory support registry designed to capture data on MCS devices from any non-US center. IMACS is an initiative of ISHLT, and is managed by UMACS, a non-profit research group at the University of Alabama at Birmingham, in cooperation with UNOS. IMACS is a high-quality database focused on collecting accurate, complete, and verifiable MCS data. IMACS data will be combined with the INTERMACS dataset to provide “scientific quality” analyses to seek truths in the global application of durable MCS.

ISHLT Thoracic Transplant Registry
700 North 4th Street
Richmond, Virginia 23219
Web address: www.ishlt.org

**BOOTH NUMBER: 29**

The ISHLT Thoracic Transplant Registry was created to collect on-going, current information on the worldwide thoracic organ transplantation experience. Our registry is the only one of its kind. The data we maintain is utilized for scientific study and contributes to the body of knowledge regarding thoracic transplantation. Our goal is to identify overall and best practices for improving cardiothoracic patient care.

This year the exhibit will make center-specific information available for review by ISHLT Transplant Registry participants. In addition, data screens can be reviewed and we will provide guidance on enrollment, submission of data and data request services.

Jarvik Heart, Inc.
333 West 52nd Street
New York, NY 10019-6238
Web address: www.jarvikheart.com

**BOOTH NUMBER: 20**

Jarvik Heart, Inc. is a privately held, New York based company that develops and manufactures miniaturized heart assist devices for the treatment of severe heart failure. The Jarvik 2000 is a battery-powered axial-flow left ventricular assist device (LVAD). It is the smallest implantable blood pump available for the long-term treatment of Heart Failure.

MicroMed CV
Erfstraat 10 a
5405 BE Uden
The Netherlands
Web address: www.micromedcv.com

**BOOTH NUMBER: 24**

HeartAssist 5® LVAD System Description:
At 92 grams and up to 10 Liters/Minute, the HeartAssist 5® LVAD System is one of only 2 full-output, pumps small enough to be consistently implanted above the diaphragm and which provides the ability to accurately measure blood flow through the exclusive, implantable Flow Probe.

This, combined with the unique ability to closely monitor pump operating parameters and flow data remotely over the internet through the exclusive HeartAssistRemote™ Monitoring System, creates an overall superior value proposition to clinicians and patients which is unparalleled in the industry today.

Novartis Pharma AG
Postfach
Basel, CH-4002
Switzerland
Web address: www.novartis.com

**BOOTH NUMBER: 4**

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas.
In 2011, the Group’s continuing operations achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group.

Novartis Group companies employ approximately 124,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com. Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

One Lambda, Inc.
21001 Kitttridge St
Canoga Park, CA 91303
Web address: www.onelambda.com

Booth Number: 17

Visit One Lambda’s booth to learn more about the company’s revolutionary LABScreen Single Antigen product line. Single Antigen beads serve as the optimal tool to identify Donor-Specific Antibodies (DSA) in transplant patients, which can significantly affect graft survival. Also take the opportunity to collect information on the newest product from One Lambda, the CIQ Screen. This product is designed to distinguish complement-binding antibodies from those that do not bind complement; another important piece of information when analyzing the profile of antibodies. Our experts will be available to discuss the role of DSA in antibody mediated rejection and more.

Scanlan International, Inc.
One Scanlan Plaza
Saint Paul, Minnesota 55107
Web address: www.scanlaninternational.com

Booth Number: 25

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 titanium and stainless steel instrument designs including needle holders, forceps, scissors, clamps and specialty instruments. Featured instruments include the SCANLAN®LEGACY titanium needle holders and forceps, full line of VATS / MIS Thoracoscopic instruments including the Chitwood Clamp, Knot Pusher, and SUPER CUT™ Suture Cutter; NEW Axial Handle needle holders and forceps, SUPER CUT™ Scissors and Rendina needle holder. Single-use products include: VASCU-STAT® bulldog clamps, Aorta/ Vein Punch and A/C Locator® graft markers. Also offering custom instrument designs and modifications for your individual needs.

Sunshine Heart
12988 Valley View Road
Eden Prairie, MN 55344
Web Address: www.sunshineheart.com

Booth Number: 16

The C-Pulse Heart Assist System is an extra-aortic balloon pump using counter-pulsation technology to treat moderate to severe heart failure (Class III/IV). It can be performed minimally invasively, is placed outside the bloodstream, and the patient has the ability to disconnect from the system. It is designed to improve heart function by increasing cardiac output, increasing coronary blood flow and decreasing afterload. C-Pulse’s goal is to halt the progression of heart failure. The FDA feasibility clinical study results showed promising results with the reduction of NYHA classification in 80% of the patients. CE mark is expected in mid-2012.

SynCardia Systems, Inc.
1992 E Silverlake Rd
Tucson, AZ 85713
Web address: www.syncardia.com

Booth Number: 14

The SynCardia temporary Total Artificial Heart (TAH-t) is the world’s only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the TAH-t is currently approved as a bridge to transplant for patients dying from end-stage biventricular failure. The 13.5 lb Freedom™ portable driver has received CE approval in Europe and is undergoing an IDE clinical study in the U.S. The Freedom driver is designed to provide mobility for stable TAH-t patients both inside and outside the hospital. Visit our booth for updates on the study, Companion 2 Driver System and the 50cc TAH-t.

Therakos
Pinewood Campus Nine Mile Ride
Wokingham, United Kingdom RG40 3EW
Web address: www.therakos.com

Booth Number: 11

Therakos Inc., a Johnson & Johnson company, develops and manufactures systems focused on immune cell therapies. Therakos Inc., a pioneer in photopheresis therapy for more than 20 years, currently markets the world’s only approved integrated systems for the provision of extracorporeal photopheresis (ECP) – the new THERAKOS™ CELLEX™ Photopheresis System and the THERAKOS™ UVAR™ XTS™ Photopheresis System.
Extracorporeal (outside the body) photopheresis can be used in the treatment of various immune mediated diseases, and is predominantly used for the treatment of cutaneous T-cell lymphoma (CTCL) and graft-versus-host disease (GVHD).

Therakos Inc. is actively engaged in basic research and actively supports innovative independent studies within the academic and medical community.

Therakos Inc. has a commercial presence in 126 centres in 26 countries, with its research and manufacturing headquarters based in the US.

**Thoratec Corporation**
6035 Stoneridge Drive
Pleasanton, CA 94588
Web address: www.thoratec.com

**BOOTH NUMBER: 5**

Thoratec is a world leader in therapies to address advanced-stage heart failure. The company’s products include the HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 18,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag® and PediMag®/PediVAS® product lines. For more information, visit the company’s website at http://www.thoratec.com.

**TransMedics, Inc.**
200 Minuteman Road, Suite 302
Andover, MA 01810
Web address: www.transmedics.com

**BOOTH NUMBER: 1**

TransMedics is dedicated to enabling increased utilization of donor organs for transplantation while enhancing patient outcomes and improving cost-effectiveness of transplant programs. The TransMedics® Organ Care System is a portable, advanced ex-vivo perfusion, monitoring and organ recruitment platform for heart and lung transplantation that is intended to maintain donor organs in a functioning state from donor to recipient.

The OCS™ HEART and LUNG systems are CE-marked and in clinical use in leading European transplant centers, and in pivotal FDA clinical trials in leading global heart & Lung transplant centers comparing the OCS™ to cold storage.

**United Therapeutics Europe LTD**
Onither House, Curfew Bell Road
Chertsey, Surrey, United Kingdom
Web address: www.unither.com

**BOOTH NUMBER: 3**

Remodulin® (treprostinil) Solution for Infusion, United Therapeutics, is a prostacyclin analogue indicated to improve exercise capacity and symptoms of patients diagnosed with idiopathic or heritable pulmonary arterial hypertension (PAH) with New York Heart Association (NYHA) functional class (FC) III symptoms.

In much of Europe, Remodulin is available for administration via the subcutaneous route and will be available via the intravenous route in selected European markets in 2012.

United Therapeutics remains committed, through its ongoing R & D activities to assist, support and meet the needs of PAH patients around the world.

**Vivoline® Medical AB**
Scheellevägen 17
SE – 223 70 Lund
Sweden
Web address: www.vivoline.se

**BOOTH NUMBER: 28**

VivoLine® LS1…..a new opportunity!

VivoLine® LS1 is intended for reconditioning, evaluation and cold preservation of lungs ex-vivo after lung donation and prior to transplantation. The system provides a simplified method that can perform an ex-vivo evaluation in a safe and controlled way, based on previous research for treating lungs ex-vivo. The possibility to test marginal lungs provides the opportunity to increase the number of organs available for transplantation. It is a compact system which can be set up quickly and easily. The organs can be stored in the system until next day for daytime surgery.
XDx
3260 Bayshore Blvd
Brisbane, CA 94005
Web address: www.allomap.com

**BOOTH NUMBER: 8**

**XDx** is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. The company has developed a proprietary method of utilizing gene expression in blood that provides a new tool for physicians to aid in the management of heart transplant patients.

XDx has one marketed product, AlloMap® Molecular Expression Testing, and other products under development.

**XVIVO Perfusion AB**
Box 9080
SE – 400 92 Göteborg
SWEDEN
Web address: www.xvivoperfusion.com

**BOOTH NUMBER: 21**

**XVIVO Perfusion AB** (Part of the Vitrolife Group) manufactures and markets solutions and equipment for transplantation and thoracic surgery, designed to preserve, evaluate and recondition organs and tissues prior to transplantation. Two of our principle solutions are Perfadex® for hypothermic flushing and preservation of donor lungs during transport and STEEN Solution™ for normothermic ex-vivo organ evaluation and reconditioning. *(approved in US for research purposes only).*

XVIVO aims to:
- minimize ischemia-reperfusion injury by improving the solutions used for ex-vivo preservation of organs and tissues.
- extend the safe ex-vivo preservation time for organs and tissues prior to transplantation.
- increase organ availability and transplantation success rates by introduction of new transplantation concepts and techniques.
See you next year!

Gilead is committed to expanding healthcare options for individuals living with cardiovascular and pulmonary disease through innovative research, access, and education programs.

INSIDE BACK COVER FOR POSTITION ONLY PRINTS CMYK
In you, we see the future of transplant medicine.

The future of transplant medicine has always been fuelled by individual efforts and collective experience.

At Astellas Transplant, we continuously seek to improve our knowledge of transplantation. We always look forward to the challenges ahead and strive to work in partnership with you to advance the future of transplantation.

Our goal is to support you in improving the quality of your patients’ lives—today and tomorrow. Whether it’s with our cornerstone therapies, our innovative compounds in development, or our support of transplant associations, clinical studies, and fellowships, we’re continually looking for ways to anticipate and meet your needs, and the needs of your patients.

Together, we can advance the future of transplantation.